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The thyroid disorders are one of the most common and exciting areas of endocrinology. 
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The thyroid disorders are one of the most common and exciting areas of endocrinology. Hy‐
pothyroidism, multinodular goiter, hyperthyroidism and thyroid cancer are only few of the
several implications that the thyroid disorders have in health. In fact, thyroid hormones reg‐
ulate not only metabolism process, but also many other molecular and physiological sys‐
tems. From this point of view, hyperthyroidism complications are a good example of the
significance of thyroid hormone actions.
In the last decade the progress and development of biochemical assays of thyroid hormones
and related peptides, new conventional or nuclear imaging techniques and a deeper knowl‐
edge in thyroid nodule and cancer physiopathology have changed the comprehension, diag‐
nosis and treatment of thyroid disorders.
This book aims to provide a general view of thyroid disorders from different but comple‐
mentary points of view: historical, physiopathology, diagnosis and treatment. Furthermore,
it is focused on hyperthyroidism and its complications and impact in health and disease due
to its severe consequences.
This book is the result of collaboration between worldwide authorities of different back‐
grounds. I am grateful to them for the quality of their contributions.
We hope that the medical and paramedical researchers will find this book helpful and stim‐
ulating. We look forward to sharing the state of the art in thyroid disorders with a wider
audience.
Dr. Gonzalo Díaz-Soto
University of Valladolid Medical School,
Clinic University Hospital, Valladolid,
Spain
Chapter 8 Surgical Management of Hyperthyroidism   207
Z. Al Hilli, C. Cheung, E.W. McDermott and R.S. Prichard
Chapter 9 Trophoblastic Hyperthyroidism and Its Perioperative




The thyroid disorders are one of the most common and exciting areas of endocrinology. Hy‐
pothyroidism, multinodular goiter, hyperthyroidism and thyroid cancer are only few of the
several implications that the thyroid disorders have in health. In fact, thyroid hormones reg‐
ulate not only metabolism process, but also many other molecular and physiological sys‐
tems. From this point of view, hyperthyroidism complications are a good example of the
significance of thyroid hormone actions.
In the last decade the progress and development of biochemical assays of thyroid hormones
and related peptides, new conventional or nuclear imaging techniques and a deeper knowl‐
edge in thyroid nodule and cancer physiopathology have changed the comprehension, diag‐
nosis and treatment of thyroid disorders.
This book aims to provide a general view of thyroid disorders from different but comple‐
mentary points of view: historical, physiopathology, diagnosis and treatment. Furthermore,
it is focused on hyperthyroidism and its complications and impact in health and disease due
to its severe consequences.
This book is the result of collaboration between worldwide authorities of different back‐
grounds. I am grateful to them for the quality of their contributions.
We hope that the medical and paramedical researchers will find this book helpful and stim‐
ulating. We look forward to sharing the state of the art in thyroid disorders with a wider
audience.
Dr. Gonzalo Díaz-Soto
University of Valladolid Medical School,








Tao Yang and Xiaoyun Liu
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/57522
1. Introduction
1.1. The centennial history of Hashimoto’s thyroiditis
One hundred years ago, a 31-year old Japanese surgeon called Hakaru Hashimoto at Kyoto
Imperial University published the description of four cases of goiter in the thyroid resection
specimens from four women in a German journal Archiv für Klinische Chirurgie in 1912 just
before World War I. This paper contained two Latin words in the title (struma lymphomatosa)
and five microphotographs. The histological appearance of these goiters characterized by a
lymphoplasmocytic infiltrate with diffuse inflammatory alterations of the thyroid parenchyma
and fibrosis was very different from the colloid goiters that he was familiar with, as well as
those from Grave’s disease, infectious thyroiditis (especially related to tuberculosis or syphilis)
and the fibrous thyroiditis described by Riedel in 1896. He emphasized similarity with the
histological data observed with lacrimal, salivary, lymph node and splenic involvement of
Mikulicz’s disease (now Sjögren's syndrome). Mickulicz was the teacher of Hayari Miyake,
the head of Hashimoto’s department.
The four observed cases involved female patients over the age of 40 years who had formed
very firm diffuse goiters, to the extent that the diagnoses were suggestive of fibrous thyroid
or cancer at that time. But these were isolated, with hardly any severe signs of compression
and no adenopathy. The postoperative course of these goiters seemed more complicated than
usual. One case was complicated by recurrence, soon followed by spontaneous reduction of
the hypertrophy.
Hashimoto decided to continue his training in Göttingen, Germany and then in England. He
was forced to return home after the outbreak of World War I. He continued to practice as a
general practitioner in rural Midai in 1916 and died in 1934 at the age of 52 years from typhoid
contracted from a patient, without achieving the recognition he deserved.
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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Hashimoto’s discovery was not exactly ignored for the next few decades, but recognition of
its existence was certainly slow, possibly related in part to the publication of the paper in
German. In 1931, Graham and McCullagh used the term ‘‘Hashimoto’’ for the first time in the
title of an article, strongly arguing that struma lymphomatosa was indeed distinct from
Riedel’s thyroiditis. The description of lymphocytic thyroiditis was rediscovered in the United
States in 1936, and the disease was labeled Hashimoto’s thyroiditis (chronic lymphocytic
thyroiditis) in medical textbooks. In 1939, the prominent British thyroid surgeon Cecil Joll
coined the term ‘‘Hashimoto disease’’ and used it in the title of a review he wrote about this
condition. Since then, Hashimoto’s thyroiditis has gone from being a rarity to one of the most
common autoimmune diseases, as well as the most common endocrine disease.
An essential step was the characterization in 1956 by Noel Rose and Ernest Witebsky of
experimental thyroiditis created by the injection of thyroid extracts and Freund adjuvant in
rabbits, which showed histological aspects similar to those described by Hashimoto. In the
same year, Ivan Roitt and Deborah Doniach reported the presence of autoantibodies directed
against thyroglobulin in the Lancet. Until then it had seemed inconceivable that an individual
would develop antibodies directed against his own body (‘‘horror autotoxicus’’). This was the
first time that the possibility of autoimmune diseases had been suggested, and Hashimoto’s
disease established itself as the model of organ-specific autoimmune diseases. It is a good
example of a situation in which a brilliant clinician provided the clinical and anatomopatho‐
logical description of a disease, leaving it to future generations to understand the mechanism
and, in the current case, to establish the far-reaching concept of autoimmune diseases,
sometimes organ-specific, polyglandular or general.
With regard to history, there is agreement that the hypertrophic forms of lymphocytic
thyroiditis, which can progress to atrophy although not inevitable, would be labeled Hashi‐
moto’s thyroiditis. In terms of the pathogenic, histologic and biologic perspectives, these forms
did not differ greatly from atrophic lymphocytic thyroiditis causing myxoedema, or asymp‐
tomatic autoimmune thyroiditis or thyroiditis occurring with nodules or cancer. These aspects
are the subject of the article by Orgiazzi. Even before the description of lymphocytic thyroiditis
by Hashimoto, the simultaneous occurrence of hypothyroidism with other endocrinopathies
had been demonstrated in Germany in 1904 by Erhlich, and in 1908 in France by Claude and
Gougerot. In 1980 these conditions of polyglandular failure were divided into four types by
Neufeld, and then grouped into two varieties. Childhood-onset type 1 autoimmune polyen‐
docrine syndrome has autosomal recessive transmission linked to a mutation of the AIRE gene,
which controls the production of antibodies at the thymic and peripheral levels. This can be
differentiated from type 2 (or 2/3), which is much more frequent, starts in adulthood, and is
polygenic and multifactorial, the characteristics of which are presented by Kahaly. Whether
isolated or occurring with polyendocrinopathies, autoimmune involvement of the adrenal
glands alters the quality of life and is life-threatening; it is explained and its care are described
in the article by Napier and Pearce. The pathogenic access and assessment of autoimmune
involvement in parathyroid and pituitary are still in the early stages, while the immunologic
and pathogenic data and management perspectives are better understood in diabetes mellitus,
as confirmed in the article by Boitard. The description of the histological changes of Hashi‐
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moto’s thyroiditis, only just a century ago, gained credibility over several decades. Hashimo‐
to’s thyroiditis is now considered the most prevalent autoimmune disease.
2. Prevalence over time
Its incidence is about 1 case per 1000 persons per year. The prevalence is 8 cases per 1000 when
estimated from a review of published articles, and 46 cases per 1000 when estimated from the
biochemical evidence of hypothyroidism and thyroid autoantibodies in subjects participating
to the Third National Health and Nutrition Examination Survey. Caturegli(Caturegli, De
Remigis et al. 2013) and colleagues have marked the centenary of Hashimoto’s seminal paper
by reviewing the extensive surgical pathology archives of the Johns Hopkins Hospital for cases
of Hashimoto thyroiditis, spanning an extremely long period from 1889 to 2012. The results
are fascinating and a fitting way to mark this important anniversary. The study reveals a
remarkable change in incidence, with very few cases for the first half of the period, and then
a significant increase between 1943 and 1967, a constant incidence up to 1992 and then another
significant increase over the last two decades.
Of course this retrospective pathological analysis can take little account of the clinical reasons
for thyroid surgery, which will have a fundamental impact on the incidence, but the results
are so striking that a rapid increase in the frequency of Hashimoto’s thyroiditis in the second
half of the 20th century seems an unavoidable conclusion. Another review supported this by
reviewing of 1050 Austrians patients who had surgery for benign goiter between 1979 and
2009; there was a significant increase in the incidence of both lymphocytic thyroiditis and
Hashimoto’s thyroiditis in resection specimens over this time. In addition, a striking rise in
Hashimoto’s thyroiditis has been reported recently in Italy. Between 1975 and 2005, there was
a 10-fold rise in incidence: patients have become relatively younger, are more likely to be male,
and have lower autoantibody responses. While some of this change in incidence could be the
result of increased thyroid function testing and earlier detection of disease, the overwhelming
conclusion is that environmental factors must be responsible. Increased iodine intake is
certainly one possible influence: a recent study in China showing increases in subclinical
hypothyroidism and autoimmune thyroiditis in an area of more than adequate iodine intake
is the latest among many such reports. But not all studies have shown an adverse effect of
excess dietary iodine (possibly related to genetic factors and the rate of the increase in iodine
intake in a population) and when it does occur, the effect of iodine may be transient. Nor is
thyroid autoimmunity alone in this regard; celiac disease, type 1 diabetes, and multiple
sclerosis have all increased in incidence over the last three decades. It is likely that aspects of
urbanized living, such as higher standards of hygiene, increased prosperity, and increased
exposure to environmental toxins, are responsible for this generalized trend, perhaps by
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3. Pathogenesis and etiology
The pathogenesis of Hashimoto’s thyroiditis has elicited interest since it was first reported. Dr.
Hashimoto himself speculated on possible explanations of what he saw under the microscope,
eventually concluding ‘‘at present we cannot say anything definite about the cause’’. Initial
theories postulated this disease was due to infection, understandably, since infections were
quite common and a large focus of clinical investigation, but no clear link with microorganisms
was ever found. Other theories considered the Hashimoto goiter a premalignant condition.
Some scholars believed the thyroid itself possessed a lymphogenic secretory capability that
became hyperactive in these patients. Others viewed the goiter as secondary to constant
anxiety and emotional unrest. In 1951, Hellwig proposed the colloidophagy theory, based on
rodent studies performed in the late 1920s and his own observations in humans that macro‐
phages exist in the thyroid gland and are capable of ingesting colloid. He postulated that
thyroid macrophages that have engulfed colloid degenerate and release colloid, which then
attracts lymphocytes into the thyroid. Finally, in the early 1950s, the field of autoimmunity
began to take shape; animal models were being developed in which injection of a tissue extract
was capable of reproducing a lymphocytic infiltration of that particular organ. This experi‐
mental approach was applied to the thyroid when, in 1956, lymphocytic infiltration of the
rabbit thyroid was induced by injection of rabbit thyroid extracts. The horror autotoxicus
dogma was dismantled and autoimmunity became recognized as an important mechanism of
disease. In the ensuing five decades, numerous studies have greatly expanded our under‐
standing of the pathogenesis of Hashimoto’s thyroiditis and helped translating research
findings into clinical practice. We have known since the mid-1980s that thyroperoxidase is a
dominant protein antigen targeted by the patient’s immune system in Hashimoto’s thyroiditis,
and, as a result, antibodies to thyroperoxidase are now considered the most sensitive and
specific biomarkers to establish this diagnosis. They also have a predictive value since their
presence precedes a clinical diagnosis of Hashimoto’s thyroiditis by at least 7 years. We have
also known since 1971 that Hashimoto’s thyroiditis, like other autoimmune diseases, has a
genetic basis. Substantial efforts have been devoted to identify the genes that predispose to
Hashimoto’s thyroiditis, but results have been less fruitful than expected. Genome-wide
association studies and candidate gene approaches have identified a handful of confirmed
susceptibility genes (MHC class II region, CTLA-4, PTPN22, and ARID5B), each making,
however, only a small contribution to the disease phenotype and through mechanisms that
remain to be discovered.
4. Susceptibility genes
4.1. Human leukocyte antigen (HLA) genes
The first gene locus identified in association with the autoimmune thyroid disease was major
histocompatibility complex (MHC) region on the chromosome 6p21 which encodes human
leukocyte antigens (HLAs). HLA region, which is highly polymorphic, comprises several
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immune response genes. HLA molecule, located on antigen presenting cell (APC), binds and
presents an antigenic peptide and in this way enables T cell recognition and response to an
antigen. Presumably, specific HLA alleles have a higher affinity for autoantigenic thyroidal
peptides and are thus likely to contribute to the development of the autoimmune thyroid
disease. Nevertheless, in order to initiate the thyroid autoimmunity autoantigen occurrence
within thyroid or thyroid draining lymph nodes is needed, being followed by HLA presenta‐
tion. In HT, aberrant expression of HLA class II molecules on thyrocytes has been demon‐
strated. Presumably, such thyrocytes may act as APCs capable of presenting the thyroid
autoantigens and initiating autoimmune thyroid disease. In Caucasians, associations of
different forms of HT with various HLA alleles were reported, including DR3, DR5, DQ7,
DQB1*03, DQw7 or DRB1*04-DQB1*0301 haplotype. In Japanese, associations with
DRB4*0101, HLA-A2 and DRw53 were demonstrated, while in Chinese patients association
with DRw9 was observed (Hawkins, Lam et al. 1987, Honda, Tamai et al. 1989, Badenhoop,
Schwarz et al. 1990, Tandon, Zhang et al. 1991, Bogner, Badenhoop et al. 1992, Wan, Kimura
et al. 1995, Hunt, Marshall et al. 2001, Petrone, Giorgi et al. 2001, Jacobson, Huber et al. 2008,
Zaletel and Gaberscek 2011).
4.2. Cytotoxic t lymphocyte antigen-4 (CTLA-4) gene
CTLA-4 gene, which is the second major immuneregulatory gene related to autoimmune
thyroid disease, lies on chromosome 2q33. The expression of CTLA-4 on the surface of T cells
induced by the activation of the T-cell receptor results in suppression of T-cell activation.
CTLA-4 gene polymorphisms may reduce expression or function of the CTLA-4 antigen and
may therefore contribute to the reduced inhibition of T-cell proliferation and subsequently
increase susceptibility to autoimmune response. In the past, several polymorphisms of the
CTLA-4 gene in HT patients were studied. Among them, the initially reported (AT)n micro‐
satellite CTLA-4 polymorphism in the 3’ untranslated region (UTR) was found to be associated
with HT in Caucasian and Japanese patients, but not in Italian population. In the exon 1 located
49A/G single nucleotide polymorphism (SNP), resulting in threonine to alanine substitution,
was associated with HT, however, certain other studies have not confirmed this observation.
A large meta-analysis, including both published and unpublished data of 866 HT patients,
indicated a significant association with 49A/G (summary OR 1.29; 95% CI, 1.11-1.50). Another
CTLA-4 polymorphism is 6230A/G SNP which is located at 3’-UTR and designated CT60.
Initial observation of the association with HT was not confirmed by later studies, however, the
results of the meta-analysis, based on six published and unpublished studies of 839 HT
patients, indicated a significant association with CT60 SNP (summary OR 1.64; 95% CI,
1.18-2.28). Nevertheless, the exact mechanism conferring the susceptibility to HT has not been
elucidated yet and further studies are needed to determine which CTLA-4 polymorphism is
causative.
4.3. Protein tyrosine phosphatase nonreceptor-type 22 (PTPN22) gene
PTPN22 is the most recently identified immuneregulatory gene associated with the autoim‐
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Thyroid Disorders - Focus on Hyperthyroidism6
immune response genes. HLA molecule, located on antigen presenting cell (APC), binds and
presents an antigenic peptide and in this way enables T cell recognition and response to an
antigen. Presumably, specific HLA alleles have a higher affinity for autoantigenic thyroidal
peptides and are thus likely to contribute to the development of the autoimmune thyroid
disease. Nevertheless, in order to initiate the thyroid autoimmunity autoantigen occurrence
within thyroid or thyroid draining lymph nodes is needed, being followed by HLA presenta‐
tion. In HT, aberrant expression of HLA class II molecules on thyrocytes has been demon‐
strated. Presumably, such thyrocytes may act as APCs capable of presenting the thyroid
autoantigens and initiating autoimmune thyroid disease. In Caucasians, associations of
different forms of HT with various HLA alleles were reported, including DR3, DR5, DQ7,
DQB1*03, DQw7 or DRB1*04-DQB1*0301 haplotype. In Japanese, associations with
DRB4*0101, HLA-A2 and DRw53 were demonstrated, while in Chinese patients association
with DRw9 was observed (Hawkins, Lam et al. 1987, Honda, Tamai et al. 1989, Badenhoop,
Schwarz et al. 1990, Tandon, Zhang et al. 1991, Bogner, Badenhoop et al. 1992, Wan, Kimura
et al. 1995, Hunt, Marshall et al. 2001, Petrone, Giorgi et al. 2001, Jacobson, Huber et al. 2008,
Zaletel and Gaberscek 2011).
4.2. Cytotoxic t lymphocyte antigen-4 (CTLA-4) gene
CTLA-4 gene, which is the second major immuneregulatory gene related to autoimmune
thyroid disease, lies on chromosome 2q33. The expression of CTLA-4 on the surface of T cells
induced by the activation of the T-cell receptor results in suppression of T-cell activation.
CTLA-4 gene polymorphisms may reduce expression or function of the CTLA-4 antigen and
may therefore contribute to the reduced inhibition of T-cell proliferation and subsequently
increase susceptibility to autoimmune response. In the past, several polymorphisms of the
CTLA-4 gene in HT patients were studied. Among them, the initially reported (AT)n micro‐
satellite CTLA-4 polymorphism in the 3’ untranslated region (UTR) was found to be associated
with HT in Caucasian and Japanese patients, but not in Italian population. In the exon 1 located
49A/G single nucleotide polymorphism (SNP), resulting in threonine to alanine substitution,
was associated with HT, however, certain other studies have not confirmed this observation.
A large meta-analysis, including both published and unpublished data of 866 HT patients,
indicated a significant association with 49A/G (summary OR 1.29; 95% CI, 1.11-1.50). Another
CTLA-4 polymorphism is 6230A/G SNP which is located at 3’-UTR and designated CT60.
Initial observation of the association with HT was not confirmed by later studies, however, the
results of the meta-analysis, based on six published and unpublished studies of 839 HT
patients, indicated a significant association with CT60 SNP (summary OR 1.64; 95% CI,
1.18-2.28). Nevertheless, the exact mechanism conferring the susceptibility to HT has not been
elucidated yet and further studies are needed to determine which CTLA-4 polymorphism is
causative.
4.3. Protein tyrosine phosphatase nonreceptor-type 22 (PTPN22) gene
PTPN22 is the most recently identified immuneregulatory gene associated with the autoim‐




nantly expressed in lymphocytes, acts as a negative regulator of T-cell activation, much like
CTLA-4. 1858C/T SNP of the PTPN22 gene, resulting in arginine to tryptophan substitution at
codon 620 (R620W), was demonstrated to be a risk factor for many autoimmune diseases. The
mechanism is not clear since the disease predisposing T allele has been demonstrated to enable
even more efficient inhibition of T-cell activation. Presumably, weaker T-cell signalling may
lead to impaired thymic deletion of autoreactive T cells or an increased PTPN22 function may
result in inhibition of regulatory T cells (Tregs), which protect against autoimmunity. An early
study in HT patients demonstrated a significant association with 1858C/T SNP (OR 1.77; 95%
CI, 1.56-3.97). Afterwards, this observation was neither confirmed in German, Tunisian and
Japanese populations nor in Slovenian patients. In a small group of patients with both HT and
autoimmune diabetes, T allele was determined in 50% compared with only 14% in healthy
controls (OR 6.14; CI, 2.62-14.38), however, in a yet another study estimating the same
polymorphism this association was not confirmed. Recently, 5 other PTPN22 SNPs have been
tested in Japanese patients, showing no relation with HT, but a novel protective haplotype
containing those SNPs has been observed (Ban, Tozaki et al. 2005, Kahles, Ramos-Lopez et al.
2005, Chabchoub, Teixiera et al. 2009, Dultz, Matheis et al. 2009, Ban, Tozaki et al. 2010,
Kordonouri, Hartmann et al. 2010, Zaletel and Gaberscek 2011).
4.4. Thyroglobulin gene
Tg is an important thyroid specific antigen, also present in the circulation, which makes it an
easy target of the autoimmune response. Gene for Tg is located on the chromosome 8q24 and
linkage of this region with HT and autoimmune thyroid disease was first identified by a
Japanese and an American whole genome studies. A subsequent fine mapping of this region
exposed Tg gene as one of the major thyroid specific susceptibility genes, linked and associated
with the autoimmune thyroid disease. Later, different alleles of various microsatellite markers
and different SNPs of Tg gene were related to HT, possibly affecting its expression, antigenic‐
ity, iodination, or binding to HLA. The association of Tgms2 microsatellite marker in intron
27 with HT was confirmed in Japanese as well as in Caucasian population. Sequencing of
human Tg revealed 14 SNPs among which four SNPs, including exon 10-12 SNP cluster and
exon 33 SNP, were associated with HT. However, this observation was neither confirmed in
a larger data set of the United Kingdom Caucasian patients nor in Chinese population.
4.5. Vitamin D receptor gene
Vitamin D, which acts via vitamin D receptor (VDR), possesses immunomodulatory properties
and its deficiency has been implicated in the development of autoimmune diseases. Many
immune cells express VDR, dendritic cells in particular, where VDR stimulation has been
shown to enhance their tolerogenicity. Tolerogenic dendritic cells promote development of
Tregs with suppressive activity and therefore peripheral tolerance. VDR gene is located on the
chromosome 12q12 and its polymorphisms have been related to different autoimmune
disorders such as type 1 diabetes or Addison’s disease. A decade ago, the association between
VDR-FokI SNP in exon 2 and HT has been identified which was later confirmed in the
observation of Taiwanese Chinese patients. In the Croatian population VDR gene 3’ region
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polymorphisms were related to HT, possibly affecting VDR mRNA expression. A significant
relation has also been discovered between HT and both promoter and intron 6 gene polymor‐
phisms of CYP27B1 hydroxylase, which is located on chromosome 12q13, catalysing the
conversion of 25 hydroxyvitamin D3 to its active form.
4.6. Cytokine genes and other immune-related genes
Lately, several genes encoding different inflammatory cytokines have been studied in HT,
some of them also influencing the severity of the disease. Interferon (IFN)-γ, produced by T-
helper type 1 (Th1) cells, promotes cell mediated cytotoxicity which underlies thyroid
destruction in HT. T allele of the+874A/T IFN-SNP, causing the increased production of IFN-
γ, was associated with severity of hypothyroidism in HT patients. Higher frequency of severe
hypothyroidism was also observed in patients carrying CC genotype of-590C/T interleukin 4
(IL-4) SNP, leading to a lower production of IL-4, one of the key Th2 cytokines which sup‐
presses cell-mediated autoimmunity. Gene polymorphism of transforming growth fac‐
tor(TGF)-β, inhibitor of cytokine production, was also associated with HT. T allele of+369T/C
SNP, leading to a lower secretion of TGF-β, was more frequent in severe hypothyroidism than
in mild hypothyroidism. Similarly, more severe form of HT was associated with-2383C/T SNP
of gene for forkhead box P3 (FoxP3), an essential regulatory factor for the Tregs development.
Unlike the severity of hypothyroidism, the development of HT itself was associated with C
allele of tumor necrosis factor (TNF)--1031T/C SNP. Namely, C-allele carriers present with
higher concentration of TNF-which acts as the stimulator of the IFN-production.
5. Risk factors
5.1. Role of female sex and reproduction
5.1.1. Female sex
As indicated by numerous epidemiological studies, females present with positive thyroid
autoantibodies (TAbs) up to three times more often than males. The largest NHANES III study
has shown that females were positive for TPOAbs and TgAbs in 17% and 15.2%, respectively,
while males only in 8.7% and 7.6%, respectively. According to the estimation provided by the
study of Danish twins, the genetic contribution to TPOAb and TgAb susceptibility in females
was 72% and 75%, respectively, while in males it was only 61% and 39%, respectively. The
possible explanation for high female predominance in thyroid autoimmunity might be
associated with the X chromosome containing a number of sex and immune-related genes
which are of key importance in the preservation of immune tolerance. Increased immunor‐
eactivity might therefore be related to genetic defects of the X chromosome, such as structural
abnormalities or monosomy. Accordingly, a higher incidence of thyroid autoimmunity was
reported in patients with a higher rate of X chromosome monosomy in peripheral white blood
cells or in patients with Turner’s syndrome. Another potential mechanism of impaired
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of X-linked self-antigens from presentation in thymus with subsequent loss of T-cell tolerance.
Skewed XCI was associated with a higher risk of developing autoimmune thyroid diseases.
Recently reported frequencies of skewed XCI in HT were 31%, 34.3%, 25.6% and 20%, respec‐
tively, which is significantly higher than in healthy controls, where the prevalences were only
8%, 8%, 8.6% and 11.2%, respectively. Furthermore, a study of Danish twins demonstrated a
significant association of skewed XCI with TPOAb serum concentrations in dizygotic but not
in monozygotic twin pairs, indicating that shared genetic determinants of XCI pattern and
TPOAb production are more likely than causal relationship.
5.1.2. Pregnancy and postpartum period
The tolerance of the fetal semi-allograft during pregnancy is enabled by the state of immuno‐
suppression which is a result of hormonal changes and trophoblast expression of key immu‐
nomodulatory molecules. The pivotal players in regulation of the immune response are Tregs,
which rapidly increase during pregnancy. Consequently, both cell-mediated and humoral
immune responses are attenuated with a shift towards humoral immune response, resulting
in immune tolerance of the conceptus tissues and suppression of autoimmunity. Accordingly,
the decrease of both TPOAb and TgAb concentrations during pregnancy has been reported,
reaching the lowest values in the third trimester. Postpartum rapid decrease of Tregs and re-
establishment of the immune response to the pre-pregnancy state may lead to the occurrence
or aggravation of the autoimmune thyroid disease. The increase of TPOAb concentrations
occurred as soon as 6 weeks after delivery, reaching the baseline level at approximately 12
weeks and the maximum level at about 20 weeks after delivery. In up to 50% of females with
positive TPOAbs in the early pregnancy, thyroid autoimmunity in the postpartum period
exacerbates in the form of postpartum thyroiditis. It may occur within the first year after
delivery, usually clinically presented with transient thyrotoxicosis and/or transient hypothyr‐
oidism, while in about a third of females permanent hypothyroidism may even develop.
5.1.3. Fetal microchimerism
The term fetal microchimerism is defined by the presence of fetal cells in maternal tissues which
are transferred in the maternal circulation during pregnancy. Several years after the delivery,
the chimeric male cells can be detected in the maternal peripheral blood as well as in maternal
tissues, such as thyroid, lung, skin, or lymph nodes. The fetal immune cells, settled in the
maternal thyroid gland, may become activated in the postpartum period when the immuno‐
tolerance ceases, representing a possible trigger that may initiate or exaggerate the autoim‐
mune thyroid disease. In HT, fetal microchimeric cells were detected in thyroid in 28% to 83%
which means that their occurrence is significantly higher than in the absence of autoimmune
thyroid disease. Furthermore, a recent study of twins supported the putative role of micro‐
chimerism in triggering thyroid autoimmunity, showing a significantly higher prevalence of
TAbs in opposite sex twins compared to monozygotic twins. Additionally, euthyroid females
having been pregnant presented significantly more often with positive TPOAb compared to
females with no history of being pregnant. However, the relation between parity and autoim‐
mune thyroid disease was not confirmed by large population-based studies, advocating
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Excessive iodine intake is well-established environmental factor for triggering thyroid
autoimmunity. Several large population-based studies demonstrated higher prevalence of
TAbs in the areas with higher iodine supply since the estimated prevalence was approximately
13% in iodine deficiency, 18% in circumstances of sufficient iodine intake and about 25% in
areas with excessive iodine intake. Moreover, up to four-fold increase in prevalence of TAbs
was demonstrated after the exposure to higher iodine intake due to the improvement of iodine
prophylaxis in previously iodine deficient areas. According to the intervention study, delib‐
erate exposure to 500 μg of iodine provoked thyroid autoimmunity in 20% of previously
healthy individuals. Valuable evidence was also provided by using experimental animal
models of autoimmune thyroiditis, where the prevalence and severity of thyroid autoimmun‐
ity significantly increased when the dietary iodine was added (Kahaly, Dienes et al. 1998, Rose,
Bonita et al. 2002, Fountoulakis, Philippou et al. 2007, Golkowski, Buziak-Bereza et al. 2007,
Heydarian, Ordookhani et al. 2007).
Several putative mechanisms by which iodine may promote thyroid autoimmunity have been
proposed. Firstly, iodine exposure leads to higher iodination of Tg and thus increases its
immunogenicity by creating novel iodinecontaining epitopes or exposing cryptic epitopes.
This may facilitate presentation by APC and enhance the binding affinity of the T-cell receptor
which may lead to specific T cell activation. Secondly, iodine exposure has been shown to
increase the level of reactive oxygen species in the thyrocyte which is generated during TPO
oxidation of excessive amounts of iodine. They enhance the expression of the intracellular
adhesion molecule-1 (ICAM-1) on the thyroid follicular cells which could attract the immu‐
nocompetent cells into the thyroid gland. Thirdly, iodine toxicity to thyrocytes has been
reported, since highly reactive oxygen species may bind to membrane lipids and proteins,
causing thyrocyte damage and release of autoantigens. Fourthly, iodine excess has been shown
to promote follicular cell apoptosis by inducing an abnormal expression of tumor necrosis
factor-related apoptosis inducing ligand (TRAIL) and its death receptor (DR)-5 in thyroid.
Fifthly, in vitro evidence also suggests an enhancing influence of iodine on the cells of the
immune system, including augmented maturation of dendritic cells, increased number of T
cells and stimulated B-cell immunoglobulin production.
6.2. Drugs
Furthermore, certain drugs were reported to trigger or exacerbate thyroid autoimmunity in
susceptible individuals (Barbesino 2010, Hamnvik, Larsen et al. 2011). Interferon-α (IFN-α) is
extensively used to treat chronic hepatitis and is frequently associated with thyroid autoim‐
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with IFN-α. Presumably, IFN-α has both thyroid toxic effects with consequent autoantigen
presentation and immune effects, such as switching to Th1 immune response, suppression of
Treg function, activation of immune cells, stimulation of cytokine release and expression of
MHC class I on thyroid cells. Similarly, IL-2 treatment, used for melanoma and renal carcino‐
ma, seems to act via immune and toxic mechanisms, leading to both TAb positivity and
hypothyroidism.
In patients with known autoimmune thyroid disease lithium may increase the risk of hypo‐
thyroidism. According to some studies, treatment with lithium has also been shown to increase
TAb titres and the prevalence of thyroid autoimmunity. Among putative mechanisms direct
toxicity of lithium on thyroid or toxicity of increased intrathyroidal iodine resulting from
lithium treatment were discussed. Similarly, amiodarone alone as well as its high iodine
content may act cytotoxically which may lead to thyroid autoantigen presentation and provoke
thyroid autoimmunity.
More recently, some small molecule tyrosine kinase inhibitors (TKIs) used for the treatment
of metastatic renal cell carcinoma (Muriel, Esteban et al. 2010, Kollmannsberger, Bjarnason et
al. 2011, Eisen, Sternberg et al. 2012, Mendez-Vidal, Martinez Ortega et al. 2012, Bianchi, Rossi
et al. 2013), gastrointestinal stromal tumours (Joensuu, Trent et al. 2011), thyroid carcinoma
and pancreatic neuroendocrine tumours have been shown to cause hypothyroidism related
symptoms to a variable extent, which can reduce a patient’s quality of life (Torino, Corsello et
al. 2009, Zygulska, Krzemieniecki et al. 2012). Sunitinib and sorafenib are multitargeted TKIs
that have been demonstrated to induce hypothyroidism and thyroid dysfunction. The reported
incidence of sunitinib-induced hypothyroidism is 53-85% and 36-46% in retrospective or
prospective studies, respectively, and 18% in patients treated with sorafenib (Torino, Corsello
et al. 2009). Mechanisms of hypothyroidism induced by TKIs include drug-induced atrophy
of the thyroid through inhibition of its vascularization, drug-induced thyroiditis, reduced
synthesis of thyroid hormones, progressive depletion of the thyroid’s functional reserve and
inhibition of the thyroidal iodine uptake (Torino, Corsello et al. 2009). Makita et al (Makita and
Iiri 2013) and Bianchi et al (Bianchi, Rossi et al. 2013) thought that sunitinib may exert these
effects via multiple receptor tyrosine kinases, including vascular endothelial growth factor
receptor (VEGFR) and the platelet-derived growth factor receptor (PDGFR). In patients treated
with sunitinib or sorafenib, routine thyroid function testing at baseline and measurement of
TSH on day 1 at the start of every new treatment cycle is recommended. Levothyroxine is the
standard treatment for overt hypothyroidism and is recommended in some patients with
subclinical hypothyroidism; overt or subclinical hypothyroidism per se does not justify the
withdrawal of TKI therapy. Thyroid function test should be included in routine toxicity
assessment of TKIs under clinical evaluation (Torino, Corsello et al. 2009, Hamnvik, Larsen et
al. 2011, Eisen, Sternberg et al. 2012); however, the clinical relevance of early diagnosis of
hypothyroidism in patients with TKIs is still controversial.
6.3. Infections
Not only the IFN-α treatment but also hepatitis C infection itself has been reportedly associated
with thyroid autoimmunity and hypothyroidism. Among possible mechanisms, the molecular
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mimicry between viral and selfantigens has been suggested, whereas the release of proin‐
flammatory mediators caused by viral infection may lead to activation of autoreactive T-cells.
Besides, in HT several other putative triggering viruses have been implicated such as parvo‐
virus, rubella, herpes simplex virus, Epstein Barr virus, and human T-lymphotropic virus type
1. A recent study of sera in pregnant women has also indicated an association between a prior
infection with Toxoplasma gondii and an increase of TPOAbs. Nevertheless, the evidences are
scarce and further studies are required in order to confirm the role of infections as causative
agents.
6.4. Chemicals
The exposure to environmental toxicants such as polyaromatic hydrocarbons or polyhalogen‐
ated biphenyls, both commonly used in a variety of industrial applications, has been shown
to provoke thyroid autoimmunity not only in experimental animals but also in humans.
Recently, a significantly higher prevalence of HT and TAb (9.3% and 17.6%, respectively) has
been demonstrated in residents living in the area of petrochemical complex of Sao Paolo
compared to the control area (3.9% and 10.3%, respectively). In Slovakia, the exposure to
polychlorinated biphenyls was associated with TAb and hypothyroidism. Although there is
strong evidence attesting the contribution of chemicals to thyroid autoimmunity, the exact
mechanisms of their action are yet to be established (Langer, Tajtakova et al. 2007, de Freitas,
Grimaldi Campos et al. 2010).
7. Hashimoto’s thyroiditis and papillary thyroid carcinoma
There has long been a controversy in the literature about a possible link between HT and PTC.
Conflicting reports continue to emerge. Some suggest a positive correlation between the two,
and even a cause-and-effect relationship, whereby the activated inflammatory response
present in HT creates a favorable setting for malignant transformation. The inflammatory
response may cause DNA damage through formation of reactive oxygen species, resulting in
mutations that eventually lead to the development of PTC. Nevertheless, it remains unclear
whether: (1) HT predisposes patients to develop PTC, (2) HT is an incidental finding with
concurrent PTC, or (3)HT is a part of the host tumor response system. A meta-analysis done
by Jankovic (McLeod, Watters et al. 2012, Jankovic, Le et al. 2013) revealed significant differ‐
ences in the prevalence and the risk ratio of PTC in HT specimens obtained via FNAB vs
thyroidectomy.
In population based studies where the specimens were obtained from FNAB, the average
prevalence of PTC in patients with HT was 1.20%, with an average risk ratio of 0.69. Con‐
versely, in studies from archival thyroidectomy specimens, the average prevalence and risk
ratio were as high as 27.56% and 1.59, respectively. This variability could be a result of different
methods of obtaining specimens and heterogeneity in the population under investigation in
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The prevalence and the risk ratio of PTC in patients with HT compared to those without HT
are significantly higher in studies of thyroidectomy specimens, compared to studies of patients
undergoing FNAB. In studies that mentioned the indications, thyroidectomy was reserved for
patients not responding to thyroid suppression therapy, those with symptoms of compression,
worrisome or inconclusive FNA cytology, and historic or physical findings warranting further
workup and treatment (e.g., irradiation, nerve paralysis, pain, or cervical lymph node
enlargement). It should be noted that the vast majority of patients with HT do not require
surgery. Hence, the patients who require thyroidectomy are already at higher risk for malig‐
nancy compared to the general population with HT.
There have been a number of proposed hypotheses to explain the linkage between the two
diseases. From a histological perspective, Tamimi (Tamimi 2002) assessed the prevalence and
severity of thyroiditis among three types of surgically resected thyroid tumors and found a
significantly higher rate of lymphocytic infiltrate in patients with PTC. However, PTC with
concurrent HT is associated with female gender, young age, less aggressive disease such as
small tumor size, less frequent capsular invasion and nodal metastasis, and better prognosis.
Furthermore, these patients are also less likely to develop recurrence and have a higher
survival rate In the study by Eisenberg et al(Eisenberg and Hensley 1989), none of the patients
with a thyroid carcinoma and HT developed relapse or metastases after 74 months of follow-
up. Kebebew (Kebebew, Treseler et al. 2001) demonstrated that CLT correlates with improved
survival in patients with PTC but is not an independent prognostic factor. Boi et al investigated
the relationship between thyroid autoimmunity and thyroid cancer in a series of FNAB of
unselected and consecutive thyroid nodules. This study revealed that the positive predictive
values for thyroid carcinoma in antithyroid antibody-positive and –negative nodules are not
statistically significant for class III (indeterminate risk) and class IV (suspected malignancy)
cytology. It should be noted that it is important to distinguish between diffuse vs focal
lymphocytic infiltration around the tumor. In the studies that described the histological
findings, HT was defined as diffuse lymphocytic infiltration, rather than peritumoral lym‐
phocytic infiltration alone. The significance of this is that HT does not represent a reaction to
tumor alone but is an independent chronic process. In chronic inflammation, there are reactive
alterations of stroma brought on by injury from chemokines, cytokines, and growth factors
that cause damage to stromal cells. This in turn may cause malignant transformation in
epithelial cells, thereby resulting in tumor development. In contrast, the lymphocytic infiltrate
of HT may be an immunological response with a cancer-retarding effect, contributing to a
favorable outcome of PTC compared to other thyroid cancers. Moreover, the relatively high
prevalence of PTC in autopsy series may represent host immune control. Interestingly,
lymphocytic infiltration within or surrounding the tumor was found to correlate with the
existence of CLT. This may explain the “protective” effect of CLT in PTC.
Another hypothesis for the causal relationship between HT and PTC is that elevated levels of
TSH found in hypothyroid patients with HT stimulate follicular epithelial proliferation,
thereby promoting the development of papillary carcinoma (Jankovic, Le et al. 2013). McLeod
et al (McLeod, Watters et al. 2012) conducted a systemic review that included 5786 thyroid
cancer cases in 43 032 subjects and found that serum TSH confers a greater likelihood of
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development of thyroid cancer (odds ratio 1.87–2.83, depending on the level of TSH). A subset
of studies that was adjusted for autoimmune thyroiditis did not find this relationship between
TSH and heightened odds ratio for thyroid cancer. Conversely, several authors identified a
few biomolecular markers, including RET/PTC rearrangements, p63 protein, and loss of
heterozygosity of hOGG1, that are potentially involved in neoplastic transformation from HT
to PTC. So far, no causal genetic linkage has been confirmed.
In conclusion, the existing data provide inconsistent evidence favoring a causal relationship
between HT and PTC. Population-based studies using FNAC show no significant increase of
PTC in patients with HT, whereas surgical series using thyroidectomy show a heightened risk
for coexistent PTC, possibly related to selection bias. Prospective studies involving a large
number of subjects and long-term follow-up are needed to further elucidate the relationship.
Several studies also suggest that HT appears to confer a better prognosis in patients with PTC,
but more research is necessary to further investigate this. At the present time, there is no valid
established criterion to identify those patients with HT at a higher risk of developing PTC.
Careful observation and follow-up of HT patients is recommended, especially those with
nodular variants.
8. Laboratory tests
Elevated anti-TPO or anti-Tg antibody titers are the most specific laboratory findings to
establish the diagnosis of autoimmune thyroid disease (AITD) or HT, typically making biopsy
unnecessary. The 24-hours thyroid radioactive iodine-123 or-131 (123I or 131I) uptake (RIU) is
also helpful to distinguish Hashitoxicosis from Graves’ disease (GD); the RIU is low in patients
with Hashitoxicosis, whereas it is elevated in those with GD. 123I is preferred than 131I because
it has a shorter half-life (13 hours for 123I, 8 days for 131I) allowing quicker dissipation of
background radiation. Since radioactive iodine is secreted in breast milk, and 123I has a short
half-life, it is recommended for diagnostic thyroid studies in nursing mothers. Breast milk must
be pumped and discarded for 2 days after the intake of 123I either used for thyroid uptake or
for thyroid scanning.
Scintigraphy reveals in-homogeneous activity throughout the gland in 50% and a pattern
suggestive of either hot or cold nodules or a combination of both in 30% of patients. Twenty
percent of patient with HT have normal findings at the scintigraphic thyroid imaging.
9. Clinical pictures
Clinical manifestations of HT are variable and commonly include diffuse or nodular goiter
with euthyroidism, subclinical hypothyroidism which shows a combination of elevated serum
TSH concentrations and normal free T4 and T3 concentrations and permanent hypothyroid‐
ism. Not often, HT causes acute destruction of thyroid tissue and release in blood of stored
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toxicosis” or “painless sporadic thyroiditis”, or “painless postpartum thyroiditis” when occurs
in women after delivery. In Hashitoxicosis serum TSH is suppressed, and total and free T3 and
T4 are elevated. Also, serum T4 is proportionally higher than T3, reflecting the ratio of stored
hormones in the thyroid gland, whereas in GD and in toxic nodular goiter, T3 is preferentially
elevated. Rarely, a hypofunctioning gland in HT may become hyperfunctioning with the onset
of coexistent GD. In patients with GD, HT is usually present concurrently.
10. Treatment
If overt hypothyroidism is present, the treatment of choice for HT is the administration of L-
thyroxine (L-T4) in the usual replacement doses. We also use L-T4 to treat patients with HT
subclinical hypothyroidism and high serum thyroid antibody concentrations, because in these
cases a progression to overt hypothyroidism is common and hyperlipidemia and atheroscler‐
otic heart disease may develop. L-T4 may mildly and indirectly suppress serum concentrations
of autoantibodies due to decreased stimulation of thyroid tissue by TSH and causing reduction
of antigenic production. The goal of treatment is to restore clinically and biochemically an
euthyroid state. For that, free T4 levels must be within the reference range and TSH at the lower
half of the reference range. The usual dose of L-T4 is 1.6-1.8 μg/kg per day and is patient
dependent. Elderly patients usually require a smaller dose of L-T4, sometimes less than
1μg/kg per day. The initial dose and the optimal time needed to establish the full replacement
dose as above should be individualised relative to age, weight and cardiac status.
In HT patients with a large goiter and normal or elevated serum TSH, we think, L-T4 may be
given in doses sufficient to suppress serum TSH in an effort to shrink the thyroid theoretically,
although randomized studies are needed to verify the long term safety of this method
concerning the potential cardiovascular and skeletal side effects. Suppressive doses of L-T4
tend to shrink the goiter by average of 30% over 6 months. If the goiter does not regress, the
L-T4 doses are lowered. Goiters that are hard and fibrotic do not respond to L-T4 treatment.
If the thyroid gland is only minimally enlarged, the patient is euthyroid and TSH levels are
normal, the patient should remain under medical supervision, since hypothyroidism may
often develop years later. Also, patients should be informed about the importance of compli‐
ance with replacement treatment and instructed to report any symptoms suggesting hyper‐
thyroidism that could be due to an overdosage of L-T4. The intake of L-T4 should be apart by
at least 4 hours from other drugs like calcium carbonate, ferrous sulfate, cholestyramine,
sucralfate, iron-containing multivitamins, antacids containing aluminum hydroxide, pheny‐
toin sodium, carbamazepine and amiodarone HCL, all of which impair the absorption/
metabolism of L-T4.
Selenium (Se) supplementation in patients with AITD, including HT, seems to modify the
inflammatory and immune responses, probably by enhancing plasma glutathione peroxidase
(GPX) and thioredoxin reductase (TR) activity and by decreasing toxic concentrations of
hydrogen peroxide (H2O2) and lipid hydroperoxides, resulting from thyroid hormone
synthesis. When Se intake is adequate the intracellular GPX and TR systems protect the
Thyroid Disorders - Focus on Hyperthyroidism16
thyrocyte from these peroxides, considering that oxidative stress induces TR1 and GPX. The
current recommended dietary intake of selenium in humans to achieve the maximal activity
of GPX in plasma or in erythrocytes is between 55 and 75μg per day. It must be considered
that organic forms of Se such as Se-methionine and yeast-bound Se, have a much lower toxicity
and a much higher effectiveness and safety than inorganic Se like sodium selenate. Several
studies have revealed a significant reduction of anti-TPO concentrations in patients with AITD
treated with 200 μg Se per day for three, six, or nine months (Gartner, Gasnier et al. 2002,
Duntas, Mantzou et al. 2003, Gartner and Gasnier 2003, Turker, Kumanlioglu et al. 2006,
Mazokopakis and Chatzipavlidou 2007). Duntas et al. found an overall decrease of 46% of
AITD at 3 months (P<0.0001) and of 55.5% at 6 months (P<0.05) of treatment with L-seleno‐
methionine plus L-T4. Others found a decrease of 26.2% at 3 months (P<0.001) and an addi‐
tional 23.7% at 6 months (P<0.01) after L-Se-methionine treatment. A significant decrease in
the mean serum anti-TPO levels was also noted after the daily intake of 200 μg sodium selenite
for 3 months. This decrease amounted to 36.4% in the selenium-taking group of patients versus
12% in the control group (P=0.013) (Gartner, Gasnier et al. 2002). A recent study in 80 Greek
women with HT showed a significant reduction of serum anti-TPO levels during the first 6
months of L-Se-methionine treatment (P<0.0001). Anti-TPO decreased by 5.6% and by 9.9%
after 3 and 6 months of L-Se-methionine treatment, respectively. The extension of L-Se-
methionine supplementation for 6 more months resulted in an additional 8% decrease, while
cessation of treatment resulted to a 4.8% increase, in the anti-TPO concentrations.
A systematic review and meta-analysis done by Toulis (Toulis, Anastasilakis et al. 2010)
provided evidence that selenomethionine at a dose of 200 mg once per day is effective in
reducing TPOAb titers in patients with HT after a 3-month period, compared with placebo. In
absolute numbers, this reduction equals ~300 IU/mL. Efficacy of Se supplementation for >3
months could not be supported, because of lack of evidence from randomized, placebo
controlled trials. Patients assigned to Se supplementation had also a threefold higher chance
of reporting an improvement in well-being and/or mood, compared with controls. No serious
adverse effects were recorded after Se supplementation, with the exception of a limited number
of gastric discomfort complaints associated with selenomethionine use. In general, there are
no data demonstrating that Se treatment had any impact on the natural course of the disease.
Further controlled and extensive studies are needed to clarify the exact mechanisms by which
Se exerts effects on anti-TPO production, and investigate the long-term clinical effects of Se
treatment.
In a study involving 21 patients with HT and subclinical hypothyroidism, simvastatin in a
daily dose of 20 mg orally for a period of eight weeks improved thyroid function inducing an
increase in serum free T3 and free T4 levels and a decrease in TSH levels. Decreases in anti-
TPO and anti-Tg antibodies were not statistically significant, possibly by stimulating apoptosis
of certain types of lymphocytes. Further controlled and extensive studies are needed to
investigate the effectiveness of statins treatment on the course of HT.
Patients with Hashitoxicosis may have only mild thyrotoxicosis and may not require treat‐
ment. Antithyroid drug treatment with thiourea drugs is contraindicated, because there is no
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months of L-Se-methionine treatment (P<0.0001). Anti-TPO decreased by 5.6% and by 9.9%
after 3 and 6 months of L-Se-methionine treatment, respectively. The extension of L-Se-
methionine supplementation for 6 more months resulted in an additional 8% decrease, while
cessation of treatment resulted to a 4.8% increase, in the anti-TPO concentrations.
A systematic review and meta-analysis done by Toulis (Toulis, Anastasilakis et al. 2010)
provided evidence that selenomethionine at a dose of 200 mg once per day is effective in
reducing TPOAb titers in patients with HT after a 3-month period, compared with placebo. In
absolute numbers, this reduction equals ~300 IU/mL. Efficacy of Se supplementation for >3
months could not be supported, because of lack of evidence from randomized, placebo
controlled trials. Patients assigned to Se supplementation had also a threefold higher chance
of reporting an improvement in well-being and/or mood, compared with controls. No serious
adverse effects were recorded after Se supplementation, with the exception of a limited number
of gastric discomfort complaints associated with selenomethionine use. In general, there are
no data demonstrating that Se treatment had any impact on the natural course of the disease.
Further controlled and extensive studies are needed to clarify the exact mechanisms by which
Se exerts effects on anti-TPO production, and investigate the long-term clinical effects of Se
treatment.
In a study involving 21 patients with HT and subclinical hypothyroidism, simvastatin in a
daily dose of 20 mg orally for a period of eight weeks improved thyroid function inducing an
increase in serum free T3 and free T4 levels and a decrease in TSH levels. Decreases in anti-
TPO and anti-Tg antibodies were not statistically significant, possibly by stimulating apoptosis
of certain types of lymphocytes. Further controlled and extensive studies are needed to
investigate the effectiveness of statins treatment on the course of HT.
Patients with Hashitoxicosis may have only mild thyrotoxicosis and may not require treat‐
ment. Antithyroid drug treatment with thiourea drugs is contraindicated, because there is no




hours thyroid RIU test and a radioiodine scan to determine whether GD may be present and
may be treated with beta-blockers. In symptomatically thyrotoxic patients with low thyroid
123I uptake test, propranolol treatment is continued and sodium ipodate or iopanoic acid may
also be given in doses of 500 mg daily orally, until the patient is euthyroid. Sodium ipodate
and iopanoic acid are known iodinated contrast oral cholecystographic agents that inhibit
peripheral 5’-monodeiodination of thyroxine, thereby blocking its conversion to active T3.
Patients having low thyroid RIU do not respond to thiourea medication.
Patients with HT and a large goiter with pressure symptoms such as dysphagia, voice
hoarseness, stridor and respiratory distress, may require surgical care. Also, in HT the presence
of a malignant nodule or of a thyroid lymphoma diagnosed by histology after a fine-needle
aspiration is an absolute indication for thyroidectomy.
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1. Introduction
1.1. Definition and gross pathology
Multinodular goiter (MNG) is a clinicopathological entity characterized by an increased
volume of the thyroid gland with formation of nodules. Goiter is defined as a thyroid gland
weighing over 20-25g or with a volume of over 19ml in women and 25ml in men. [1-2] Gross
examination of a MNG specimen with full-blown features would reveal a heterogeneous
formation of solid and cystic nodules. A solid nodule can be adenoma, as defined by possession
of a well-formed capsule, or more commonly a hyperplastic nodule, which lacks a complete
encapsulation. Cystic lesions can be colloid cysts or hemorrhagic cyst from a degenerated
nodule. Lymphocytic infiltration and fibrous deposition among the follicular parenchyma is
a common microscopic observation seen in about 10% of cases. [3, 4]
2. Epidemiology
MNG is endemic in regions with low iodine level in the soil, such as countries in the moun‐
tainous areas in South-East Asia, Latin America and Central Africa. The World Health
Organization reported a worldwide iodine deficiency rate of 9. 8 – 56. 9% and total goiter
prevalence of 4. 7 – 37. 3% by year 2003. [5] The Whickham study conducted in the 1970s found
15. 5% of participants had a palpable goiter with a female to male ratio of 4. 5 to 1. [6] In the
iodine-deficient Danish population, the goiter prevalence is 9. 8 – 14. 6%. [7] And in the iodine
sufficient areas of Framingham, Massachusetts and Connecticut, the goiter prevalence is 1 –
2%. [8-10] By ultrasound screening, the prevalence of nodular goiter worldwide ranges
between 15 – 22. 6%. [11] Thyroid nodules are more commonly diagnosed in women, with
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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1.1. Definition and gross pathology
Multinodular goiter (MNG) is a clinicopathological entity characterized by an increased
volume of the thyroid gland with formation of nodules. Goiter is defined as a thyroid gland
weighing over 20-25g or with a volume of over 19ml in women and 25ml in men. [1-2] Gross
examination of a MNG specimen with full-blown features would reveal a heterogeneous
formation of solid and cystic nodules. A solid nodule can be adenoma, as defined by possession
of a well-formed capsule, or more commonly a hyperplastic nodule, which lacks a complete
encapsulation. Cystic lesions can be colloid cysts or hemorrhagic cyst from a degenerated
nodule. Lymphocytic infiltration and fibrous deposition among the follicular parenchyma is
a common microscopic observation seen in about 10% of cases. [3, 4]
2. Epidemiology
MNG is endemic in regions with low iodine level in the soil, such as countries in the moun‐
tainous areas in South-East Asia, Latin America and Central Africa. The World Health
Organization reported a worldwide iodine deficiency rate of 9. 8 – 56. 9% and total goiter
prevalence of 4. 7 – 37. 3% by year 2003. [5] The Whickham study conducted in the 1970s found
15. 5% of participants had a palpable goiter with a female to male ratio of 4. 5 to 1. [6] In the
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2%. [8-10] By ultrasound screening, the prevalence of nodular goiter worldwide ranges
between 15 – 22. 6%. [11] Thyroid nodules are more commonly diagnosed in women, with
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incidence increasing with age and plateauing by the age of 60. Other risk factors for developing
thyroid nodules and increased thyroid volume include number of childbirths, smoking and
increased body mass index. [12-13]
3. Pathogenesis
The pathogenesis of MNG encompasses processes of diffuse follicular hyperplasia, focal
nodular proliferation and eventual acquisition of functional automaticity. The development
of MNG is a result of long-term exposure of the thyroid gland to proliferative stimuli, such as
iodine deficiency, goitrogens and inborn error of thyroid hormone synthesis. All of the above
results in insufficient thyroid hormone production and stimulate pituitary secretion of thyroid
stimulating hormone (TSH).
TSH is a glycoprotein with stimulatory effect on the trophic and iodine metabolism pathway
in the thyroid follicular cells. TSH binding to the cell membrane G protein-coupled receptor
activates the cAMP and phospholipase C signalling pathways, which in turn upregulates the
process of iodine uptake and organification, thyroglobulin synthesis, iodotyrosine coupling
and iodothyronine (T3, T4) secretion, leading to a short-term response in thyroid hormone
production. [14] In the long-term, TSH also stimulates proliferation of follicular cells to increase
the functional mass of thyroid gland. Clinically, TSH stimulation results in enlargement of
thyroid gland, increased radio-iodine uptake and increased T4 and T3 levels. (Figure 1)
Nodule formation is postulated to be the result of both an inherent and acquired heterogeneity
in proliferative and functional upregulation of the follicular cells. The thyroid follicular cells
are inherently heterogeneous with regard to thyroid hormone production and proliferation in
response to TSH stimulation, such that under intermediate level of stimulation, a subpopula‐
tion of follicular cells outgrows other cells and expand into macroscopic nodules. [15] On the
other hand, follicular cells acquiring activating somatic mutations in the cell proliferation
pathways can expand clonally to form a nodule. About 60 – 70% of nodules form by the later
mechanism and are monoclonal in origin. Somatic mutations leading to constitutive activation
of TSH receptors are found in about 60% of autonomously functioning nodules. The remaining
40% of functioning nodules are TSH receptor mutation negative with poorly understood
genetic mechanism behind.
An adenoma with reduced iodine uptake is scintigraphically detected as a “cold nodule”. A
defective iodine transport (membrane expression of sodium / iodine symporter protein) and
iodine organification is implicated in the hypofunctionality. However, the molecular event
accounting for the proliferative advantage is yet to be identified. [16] Unlike thyroid carcino‐
mas, which also manifest as cold nodules in scintigraphy, BRAF and ras mutation are uncom‐
mon in benign cold adenoma. [17, 18] Recently, oestrogen was shown to stimulate growth of
thyroid progenitor cells while simultaneously inhibiting the expression of sodium / iodine
symporter mRNA, providing a possible explanation of growth / function dissociation in cold
thyroid adenomas. [19]
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Although the majority of thyroid nodules are benign, about 5-10% of nodules may harbour a
cancerous focus. In addition, it is known that about 6% of goiter patients eventually develop
thyroid cancer, especially from MNG to thyroid cancer, suggesting a possible progression from
benign thyroid lesions to malignant disease. [20] More recently, one group has identified a
germline missense mutation (1016C>T) in TITF-1/NKX2. 1 encoding a mutant TTF-1 protein
(A339V), which may contribute to predisposition for MNG patients to papillary thyroid
carcinoma (PTC), further highlighting a causal link between these two diseases. [21] Ectopic
expression of the A339V mutant protein in a normal rat thyroid PCCL3 cell line results in a
significant up-regulation of cellular proliferation of these thyroid cells and promotes their
TSH-independent growth, which was in part attributed to activated Stat3 survival signal in
these cells.
4. Natural history
The natural history of MNG is nodular growth and acquisition of autonomy. Yet not all patients
with nodular goiter will progress to develop compressive or thyrotoxic complications that
indicates treatment intervention. The reported incidence rate of nodule growth is 39% of
patients over a period of 5 years in the North America, 2 – 56% of patients over 2 – 5 years in
European countries and 21% over 11 years in Japan. Nodule with cystic component is less
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incidence increasing with age and plateauing by the age of 60. Other risk factors for developing
thyroid nodules and increased thyroid volume include number of childbirths, smoking and
increased body mass index. [12-13]
3. Pathogenesis
The pathogenesis of MNG encompasses processes of diffuse follicular hyperplasia, focal
nodular proliferation and eventual acquisition of functional automaticity. The development
of MNG is a result of long-term exposure of the thyroid gland to proliferative stimuli, such as
iodine deficiency, goitrogens and inborn error of thyroid hormone synthesis. All of the above
results in insufficient thyroid hormone production and stimulate pituitary secretion of thyroid
stimulating hormone (TSH).
TSH is a glycoprotein with stimulatory effect on the trophic and iodine metabolism pathway
in the thyroid follicular cells. TSH binding to the cell membrane G protein-coupled receptor
activates the cAMP and phospholipase C signalling pathways, which in turn upregulates the
process of iodine uptake and organification, thyroglobulin synthesis, iodotyrosine coupling
and iodothyronine (T3, T4) secretion, leading to a short-term response in thyroid hormone
production. [14] In the long-term, TSH also stimulates proliferation of follicular cells to increase
the functional mass of thyroid gland. Clinically, TSH stimulation results in enlargement of
thyroid gland, increased radio-iodine uptake and increased T4 and T3 levels. (Figure 1)
Nodule formation is postulated to be the result of both an inherent and acquired heterogeneity
in proliferative and functional upregulation of the follicular cells. The thyroid follicular cells
are inherently heterogeneous with regard to thyroid hormone production and proliferation in
response to TSH stimulation, such that under intermediate level of stimulation, a subpopula‐
tion of follicular cells outgrows other cells and expand into macroscopic nodules. [15] On the
other hand, follicular cells acquiring activating somatic mutations in the cell proliferation
pathways can expand clonally to form a nodule. About 60 – 70% of nodules form by the later
mechanism and are monoclonal in origin. Somatic mutations leading to constitutive activation
of TSH receptors are found in about 60% of autonomously functioning nodules. The remaining
40% of functioning nodules are TSH receptor mutation negative with poorly understood
genetic mechanism behind.
An adenoma with reduced iodine uptake is scintigraphically detected as a “cold nodule”. A
defective iodine transport (membrane expression of sodium / iodine symporter protein) and
iodine organification is implicated in the hypofunctionality. However, the molecular event
accounting for the proliferative advantage is yet to be identified. [16] Unlike thyroid carcino‐
mas, which also manifest as cold nodules in scintigraphy, BRAF and ras mutation are uncom‐
mon in benign cold adenoma. [17, 18] Recently, oestrogen was shown to stimulate growth of
thyroid progenitor cells while simultaneously inhibiting the expression of sodium / iodine
symporter mRNA, providing a possible explanation of growth / function dissociation in cold
thyroid adenomas. [19]
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Although the majority of thyroid nodules are benign, about 5-10% of nodules may harbour a
cancerous focus. In addition, it is known that about 6% of goiter patients eventually develop
thyroid cancer, especially from MNG to thyroid cancer, suggesting a possible progression from
benign thyroid lesions to malignant disease. [20] More recently, one group has identified a
germline missense mutation (1016C>T) in TITF-1/NKX2. 1 encoding a mutant TTF-1 protein
(A339V), which may contribute to predisposition for MNG patients to papillary thyroid
carcinoma (PTC), further highlighting a causal link between these two diseases. [21] Ectopic
expression of the A339V mutant protein in a normal rat thyroid PCCL3 cell line results in a
significant up-regulation of cellular proliferation of these thyroid cells and promotes their
TSH-independent growth, which was in part attributed to activated Stat3 survival signal in
these cells.
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The natural history of MNG is nodular growth and acquisition of autonomy. Yet not all patients
with nodular goiter will progress to develop compressive or thyrotoxic complications that
indicates treatment intervention. The reported incidence rate of nodule growth is 39% of
patients over a period of 5 years in the North America, 2 – 56% of patients over 2 – 5 years in
European countries and 21% over 11 years in Japan. Nodule with cystic component is less
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tation did not predict subsequent growth of nodules. Based on cross-sectional studies, the age-
related increase in thyroid volume in patients with MNG is 4. 5% per year. [16, 22]
Functional autonomy develops in long-standing MNGs. Thyroid autonomy in euthyroid
nodular goiters, as determined by presence of TSH suppression by thyrotropin releasing
hormone (TRH) stimulation tests and failure of T3 suppression of radio-iodine uptake, was
shown to precede development of biochemical and overt hyperthyroidism. Up to 40% of
euthyroid goiters harbour areas of autonomy.
Transition to overt hyperthyroidism in euthyroid MNGs occurs at an incidence rate of 9 – 10%
over a period of 7 – 12 years. Development of hyperthyroidism is more likely in patients with
autonomously functioning nodules of larger than 3cm and an autonomous goiter volume of
16ml. Hyperthyroidism can be induced by exposing an autonomous gland to excessive iodine,
such as the iodine-containing amiodarone. [23–25]
5. Clinical evaluation & investigation
Clinical evaluation of MNG aims at establishing diagnosis and clinical stage of disease,
stratifying risk of occurrence of malignancy, identifying indications for thyroid ablation and
addressing patient’s concern.
Diagnosis of MNG is usually straight forward with the readily evaluable location of the thyroid
gland. Clinically inconspicuous MNG are usually documented by imaging studies covering
the neck and thoracic inlet performed for unrelated indications. MNGs with predominant
retrosternal component are difficult to diagnose with patients undergoing prolonged investi‐
gations for symptoms of exertional or recumbent dyspnoea that mimic asthma, congestive
heart failure or obstructive sleep apnoea. The tell-tail clue leading to thoracic inlet imaging
and diagnosis of retrosternal goiter is frequently a flow-volume loop spirometry suggesting
extra-thoracic airway obstruction or chest X-ray showing a mediastinal shadow causing
tracheal deviation. Symptoms arising from airway irritation, compression and dragging by
the goiter should be noted and addressed in patient counselling for treatment indications.
Physical findings of nodule consistency and mobility, cervical lymphadenopathy, tracheal
deviation, retromanubrial extension, thoracic outlet obstruction and thyrotoxicosis are
determined. When thyrotoxicosis is suspected, the differential diagnosis of Grave’s disease
with nodules should be considered and the signs specific to Grave’s disease, including
ophthalmopathy and pre-tibial myxoedema be documented.
Serum thyroid stimulating hormone and free serum thyroxine levels are measured to deter‐
mine the functioning status of the nodular goiter. A suppressed TSH level is commonly found
in long-standing MNGs in which functional autonomy has developed. Hypothyroidism, on
the other hand, may suggest Hashimoto thyroiditis and measurement of anti-thyroperoxidase
antibody titre helps to confirm the diagnosis.
Thyroid scintigraphy using iodine-123 or technetium-99m is recommended for patients with
suppressed serum TSH level to determine the relative iodine uptake of a nodule in contrast to
its adjacent thyroid tissue. A hyperfunctioning nodule that can account for the thyrotoxicosis
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carries low risk of malignancy and further investigation is not required. An index nodule that
is iso-or hypofunctional against the rest of thyroid gland has a reported malignancy risk of 3%
to 15% and should be investigated with fine needle aspiration cytology (FNAC). [26-29]
Evaluating for risk of malignancy in MNG follows the same approach as in solitary thyroid
nodules. Demographical risk factors include age of < 20 or > 60 years, male gender, history of
head and neck irradiation, history of multiple endocrine neoplasia or family history of thyroid
cancer. Suspicious symptoms include progressive enlargement, recent onset of voice change,
airway irritation and compression. Objective physical findings of hard and fixed nodule, size
> 4cm, cervical lymphadenopathy and vocal cord paralysis all points to features of local-
regional invasion and prompts investigation for definitive diagnosis. If the rarer entity of
medullary carcinoma is suspected from a positive family history or features of multiple
endocrine neoplasia (type 2), spot serum calcitonin level should be measured as a screening
test. A 33% risk of malignancy is reported in avid nodules detected by fluorodeoxyglucose
positron emission tomography (18FDG-PET), so such nodules should also undergo cytological
evaluation. [30]
Use of ultrasound as routine clinical examination has compensated for the lack of sensitivity
and precision of neck palpation alone in determining the number and size of nodules. Fifty
percent of patients with single palpable thyroid nodule will demonstrate additional nodules
when ultrasound exam is performed. More importantly, nodules with high risk features of
malignancy, including irregular margin, lack of circumferential halo, heterogenous echoge‐
necity, increased vascularity and presence of microcalcification, can be selected for cytological
sampling.
FNAC is an accurate, safe, simple, and cost-effective investigation in the evaluation of nodular
goiter. Diagnostic performance of FNAC is enhanced by ultrasound guidance in the identifi‐
cation of nodules with high risk features for aspiration. In complex cystic lesions, ultrasound
guidance also allows positioning of needle to the solid component while avoiding acellular
cystic area. Availability of pre-operative diagnostic information has increased diagnostic yield
of thyroidectomies while reducing the number of surgeries performed for suspected malig‐
nancy by 35 – 75%. [31–33]
A review of diagnostic performance of FNAC reported a sensitivity of 65 – 98% and specificity
of 72 – 100% for the detection of thyroid carcinoma. In general, the relative frequencies of FNAC
findings in thyroid nodules are benign in 69%, suspicious 10%, malignant 4% and non-
diagnostic in 17%. [34] In the “non-diagnostic” category, repeating FNA under ultrasound
guidance will produce satisfactory specimen in 50% of the cases. The risk of malignancy in
nodules with non-diagnostic cytology is 2 – 9%, and such lesions should be closely monitored
or excised for histological evaluation. The category of “suspicious” cytology includes findings
of follicular and Hurthle cell neoplasm. Differentiation between adenoma and carcinoma
cannot be made because histological evidence of capsular or vascular invasion cannot be
obtained from cytological examination. In patients referred for surgery for suspicious cytology,
20 – 30% are proven to have carcinoma on final pathology. [35-36] Molecular markers upre‐
gulated in thyroid carcinomas are being evaluated for their diagnostic value. Detection of
protein markers (Galectin-3, HBME-1, cytokeratin-19, telomerase) by immunocytochemistry,
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tation did not predict subsequent growth of nodules. Based on cross-sectional studies, the age-
related increase in thyroid volume in patients with MNG is 4. 5% per year. [16, 22]
Functional autonomy develops in long-standing MNGs. Thyroid autonomy in euthyroid
nodular goiters, as determined by presence of TSH suppression by thyrotropin releasing
hormone (TRH) stimulation tests and failure of T3 suppression of radio-iodine uptake, was
shown to precede development of biochemical and overt hyperthyroidism. Up to 40% of
euthyroid goiters harbour areas of autonomy.
Transition to overt hyperthyroidism in euthyroid MNGs occurs at an incidence rate of 9 – 10%
over a period of 7 – 12 years. Development of hyperthyroidism is more likely in patients with
autonomously functioning nodules of larger than 3cm and an autonomous goiter volume of
16ml. Hyperthyroidism can be induced by exposing an autonomous gland to excessive iodine,
such as the iodine-containing amiodarone. [23–25]
5. Clinical evaluation & investigation
Clinical evaluation of MNG aims at establishing diagnosis and clinical stage of disease,
stratifying risk of occurrence of malignancy, identifying indications for thyroid ablation and
addressing patient’s concern.
Diagnosis of MNG is usually straight forward with the readily evaluable location of the thyroid
gland. Clinically inconspicuous MNG are usually documented by imaging studies covering
the neck and thoracic inlet performed for unrelated indications. MNGs with predominant
retrosternal component are difficult to diagnose with patients undergoing prolonged investi‐
gations for symptoms of exertional or recumbent dyspnoea that mimic asthma, congestive
heart failure or obstructive sleep apnoea. The tell-tail clue leading to thoracic inlet imaging
and diagnosis of retrosternal goiter is frequently a flow-volume loop spirometry suggesting
extra-thoracic airway obstruction or chest X-ray showing a mediastinal shadow causing
tracheal deviation. Symptoms arising from airway irritation, compression and dragging by
the goiter should be noted and addressed in patient counselling for treatment indications.
Physical findings of nodule consistency and mobility, cervical lymphadenopathy, tracheal
deviation, retromanubrial extension, thoracic outlet obstruction and thyrotoxicosis are
determined. When thyrotoxicosis is suspected, the differential diagnosis of Grave’s disease
with nodules should be considered and the signs specific to Grave’s disease, including
ophthalmopathy and pre-tibial myxoedema be documented.
Serum thyroid stimulating hormone and free serum thyroxine levels are measured to deter‐
mine the functioning status of the nodular goiter. A suppressed TSH level is commonly found
in long-standing MNGs in which functional autonomy has developed. Hypothyroidism, on
the other hand, may suggest Hashimoto thyroiditis and measurement of anti-thyroperoxidase
antibody titre helps to confirm the diagnosis.
Thyroid scintigraphy using iodine-123 or technetium-99m is recommended for patients with
suppressed serum TSH level to determine the relative iodine uptake of a nodule in contrast to
its adjacent thyroid tissue. A hyperfunctioning nodule that can account for the thyrotoxicosis
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carries low risk of malignancy and further investigation is not required. An index nodule that
is iso-or hypofunctional against the rest of thyroid gland has a reported malignancy risk of 3%
to 15% and should be investigated with fine needle aspiration cytology (FNAC). [26-29]
Evaluating for risk of malignancy in MNG follows the same approach as in solitary thyroid
nodules. Demographical risk factors include age of < 20 or > 60 years, male gender, history of
head and neck irradiation, history of multiple endocrine neoplasia or family history of thyroid
cancer. Suspicious symptoms include progressive enlargement, recent onset of voice change,
airway irritation and compression. Objective physical findings of hard and fixed nodule, size
> 4cm, cervical lymphadenopathy and vocal cord paralysis all points to features of local-
regional invasion and prompts investigation for definitive diagnosis. If the rarer entity of
medullary carcinoma is suspected from a positive family history or features of multiple
endocrine neoplasia (type 2), spot serum calcitonin level should be measured as a screening
test. A 33% risk of malignancy is reported in avid nodules detected by fluorodeoxyglucose
positron emission tomography (18FDG-PET), so such nodules should also undergo cytological
evaluation. [30]
Use of ultrasound as routine clinical examination has compensated for the lack of sensitivity
and precision of neck palpation alone in determining the number and size of nodules. Fifty
percent of patients with single palpable thyroid nodule will demonstrate additional nodules
when ultrasound exam is performed. More importantly, nodules with high risk features of
malignancy, including irregular margin, lack of circumferential halo, heterogenous echoge‐
necity, increased vascularity and presence of microcalcification, can be selected for cytological
sampling.
FNAC is an accurate, safe, simple, and cost-effective investigation in the evaluation of nodular
goiter. Diagnostic performance of FNAC is enhanced by ultrasound guidance in the identifi‐
cation of nodules with high risk features for aspiration. In complex cystic lesions, ultrasound
guidance also allows positioning of needle to the solid component while avoiding acellular
cystic area. Availability of pre-operative diagnostic information has increased diagnostic yield
of thyroidectomies while reducing the number of surgeries performed for suspected malig‐
nancy by 35 – 75%. [31–33]
A review of diagnostic performance of FNAC reported a sensitivity of 65 – 98% and specificity
of 72 – 100% for the detection of thyroid carcinoma. In general, the relative frequencies of FNAC
findings in thyroid nodules are benign in 69%, suspicious 10%, malignant 4% and non-
diagnostic in 17%. [34] In the “non-diagnostic” category, repeating FNA under ultrasound
guidance will produce satisfactory specimen in 50% of the cases. The risk of malignancy in
nodules with non-diagnostic cytology is 2 – 9%, and such lesions should be closely monitored
or excised for histological evaluation. The category of “suspicious” cytology includes findings
of follicular and Hurthle cell neoplasm. Differentiation between adenoma and carcinoma
cannot be made because histological evidence of capsular or vascular invasion cannot be
obtained from cytological examination. In patients referred for surgery for suspicious cytology,
20 – 30% are proven to have carcinoma on final pathology. [35-36] Molecular markers upre‐
gulated in thyroid carcinomas are being evaluated for their diagnostic value. Detection of
protein markers (Galectin-3, HBME-1, cytokeratin-19, telomerase) by immunocytochemistry,
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gene mutations (BRAF, RAS, RET/PTC rearrangement, PAX8-PPARγ) by polymerase chain
reaction (PCR), microRNAs by reverse transcriptase PCR, or multi-gene assays. [37] Yet a test
with sufficient sensitivity that allows exclusion of malignancy in an indeterminate cytological
category is still awaited. [38]
6. Treatment of MNG
MNG is benign disease with slow progression and at different stage of its natural history
presents with different clinical problems. The clinical problem at earlier stage of disease before
gross enlargement of the thyroid gland is usually a concerning dominant nodule, while later
in the course patients tends to present with the mass effect of a voluminous goiter or hyper‐
thyroidism. The indications of treatment include suspected or confirmed malignancy, thyro‐
toxicosis, goiters giving rise to compressive, irritative symptoms or cosmetic concern. Only the
management of benign non-toxic MNG is discussed in the following text.
Asymptomatic non-toxic MNG with malignancy being ruled-out should be observed clinically
or with ultrasound surveillance for nodule growth. TSH suppression by levothyroxine was
shown to prevent increase in nodule size but nodule growth resumed after cessation of
therapy. Long-term TSH suppression with levothyroxine is not recommended because of the
increased risk of cardiac arrhythmia and osteoporosis associated with chronic subclinical
hyperthyroidism. [39-40]
Evidence of significant mass effect of a nodular goiter, including symptoms of recumbent or
exertional dyspnoea and signs of tracheal deviation and thoracic inlet obstruction, prompts
amelioration by radio-iodine or surgery.
131I radio-iodine is effective in reducing volume of euthyroid MNG with a response rate of 80%.
Volume reductions at 1 to 3 years are up to 40 – 60% respectively, with half of volume reduction
occurring within 3 months of treatment. The efficacy of radio-iodine is proportional to the
absorbed radiation dose, which in turn depends on the goiter volume and functioning status.
Therefore, in goiters with less than 20% radioactive iodine uptake, conventional 131iodine
therapy is not recommended as an unacceptably high dose of radioactivity would be required
to achieve satisfactory goiter volume reduction. Pre-treatment with rhTSH before 131iodine
administration can stimulate radioactive iodine uptake and was shown by randomized
controlled trials to increase goiter volume reduction by 35 – 56%. rhTSH-augmentation may
therefore extend the application of 131iodine therapy in euthyroid multinodular goiters by
reducing the radioactive dose requirement, especially in goiters with low radioactive iodine
intake. [41] Adverse effects of radio-iodine include radiation thyroiditis in 3%, transient
thyrotoxicosis in 5% and later hypothyroidism in 22 – 58% in 5 – 8 years after therapy. For large
goiters, radio-iodine is probably an inferior option due to incomplete volume reduction,
requirement of higher radiation dose and, transient post-treatment increase in thyroid volume
leading to risk of airway compression.
Surgery provides instantaneous relief of pressure effects and cosmetic concern of MNG.
Subtotal thyroidectomy carries low risk of recurrent laryngeal nerve injury and hypopara‐
thyroidism but results in a recurrence rate up to 40% in the long term. Total thyroidectomy
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can achieve a negligible recurrence rate [42] and carries low complication rate in specialized
centers, with < 1% risk of permanent recurrent laryngeal nerve injury or hypoparathyroidism,
even in the elderly population where massive goiters are more common. [43] Due to the loss
of normal tissue plane and anatomical relationship between the thyroid tissue, recurrent
laryngeal nerve and parathyroid glands, reoperating on a previously explored surgical field
carries a 3-to 10-fold increase in risk of permanent recurrent laryngeal nerve damage or
hypoparathyroidism, rendering sub-total thyroidectomy the less preferred option. [44] Total
thyroidectomy has an added advantage in case of incidentally diagnosed thyroid carcinoma,
which is diagnosed in about 10% of MNG specimens [45], that completion thyroidectomy is
avoided. Other forms of thyroid resection, namely hemithyroidectomy or hemithyroidectomy
with contralateral subtotal resection (Dunhill’s operation) may have merits in the management
of selected patient group, such as those with predominantly unilateral disease and without
pre-operative suspicion of malignancy. Hemithyroidectomy has the advantage of preserving
thyroid function in 65 – 88% of cases and avoiding life-long thyroxine replacement. [46-47] A
summary of management of MNG is schematically presented in Figure 2.
TRH, thyrotropin releasing hormone; TSH, thyroid stimulating hormone; Tg, thyroglobulin;




















Thyroid function Mass effect Nodule pathology
Figure 2. Management of a multinodular goiter (MNG)
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gene mutations (BRAF, RAS, RET/PTC rearrangement, PAX8-PPARγ) by polymerase chain
reaction (PCR), microRNAs by reverse transcriptase PCR, or multi-gene assays. [37] Yet a test
with sufficient sensitivity that allows exclusion of malignancy in an indeterminate cytological
category is still awaited. [38]
6. Treatment of MNG
MNG is benign disease with slow progression and at different stage of its natural history
presents with different clinical problems. The clinical problem at earlier stage of disease before
gross enlargement of the thyroid gland is usually a concerning dominant nodule, while later
in the course patients tends to present with the mass effect of a voluminous goiter or hyper‐
thyroidism. The indications of treatment include suspected or confirmed malignancy, thyro‐
toxicosis, goiters giving rise to compressive, irritative symptoms or cosmetic concern. Only the
management of benign non-toxic MNG is discussed in the following text.
Asymptomatic non-toxic MNG with malignancy being ruled-out should be observed clinically
or with ultrasound surveillance for nodule growth. TSH suppression by levothyroxine was
shown to prevent increase in nodule size but nodule growth resumed after cessation of
therapy. Long-term TSH suppression with levothyroxine is not recommended because of the
increased risk of cardiac arrhythmia and osteoporosis associated with chronic subclinical
hyperthyroidism. [39-40]
Evidence of significant mass effect of a nodular goiter, including symptoms of recumbent or
exertional dyspnoea and signs of tracheal deviation and thoracic inlet obstruction, prompts
amelioration by radio-iodine or surgery.
131I radio-iodine is effective in reducing volume of euthyroid MNG with a response rate of 80%.
Volume reductions at 1 to 3 years are up to 40 – 60% respectively, with half of volume reduction
occurring within 3 months of treatment. The efficacy of radio-iodine is proportional to the
absorbed radiation dose, which in turn depends on the goiter volume and functioning status.
Therefore, in goiters with less than 20% radioactive iodine uptake, conventional 131iodine
therapy is not recommended as an unacceptably high dose of radioactivity would be required
to achieve satisfactory goiter volume reduction. Pre-treatment with rhTSH before 131iodine
administration can stimulate radioactive iodine uptake and was shown by randomized
controlled trials to increase goiter volume reduction by 35 – 56%. rhTSH-augmentation may
therefore extend the application of 131iodine therapy in euthyroid multinodular goiters by
reducing the radioactive dose requirement, especially in goiters with low radioactive iodine
intake. [41] Adverse effects of radio-iodine include radiation thyroiditis in 3%, transient
thyrotoxicosis in 5% and later hypothyroidism in 22 – 58% in 5 – 8 years after therapy. For large
goiters, radio-iodine is probably an inferior option due to incomplete volume reduction,
requirement of higher radiation dose and, transient post-treatment increase in thyroid volume
leading to risk of airway compression.
Surgery provides instantaneous relief of pressure effects and cosmetic concern of MNG.
Subtotal thyroidectomy carries low risk of recurrent laryngeal nerve injury and hypopara‐
thyroidism but results in a recurrence rate up to 40% in the long term. Total thyroidectomy
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can achieve a negligible recurrence rate [42] and carries low complication rate in specialized
centers, with < 1% risk of permanent recurrent laryngeal nerve injury or hypoparathyroidism,
even in the elderly population where massive goiters are more common. [43] Due to the loss
of normal tissue plane and anatomical relationship between the thyroid tissue, recurrent
laryngeal nerve and parathyroid glands, reoperating on a previously explored surgical field
carries a 3-to 10-fold increase in risk of permanent recurrent laryngeal nerve damage or
hypoparathyroidism, rendering sub-total thyroidectomy the less preferred option. [44] Total
thyroidectomy has an added advantage in case of incidentally diagnosed thyroid carcinoma,
which is diagnosed in about 10% of MNG specimens [45], that completion thyroidectomy is
avoided. Other forms of thyroid resection, namely hemithyroidectomy or hemithyroidectomy
with contralateral subtotal resection (Dunhill’s operation) may have merits in the management
of selected patient group, such as those with predominantly unilateral disease and without
pre-operative suspicion of malignancy. Hemithyroidectomy has the advantage of preserving
thyroid function in 65 – 88% of cases and avoiding life-long thyroxine replacement. [46-47] A
summary of management of MNG is schematically presented in Figure 2.
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1. Introduction
Abnormalities in the thyroid anatomy or physiology often arise when the clinician suspect
hyperthyroidism or hypothyroidism detecting on physical examination a goiter or a thyroid
nodule and confirms the suspicion by serum measurements of thyroxine (T4), or thyroid
stimulating hormone (TSH).
Hyperthyroidism is the result of several diseases that may be located in the thyroid gland
(primary), as well as in other locations (secondary), or be the product of an overeating of high-
iodinated foods or being an undesirable effect of some drugs (amiodarone, antitussives). They
will have different expressions in the clinical, laboratory and diagnostic imaging.
Primary hyperthyroidism is the most common condition where diseases like Graves Basedow
disease, toxic multinodular goiter and toxic adenoma are the most common pathologies.
Although rare, also the hyperthyroidism associated with thyroid carcinoma [1], extracervical
ectopic thyroid tissue [2], mutation with activation of the TSH receptor [3], activating muta‐
tions of the stimulatory G protein in the McCune-Albright syndrome [4], Struma Ovarii [5]
and medications such as the excess of iodine intake (Jod-Basedow phenomenon).
The secondary hyperthyroidism is characterized by an increased thyroid hormone caused by
extrathyroid pathologies like the TSH high secreting pituitary adenoma [7], thyroid hormone
resistance syndrome [8], human chorionic gonadotropin secreting tumor [9].
Within the thyrotoxicosis without hyperthyroidism will be the acute, subacute and silent
thyroiditis and other causes such as medication with amiodarone, radiation, adenoma
infarction or excessive thyroid hormone intake (factitious hyperthyroidism). These diseases
will present a clinical picture similar to hyperthyroidism.
All these pathology will need to be studied using various imaging techniques (Figure 1).
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Figure 1. Medical imaging devices used in Radiology and Nuclear Medicine Departments.
Imaging studies will be in the first line for thyroid exploration techniques. There will be others
that will serve to confirm or distinguish between thyroid pathologies as well as to locate
pathology in extracorporeal way when it is secondary.
2. Introduction to imaging studies
Ultrasonography is a technique of first choice, based on the study of the thyroid gland by the
emission and reception of ultrasound signal that according to its characteristic of reflection of
sound wave in the different tissues studied will display them in different graduations of gray
color on a scale that will go from white to black. Main advantages are their cost, non-invasive
and that they not emit ionizing radiation. Within the disadvantages will be the need for
experienced staff.
Then we will have a second imaging technique that will be of great importance in the study
of hyperthyroidism, the scintigraphy, a non-invasive technique that through the use of
radioactive material will be able to assess not only anatomy and glandular function, but
exploring the whole body searching for extraglandular pathology. Of additional contribution
will be the Radioactive Iodine Uptake (RAIU), is a test that evaluate the thyroid function,, it
measures how much radioactive iodine is taken up by the thyroid gland in a certain time
period, normally obtaining values in a few hours (4-6), 24 hours, and 48 hours.
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And two imaging methods of high resolution, computed tomography (CT) and magnetic
resonance imaging (MRI) techniques are used to assess cervical gland pathologies as well as
extracervical level giving a greater resolution than other imaging studies. It is useful in the
surgical planning and for their subsequent evaluation and monitoring. MRI will allow
improved visualization of soft tissues and the identification of pathologies at thoracic as in
abdominopelvic level.
When an intraglandular lesion is identified in thyroid, ultrasound technique will be useful for
the intralesional correct approach and extraction of material by the Fine Needle Aspiration
Biopsy (FNAB) for the cytopathology evaluation (Figure 2).
Figure 2. Fine needle aspiration biopsy guided by ultrasonography.
FNAB is the cornerstone in the solitary thyroid node assessment detected in the clinical exam
as well as the evaluation of the dominant node in multinodular goiter disease.
In places where a nodule or a lymph node is difficult to be identified by fisical exam, or if there
are multiple nodules, an echo-guided biopsy provides high precision for the nodule/ganglion
sampling.
As we mentioned above the procedure requires skilled and experienced hands as well as an
experienced cytopathologist. Even more, in experienced hands, 10% approximately of the
biopsies are non diagnostics.
Thyroid nodules are discovered by palpation in a 3-7 percent of cases and by ultrasound in a
20-76% in the general population [10].
3. Ultrasonography
The ultrasound images tend to be reserved for those cases in which there are doubts about
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between a suspicious nodule and a prominent lobe or thyroid hemiagenesis, to distinguish
between a solitary nodule and a multinodular goiter, for the evaluation of a thyroid mass when
cytology is not diagnostic.
Thyroid nodules are common. The most palpable nodules are benign (solid, cystic, mixed)
being the minor, less than 10%, malignant [11]; however, the risk of malignancy in nodule rises
in children, adolescents, and adults. The risk is substantially increased if the patient has been
previously irradiated by head and neck pathology [12].
Multiple publications have documented that certain sonographic features by B-mode ultra‐
sound and Doppler color, Figure 3, (hypoechogenicity, irregular margin, microcalcifications,
intralesional vascular signals) are suggestive of malignancy [13-17].
Figure 3. Colour Doppler of a thyroid nodule. In color is displayed the vascular distribution inside the nodule, showing
periferic and central vascularization. The image shows multiple microcalcifications too, being in relation to papillary
carcinoma. (Image courtesy by Dr. Alejandro Blando)
Ultrasound clearly defines the thyroid gland, it is more sensitive than scintigraphy in the
detection of thyroid nodules and determines their intra/extra glandular location. Ultrasound
is done when a clinician suspect the presence of a thyroid nodule or for the confirmation of
the location inside or outside the gland.
Although radiation dose in scintigraphic studies and RAIU are extremely low and that there
is no known health risk up to date, the ultrasonography avoid ionizing radiation and always
it is used as initial imaging technique for the gland evaluation in children. Also, the ultraso‐
nography is the initial imaging method for pregnancy assessment. In the presence of a nodule,
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the ultrasonography will be helpful in determinate his composition (cystic, solid, miced). The
ultrasound technique has an important limitation, being unable to differentiate between
malignant and benigne nodule, only giving an estimation.
Ultrasonography also can be used for the degree of the nodule growth in patients under
suppresing therapy. Their limitations are the necesity of experienced operator, high interop‐
erator variability in the nodule identification and the uncertain signification of the thyroid
micronodule in the moment of the detection in the adult population. The ultrasonography is
so sensitive and the nodules so prevalent that may be difficult to be interpreted in some
situations.
4. Doppler
Also the Doppler Ultrasonography is useful for the thyroid gland evaluation. It meassures the
vascular flow in the inferior thyroid artery, being 6 ml/min in norml gland and increased more
than 5-folds in hyperthyroidism. Doppler is very useful in Graves Disease for the global flow
increase assessment (Figure 4), also the therapeutic response control showing a flow constant
reduction and the posterior increase in case of recurrence.
Figure 4. Color Doppler Ultrasound of the Thyroid Gland in longitudinal view (image A) as in transversal view (image
B). High and diffuse hypervascular thyroid related to Graves Disease ("Thyroid Inferno Sign"). (Image courtesy by Dr.
Alejandro Blando).
In the last years also it has also been evaluated the Doppler utility in the nodule feature
determination between malignancy and benign as weel as inflamatory or malignant lymph
nodes [18].
5. Elastography
Even more, recent studies shows that are ultrasopnography techniques that reduce the false
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suppresing therapy. Their limitations are the necesity of experienced operator, high interop‐
erator variability in the nodule identification and the uncertain signification of the thyroid
micronodule in the moment of the detection in the adult population. The ultrasonography is
so sensitive and the nodules so prevalent that may be difficult to be interpreted in some
situations.
4. Doppler
Also the Doppler Ultrasonography is useful for the thyroid gland evaluation. It meassures the
vascular flow in the inferior thyroid artery, being 6 ml/min in norml gland and increased more
than 5-folds in hyperthyroidism. Doppler is very useful in Graves Disease for the global flow
increase assessment (Figure 4), also the therapeutic response control showing a flow constant
reduction and the posterior increase in case of recurrence.
Figure 4. Color Doppler Ultrasound of the Thyroid Gland in longitudinal view (image A) as in transversal view (image
B). High and diffuse hypervascular thyroid related to Graves Disease ("Thyroid Inferno Sign"). (Image courtesy by Dr.
Alejandro Blando).
In the last years also it has also been evaluated the Doppler utility in the nodule feature
determination between malignancy and benign as weel as inflamatory or malignant lymph
nodes [18].
5. Elastography
Even more, recent studies shows that are ultrasopnography techniques that reduce the false




thyroid lesions in 2005 by Lyshchik et al. [19] This method consist in the evaluation in real time
(RTE) of a region of interest during the aplication of external force with the probe of the
ultrasonography, the software meassure the tissue displacement wich is visualized in color
scale depending on the nodular/extranodular consistency. It has been reported as a great tool
that could optimize the thyroid nodule management because of his high sensitivity and
specificity in the prediction of thyroid carcinoma (Figure 5). [20,21]
Figure 5. Dual Modality US Imaging. There is a small hypoecoic solid nodule related to papillary carcinoma (image at
the left). Elastography method (image at the right) showing a nodular stiffness, hence the lack of nodular elasticity
represented as red colour between arrows. (Image courtesy by Dr. Alejandro Blando)
6. Thyroid scintigraphy and radioactive iodine uptake
Thyroid assessment by radionuclides can contribute to the management of the patient under
thyroid disease suspicious.
Thyroid scintigraphy helps to determinate the gland location, morfology and functional
features (Figure 6).
Unlike ultrasonography, the scintigraphy assess the thyroid nodule and gland physiology.
Hot nodules (Figure 7) acumulates I-123 or Tc-99m in a major degree than normal thyroid,
they are very uncommon to express malignancy and FNAB or surgery can be avoided.
Warm nodules acumulates radiotracers in the same intensity as normal thyroid tissue. They
are low probably to be malignant, but doctors would try FNAB depending on the size,
consistency and clinical presentation.
Thyroid Disorders - Focus on Hyperthyroidism44
Figure 6. Thyroid Scintigraphy with Tc-99m-Pertecnetate. Anterior, Left Oblique and Right Oblique projections (top
left, top right and botom right respectivelly) magnified with pin-hole collimator. Showing a normal thyroid gland with
a normal radiotracer distribution.
Figure 7. Thyroid Scintigraphy with Tc-99m-Pertecnetate in anterior projection. High focal uptake in right lobe related
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Cold nodules (Figure 8) lacks of radioisotope acumulation, they do not trap Tc-99m nor
organify I-123 either. They have a 10-20 % of probability of malignancy [22], for this reason,
the thyroid scintigraphy can be useful when a FNAB result is uncertain [23].
Figure 8. Thyroid Scintigraphy with Tc-99m-Pertecnetate in anterior projection. The image display a cold nodule (ar‐
row) in the right lobe. (Image courtesy by Dr. Charles Bouirsot)
The presence of toxic multinodular goiter diminish the malignancy risk. The typical multi‐
nodular scintigraphic image shows areas of high and low uptake of radiotracer and always
the two thyroid lobes affected (Figure 9). There are last articles that inform that multinodular
goiter and solitary nodules have the same risk of malignancy.
Nevertheless, the presence of a dominant cold nodule it will be recomended a FNAB (Figure
10).
Radioactive Iodine Uptake complements the thyroid scan, and can meassure the percentage
of glandular iodine uptake in order to find utility to the I-131 therapy (Figure 11). There are
pathologies in which uptake will be negligible and not I-131 therapy will be needed such as
subacute Thyroiditis, struma ovarii, or factitious hyperthyroidism.
The functional and structural information given by the Scintigraphy thyroid and thyroid
uptake combined with physical exam and hormonal serology always allows a correct diagnosis
and a logical therapeutic approach or next diagnostic procedures.
It is important to distinguish between hyperthyroidism associated with an increased iodine
uptake (Graves, BMN, toxic adenoma disease) and a decreased uptake (Thyroiditis, factitious
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hyperthyroidism, struma ovarii, functioning metastasis of thyroid carcinoma, extracervical
ectopic thyroid tissue), because the treatment for these two categories of hyperthyroidism is
going to be different.
The diagnosis of Graves disease can be based on clinical data and laboratory. A thyroid
scintigraphy and a thyroid uptake curve can be usefull to confirm the Graves disease when it
is a hyperthyroidism without signs of proptosis, pretibial myxedema and exophthalmos.
Thyroid scan shows a homogeneous uptake of radiotracer in both lobes. Sometimes the Graves
disease can be confused with toxic Multinodular goiter, but both can be easily recognized by
a thyroid scintigraphy. This differentiation is important because the therapeutic dose is much
higher for toxic Nodular goiter.
Occasionally, a silent or subacute thyroiditis can be confused with Graves disease because in
both situations the patient is hyperthyroid with abnormal analytic function. The patient with
thyroiditis may have fever, pain and local inflammation, but it could be confused with an
infection or inflammation of upper air tract. It could also happen that at the time of the elevated
thyroid hormones in blood the clinic of thyroiditis had already disappeared.
Figure 9. Thyroid Scitigraphy with Tc-99m-Pertecnetate, anterior projection images with different collimators (paralel
hole and pin-hole, top and bottom respectivelly). The images displayed show a great hyperactivity with heterogene‐
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Figure 10. Thyroid Scintigraphy with Tc-99m-Pertecnetate. Anterior, Left Oblique and Right Oblique projections (top
left, top right and botom right respectivelly) magnified with pin-hole collimator. Showing a right enlarged thyroid
lobe (patient with hemithyroidectomy) with heterogenous distribution of the radiotracer. There is a hot nodule in the
upper pole and a cold area at the right of the midlower part of the lobe.
Figure 11. Radioactive Iodine Uptake Curve Plot. The image shows different uptake intensity (in percentage) depend‐
ing on the thyroid disease represented in time (hours).
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Because of glandular inflammation in acute or subacute Thyroiditis, this is not able to trap
Tc-99m or organify I-123, consequently, the capture of 24 hours will be close to 0% (Figure 12).
Figure 12. Thyroid Scintigraphy with Tc-99m-Pertecnetate in anterior projection with two different collimators (pin-
hole and paralel hole, left and right respectivelly). The image displayed show no uptake of radiotracer by the thyroid
gland.
The scintigraphy can be used to distinguish between the thyroiditis and Graves disease.
Another problem that can arise is that of a patient with hyperthyroidism in which we do not
know if the pathology is toxic adenoma or toxic multinodular goiter. Thyroid scintigraphy is
suitable technique for their differentiation. The importance of the difference between toxic
adenoma, multinodular goiter and Graves disease is that the first two needs higher therapeutic
dose.
Another situation is that the factitious hyperthyroidism where the scintigraphy will help
showing absence of glandular uptake and a radioactive iodine uptake value of 24 hours close
to 0%. The difference between thyroiditis and factitious hyperthyroidism will be through
laboratory, where the values of TG and Ac anti thyroid (AAT) will be the key.
Extremely rare conditions where a hyperthyroidism due to struma ovarii will supress the
thyroid  gland  activity  uptake.  24-Hour  uptake  will  be  close  to  0%.  If  this  condition  is
suspected, the solution will be a whole body Tc-99m scintigraphy or MRI imaging of the
pelvis. A case of struma ovarii is displayed in Figure 13.
There are also rare situations like functioning thyroid carcinoma metastases where they are
going to be seen enhanced hot spots dispersed in multiple parts of the body (Figure 14).
When a mass in neck or retrosternal area is detected and the suspicion could be a goiter,
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Figure 13. Thyroid Scintigraphy with I-131 in a patient under control for his thyroidectomy. There are displayed parti‐
ally wholebody scan and craneocervical and pelvic statics views in anterior projection. There is a fical uptake at cervical
level and a high activity mass lesion at the left hemipelvic region. This images is related to Struma Ovarii.
Figure 14. Thyroid Scintigraphy with I-131. Wholebody scanning in anterior and posterior views (at left) and cervico‐
mediastinal statics in anterior and posterior views (at right, top and bottom respectively).
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radioactive labelling at the level of the suprasternal notch location cervicomediastinal thyroid
or thyroid nodule in study can be defined with great precision.
A retrosternal goiter may be the manifestation of a multinodular goiter, which characteristi‐
cally will presents with decreased radiotracer uptake of the area. There has been publicated a
case of hyperthyroidism for multinodular ectopic goiter (Figure 15) where can be observed the
great utility that will have the anatomical as well as functional images [2].
Figure 15. Thyroid Scintigrahpy with I-131 radiotracer, Chest Radiograph, Axial contrast enhanced CT scan at media‐
stinum level and a the ectopic goiter extracted by surgery (Top left, top right, bottom left, bottom right, respectivelly).
Thyroid scintigraphy can also differentiate between benign adenomatous nodule or a hot
nodule. The scintigraphy is made after intravenous administration of thyroid hormone and
can differentiate between a hot nodule if this decrease its level of uptake or will still be hot
when we are in the presence of a autonomous node. It will be useful to measure the therapeutic
approach, where is going to be useful to use thyroid hormone in order to decrease the size of
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Scintigraphic characteristics between I-123/I-131 and Tc-99m
I-123 / I-131 Tc-99m
∙ Half life: 13,22 Hs / 8 days
∙ Energy: 159 keV / 354 keV
∙ Administration path: oral
∙ Trasported actively to the intracelular space (Trapped)
∙ Bounded to thyrosine (Organified)
∙ The scintigraphy will show tissue distribution of both
functions (Trapped and Organified)
∙ 3-4 hs pos oral administration imaging
∙ Thyroid nodule evaluation
∙ Nodular function assessment
∙ To determine retrosternal mass
∙ To confirm the presence of Graves Disease
∙ To confirm the presence of multi nodular goiter
∙ To confirm the presence of toxic adenoma
∙ It is useful in Radioactive Iodine Uptake study and to
determine the I-131 dose for radiotherapy.
∙ Half life: 6,02 Hs
∙ Energy: 140 keV
∙ Administration path: intravenous
∙ Transported actively to the intracelular space (Trapped)
∙ NOT bounded to thyrosine (NOT organified)
∙ The scintigraphy will show distribution of the function of
Trap but no of organification.
∙ 10-30 minutes pos intravenous administration
∙ Thyroid nodule evaluation
∙ Nodular function assessment
∙ To determine retrosternal mass
∙ To confirm the presence of multi nodular goiter
∙ To confirm the presence of toxic adenoma
∙ The Thyroid uptake is not standardized like I-123 y Tc-
The measure of thyroid uptake has NO standard like I-123
y I-131, but can be evaluated in order to see the capacity of
the glandular trap.
7. Positron emission tomography
PET/CT study is a nuclear medicine imaging based on the gamma acquisition coming from
the aniquilation of the posittron emited by a radiotracer administered intravenously, that in
their majority of nuclear medicine centers is going to be F-18-FDG (fluorodeoxyglucose), useful
for the measurement of the glucose metabolism in the wholebody, being higher in those very
active and normal tissue (heart, brain, brown adipose tissue, Waldeyer ring), pathologic tissue
(adenomas, multinodular goiter, Graves disease, autoinmune disease, cancer) and the
radiotracer's collecting and excreting system (kidney, ureter, urinary bladder).
Primary hyperthyroidism will present a pathological increase in the activity of the thyroid
gland, which can be presented as a homogeneous hyperactivity as is the typical case of Graves
disease or can be a focal hyperactivity like toxic adenoma, which must be studied by FNAB
since the focal hyperactivity may also been caused by malignant processes such as papillary
or follicular carcinomas.
A recent publication relates the hyperthyroidism with an increase in the glucose metabolism
by the brown adipose tissue. That means a problem in the assessment in the cervical soft tissue
surrounding the thyroid gland because sometimes it is difficult to determine if the increased
focal activity comes from a lymph node, metastasis or brown adipose tissue [24].
The PET study also is useful for assessing patients with hyperthyroidism and its mental
behavior change. An article has been published in which there is a relationship between
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hyperthyroidism and alteration in brain glucose metabolism, showing a decrease in glucose
activity at the level of the limbic system (uncus and inferior temporal gyrus), metabolic
activation in the lower area of the parietal lobe and posterior cingulated level which was related
to depression and anxiety, this last symptom was also associated with the increased metabolic
activity at the level of the bilateral sensory associative cortex [25]
Multiple retrospective studies have reported that incidentalomas in thyroid gland with
increased focal uptake of F-18 FDG has been found in 1.2 to 4.3% of healthy patients under
study by PET/CT [26-29].
It was also suggested that a diffuse increase of the uptake into the thyroid gland was more in
relation with benign lesion such as chronic thyroiditis or Graves disease [30].
We display in Figure 16 a normal thyroid gland with a normal F-18 FDG activity.
Figure 16. PET/CT scan at the thyroid gland level. Axial CT scan, emission image at thyroid level, axial PET/CT hybrid
image and MIP emission image from mid-brain to bladder. The image displayed show an homogeneous activity in
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Although focal lesions with a high SUV (> 10) had a high probability of malignancy, the thyroid
lesions with SUV < 10 have not demonstrated a high probability of benign lesion.
Inside those non-FDG radiotracers, the I-124 used for volumetric meassure for dosimetric
planning in the treatment of hyperthyroidism with I-131, being their results better than those
obtained by ultrasonography or conventional scintigraphy [31-33]. Although I-124 is not
generally available and its use is limited to specialized centres.
Either, it has been done multiple studies with the radiotracer Ga-68 DOTATOC in an attempt
to find differences between benign and malignant thyroid diseases, but no good conclusion
were obtained. An increased DOTATOC uptake (target to background ratio >3.4) was found
in hot nodules, disseminated thyroid autonomy, and in most cases (5 of 8) of active Hashimo‐
to's disease. In Ga-68 DOTATOC PET, normal thyroid glands show a clearly detectable
radiotracer uptake with a large variability and significantly higher target to background ratios
in male patients. All patients with thyroid autonomy and most patients with active Hashimo‐
to's disease have an increased thyroid DOTATOC uptake [34].
8. Computed tomography and magnetic resonance imaging
Both studies are useful for the anatomic description in high resolution of the thyroid gland,
their nodes compositions, the adjacent structures characteristics when a thyroid goiter is
present (trachea and esophagous principally), ophtalmopaties associated to Graves Disease,
pituitary gland in secondary hyperparathyroidism, mediastinal structures in ectopic goiters
and pelvic alteration when a struma ovarii exist.
They will be useful in the gland meassurement for the surgery planning or metabolic therapy
with I-131.
In pos-therapy control period, both imaging studies are going to be useful for the follow-up
of the cervical and extracervical region.
One of the most undesirable effects that might occur in a thyroid enhanced contrast CT is the
induction of a thyrotoxicosis or thyroid storm [35-39].
9. Characteristic of imaging reports
9.1. Ultrasonography report
• Classification of a palpated nodule. eg solid, cystic, mixed
• Evaluate adjacent structures
• Determining the location of a palpable lump (within or outside of the thyroid)
• Identifying a cause for Hyperthyroidism
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• Post surgical complications eg abscess, oedema
• Multi Nodular Goiter: Follow up nodules
• Guidance of injection, aspiration or biopsy
• Relationship of normal anatomy and pathology to each other
9.2. Scintigraphic report
• Configuration of the thyroid gland (homogeneity, nodules, size, location)
• Nodules activity (hot-warm-cold) respect to normal thyroid parenchima
• Extracervical pathologic activities
• Wholebody physiologic activities
• Thyroid Radioiodide Uptake Curve (RAIU)
9.3. Positron emission tomography report
• Metabolic feature of the thyroid gland (homogeneity, size, location)
• Nodular metabolic activity respect the normal thyroid parenchima
• Metabolic activity of Thyroid Goiter
• Semicuantification by SUV (Standard Uptake Value)
• Metabolic scanning of the whole body
• Metabolic activity of the pituitary gland, mediastinum and genitals (secondary hyperthyr‐
oidism)
9.4. Computed tomography report
• Configuration of thyroid gland (homogeneity, nodules, size, location)
• Nódules density (solid, cystic, mixed, calcium inside, abscess)
• Cervical and mediastinal lymphadenopathies
• Extracervical metastatic lesions (cranial, thorax, abdomen, pelvis, limbs)
9.5. Magnetic resonance imaging report
• Configuration of thyroid gland (homogeneity, nodules, size, location)
• Nódules density (solid, cystic, mixed, abscess)
• Cervical and mediastinal lymphadenopathies
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to's disease. In Ga-68 DOTATOC PET, normal thyroid glands show a clearly detectable
radiotracer uptake with a large variability and significantly higher target to background ratios
in male patients. All patients with thyroid autonomy and most patients with active Hashimo‐
to's disease have an increased thyroid DOTATOC uptake [34].
8. Computed tomography and magnetic resonance imaging
Both studies are useful for the anatomic description in high resolution of the thyroid gland,
their nodes compositions, the adjacent structures characteristics when a thyroid goiter is
present (trachea and esophagous principally), ophtalmopaties associated to Graves Disease,
pituitary gland in secondary hyperparathyroidism, mediastinal structures in ectopic goiters
and pelvic alteration when a struma ovarii exist.
They will be useful in the gland meassurement for the surgery planning or metabolic therapy
with I-131.
In pos-therapy control period, both imaging studies are going to be useful for the follow-up
of the cervical and extracervical region.
One of the most undesirable effects that might occur in a thyroid enhanced contrast CT is the
induction of a thyrotoxicosis or thyroid storm [35-39].
9. Characteristic of imaging reports
9.1. Ultrasonography report
• Classification of a palpated nodule. eg solid, cystic, mixed
• Evaluate adjacent structures
• Determining the location of a palpable lump (within or outside of the thyroid)
• Identifying a cause for Hyperthyroidism
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• Post surgical complications eg abscess, oedema
• Multi Nodular Goiter: Follow up nodules
• Guidance of injection, aspiration or biopsy
• Relationship of normal anatomy and pathology to each other
9.2. Scintigraphic report
• Configuration of the thyroid gland (homogeneity, nodules, size, location)
• Nodules activity (hot-warm-cold) respect to normal thyroid parenchima
• Extracervical pathologic activities
• Wholebody physiologic activities
• Thyroid Radioiodide Uptake Curve (RAIU)
9.3. Positron emission tomography report
• Metabolic feature of the thyroid gland (homogeneity, size, location)
• Nodular metabolic activity respect the normal thyroid parenchima
• Metabolic activity of Thyroid Goiter
• Semicuantification by SUV (Standard Uptake Value)
• Metabolic scanning of the whole body
• Metabolic activity of the pituitary gland, mediastinum and genitals (secondary hyperthyr‐
oidism)
9.4. Computed tomography report
• Configuration of thyroid gland (homogeneity, nodules, size, location)
• Nódules density (solid, cystic, mixed, calcium inside, abscess)
• Cervical and mediastinal lymphadenopathies
• Extracervical metastatic lesions (cranial, thorax, abdomen, pelvis, limbs)
9.5. Magnetic resonance imaging report
• Configuration of thyroid gland (homogeneity, nodules, size, location)
• Nódules density (solid, cystic, mixed, abscess)
• Cervical and mediastinal lymphadenopathies





This therapy has a high success rate and carries a minimum risk. More than 80% of patients
are successfully treated with a single dose. The disadvantages are minimal between them:
• Hypothyroidism (0-45 %)
• cervical compressive symptoms (2-4 days post administration of I-131)
• acute inflammation
• post-radiation thyroiditis (1-5%) (5-10 days post administration of I-131)
• exacerbation of thyrotoxicosis (7-10 days post administration of I-131)
• development of Graves (< 1%) disease
• acute sialitis
If there is no suspicion of malignancy, metabolic radiotherapy is indicated when the goiter
causes local symptoms, such as dyspnoea or dysphagia. It is the therapy of choice, particularly
in elderly patients, with diseases that increase the risk of surgical results or have a recurrence
in post-surgery period (they have 10 times more likely to suffer damage to the laryngeal nerve).
The radiation dose to the thyroid following an administration of I-131 depends on:
• administered dose
• glandular size
• homogeneity in glandular distribution
• percentage of uptake at 24 hours
• Time of the I-131 inside the gland.
Patients with multi nodular goiter or toxic adenoma need one radioactive dose greater than
grave's disease to achieve an euthyroid state.
10.1. Meassuring procedure
The pretherapy dosimetry should include the following tasks [40]:
• Target mass delineation by sonography or other suitable procedure.
• Quantification of the tracer activity with a dose calibrator.
• Measurement of the tracer activity with the test device, probe or gamma camera, with the
activity located in the phantom or in free air with the relevant count rate correction.
• Verification that the observed count rate per activity matches the expected sensitivity value
of the device.
• Administration of the tracer activity with accurate documentation
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• If liquid 131I-NaI is administered, measurement of the residual activity and determination
of the activity administered and the corresponding count rate.
• In-vivo measurements of the 131I uptake in the target tissue at the times stated in section
Time lines.
• Calculation of the radioiodine activity needed for therapy according to section Data
evaluation.
10.2. Potential sources of error
The evaluation of the therapeutic activity necessary to administer a specified target dose might
be erroneous due to [40]:
• Errors in target volume determination
• Inappropriate attenuation correction (no or inadequate phantom)
• Contamination of the phantom
• Incorrect distance between the detector and the patient or phantom
• Deviation of the individual target tissue depth from the calibration depth
• Inappropriate centring of the probe over the phantom or the target tissue (target tissue
partially outside the probe’s FoV)
• Instability of the electronics of the measuring device, especially if quality control is inade‐
quate
• Variation in background count rate (e.g. from radiation emitted by other patients) for the
different uptake measurements
• Reduced or delayed absorption due to recent food intake
• Recent administration of another radionuclide
• Unfavourable choice of timing of the uptake measurements
11. Nanoparticles and future vision
According to Ramsden [41], increased vascularity in the thyroid can occur in hyperplastic
goiter, Graves' disease and cancer, and may be associated with a vascular hum because of
increased blood flow.
Interestingly, in experimental induction of goiter by low Iodine and thiouracil in rats, Wollman
et al. [42] showed that the capillaries within the thyroid clearly enlarged within 3 days of
treatment, and by 20 days, they surrounded the follicles with a continuous endothelial sheet.
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Data suggest that, in human thyroid tumors, angiogenesis factors seem involved in neoplastic
growth and aggressiveness.
The thyroid is an excellent model for the integrated control of angiogenesis, because of the
vascularity of the thyroid gland, and its capacity to increase its blood flow in disease [43].
Biomolecular nanotechnology defined as “the threedimensional positional control of molec‐
ular structure to create materials and devices to molecular precision" recently has grown to
the multifaceted industry providing new approaches to the old problems [44].
Nanodevices can receive the natural chemical messages transmitted from and between cells
simply by eavesdropping on the natural molecular message traffic. Of course, mechanical (e.g.,
cytoskeletal) and electrical (e.g., ionic) cellular emanations may also be detectable by nanode‐
vices [44].
Nanoparticles have emerged as agents for diagnosis and treatment with the distinction of being
manipulated in their surface structure, thereby allowing a longer intravascular circulation
period, physical and chemical manipulation of nergy, and being directed specifically to the
target, achieving a target cell-specific uptake, allowing increased detection sensitivity through
pathological signal amplification [45].
The application of nanoparticle-labelbased all-in-one dry-reagent immunoassay for thyroid
stimulating hormone was reported by Huntinen et al. [46]. The magnetic properties of
magnetic nanoparticles (MNPs) allow them to be imaged via magnetic resonance imaging
(MRI) and targeted to a particular region by an externally applied MF (magnetic field). Once
loaded with drug, MNPs can be targeted to a region of interest through an externally applied
MF, and the drug released over a period of weeks. This helps to achieve optimal dosing by
reducing the systemic toxicity of the drug, and decreases the likelihood of drug resistance that
would result from insufficient drug present. Through MRI imaging, the biodistribution of
MNPs and indirectly the drug concentration may be determined [47].
Mousa et al. [48] described methods of treating subjects having conditions related to angio‐
genesis including administering an effective amount of a polymeric nanoparticle form of
thyroid hormone agonist, partial agonist or an antagonist to promote or inhibit angiogenesis
in the organism.
Huang et al. [49] demonstrated an implementation of a time-resolved luminescence (TRL)
assay for the sensitive and selective detection of thyroglobulin (Tg), a thyroid cancer marker,
in homogeneous solution using water-soluble alpha-Dmannose-conjugated Au nanodots
(Man-Au NDs). They employed those nanodots as a luminescence sensor for the detection of
the thyroid-cancer marker thyroglobulin (Tg) in homogeneous solutions. Because lumines‐
cence quenching of the Man-Au NDs by Con A is inhibited by Tg selectivity, scientists obtained
a highly sensitive and selective assay for Tg.
Many drugs can be delivered as NP and the opportunities for applying single and combined
experimental medical therapy are almost inexhaustible.
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12. Future works
The other idea is to investigate the effect of ionizing radiation and cancerogens on vascular
structures observed in thyroid tissues. That research might elucidate the pathological changes
similar to those which occur in nuclear atomic disaster survivors and provide knowledge for
the implementation of drugs for radiation damage prevention and cancer treatment.
Could be interesting to develop more works into the endocrine imaging field in order to
improve the differentiation between benign and malignant thyroid lesions.
Regarding the nanotechnology applied to the sphere of endocrine cancers and thyroid disease
in particular, it is difficult to predict all the effects of NP to the alive human organism and that
is why the major sources of experimental evidence are animal studies where tumors are
produced unnaturally and NP are delivered during various stages of pathological process.
Acknowledgements
I would like to express my sincere appreciation to Ms Melina Masciotra for her great contri‐
bution to this chapter to english translation.
Author details
Javier L. Pou Ucha
Nuclear Medicine Department, Hospital Provincial de Rosario, Rosario, Argentina
Author is a permanent Member of the European Association of Nuclear Medicine
References
[1] Steffensen FH, Aunsholt NA. Hyperthyroidism associated with metastatic thyroid
carcinoma. Clin Endocrinol (Oxf). 1994 Nov;41(5):685-7
[2] Pou Ucha J, Loira Bamio F, Campos Villarino LM, Serena Puig A, Nuño Vázquez-
Garza J, Pena González E. Hyperthyroidism due to an ectopic intrathoracic thyroid.
Rev Esp Med Nucl. 2009 Jan-Feb;28(1):15-7
[3] Sunthornthepvarakui T, Gottschalk ME, Hayashi Y, Refetoff S. Brief report: resist‐
ance to thyrotropin caused by mutations in the thyrotropin-receptor gene. N Engl J




Data suggest that, in human thyroid tumors, angiogenesis factors seem involved in neoplastic
growth and aggressiveness.
The thyroid is an excellent model for the integrated control of angiogenesis, because of the
vascularity of the thyroid gland, and its capacity to increase its blood flow in disease [43].
Biomolecular nanotechnology defined as “the threedimensional positional control of molec‐
ular structure to create materials and devices to molecular precision" recently has grown to
the multifaceted industry providing new approaches to the old problems [44].
Nanodevices can receive the natural chemical messages transmitted from and between cells
simply by eavesdropping on the natural molecular message traffic. Of course, mechanical (e.g.,
cytoskeletal) and electrical (e.g., ionic) cellular emanations may also be detectable by nanode‐
vices [44].
Nanoparticles have emerged as agents for diagnosis and treatment with the distinction of being
manipulated in their surface structure, thereby allowing a longer intravascular circulation
period, physical and chemical manipulation of nergy, and being directed specifically to the
target, achieving a target cell-specific uptake, allowing increased detection sensitivity through
pathological signal amplification [45].
The application of nanoparticle-labelbased all-in-one dry-reagent immunoassay for thyroid
stimulating hormone was reported by Huntinen et al. [46]. The magnetic properties of
magnetic nanoparticles (MNPs) allow them to be imaged via magnetic resonance imaging
(MRI) and targeted to a particular region by an externally applied MF (magnetic field). Once
loaded with drug, MNPs can be targeted to a region of interest through an externally applied
MF, and the drug released over a period of weeks. This helps to achieve optimal dosing by
reducing the systemic toxicity of the drug, and decreases the likelihood of drug resistance that
would result from insufficient drug present. Through MRI imaging, the biodistribution of
MNPs and indirectly the drug concentration may be determined [47].
Mousa et al. [48] described methods of treating subjects having conditions related to angio‐
genesis including administering an effective amount of a polymeric nanoparticle form of
thyroid hormone agonist, partial agonist or an antagonist to promote or inhibit angiogenesis
in the organism.
Huang et al. [49] demonstrated an implementation of a time-resolved luminescence (TRL)
assay for the sensitive and selective detection of thyroglobulin (Tg), a thyroid cancer marker,
in homogeneous solution using water-soluble alpha-Dmannose-conjugated Au nanodots
(Man-Au NDs). They employed those nanodots as a luminescence sensor for the detection of
the thyroid-cancer marker thyroglobulin (Tg) in homogeneous solutions. Because lumines‐
cence quenching of the Man-Au NDs by Con A is inhibited by Tg selectivity, scientists obtained
a highly sensitive and selective assay for Tg.
Many drugs can be delivered as NP and the opportunities for applying single and combined
experimental medical therapy are almost inexhaustible.
Thyroid Disorders - Focus on Hyperthyroidism58
12. Future works
The other idea is to investigate the effect of ionizing radiation and cancerogens on vascular
structures observed in thyroid tissues. That research might elucidate the pathological changes
similar to those which occur in nuclear atomic disaster survivors and provide knowledge for
the implementation of drugs for radiation damage prevention and cancer treatment.
Could be interesting to develop more works into the endocrine imaging field in order to
improve the differentiation between benign and malignant thyroid lesions.
Regarding the nanotechnology applied to the sphere of endocrine cancers and thyroid disease
in particular, it is difficult to predict all the effects of NP to the alive human organism and that
is why the major sources of experimental evidence are animal studies where tumors are
produced unnaturally and NP are delivered during various stages of pathological process.
Acknowledgements
I would like to express my sincere appreciation to Ms Melina Masciotra for her great contri‐
bution to this chapter to english translation.
Author details
Javier L. Pou Ucha
Nuclear Medicine Department, Hospital Provincial de Rosario, Rosario, Argentina
Author is a permanent Member of the European Association of Nuclear Medicine
References
[1] Steffensen FH, Aunsholt NA. Hyperthyroidism associated with metastatic thyroid
carcinoma. Clin Endocrinol (Oxf). 1994 Nov;41(5):685-7
[2] Pou Ucha J, Loira Bamio F, Campos Villarino LM, Serena Puig A, Nuño Vázquez-
Garza J, Pena González E. Hyperthyroidism due to an ectopic intrathoracic thyroid.
Rev Esp Med Nucl. 2009 Jan-Feb;28(1):15-7
[3] Sunthornthepvarakui T, Gottschalk ME, Hayashi Y, Refetoff S. Brief report: resist‐
ance to thyrotropin caused by mutations in the thyrotropin-receptor gene. N Engl J




[4] Mastorakos G, Mitsiades NS, Doufas AG, Koutras DA. Hyperthyroidism in McCune-
Albright syndrome with a review of thyroid abnormalities sixty years after the first
report. Thyroid. 1997 Jun;7(3):433-9
[5] Dunzendorfer T, deLas Morenas A, Kalir T, Levin RM. Struma ovarii and hyperthyr‐
oidism. Thyroid. 1999 May;9(5):499-502
[6] El-Shirbiny AM, Stavrou SS, Dnistrian A, Sonenberg M, Larson SM, Divgi CR. Jod-
Basedow syndrome following oral iodine and radioiodinated-antibody administra‐
tion. J Nucl Med. 1997 Nov;38(11):1816-7
[7] Hamilton CR Jr, Adams LC, Maloof F. Hyperthyroidism due to thyrotropin-produc‐
ing pituitary chromophobe adenoma. N Engl J Med. 1970 Nov 12;283(20):1077-80
[8] McDermott MT, Ridgway EC. Thyroid hormone resistance syndromes. Am J Med.
1993 Apr;94(4):424-32
[9] Hershman JM. Human chorionic gonadotropin and the thyroid: hyperemesis gravi‐
darum and trophoblastic tumors. Thyroid. 1999 Jul;9(7):653-7
[10] Hegedüs L. Clinical practice. The thyroid nodule. N Engl J Med 351:1764-1771
[11] Ezzat S, Sarti DA, Cain DR, Braunstein GD. Thyroid incidentalomas. Prevalence by
palpation and ultrasonography. Arch Intern Med 154:1838-1840
[12] Favus MJ, Schneider AB, Stachura ME, Arnold JE, Ryo UY, Pinsky SM, Colman M,
Arnold MJ, Frohman LA. Thyroid cancer occurring as a late consequence of head-
and-neck irradiation. Evaluation of 1056 patients. N Engl J Med 1976; 294:1019-1025
[13] Solbiati L, Osti V, Cova L, Tonolini M. Ultrasound of thyroid, parathyroid glands
and neck lymph nodes. Eur Radiol 11:2411-2424
[14] Kim EK, Park CS, Chung WY, Oh KK, Kim DI, Lee JT, Yoo HS. New sonographic cri‐
teria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules
of the thyroid. Am J Roentgenol 178:687-691
[15] Görges R, Eising EG, Fotescu D, Renzing-Köhler K, Frilling A, Schmid KW, Bockisch
A, Dirsch O. Diagnostic value of high-resolution B-mode and power-mode sonogra‐
phy in the follow-up of thyroid cancer. Eur J Ultrasound. 2003 Feb;16(3):191-206
[16] Fukunari N, Nagahama M, Sugino K, Mimura T, Ito K, Ito K. Clinical evaluation of
color Doppler imaging for the differential diagnosis of thyroid follicular lesions.
World J Surg. 2004 Dec;28(12):1261-5
[17] Fukunari N. Thyroid ultrasonography B-mode and color-Doppler. Biomed Pharmac‐
other. 2002;56 Suppl 1:55s-59s
[18] Belzarena C, Lago G, Lang R, et al. Propuesta 2000 para el tratamiento y seguimiento
del carcinoma diferenciado de tiroides. Endocrinología y nutrición 2001; 48(3): 70-77
Thyroid Disorders - Focus on Hyperthyroidism60
[19] Lyshchik A, Higashi T, Asato R, Tanaka S, Ito J, Mai JJ, Pellot-Barakat C, Insana MF,
Brill AB, Saga T, Hiraoka M, Togashi K. Thyroid gland tumor diagnosis at US elas‐
tography. Radiology. 2005 Oct;237(1):202-11
[20] Rago T, Santini F, Scutari M, Pinchera A, Vitti P. Elastography: new developments in
ultrasound for predicting malignancy in thyroid nodules. Clin Endocrinol Metab
92:2917-2922
[21] Unlütürk U, Erdoğan MF, Demir O, Güllü S, Başkal N. Ultrasound elastography is
not superior to grayscale ultrasound in predicting malignancy in thyroid nodules.
Thyroid 2012 Oct;22(10):1031-8
[22] Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, Vigneri P, Wicker R,
Chiefari E, Suarez HG, Filetti S. Iodide symporter gene expression in human thyroid
tumors. Clin Endocrinol Metab 83:2493-96
[23] Pino Rivero V, Montero García C, Keituqwa Yáñez T, Rejas Ugena E, Blasco Huelva
A. The use of scintigraphy and fine needle aspiration biopsy (FNAB) in thyroid sur‐
gery and review of literature. An Otorrinolaringol Ibero Am. 2003;30(2):161-9.
[24] Lahesmaa M, Orava J, Schalin-Jäntti C, Soinio M, Hannukainen JC, Noponen T, Kirja‐
vainen A, Iida H, Kudomi N, Enerbäck S, Virtanen KA, Nuutila P. Hyperthyroidism
increases brown fat metabolism in humans. J Clin Endocrinol Metab. 2013 Oct 23
[Epub ahead of print]
[25] Schreckenberger MF, Egle UT, Drecker S, Buchholz HG, Weber MM, Bartenstein P,
Kahaly GJ. Positron emission tomography reveals correlations between brain metab‐
olism and mood changes in hyperthyroidism. J Clin Endocrinol Metab. 2006 Dec;
91(12):4786-91
[26] Cohen MS, Arslan N, Dehdashti F, Doherty GM, Lairmore TC, Brunt LM, Moley JF.
Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-posi‐
tron emission tomography. Surgery. 2001;130:941–946
[27] Kang KW, Kim SK, Kang HS, Lee ES, Sim JS, Lee IG, Jeong SY, Kim SW. Prevalence
and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglu‐
cose positron emission tomography for metastasis evaluation and cancer screening in
healthy subjects. J Clin Endocrinol Metab. 2003;88:4100–4104
[28] Chen YK, Ding HJ, Chen KT, Chen YL, Liao AC, Shen YY, Su CT, Kao CH. Preva‐
lence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeox‐
yglucose positron emission tomography for cancer screening in healthy subjects.
Anticancer Res. 2005;25:1421–1426
[29] Yi JG, Marom EM, Munden RF, Truong MT, Macapinlac HA, Gladish GW, Sabloff
BS, Podoloff DA. Focal uptake of fluorodeoxyglucose by the thyroid in patients un‐





[4] Mastorakos G, Mitsiades NS, Doufas AG, Koutras DA. Hyperthyroidism in McCune-
Albright syndrome with a review of thyroid abnormalities sixty years after the first
report. Thyroid. 1997 Jun;7(3):433-9
[5] Dunzendorfer T, deLas Morenas A, Kalir T, Levin RM. Struma ovarii and hyperthyr‐
oidism. Thyroid. 1999 May;9(5):499-502
[6] El-Shirbiny AM, Stavrou SS, Dnistrian A, Sonenberg M, Larson SM, Divgi CR. Jod-
Basedow syndrome following oral iodine and radioiodinated-antibody administra‐
tion. J Nucl Med. 1997 Nov;38(11):1816-7
[7] Hamilton CR Jr, Adams LC, Maloof F. Hyperthyroidism due to thyrotropin-produc‐
ing pituitary chromophobe adenoma. N Engl J Med. 1970 Nov 12;283(20):1077-80
[8] McDermott MT, Ridgway EC. Thyroid hormone resistance syndromes. Am J Med.
1993 Apr;94(4):424-32
[9] Hershman JM. Human chorionic gonadotropin and the thyroid: hyperemesis gravi‐
darum and trophoblastic tumors. Thyroid. 1999 Jul;9(7):653-7
[10] Hegedüs L. Clinical practice. The thyroid nodule. N Engl J Med 351:1764-1771
[11] Ezzat S, Sarti DA, Cain DR, Braunstein GD. Thyroid incidentalomas. Prevalence by
palpation and ultrasonography. Arch Intern Med 154:1838-1840
[12] Favus MJ, Schneider AB, Stachura ME, Arnold JE, Ryo UY, Pinsky SM, Colman M,
Arnold MJ, Frohman LA. Thyroid cancer occurring as a late consequence of head-
and-neck irradiation. Evaluation of 1056 patients. N Engl J Med 1976; 294:1019-1025
[13] Solbiati L, Osti V, Cova L, Tonolini M. Ultrasound of thyroid, parathyroid glands
and neck lymph nodes. Eur Radiol 11:2411-2424
[14] Kim EK, Park CS, Chung WY, Oh KK, Kim DI, Lee JT, Yoo HS. New sonographic cri‐
teria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules
of the thyroid. Am J Roentgenol 178:687-691
[15] Görges R, Eising EG, Fotescu D, Renzing-Köhler K, Frilling A, Schmid KW, Bockisch
A, Dirsch O. Diagnostic value of high-resolution B-mode and power-mode sonogra‐
phy in the follow-up of thyroid cancer. Eur J Ultrasound. 2003 Feb;16(3):191-206
[16] Fukunari N, Nagahama M, Sugino K, Mimura T, Ito K, Ito K. Clinical evaluation of
color Doppler imaging for the differential diagnosis of thyroid follicular lesions.
World J Surg. 2004 Dec;28(12):1261-5
[17] Fukunari N. Thyroid ultrasonography B-mode and color-Doppler. Biomed Pharmac‐
other. 2002;56 Suppl 1:55s-59s
[18] Belzarena C, Lago G, Lang R, et al. Propuesta 2000 para el tratamiento y seguimiento
del carcinoma diferenciado de tiroides. Endocrinología y nutrición 2001; 48(3): 70-77
Thyroid Disorders - Focus on Hyperthyroidism60
[19] Lyshchik A, Higashi T, Asato R, Tanaka S, Ito J, Mai JJ, Pellot-Barakat C, Insana MF,
Brill AB, Saga T, Hiraoka M, Togashi K. Thyroid gland tumor diagnosis at US elas‐
tography. Radiology. 2005 Oct;237(1):202-11
[20] Rago T, Santini F, Scutari M, Pinchera A, Vitti P. Elastography: new developments in
ultrasound for predicting malignancy in thyroid nodules. Clin Endocrinol Metab
92:2917-2922
[21] Unlütürk U, Erdoğan MF, Demir O, Güllü S, Başkal N. Ultrasound elastography is
not superior to grayscale ultrasound in predicting malignancy in thyroid nodules.
Thyroid 2012 Oct;22(10):1031-8
[22] Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, Vigneri P, Wicker R,
Chiefari E, Suarez HG, Filetti S. Iodide symporter gene expression in human thyroid
tumors. Clin Endocrinol Metab 83:2493-96
[23] Pino Rivero V, Montero García C, Keituqwa Yáñez T, Rejas Ugena E, Blasco Huelva
A. The use of scintigraphy and fine needle aspiration biopsy (FNAB) in thyroid sur‐
gery and review of literature. An Otorrinolaringol Ibero Am. 2003;30(2):161-9.
[24] Lahesmaa M, Orava J, Schalin-Jäntti C, Soinio M, Hannukainen JC, Noponen T, Kirja‐
vainen A, Iida H, Kudomi N, Enerbäck S, Virtanen KA, Nuutila P. Hyperthyroidism
increases brown fat metabolism in humans. J Clin Endocrinol Metab. 2013 Oct 23
[Epub ahead of print]
[25] Schreckenberger MF, Egle UT, Drecker S, Buchholz HG, Weber MM, Bartenstein P,
Kahaly GJ. Positron emission tomography reveals correlations between brain metab‐
olism and mood changes in hyperthyroidism. J Clin Endocrinol Metab. 2006 Dec;
91(12):4786-91
[26] Cohen MS, Arslan N, Dehdashti F, Doherty GM, Lairmore TC, Brunt LM, Moley JF.
Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-posi‐
tron emission tomography. Surgery. 2001;130:941–946
[27] Kang KW, Kim SK, Kang HS, Lee ES, Sim JS, Lee IG, Jeong SY, Kim SW. Prevalence
and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglu‐
cose positron emission tomography for metastasis evaluation and cancer screening in
healthy subjects. J Clin Endocrinol Metab. 2003;88:4100–4104
[28] Chen YK, Ding HJ, Chen KT, Chen YL, Liao AC, Shen YY, Su CT, Kao CH. Preva‐
lence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeox‐
yglucose positron emission tomography for cancer screening in healthy subjects.
Anticancer Res. 2005;25:1421–1426
[29] Yi JG, Marom EM, Munden RF, Truong MT, Macapinlac HA, Gladish GW, Sabloff
BS, Podoloff DA. Focal uptake of fluorodeoxyglucose by the thyroid in patients un‐





[30] Yasuda S, Shohtsu A, Ide M, Takagi S, Takahashi W, Suzuki Y, Horiuchi M. Chronic
thyroiditis: diffuse uptake of FDG at PET. Radiology. 1998;207:775-778
[31] Eschmann SM, Reischl G, Bilger K, Kupferschläger J, Thelen MH, Dohmen BM, Be‐
senfelder H, Bares R. Evaluation of dosimetry of radioiodine therapy in benign and
malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol
Imaging. 2002 Jun;29(6):760-7
[32] Matheoud R, Canzi C, Reschini E, Zito F, Voltini F, Gerundini P. Tissue-specific dos‐
imetry for radioiodine therapy of the autonomous thyroid nodule. Med Phys.
2003;30:791–8
[33] Canzi C, Zito F, Voltini F, Reschini E, Gerundini P. Verification of the agreement of
two dosimetric methods with radioiodine therapy in hyperthyroid patients. Med
Phys. 2006;33:2860–7
[34] Lincke T, Orschekowski G, Singer J, Sabri O, Paschke R. Increased gallium-68 DOTA‐
TOC uptake in normal thyroid glands. Horm Metab Res. 2011 Apr;43(4):282-6
[35] Blum M, Weinberg U, Shenkman L, Hollander CS. Hyperthyroidism after iodinated
contrast medium. N Engl J Med. 1974 Jul 4;291(1):24-5
[36] Hehrmann R, Klein D, Mayer D, Ploner O. Risk of hyperthyroidism in examinations
with contrast media. Aktuelle Radiol. 1996 Sep;6(5):243-8
[37] Alkhuja S, Pyram R, Odeyemi O. In the eye of the storm: iodinated contrast medium
induced thyroid storm presenting as cardiopulmonary arrest. Heart Lung. 2013 Jul-
Aug;42(4):267-9
[38] Rhee CM, Bhan I, Alexander EK, Brunelli SM. Association between iodinated con‐
trast media exposure and incident hyperthyroidism and hypothyroidism. Arch In‐
tern Med. 2012 Jan 23;172(2):153-9
[39] Grady D. Another reason to be cautious about imaging: comment on "association be‐
tween iodinated contrast media exposure and incident hyperthyroidism and hypo‐
thyroidism". Arch Intern Med. 2012 Jan 23;172(2):161
[40] Eur J Nucl Med Mol Imaging. 2013 Jul;40(7):1126-34
[41] Rhee CM, Bhan I, Alexander EK, Brunelli SM. Association between iodinated con‐
trast media exposure and incident hyperthyroidism and hypothyroidism. J Endocri‐
nol. 2000 Sep;166(3):475-80
[42] Wollman SH, Herveg JP, Zeligs JD, Ericson LE. Blood capillary enlargement during
the development of thyroid hyperplasia in the rat. Endocrinology. 1978 Dec;103(6):
2306-14
[43] Ramsden JD. Angiogenesis in the thyroid gland. J Endocrinol. 2000 Sep;166(3):475-80
[44] Freitas, R.A., Nanomedicine. 1999, Austin, TX: Landes Bioscience
Thyroid Disorders - Focus on Hyperthyroidism62
[45] Pou Ucha, Javier L. (2013). Nanoparticles in bioimaging. In Arun Kumar, et al (Ed.),
Nanomedicine in Drug Delivery. Boca Ratón, FL: Taylor & Francis Group; 2013 (pp.
187-212).
[46] Huhtinen P, Pelkkikangas AM, Jaakohuhta S, Lövgren T, Härmä H. Quantitative,
rapid europium(III) nanoparticle-label-based all-in-one dry-reagent immunoassay
for thyroid-stimulating hormone. Clin Chem. 2004 Oct;50(10):1935-6
[47] Varadan, Vijay K., Linfeng Chen, and Jining Xie, “Magnetic nanomaterails, nano‐
tubes, and nanomedicine”, Chapter 9, “Nanomedicine-Design of particles, sensors,
motors, implants, robots, and devices”, Artech House, 2009
[48] Mousa SA, Davis PJ, Hercbergs A (2009). Nanoparticle and polymer formulations for
thyroid hormone analogs, antagonists and formulations and uses thereof.United
States Patent and Trademark Office Pre-Grant Publication
[49] Huang CC, Hung YL, Shiang YC, Lin TY, Lin YS, Chen CT, Chang HT. Photoassisted
synthesis of luminescent mannose-Au nanodots for the detection of thyroglobulin in




[30] Yasuda S, Shohtsu A, Ide M, Takagi S, Takahashi W, Suzuki Y, Horiuchi M. Chronic
thyroiditis: diffuse uptake of FDG at PET. Radiology. 1998;207:775-778
[31] Eschmann SM, Reischl G, Bilger K, Kupferschläger J, Thelen MH, Dohmen BM, Be‐
senfelder H, Bares R. Evaluation of dosimetry of radioiodine therapy in benign and
malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol
Imaging. 2002 Jun;29(6):760-7
[32] Matheoud R, Canzi C, Reschini E, Zito F, Voltini F, Gerundini P. Tissue-specific dos‐
imetry for radioiodine therapy of the autonomous thyroid nodule. Med Phys.
2003;30:791–8
[33] Canzi C, Zito F, Voltini F, Reschini E, Gerundini P. Verification of the agreement of
two dosimetric methods with radioiodine therapy in hyperthyroid patients. Med
Phys. 2006;33:2860–7
[34] Lincke T, Orschekowski G, Singer J, Sabri O, Paschke R. Increased gallium-68 DOTA‐
TOC uptake in normal thyroid glands. Horm Metab Res. 2011 Apr;43(4):282-6
[35] Blum M, Weinberg U, Shenkman L, Hollander CS. Hyperthyroidism after iodinated
contrast medium. N Engl J Med. 1974 Jul 4;291(1):24-5
[36] Hehrmann R, Klein D, Mayer D, Ploner O. Risk of hyperthyroidism in examinations
with contrast media. Aktuelle Radiol. 1996 Sep;6(5):243-8
[37] Alkhuja S, Pyram R, Odeyemi O. In the eye of the storm: iodinated contrast medium
induced thyroid storm presenting as cardiopulmonary arrest. Heart Lung. 2013 Jul-
Aug;42(4):267-9
[38] Rhee CM, Bhan I, Alexander EK, Brunelli SM. Association between iodinated con‐
trast media exposure and incident hyperthyroidism and hypothyroidism. Arch In‐
tern Med. 2012 Jan 23;172(2):153-9
[39] Grady D. Another reason to be cautious about imaging: comment on "association be‐
tween iodinated contrast media exposure and incident hyperthyroidism and hypo‐
thyroidism". Arch Intern Med. 2012 Jan 23;172(2):161
[40] Eur J Nucl Med Mol Imaging. 2013 Jul;40(7):1126-34
[41] Rhee CM, Bhan I, Alexander EK, Brunelli SM. Association between iodinated con‐
trast media exposure and incident hyperthyroidism and hypothyroidism. J Endocri‐
nol. 2000 Sep;166(3):475-80
[42] Wollman SH, Herveg JP, Zeligs JD, Ericson LE. Blood capillary enlargement during
the development of thyroid hyperplasia in the rat. Endocrinology. 1978 Dec;103(6):
2306-14
[43] Ramsden JD. Angiogenesis in the thyroid gland. J Endocrinol. 2000 Sep;166(3):475-80
[44] Freitas, R.A., Nanomedicine. 1999, Austin, TX: Landes Bioscience
Thyroid Disorders - Focus on Hyperthyroidism62
[45] Pou Ucha, Javier L. (2013). Nanoparticles in bioimaging. In Arun Kumar, et al (Ed.),
Nanomedicine in Drug Delivery. Boca Ratón, FL: Taylor & Francis Group; 2013 (pp.
187-212).
[46] Huhtinen P, Pelkkikangas AM, Jaakohuhta S, Lövgren T, Härmä H. Quantitative,
rapid europium(III) nanoparticle-label-based all-in-one dry-reagent immunoassay
for thyroid-stimulating hormone. Clin Chem. 2004 Oct;50(10):1935-6
[47] Varadan, Vijay K., Linfeng Chen, and Jining Xie, “Magnetic nanomaterails, nano‐
tubes, and nanomedicine”, Chapter 9, “Nanomedicine-Design of particles, sensors,
motors, implants, robots, and devices”, Artech House, 2009
[48] Mousa SA, Davis PJ, Hercbergs A (2009). Nanoparticle and polymer formulations for
thyroid hormone analogs, antagonists and formulations and uses thereof.United
States Patent and Trademark Office Pre-Grant Publication
[49] Huang CC, Hung YL, Shiang YC, Lin TY, Lin YS, Chen CT, Chang HT. Photoassisted
synthesis of luminescent mannose-Au nanodots for the detection of thyroglobulin in






Irmak  Sayin, Sibel Ertek and Mustafa Cesur
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/58196
1. Introduction
Some clinical views which appear during hyperthyroidism can be called complications of
hyperthyroidism. These clinical events are as follows.
1. Thyrotoxic heart disease
2. Progressive infiltrative ophtalmopathy in hyperthyroidism
3. Hyperthyroidism and bone
4. Thyroid chrisis
5. Thyrotoxic periodic paralysis
6. Thyrotoxicosis related psychosis and convulsion
7. Thyrotoxicosis related diabetes mellitus
2. Thyrotoxic heart disease
2.1. Effects of hyperthyroidism on heart-from pathophysiology to clinical complications
Cardiovascular signs and complications are generally the first alarming signs of hyperthyr‐
oidism for any physician. Effects of thyroid hormones on the heart and cardiovascular system
could be direct or indirect. Palpitations and exercise intolerance are the most frequent signs [1,
2]. Although effects of iodization and world-wide use of radiocontrast agents may change the
incidence, overt hyperthyroidism is common and affects 2-5% of the population [3,4]. In
hyperthyroid patients mortality is increased 20% and the major causes of death are cardiac
problems [5]. Atrial fibrillation is the most common and fearful arrythmic complication of
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hyperthyroidism which occurs in an estimated 10-25% of all overtly hyperthyroid patients [6].
Susceptibility to arrhythmic effects of thyroid hormones may have a genetic basis and recently
the studies on molecular details of cardiac actions of thyroid hormones revealed some
important knowledge [7]. Meanwhile, the cause of hyperthyroidism may also change the
cardiovascular risk; patients with toxic multinoduler goitre have higher cardiovascular risk
than patients with Graves’ disease, probably because of older age, and patients with Graves
disease may have autoimmune complications, such as valvular involvement, cardiomyopathy
and pulmonary arterial hypertension [8]. Effects of thyroid hormones on the heart may be
grouped as molecular or cellular mechanisms and hemodynamic effects. On the other hand,
thyroid hormones have 2 types of effects on every tissue; genomic effects which occur more
slowly, and non-genomic effects. Severity of hyperthyroidism may also cause differences in
clinical presentation of the patient, overt hyperthyroidism and subclinical hyperthyroidism
bring differing degrees of risks to patients.
2.2. Molecular and cellular mechanisms of thyroid hormone effects on heart
Both  T3  and  T4  are  lipophylic  and  they  pass  through  the  cellular  membranes  and  the
conversion of  T4  to  T3  occurs  in  many cells.  Triiodothyronin  (T3)  is  the  active  thyroid
hormone and it has genetic and cellular effects on cardiac muscle and blood vessels. It acts
on THRs (thyroid hormone receptors) in the nucleus, creating dimers of 9-cis-retinoic acid
receptor (RXR) (9): the formed complexes recognize some specific DNA consensus sequen‐
ces, the thyroid response elements (TRE), located in the enhanced region of the genes initiate
the transcription [9].
In myocytes, thyroid hormones act on many TREs, such as alpha myosin heavy chain fusion
(MHC-α), sarcoplasmic reticulum calcium-activated ATPase (SERCA), the cellular membrane
Na-K pump (Na-K ATPase), β1 adrenergic receptor, cardiac troponin I, atrial natriuretic
peptide (ANP) [10-12] and some genes are also suppressed such as β-myosin heavy chain
fusion (MHC-β), adenylic cyclase (IV and V) and the Na-Ca antiporter [13].
Thyroid hormone upregulates α, but downregulates β-chain in myocytes [14]. The final effect
of thyroid hormones in animal studies is an increased rate of V1 isoform of MHC (MHCα/α)
synthesis that is characteristically faster in myocardial fibre shortening [13,15]. A similar effect
has been also observed in preliminary human studies [16,17].
Thyroid hormones also have effects on SERCA, which is responsible for the rate of calcium
uptake during diastole, by actions on calcium activated ATPase and its inhibitory cofactor
phospholamban [18,19]. Thyroid hormones enhance myocardial relaxation by upregulating
expression of SERCA, and downregulating expression of phospholamban. The greater
reduction in cytoplasmic calcium concentration at the end of the diastole increases the
magnitude of systolic transient of calcium and augments its ability for activation of actin-
myosin subunits. As a confirmation, phospholamban deficient mice showed no increase in
heart rate after thyroid hormone treatment [20].
On the plasma membranes, T3 exerts direct extragenic actions on the functions other ion
channels such as Na/K ATPase, Na/Ca++exchanger, and some voltage gated K channels (Kv
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1.5, Kv 4.2, Kv 4.3) affecting myocardial and vascular functions [21,22] coordinating electro‐
chemical and mechanical responses of myocardium [23,24]. It prolongs the activation of Na
channels in myocardial cells [25] and induces intracellular Na uptake and secondary activation
of the Na-Ca antiporter, which can partly explain the positive inotropic effect. T3 exerts direct
effect on L-type calcium channels resulting in abbreviation of action potential duration and
possibly L-type calcium channel mRNA expression [26,27].
The strong inotropic activity of thyroid hormones is probably due to an increased number of
β-adrenergic receptors [28]. Circulating cathecholamine levels are in fact the same, but G
protein and β-receptors increase [29]. The sensitivity of cardiovascular system to adrenergic
stimulation does not change by thyroid hormones [30,31]. The changes in the heart rate result
from both an increase in sympathetic tone and decrease in parasympathetic tone [32,33].
These genomic effects fail to explain the fast actions of thyroid hormones on the cardiovascular
system. Non-genomic effects promote rapid changes, such as increased cardiac output [34-36].
The hemodynamic consequences of hyperthyroidism and nongenomic changes on plasma
membranes occur acutely and contribute to these rapid changes. Studies indicate that thyroid
hormone activates acute phosphorylation of phospholamban, and that also partly explains the
homology between thyroid hormone and adrenergic system on the heart [32].
In an experimental study on rats, thyroid hormones upregulate connexin-40, a gap junction
protein of myocardium important for the transport of electrical activity, and this may be one
of the pathogenetic mechanisms of atrial fibrillation in hyperthyroidism [37]. In another animal
study the authors suggested that the connexin-43 phosphorylation was downregulated by T3
in diabetic rats and decrease adaptation of heart to hyperglycemia and this may render the
heart prone to ventricular arrythmias [38]. In fact thyroid hormone receptor alpha 1 is
predominantly expressed in cardiac myocardium and may have an important role in cardiac
myoblast differentiation by ERK kinase dependent process, but its clinical relevance is not
known [39]. Also ERK (extracellular signal-regulated kinase) pathway may have a role in
negative cardiac remodelling and decreased cardiac contractile function in hyperthyroidism,
by inhibition of the Raf-1/ERK pathway by T3 [40,41].
Meanwhile, the thyroid hormone may have direct (without autonomous nervous system)
effects on the sinoatrial node [42,43] and oxidative stress in animal studies [44]. The heart rate
increases due to increased sinoatrial activity, a lower threshold for atrial activity, and a
shortened atrial repolarisation [45,46]. Together with hemodynamic changes, i.e. the volume
preload increases due to activation of the renin-angiotensin system [47], contractility increases
due to increased metabolic demand and the direct effect of the thyroid hormone on heart
muscle [48] and systemic vascular resistance decreases because of triiodotyronine-induced
peripheral vasodilatation [49]. The result is a dramatic increase in cardiac output [50].
Local type 2 iodothyronine deiodinase up-regulation may also be involved in cardiac remod‐
elling via activation of thyroid hormone signalling pathways involving Akt and p38 MAPK
(mitogen-activated protein kinase) in thyrotoxic-dilated cardiomyopathy [51]. Animal studies
show the effects of thyroid hormones on soluble fractions of 5’-nucleosidase activity, via
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2 receptor blocker showed that this blockage might prevent thyroxine-mediated cardiac
hypertrophy [53]. Meanwhile, hypertrophied myocytes may be susceptible to apoptotic
stimulation by angiotensin II in hyperthyroidism [54].
Studies on rats show that mitochondrial ultrastructure was damaged in T3 treated hyperthy‐
roid rat heart, leading to energy depletion and cardiac dysfunction [55]. Another study on
hamsters revealed that long term hyperthyroidism cause increased left ventricular interstitial
fibrosis, significant cardiac hypertrophy and deleterious cardiac remodeling characterized by
myocyte lengthening, chamber dilatation, decreased relative wall thickness, increased wall
stress, and impaired global cardiac function whereas cardiomyocyte functions may be
enhanced [56]. Some animal studies Show beneficial effects of angiotensin receptor blockers
on myocytes as improved left ventricular longitudinal strain, heart rate and reduced cardio‐
myocyte width, affecting structural remodelling beyond the anti-tachycardic effect of beta-
blockers [57].
2.3. Hemodynamic effects of thyroid hormones
Hemodynamic effects of thyroid hormones are generally nongenomic and faster, by direct
effects on the heart and blood vessels. In the peripheral vascular system, the rapid use of
oxygen, increased production of metabolic end products and relaxation of arterial smooth
muscle fibres by thyroid hormone cause peripheral vasodilatation [21]. This fall in peripheral
vascular resistance (PVR) plays the central role in all hemodynamic changes caused by thyroid
hormones [58]. Decreased PVR causes an increase in heart rate and selective increase in blood
flow of some organs (skin, skeletal muscles, heart), and a fall in diastolic pressure with
consequent widening of pulse pressure. Vasodilatation without an increase in renal blood flow
causes reduction in renal perfusion and activation of the renin-angiotensin system which
causes sodium retention and increased blood volume [59]. In addition, thyroid hormones
regulate erythropoietin secretion and increased red cell mass may also contribute to blood
volume increase [60]. Improved diastolic relaxation and increased blood volume increased left
ventricular end-diastolic volume (LVEDV). Reduced PVR and increased LVEDV means
increased preload and decreased afterload, thus the stroke volume increases. Increased stroke
volume and increased heart rate leads to a doubling or tripling of cardiac output which cannot
be solely explained by the increased metabolic rate of the body [61].
The importance of the contribution of decreased systemic vascular resistance to the increase
in systemic blood flow in patients with hyperthyroidism is evidenced by studies in which the
administration of arterial vasoconstrictors, atropine and phenylephrine, decreased peripheral
blood flow and cardiac output by 34% in patients with hyperthyroidism but not in normal
subjects [62,63].
2.4. Clinical aspects of hyperthyroidism and subclinical hyperthyroidism on heart
Increased rate and strength of the heart contractility, together with an exaggerated response
of heart rate to exercise is present in hyperthyroid patients who describe this as palpitations.
Diurnal heart rate variations are generally preserved. The most common ECG abnormality is
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sinusal tachycardia and shortened PR interval, and frequently intra-atrial conduction is
prolonged, which is seen as increase in P wave duration. Intraventricular conduction delay in
the form of right bundle branch block is present in around 15% of patients, and atrioventricular
block may also occur due to unknown reasons. The most common rhythm disturbance in
hyperthyroid patients is sinus tachycardia [32]. Its clinical impact however is overshadowed
by that of patients with atrial fibrillation. The prevalence of atrial fibrillation (AF) and less
common forms of supraventricular tachycardia in this disease ranges between 2 to 20 percent
[64,65]. AF is generally accompanied by rapid ventricular response. It is more common in men
and its significance increases by age, after 40 years [65]. As in the case of angina or heart failure,
the development of AF should not be attributed only to hyperthyroidism, and the underlying
organic heart diseases should be investigated.
Atrial fibrillation usually reverses to a sinus rhythm by achievement of a euthyroid state, if the
patient is younger and the duration of hyperthyroidism is not long. The beta-adrenergic
blockade may be effective in controlling the ventricular rate. Increased plasma clearance of
beta-blockers may necessitate higher doses [66]. Among them propranolol has the advantage
of blocking the conversion of T4 to T3 in peripheral tissues, however other cardioselective beta-
blockers have a longer half-life and can be equally effective on the heart. In cardiac arrhythmias
intravascular infusion of calcium blockers should be avoided due to the risk of a further fall
in PVR [67]. It is still controversial whether the patients with AF should have anticoagulant
therapy to prevent systemic embolization. It is advised to evaluate each patient on a case-by-
case basis, and determine the risk of bleeding over embolization [68,69]. In younger patients
with hyperthyroidism and AF, who do not have other heart disease, hypertension, or inde‐
pendent risk factors for embolization, the risk of anticoagulant therapy may suppress its
benefits. But it would be appropriate to administer anticoagulant agents to older patients with
known or suspected heart diseases, or AF with longer duration. When oral anticoagulants will
be used, it should be considered that hyperthyroid patients will need smaller doses than
euthyroid ones, due to faster elimination of vitamin-K dependent clotting factors [70].
In the patients with AF the maintenance of sinus rhythm is not possible until the euthyroid
state is restored, so electrical cardioversion is not recommended without confirming the
euthyroid status.
Many hyperthyroid patients experience exercise intolerance and exertional dyspnea, in part
because of weakness in the skeletal and respiratory muscle [71] and also due to inability to
increase heart rate or lower vascular resistance further, as normally occurs in exercise [72]. The
tem “high output heart failure” has not been used in recent decades, because it is clear that the
heart is still able to increase cardiac output at rest and with exercise. In the setting of low
vascular resistance and decreased preload, the cardiac functional reserve is compromised and
cannot rise further to accommodate the demands of submaximal or maximal exercise [73].
About 6% of thyrotoxic patients develop heart failure and less than 1% develop dilated
cardiomyopathy with impaired left ventricular systolic dysfunction, due to the tachycardia-
mediated mechanism leading to an increased level of cytosolic calcium during diastole, with
reduced contractility of the ventricle and diastolic dysfunction, often with tricuspid regurgi‐
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vascular resistance (PVR) plays the central role in all hemodynamic changes caused by thyroid
hormones [58]. Decreased PVR causes an increase in heart rate and selective increase in blood
flow of some organs (skin, skeletal muscles, heart), and a fall in diastolic pressure with
consequent widening of pulse pressure. Vasodilatation without an increase in renal blood flow
causes reduction in renal perfusion and activation of the renin-angiotensin system which
causes sodium retention and increased blood volume [59]. In addition, thyroid hormones
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2.4. Clinical aspects of hyperthyroidism and subclinical hyperthyroidism on heart
Increased rate and strength of the heart contractility, together with an exaggerated response
of heart rate to exercise is present in hyperthyroid patients who describe this as palpitations.
Diurnal heart rate variations are generally preserved. The most common ECG abnormality is
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sinusal tachycardia and shortened PR interval, and frequently intra-atrial conduction is
prolonged, which is seen as increase in P wave duration. Intraventricular conduction delay in
the form of right bundle branch block is present in around 15% of patients, and atrioventricular
block may also occur due to unknown reasons. The most common rhythm disturbance in
hyperthyroid patients is sinus tachycardia [32]. Its clinical impact however is overshadowed
by that of patients with atrial fibrillation. The prevalence of atrial fibrillation (AF) and less
common forms of supraventricular tachycardia in this disease ranges between 2 to 20 percent
[64,65]. AF is generally accompanied by rapid ventricular response. It is more common in men
and its significance increases by age, after 40 years [65]. As in the case of angina or heart failure,
the development of AF should not be attributed only to hyperthyroidism, and the underlying
organic heart diseases should be investigated.
Atrial fibrillation usually reverses to a sinus rhythm by achievement of a euthyroid state, if the
patient is younger and the duration of hyperthyroidism is not long. The beta-adrenergic
blockade may be effective in controlling the ventricular rate. Increased plasma clearance of
beta-blockers may necessitate higher doses [66]. Among them propranolol has the advantage
of blocking the conversion of T4 to T3 in peripheral tissues, however other cardioselective beta-
blockers have a longer half-life and can be equally effective on the heart. In cardiac arrhythmias
intravascular infusion of calcium blockers should be avoided due to the risk of a further fall
in PVR [67]. It is still controversial whether the patients with AF should have anticoagulant
therapy to prevent systemic embolization. It is advised to evaluate each patient on a case-by-
case basis, and determine the risk of bleeding over embolization [68,69]. In younger patients
with hyperthyroidism and AF, who do not have other heart disease, hypertension, or inde‐
pendent risk factors for embolization, the risk of anticoagulant therapy may suppress its
benefits. But it would be appropriate to administer anticoagulant agents to older patients with
known or suspected heart diseases, or AF with longer duration. When oral anticoagulants will
be used, it should be considered that hyperthyroid patients will need smaller doses than
euthyroid ones, due to faster elimination of vitamin-K dependent clotting factors [70].
In the patients with AF the maintenance of sinus rhythm is not possible until the euthyroid
state is restored, so electrical cardioversion is not recommended without confirming the
euthyroid status.
Many hyperthyroid patients experience exercise intolerance and exertional dyspnea, in part
because of weakness in the skeletal and respiratory muscle [71] and also due to inability to
increase heart rate or lower vascular resistance further, as normally occurs in exercise [72]. The
tem “high output heart failure” has not been used in recent decades, because it is clear that the
heart is still able to increase cardiac output at rest and with exercise. In the setting of low
vascular resistance and decreased preload, the cardiac functional reserve is compromised and
cannot rise further to accommodate the demands of submaximal or maximal exercise [73].
About 6% of thyrotoxic patients develop heart failure and less than 1% develop dilated
cardiomyopathy with impaired left ventricular systolic dysfunction, due to the tachycardia-
mediated mechanism leading to an increased level of cytosolic calcium during diastole, with
reduced contractility of the ventricle and diastolic dysfunction, often with tricuspid regurgi‐




thyrotoxic patients older than 40 years of age, whereas in younger ones marked reduction in
peripheral vascular resistance and increased cardiac output were prominent [75].
Hyperthyroidism may complicate or cause pre-existing cardiac disease because of increased
myocardial oxygen demand, increased contractility and heart rate, and may cause silent
coronary artery disease, anginas or compensated heart failure and even endothelial dysfunc‐
tion [76]. Treatment of heart failure with tachycardia should include a beta-blocker, by
considering its contraindications in each patient. Furosemide may help to reverse the volume
overload, but digoxin is less beneficial when compared with euthyroid heart failure patients
because there may be relative resistance to its action, due to greater blood volume (distribution)
and the need to block more Na-K-ATPase in myocardium [70].
Subclinical hyperthyroidism is a state characterised by low serum thyrotropin levels and
normal serum thyroid hormone concentrations. Over recent decades this state has also been
found to be associated with some abnormalities in cardiac function. Enhanced systolic function
and impaired diastolic function due to slowed myocardial relaxation may cause increased left
ventricular mass in these subjects, together with increased heart rate and arrhythmias by
similar mechanisms as overt hyperthyroidism [77,78]. In people over 60 years of age subclinical
hyperthyroidism was associated with a tripled risk of atrial fibrillation during a 10-year follow-
up period [79]. In a recent cross-sectional study with 29 patients, subclinical hyperthyroidism
was found to be related with impaired functional response to exercise with low oxygen
consumption and exercise threshold, together with slower heart rate recovery [80].
Besides  antithyroid  treatment  strategies,  beta-blocker  therapy  reduces  heart  rate  and
improves  left  ventricular  mass,  but  positive  inotropic  response  persists.  This  subclinical
hyperthyroidism is associated with increased cardiovascular mortality [81]. In the study of
Heeringa et al with 1,426 patients, it was shown that even the high-normal thyroid function
may  increase  the  risk  of  AF  [82].  Besides  increased  AF  and  thromboembolic  events,
increased left ventricular mass and left ventricular function may be the reason. Thus, it is
advised to measure serum thyrotropin in all elderly patients with systolic hypertension, a
widened  blood  pressure,  recent-onset  angina,  atrial  fibrillation  and  any  exacerbation  of
ischemic heart disease and treat it [72,83].
3. Progressive infiltrative ophtalmopathy in hyperthyroidism
3.1. Hyperthyroidism and eye disease
Thyroid eye disease (TED), also called thyroid-associated ophthalmopathy (TAO) and Graves'
ophthalmopathy (GO), affects 25–50% of patients with Graves' disease [84]. Regardless of
whether hyperthyroidism occurs first, the signs and symptoms of GO become manifest in 85%
of patients within 18 months [85]. The clinical features are usually mild. Most common
symptoms are; ocular irritation with redness and tearing,, sensitivity to light, double vision,
blurring of vision, and feeling a pressure sensation behind the eyes. On physical examination,
extraocular muscle dysfunction, proptosis, periorbital and eyelid edema, conjunctival chemos,
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lid lag and retraction (or stare), or exposure keratitis may be detected [86]. Most patients
experience only the minor congestive signs of TAO (chemosis, injection, lid edema), with
improvement in several months without treatment. Approximately 28% of TAO cases are
severe and symptomatic for several years. Symptoms and signs include, restricted motility
leading to diplopia, exposure keratopathy, optic neuropathy and loss of vision [87,88].
TAO can be divided into two clinical stages; congestive and fibrotic. In the congestive or
inflammatory stage, auto-immunity leads to inflammatory cellular infiltration of the muscles
and transformation of fibroblasts into adipose tissue. The fibrotic stage is characterized by
fibrosis which causes proptosis and strabismus [89,90].
3.2. Pathophysiology
In TAO, the most important pathological changes are enlarged extraocular muscles and
increased orbital fat. These changes result from a complex interplay among orbital fibroblasts,
immune cells, cytokines, auto-antibodies, genetics, and environmental factors [84].
Interactions between orbital fibroblasts, immune cells, cytokines and autoantibodies
Patients with TAO, orbital tissue is infiltrated by inflammatory cells (T helper type 1 (Th1)
and T helper type 2 (Th2) lymphocytes, B lymphocytes, mast cells, and macrophages) [91,92].
These  cells  release  cytokines  which  participate  in  tissue  reactivity  and  remodeling.
Normally, the antigens to which lymphocytes respond are foreign, and several tolerance
mechanisms act to prevent the development of reactivity to self-antigens or autoimmuni‐
ty,  but  these  tolerance  mechanisms  sometimes  fail  and  autoimmunity  develops  [93,94].
Fibroblasts are a highly interactive cell type, described as “sentinel cells” [95]. They, respond
to immune stimulation and actively participate  in  the inflammatory pathway [96,97].  In
patients  with  TAO,  orbital  fibroblasts  synthesize  excess  glycosaminoglycans  (GAGs),
including  hyaluronan.  These  can  differentiate  into  adipocytes,  leading  to  the  accumula‐
tion of fat [98]. Orbital fibroblasts do not express the IL-1 receptor antagonist at levels found
in other fibroblasts,  but also display lymphocyte costimulatory molecules such as CD40.
These differentations result  in excessively high levels  of  Cox-2 and PGE2 in response to
proinflammatory  cytokines  [99,100].  T  lymphocytes  in  the  orbital  tissue  interact  with
fibroblasts. This interaction results with activation and proliferation of fibroblasts, synthe‐
sis of extracellular macromolecules, and differentiation to adipocytes [101]. A summary of
this model for the pathogenesis of TED is depicted in Figure 1 [102].
Autoantigen expression by orbital fibroblasts results in T lymphocyte accumulation to the orbit
[103]. The autoantigen may be a TSH receptor (TSH-R) or an insulin-like growth factor-1
receptor (IGF-1R) [103,104]. T lymphocytes in the orbital tissue induce fibroblast proliferation
and hyaluronan synthesis. This result in orbital tissue remodeling [101]. Stimulation of orbital
fibroblasts by T lymphocytes results in production of chemokines (e.g. IL-16, RANTES) and
cytokines (e.g. IL-6). These molecules initiate migration of T and B lymphocytes to the orbital
tissue and increase fibroblast presentation of autoantigens [97,101,105). Costimulatory
molecules, adhesion molecules, and cytokines like IFNγ, IL-1β, and TNFα play an important
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pathways of T lymphocytes and orbital fibroblasts is the CD40-CD40 ligand pathway
[97,100,101]. In TAO orbital fibroblasts express high levels of CD40 [97,106]. Activation by
CD40L induces hyaluronan synthesis, IL-6 and IL-8, Cox-2 and PGE2 [97,101,107].
T lymphocyte-mediated activated fibroblasts release factors which promote and activate the
proliferation of T lymphocytes. In this way fibroblasts perpetuate inflammation [101,108].
Antonelli et al. found that orbital fibroblasts from TAO patients may modulate the activity of
T lymphocytes through the production of CXCL10. Serum CXCL10 levels were higher in active
TAO patients than in those with inactive disease. CXCL10 release enhances the migration of
T lymphocytes into the orbital tissue. These lymphocytes secrete IFNγ and TNFα. There is a
positive feedback between CXCL10 and IFNγ – TNFα. Peroxisome proliferator-activated
receptor-gamma (PPAR-γ) activation has an inhibitory role in this process [108]. Feldon et al.
found that activated human T lymphocytes drive the differentiation of human fibroblasts to
adipocytes. They showed that human T cells, when activated, strongly express Cox-2 and
produce PGs, possibly 15d-PGJ2, that are PPAR-γ ligands and human T cells also produce
PGD2. These findings showed that PGD2 converts to the PGJ series of PGs with the final product
being 15d-PGJ2, a notable potent PPAR-γ ligand [109-111]. Feldon et al. also showed that
human orbital fibroblasts express PPAR-γ and that 15d-PGJ2, PGD2, and 15d-PGD2 strongly
induce adipogenesis [109]. Natural and synthetic activators of PPAR-γ stimulate lipid
accumulation and the expression and secretion of adiponectin [112,113]. PPAR-γ levels are
higher in orbital tissue from patients with active TAO [108,114].
Chen et al. showed higher mRNA levels of a macrophage chemoattractant called C-C motif
chemokine ligand-2 (CCL2)/monocyte chemoattractant protein-1 (MCP-1) and dense infiltra‐
tion with macrophages in the orbital fat compared with normal controls [115].
3.3. Smoking
There is a strong and consistent association between smoking and TAO [116]. But the exact
mechanism by which smoking affects TAO is not known. Formation of superoxide radicals
and tissue hypoxia could be responsible. Cigarette smoke either contains or can generate a
variety of oxidants and free radicals [117]. Orbital fibroblasts can be induced by tissue hypoxia
(5% CO2 and 95% N2) and superoxide radicals, thus they proliferate and synthesize GAGs
[118,119]. Mack et al. cultured orbital fibroblasts, obtained from patients undergoing orbital
decompression for severe GO. They showed that, inreased human leukocyte antigen (HLA-
DR) expression of orbital fibroblasts occurred in response to nicotine and tar only in the
presence of interferon-γ. These findings suggest that there is an interaction between smoking
and orbital immune responses [120]. Many studies demonstrated a dose-response relationship
between the numbers of cigarettes smoked per day and TAO [121]. Smokers suffer more severe
TAO than non-smokers. Smoking increases the progression of TAO after radioiodine therapy
for hyperthyroidism [116]. Eckstein et al. demonstrated that smoking influences the course of
TAO during treatment in a dose dependent manner. The response to treatment is delayed and
considerably poorer in smokers [122]. Pfeilschifter et al. showed that former smokers had a
significantly lower risk for the occurrence of proptosis and diplopia than active smokers with
a comparable lifetime cigarette consump
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Figure 1. Pathophysiology of thyroid eye disease
3.4. Genetics
For the development of TAO the presence of autoimmune thyroid disease appears to be
necessary, but not sufficient [124]. The interaction between genetic and environmental factors
plays a major role for the development of TAO in a patient with autoimmune thyroid disease.
TAO and autoimmune thyroid disease share a common etiology; regardless of which occurs
first, the other develops within 18 months in 80% of affected patients [125]. Polymorphic
variations in individual somatic genes or groups of genes known to be involved in thyroid
autoimmunity might also predispose to TAO.
Thymic stromal lymphopoietin (tslp) gene promoter polymorphisms
The role of TSLP in Th17 cell differentiation implicates TSLP in the pathogenesis of TAO. Tsai
et al. genotyped 470 patients with TAO at 3 single nucleotide polymorphisms (SNPs) in TSLP
and determined the serum concentrations of TSLP in 432 patients and 272 controls. They
showed that TSLP polymorphisms are associated with TAO and that expression levels of TSLP
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Figure 1. Pathophysiology of thyroid eye disease
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the differentiation of CD4+T cells into Th17 cells. According to this study the TSLP gene may
be a relevant candidate gene for susceptibility to TAO. TSLP genotypes may be used as genetic
markers for the diagnosis and prognosis of TAO [126].
Toll-like receptor gene polymorphisms
Toll-like receptors (TLRs) are a family of pattern-recognition receptors, which play a role in
eliciting innate/adaptive immune responses and developing chronic inflammation. Liao et al
evaluated 6 TLR-4 and 2 TLR-9 gene polymorphisms in 471 GD patients (200 patients with
TAO and 271 patients without TAO) from a Taiwan Chinese population. There was no
statistically significant difference in the genotypic and allelic frequencies of TLR-4 and TLR-9
gene polymorphisms between the GD patients with and without TAO. In the sex-stratified
analyses they showed that the association between TLR-9 gene polymorphism and the TAO
phenotype was more pronounced in the male patients. Their data suggest that TLR-9 gene
polymorphisms are significantly associated with increased susceptibility of ophthalmopathy
in male GD patients [127].
Polymorphisms of B7 molecules (CD80 and CD86)
Liao et al. evaluated genotypes of CD80 and CD86 polymorphism in GD patients. They found
that the frequency of C allele at position rs_9831894 of the CD86 gene is different in patients
with GD (with and without TAO). They showed that the G-A haplotype has a protective effect
in the development of TAO among patients with GD. Their data suggest that the polymor‐
phisms of the CD86 gene may be used as genetic markers for making the diagnosis and
prognosis of TAO [128].
Interleukin-1beta (IL1β) polymorphisms
Recent studies have demonstrated that IL1β plays a role in the development of TAO by
inducing adipogenesis and accumulation of GAGs and prostaglandin E2 (PGE2) [129,130]. Liu
et al. found that the SNPs rs3917368 and rs1143643 in the 3′ UTR and intron regions of IL1β
and patients with the genotypes containing both rs3917368 A/A and rs1143643 A/A may bear
a higher risk of developing TAO. Thus we can speculate that IL1β polymorphisms can be
related with the development of TAO in GD [131].
Cytotoxic T lymphocyte antigen-4
Vaidya et al. firstly reported an association between CTLA-4A/G polymorphism at codon 17
and TAO [132], but this data was not confirmed by Allahabadia et al. in a larger cohort of
patients [133]. Daroszewski et al. evaluated the relation between soluable CTLA-4 level and
clinical manifestation of TAO and CTLA-4 gene polymorphisms. They found higher levels
of Serum sCTLA-4 in the TAO group than in controls. The level of sCTLA-4 was higher in
severe TAO patients than in non-severe cases. They showed for the first time that the pres‐
ence of the CTLA-4 gene polymorphisms Jo31 and CT60 were related with elevated sCTLA-4
levels [134]. These data suggest that the polymorphisms of the CTLA-4 gene may be used as
a genetic marker for making the diagnosis and prognosis of TAO. The role of sCTLA-4 and
its full-length cell-bound analogue in autoimmunity remains uncertain.
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PPAR-γ gene polymorphism
The PPAR-γ transcription factor is involved in both adipogenesis and inflammation which
have been implicated in the pathogenesis of TAO. Alevizaki et al. found no difference in the
distribution of the Pro(12)Ala PPAR-γ gene polymorphism between GD patients with and
without TAO. But they showed that PPAR-γ polymorphism carriers had lower TSH-Rab levels
and lower clinical activity scores (CAS). According to this study patients with TAO who have
this polymorphism are associated with less-severe and less-active disease [135].
IL-23R polymorphisms
Huber et al. demonstrated that two IL-23R polymorphisms (rs10889677 and rs2201841) were
associated with TAO. According to this study we can speculate that these variants may induce
TAO by changing the expression and/or function of IL-23R, by promoting a pro-inflammatory
signaling cascade [136].
Protein tyrosine phosphatase-22
Lymphoid protein tyrosine phosphatase (LYP, aka PTPN-22) represents another negative
regulator of T cell activation. Syed et al. found an association between certain single nucleotide
polymorphisms (SNPs) in the protein tyrosine phosphatase (PTP) called PTPN12 and in‐
creased risk of mild/moderate ophthalmopathy [137]. But this data should be confirmed in
larger studies.
Nuclear factor (NF)-[kappa]B1
Kurylowicz et al. showed a correlation between a polymorphism in the NF-[kappa]B1 gene
promoter (-94ins/del adenine, thymine, thymine, guanine) and the development of TAO [138].
Human leukocyte antigen (HLA)
HLA class I-II genes are related for the development of TAO [139]. Akaishi et al. found TAO
patients with major extraocular muscle involvement have had a higher frequency of the HLA-
DRB1*16 allele, but patients with minor extraocular muscle involvement have had a higher
frequency of the HLA-DRB1*03 allele [140]. In another study an association between HLA-
A11,-B5,-DW12 and-DR14 and TAO has been found [141,142].
3.5. Cytokines
Autoimmune thyroid disease involves the activation of multiple cytokine networks. Serum
IL-6 levels were greater in the patients with TAO than in those without eye disease [143] and
both Th1-and Th2-derived cytokines were elevated in TAO patients compared with control
samples [144]. Chen et al. found that the exaggerated capacity of orbital fibroblasts to express
high levels of both IL-6 and its receptor in an anatomic site-selective manner could represent
an important basis for immune responses in TAO [145]. Higher serum levels of IL-17 were
obtained in TAO patients than in controls. Serum IL-17 concentration had significant correla‐
tion with CAS [146]. Significantly higher PAI-1 [147] and IgE levels [148] were found in TAO
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PPAR-γ gene polymorphism
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3.6. Imaging procedures in TAO
Ultrasound (US)
US is of primary importance in orbital pathology because of its safety, non-invasiveness, short
time of investigation, low cost, lack of radiation and application without need to prepare the
patient. In endocrine orbitopathy; the A scan demonstrates echographical widening of the
peripheral orbital space and a widening of the muscle echo, while the B scan shows a high
internal echo of the connective tissue septa, increased reflection of the muscle belly and
distension of the retrobulbar optic nerve sheaths, enlargement of lacrimal gland and dilatation
of the superior ophthalmic vein [149]. Although it has many advantages, US cannot effectively
display the muscles at the apex of the orbit. US is not as effective as other diagnostic procedures
in delineating the relationship of orbital pathology to contiguous structures, nor is it reliable
in imaging lesions of either the posterior orbit or those involving the bone walls [150].
Computed tomography (CT)
According to differential X-ray absorption CT can differentiate normal and abnormal struc‐
tures of different tissue density. In CT orbital fat images as a black, low-density area, while in
contrast to this extraocular muscles and the optic nerve image as higher-density areas [151].
The primary areas of orbital involvement are extraocular muscles, and CT findings correlate
with clinical impressions of the severity of extraocular muscle enlargement [152]. Muscle
involvement on CT of TAO is usually limited to the non-tendonous portion of the muscle. Due
to compression of the optic nerve by enlarged extraocular muscles near the orbital apex, optic
nerve dysfunction can be seen in TAO [153]. Other findings that may be noted on CT are
lachrymal gland enlargement, a dilated superior opthalmic vein, muscle belly enlargement
and increase in orbital fat volume [154,55]. CT imaging is a non-invasive, simple, fast, and cost
effective imaging procedure. Furthermore, having high sensitivity and correlation with clinical
findings, CT imaging should be considered first during diagnostic evaluation of TAO.
Magnetic resonance imaging (MRI)
Pulse sequences that examine T2 in MRI can estimate the water content of tissues. In TAO
lymphocytes infiltrate the orbital tissue that causes fibroblast stimulation. Fibroblasts produce
large amounts of GAGs. By binding large amounts of water, GAGs cause edema. Increased
water content of thickened extra-ocular muscles cause elevated T2 [156]. In TAO there are two
different phases with disease activity. Medical treatment can be effective in the active stage.
Therefore, for predicting the outcome of medical management the evaluation of disease
activity is important. Yokoyama et al. investigated whether MRI could assess the disease
activity in TAO. They found that MRI is not only a useful tool for detection of extraocular
muscle enlargement, but also for assessment of disease activity in TAO [157]. In conclusion,
MRI is useful to assess TAO. But cost and availability are current limitations of this modality.
Therefore, MRI should be used for the management of TAO in specialized patients and clinics.
Octreoscan (OCT)
It is thought that radionuclide accumulation is probably due to binding to somatostatin
receptors on lymphocytes, myoblasts, fibroblasts and endothelial cells. Another explanation
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is local blood pooling due to venous stasis by the orbital inflammation [158,159]. Krassas et al.
found that OCT positivity is higher in Graves' patients with than in those without ophthalm‐
opathy, and higher in patients with active TAO than in those with inactive TAO [160]. Postema
et al. demonstrated that OCT positivity correlates with activity of the TAO such as high CAS
[161]. Thus, a positive orbital OCT means clinically active TAO, in which immunosuppressive
treatment might be of therapeutic benefit [162]. However, limitations such as cost, non-
negligible radiation burden, non-specific examination for TAO, and finally, lack of evaluation
of eye muscle swelling restrict the widespread use of this technique [163]. Orbital OCT is
mainly indicated to select patients with TAO who will benefit from immunosuppression [162].
3.7. Other diagnostic techniques
Kuo et al. were first described in a positron emission tomography (PET/CT) study in a patient
with TAO. The detection of inflammation by 18F-fluorodeoxyglucose (FDG) uptake was
sensitive and objectively demonstrable by this semi-quantitative imaging method [164].
García-Rojas et al. carried out the first prospective study. FDG uptake of extra-ocular muscles
was statistically different between patients with and without TAO. In cases with TAO where
clinical doubt exists, PET/CT provides valuable and useful information for the diagnosis,
characterization, and therapeutic decision [165]. Further research is required to define the role
of FDG-PET/CT in the management of TAO.
Another tool to measure orbital inflammation is the uptake of radioactively labeled substances,
such as 67Gallium (Ga) citrate [166] and 99mTechnetium (Tc)-labeled agents [167,168]. In medical
literature there are few studies about these nuclear imaging techniques.
3.8. Clinical classification systems
The treatment for TAO varies according to the level of disease activity. Thus, methods have
been proposed to determine whether TAO is active (33). There are two main scoring systems
[169,170]:
1. NOSPECS (No signs or symptoms; Only signs; Soft tissue involvement with symptoms
and signs; Proptosis; Eye muscle involvement; Corneal involvement; Sight loss)
2. CAS (Clinical Activity Score) systems.
Neither NOSPECS nor CAS are both specific and completely reliable, but CAS is a simple
office-based tool. The modified NOSPECS criteria include lid retraction, soft tissue inflamma‐
tion, proptosis, size difference, extra-ocular muscle involvement, corneal defects, and optic
nerve compression [169]. CAS demonstrates the presence or absence of seven symptoms or
signs that indicate inflammation (Table-1) [171].
The score ranges from 0 to 7, with 0 to 2 characteristics indicating inactive TAO and 3 to 7
characteristics indicating active TAO. The CAS has a high predictive value for the outcome of
immunosuppressive treatment in TAO. The main determinant of therapeutic outcome is




3.6. Imaging procedures in TAO
Ultrasound (US)
US is of primary importance in orbital pathology because of its safety, non-invasiveness, short
time of investigation, low cost, lack of radiation and application without need to prepare the
patient. In endocrine orbitopathy; the A scan demonstrates echographical widening of the
peripheral orbital space and a widening of the muscle echo, while the B scan shows a high
internal echo of the connective tissue septa, increased reflection of the muscle belly and
distension of the retrobulbar optic nerve sheaths, enlargement of lacrimal gland and dilatation
of the superior ophthalmic vein [149]. Although it has many advantages, US cannot effectively
display the muscles at the apex of the orbit. US is not as effective as other diagnostic procedures
in delineating the relationship of orbital pathology to contiguous structures, nor is it reliable
in imaging lesions of either the posterior orbit or those involving the bone walls [150].
Computed tomography (CT)
According to differential X-ray absorption CT can differentiate normal and abnormal struc‐
tures of different tissue density. In CT orbital fat images as a black, low-density area, while in
contrast to this extraocular muscles and the optic nerve image as higher-density areas [151].
The primary areas of orbital involvement are extraocular muscles, and CT findings correlate
with clinical impressions of the severity of extraocular muscle enlargement [152]. Muscle
involvement on CT of TAO is usually limited to the non-tendonous portion of the muscle. Due
to compression of the optic nerve by enlarged extraocular muscles near the orbital apex, optic
nerve dysfunction can be seen in TAO [153]. Other findings that may be noted on CT are
lachrymal gland enlargement, a dilated superior opthalmic vein, muscle belly enlargement
and increase in orbital fat volume [154,55]. CT imaging is a non-invasive, simple, fast, and cost
effective imaging procedure. Furthermore, having high sensitivity and correlation with clinical
findings, CT imaging should be considered first during diagnostic evaluation of TAO.
Magnetic resonance imaging (MRI)
Pulse sequences that examine T2 in MRI can estimate the water content of tissues. In TAO
lymphocytes infiltrate the orbital tissue that causes fibroblast stimulation. Fibroblasts produce
large amounts of GAGs. By binding large amounts of water, GAGs cause edema. Increased
water content of thickened extra-ocular muscles cause elevated T2 [156]. In TAO there are two
different phases with disease activity. Medical treatment can be effective in the active stage.
Therefore, for predicting the outcome of medical management the evaluation of disease
activity is important. Yokoyama et al. investigated whether MRI could assess the disease
activity in TAO. They found that MRI is not only a useful tool for detection of extraocular
muscle enlargement, but also for assessment of disease activity in TAO [157]. In conclusion,
MRI is useful to assess TAO. But cost and availability are current limitations of this modality.
Therefore, MRI should be used for the management of TAO in specialized patients and clinics.
Octreoscan (OCT)
It is thought that radionuclide accumulation is probably due to binding to somatostatin
receptors on lymphocytes, myoblasts, fibroblasts and endothelial cells. Another explanation
Thyroid Disorders - Focus on Hyperthyroidism76
is local blood pooling due to venous stasis by the orbital inflammation [158,159]. Krassas et al.
found that OCT positivity is higher in Graves' patients with than in those without ophthalm‐
opathy, and higher in patients with active TAO than in those with inactive TAO [160]. Postema
et al. demonstrated that OCT positivity correlates with activity of the TAO such as high CAS
[161]. Thus, a positive orbital OCT means clinically active TAO, in which immunosuppressive
treatment might be of therapeutic benefit [162]. However, limitations such as cost, non-
negligible radiation burden, non-specific examination for TAO, and finally, lack of evaluation
of eye muscle swelling restrict the widespread use of this technique [163]. Orbital OCT is
mainly indicated to select patients with TAO who will benefit from immunosuppression [162].
3.7. Other diagnostic techniques
Kuo et al. were first described in a positron emission tomography (PET/CT) study in a patient
with TAO. The detection of inflammation by 18F-fluorodeoxyglucose (FDG) uptake was
sensitive and objectively demonstrable by this semi-quantitative imaging method [164].
García-Rojas et al. carried out the first prospective study. FDG uptake of extra-ocular muscles
was statistically different between patients with and without TAO. In cases with TAO where
clinical doubt exists, PET/CT provides valuable and useful information for the diagnosis,
characterization, and therapeutic decision [165]. Further research is required to define the role
of FDG-PET/CT in the management of TAO.
Another tool to measure orbital inflammation is the uptake of radioactively labeled substances,
such as 67Gallium (Ga) citrate [166] and 99mTechnetium (Tc)-labeled agents [167,168]. In medical
literature there are few studies about these nuclear imaging techniques.
3.8. Clinical classification systems
The treatment for TAO varies according to the level of disease activity. Thus, methods have
been proposed to determine whether TAO is active (33). There are two main scoring systems
[169,170]:
1. NOSPECS (No signs or symptoms; Only signs; Soft tissue involvement with symptoms
and signs; Proptosis; Eye muscle involvement; Corneal involvement; Sight loss)
2. CAS (Clinical Activity Score) systems.
Neither NOSPECS nor CAS are both specific and completely reliable, but CAS is a simple
office-based tool. The modified NOSPECS criteria include lid retraction, soft tissue inflamma‐
tion, proptosis, size difference, extra-ocular muscle involvement, corneal defects, and optic
nerve compression [169]. CAS demonstrates the presence or absence of seven symptoms or
signs that indicate inflammation (Table-1) [171].
The score ranges from 0 to 7, with 0 to 2 characteristics indicating inactive TAO and 3 to 7
characteristics indicating active TAO. The CAS has a high predictive value for the outcome of
immunosuppressive treatment in TAO. The main determinant of therapeutic outcome is




assessed (Table-2). Dysthyroid optic neuropathy, corneal breakdown or both indicate that the
TAO is sight-threatening and requires immediate treatment [116].
∙ Spontaneous retrobulbar pain
∙ Pain with eye movement
∙ Redness of the eyelids
∙ Redness of the conjunctiva
∙ Swelling of the eyelids
∙ Swelling of the caruncle
∙ Conjunctival edema (chemosis)
Table 1. Components of the Clinical Activity Score
∙ Lid aperture
∙ Swelling of the eyelids
∙ Redness of the eyelids
∙ Redness of the conjunctivae
∙ Conjunctival edema
∙ Inflammation of the caruncle or plica
∙ Exophthalmos
∙ Subjective diplopia score
∙ Eye muscle involvement
∙ Corneal involvement
∙ Optic nerve involvement
Table 2. Assesment of Disease Severity
3.9. Management
Smoking and TAO
Patients should be encouraged to quit smoking. In an observational study smoking cessation
has been associated with a decreased risk of the development of exophthalmos and diplopia
in patients with Graves' disease [171].
Management of hyperthyroidism in patients with TAO
Uncontrolled thyroid functions (both hyper-and hypothyroidism) are related to severe TAO.
Patients with hyperthyroidism can be treated with anti-thyroid drugs (ATDs), radioactive
iodine (RAI) therapy and surgical therapy. Some different studies have shown improve‐
ment  in  TAO  [173]  by  indirect  beneficial  effects  [174]  and  a  gradual  decrease  in  TSH-
receptor antibody (TRAb) levels during ATDs treatment [175]. There are confliciting reports
in  medical  literature  about  RAI  therapy and severe  TAO [176,177].  But  this  association
cannot be excluded. This risk can be eliminated by therapy with oral glucocorticoids (GCs)
after RAI therapy and avoiding post-treatment hypothyroidism [116]. Thyroidectomy is an
effective treatment choice for the definitive cure of hyperthyroidism. Wilhelm et al. showed
that  near-total/total  thyroidectomy  is  safe  and  superior  to  subtotal  thyroidectomy  for
management of hyperthyroidism in Graves' disease [178]. According to the European Group
on Graves' Orbitopathy (EUGOGO) Consensus Statement; ATD therapy and thyroidecto‐
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my  do  not  affect  the  course  of  TAO.  No  particular  ATD  or  regimen,  nor  any  type  of
thyroidectomy (subtotal or total) has been demonstrated to have any advantages in terms
of outcome of TAO in hyperthyroidism [116].
3.10. Pharmacologic treatments
TAO represents a complex therapeutic problem. Currently available pharmacologic treatment
options result in a partial or absent response of the ophthalmopathy. Up to date available
treatments for TAO are as follows:
Glucocorticoids
Glucocorticoids (GCs) are effective treatment options in TAO because of their antiinflamma‐
tory and immunosuppressive actions (96). Moreover they decrease GAGs synthesis and
secretion by orbital fibroblasts [180].
GCs can be administrated by oral, local (retrobulbar or subconjunctival) and intravenous
routes. Oral GCs are generally used in high doses (prednisone, 60–100 mg/day or equiva‐
lent  doses  of  other  steroids)  and  for  long-time  periods  (several  months).  It  has  been
demonstrated  that  high-dose  oral  GCs  are  effective  on  soft  tissue  changes  and  optic
neuropathy. But when its dose is tapered down and/or withdrawn, recurrence of active eye
disease is a frequent problem [181]. In slightly more than 60% of cases (range: 40–100%)
favorable effects of high-dose oral GCs are reported. GCs have also been used intravenous‐
ly.  In  most  studies  effects  have  been  observed  on  inflammatory  signs  and  optic  nerve
involvement.  But  the effects  on extra-ocular  muscle involvement,  and especially propto‐
sis, have not been constantly impressive [90].
In most studies patients treated with intravenous GCs have had more favorable results
compared with patients treated with oral GCs [18,183]. But in almost all studies treatment with
intravenous GCs have been associated with, in the interpulse periods, or followed by (often
prolonged) treatment with oral GCs. Moreover there have been biases in patient selections
(different degrees of disease activity and duration). Bartalena et al. compared the efficacy and
safety of three doses of intravenous (IV) methylprednisolone (2.25, 4.98, or 7.47 g in 12 weekly
infusions) in patients with moderate to severe and active TAO. They demonstrated that the
use of a cumulative dose of 7.47 g of methylprednisolone provides short-term advantage over
lower doses. This benefit was transient and associated with slightly greater toxicity. According
to this study we can speculate that an intermediate-dose regimen be used in most cases and
the high-dose regimen be reserved to the most severe cases of TAO [184]. Systemic glucocor‐
ticoid therapy relates with some side effects and complications. Therefore, local (retrobulbar
or subconjunctival) glucocorticoid therapy has been raised. But in most studies local gluco‐
corticoid therapy had been less effective than systemic administration. As a result, local
glucocorticoid therapy can be a treatment option in patients with active ophthalmopathy and
with major contraindications to the systemic administration [181].
GCs are generally used for severe and active TAO [90]. Furthermore, patients with sight-
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glucocorticoid agents [116]. Additionally, there are some case reports in medical literature,
who had severe complicatons related with high-dose glucocorticoid pulse therapy [185].
Somatostatin (SST) analogues
SST receptors (SSTR) are expressed in many tissues, including activated lymphocytes. OCT
was proposed as a method to evaluate orbital inflammation in TAO. The use of the SST analog,
octreotide, was first reported in TAO patients by Chang et al [186]. Uysal et al. evaluated the
effect of octreotide treatment in nine patients with TAO. Seven of the patients showed
improvement in CAS. Proptosis improved either slightly or significantly in seven patients.
None of the patients has showed deterioration in the eye according to their findings [187]. A
major disadvantage of octreotide is its short half-life, which requires multiple injections. To
overcome this limitation, new long-acting SST analogs (lanreotide / octreotide-LAR) have been
developed. Stan et al. carried out a randomized, double-blind, placebo-controlled trial of
octreotide-LAR for treatment of TAO. In octreotide-LAR-treated patients, the CAS improved
with a greater degree than in the placebo group. They noted improvement in eyelid fissure
width, which suggest that octreotide LAR treatment may be effective in TAO patients with
significant lid retraction [188]. In another study Krassas et al. aimed to investigate the orbital
Indium-111-pentetreotide activity after treatment with octreotide and lanreotide in patients
with TAO. All patients treated with SST analogs had a negative follow-up OCT, whereas
controls had a positive OCT. Both NOSPECS score and CAS had improved in the treatment
group, but there have been no changes in control subjects [189]. Most common side effects of
SST analog therapy in TAO patients were mild gastrointestinal symptoms occurring during
the first week of treatment. Because of minimal side effects and proven efficacy, SST analogs
could be a treatment option in selected patients. But we need further large, multi-center,
prospective and randomized clinical trials and a comparable series of patients with other
established treatment options, to achieve more accurate outcomes. In addition, the high cost
of this treatment must also be taken into account.
Intravenous immunoglobulins (IVIG)
Antonelli et al. was published as the first non-randomized study on the use of IVIGs for TAO.
They treated 7 patients with high-dose IVIGs alone (400 mg/kg/day for 5 consecutive days; the
cycle was repeated five times at 3-week intervals) and 7 patients with IVIGs associated with
orbital radiotherapy. The results were compared with a historical group of patients previously
treated with high-dose GCs and orbital radiotherapy. They found that IVIGs, either alone or
combined with orbital radiotherapy, had improved the ocular conditions. This result did not
differ from those obtained in the historical group [190]. In a randomized trial by Kahaly et al.
19 patients with active TAO were treated with a 20-week course of oral prednisolone (P,
starting dose 100 mg/day), and 21 received 1g immunoglobulin/kg body weight for 2 consec‐
utive days every 3 weeks. The immunoglobulin course was repeated six times. The degree of
clinical improvement between two groups was not significant. There was a marked reduction
of thyroid antibody titres in the immunoglobulin group. Side effects were more frequent and
severe during P than during immunoglobulin therapy [191]. But another study by Seppel et
al. failed to show any beneficial effects of IVIGs in TAO [192]. In summary, treatment studies
with IVIGs include small numbers of patients and all of them are not randomized. In addition
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to this, treatment is quite expensive and is related with disease transmission using plasma-
derived products. More prospective, randomized and controlled trials, which includes large
series of patients are required to obtain more accurate results.
Immunosuppressive drugs
a. Cyclosporine A (CyA): The first report by Weetman et al. showed that CyA had positive
effects  on  ocular-muscle  function,  visual  acuity,  exophthalmos  and orbital  muscle  swel‐
ling [193]. Prummel et al. compared two groups of 18 patients each of which were treated
with either cyclosporine or prednisone. At the end of the study, treatment response was
observed  in  11  patients  treated  with  prednisone,  but  only  in  4  patients  treated  with
cyclosporine [194]. Weissel et al. treated 8 patients with TAO, all of whom had compres‐
sive optic nerve disease (CON), by a combined treatment with CyA and cortisone. CON
disappeared completely in all patients [195]. In summary, the use of CyA has been reported
in several studies. Given the side effects of CyA, some of which can be severe, it should
not be considered as a first-line treatment in TAO. The use of CyA might be maintained
in patients who are resistant to GCs alone, and in whom the persistent activity of the disease
warrants  a  continuing  medical  intervention.  According  to  the  recent  European  Thyroid
Association survey CyA or azathioprine were indicated as suitable therapeutic options by
only 6% and 2% of respondents respectively [196].
b. Methotrexate (MTX): MTX is not a novel drug, but it has not systematically been evaluated
in TAO management. Smith et al. carried out the unique study on the use of MTX for non-
infectious orbital inflammatory disorders like TAO. They included 14 patients, and three of
them had TAO. All three patients with TAO had an improvement in their ocular conditions
after MTX treatment [196] According to the recent European Thyroid Association survey MTX
was indicated as a therapeutic option by only 1% of respondents [197]. MTX has many dose-
dependent and reversible side effects and should not be used as a first-line treatment. In
patients with GC dependency, it can be used at low doses with the aim of reducing the dose
of GCs. However, to clarify the effectiveness of MTX in TAO management we need more
controlled and randomized prospective studies.
Antioxidants
Bouzas et al. carried out a prospective, nonrandomized, comparative study on the effects of
the antioxidant agents allopurinol and nicotinamide in TAO patients. Ocular conditions
significantly improved in antioxidant-treated patients, more than placebo-treated patients
[198]. Yoon et al. investigated the inhibitory effect of quercetin on inflammation in cultured
whole orbital tissue. Quercetin had a significant suppression of tissue IL-6,IL-8, IL-1β and
TNFα mRNA expression in cultured orbital tissues from three TAO samples relative to
untreated control tissue [199]. Marcocci et al. demonstrated that selenium administration (100
μg twice daily) significantly improved quality of life, reduced ocular involvement, and slowed
progression of the disease in patients with mild TAO [200].
There is limited data about treatment TAO with antioxidants. We need larger, prospective and
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Chang et al. aimed to determine the effects of pentoxifylline (Ptx); a cytokine antagonist, on
fibroblasts derived from patients with Graves' ophthalmopathy. Ptx treatment caused a dose-
dependent inhibition of serum-driven fibroblast proliferation and glycosaminoglycan synthe‐
sis [201]. Balazs et al. showed that Ptx has had beneficial effects on inflammatory symptoms
of TAO and associated laboratory parameters [202]. In another study Ptx has improved the
quality of life (QOL) of patients in the inactive phase of TAO [203]. According to these studies
Ptx may be an effective and promising drug in the treatment of TAO.
TNF-α antagonists
Paridaens et al. assessed the effect of etanercept on clinical signs in TAO. After treatment the
mean CAS and ophthalmopathy index (OI) had decreased significantly. No adverse effects
were noted [204]. İnfliximab administration resulted with a significant reduction of inflam‐
mation and improvement of visual function without noticeable short-term side effects in two
patients with active TAO [205,206]. But randomized prospective clinical trials are needed to
obtain whether TNF-α antagonists are effective in reducing the inflammatory symptoms of
TAO, and can be administered safely for a long-term period without serious side effects.
Rituximab (RTX)
A patient with TAO, who was unresponsive to steroids, was treated with RTX. The CAS
declined from 5 to 2 in 3 months and the patient had peripheral B-cell depletion [207]. When
the effect of RTX therapy was compared with IV GCs, RTX had positively affected the clinical
course of TAO, independently of either thyroid function or circulating antithyroid antibodies,
including TSH receptor antibody [208]. Silkiss et al. demonstrated a statistically significant
decrease in CAS from the baseline value. B-cell depletion had been observed and was well
tolerated, and there were no adverse effects from the RTX infusions [206]. There is currently
insufficient evidence to support the use of RTX in patients with TAO. We need large rando‐
mised conrolled trials (RCTs) for investigating the efficacy and safety of RTX versus placebo
or corticosteroids in patients with active TAO to make adequate judgement of this novel
therapy for this condition
Rapamycin
A case of TAO, with dysthyroid optic neuropathy, who was refractory to steroids and orbital
decompression surgery reported. Symptoms, visual acuity, color plate testing, and visual fields
of the patient had been improved; despite the prednisone tapering [210]. On the basis the
pathogenesis of TAO, rapamycin can be considered as a therapeutic option. But we need more
RCTs to assess the efficacy and safety of this drug.
Colchicine
A randomized clinical study showed that colchicine had a beneficial effect on the inflammatory
phase of TAO. Therefore, it was equally effective when compared to the classic treatment with
corticosteroids, but safer and better tolerated [211]. Due to the lack of controlled trials, it is not
clear that these effects were related to the natural history of the ophthalmopathy or to the
effects of the drug.
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Thalidomide
Thalidomide plays a role in inhibiting adipogenesis of orbital fibroblasts in TAO [212]. Han et
al. demonstrated the immunoregulatory effect of thalidomide on peripheral blood mononu‐
clear cells in patients with TAO [213].
Peroxisome proliferator-activated receptor (PPAR) agonists / antagonists
Orbital fibroblasts from patients with TAO have treated with rosiglitazone, and the results
suggested that TSHR expression in TAO orbital preadipocyte fibroblasts is linked to adipo‐
genesis [214]. Several case reports of TAO exacerbation following the initiation of PPAR
agonists have been reported in the literature [215,216]. These findings suggest that novel drugs
which antagonize the PPAR signalling system can also be considered as a treatment option in
TAO. The effects of PPAR-γ activation on CXCL10, CXCL9 and CXCL11 secretion in orbital
fibroblasts and preadipocytes were evaluated. The inhibitory role of PPAR-γ activation in the
process demonstrated [217,218].These studies suggest that PPAR agonists can also be consid‐
ered as a treatment option in TAO. There are conflicting reports in the medical literature,
regarding the use of PPAR agonists and antagonists in the treatment of TAO.
3.11. Radiotherapy
Radiotherapy (RT) is a treatment option in TAO because of its non-specific anti-inflammatory
and specific immunosuppressive effects (lymphocytes infiltrating the orbital space are highly
radiosensitive) [219]. Moreover RT reduces GAG production by orbital fibroblasts [220]. RT
has especially benefical effects on soft tissue changes and optic neuropathy. Unfortunately, in
longstanding TAO, the benefical effects for reduction in proptosis and the improvement in
ocular motility are not satisfactory [90]. A systematic review and meta-analysis of eight
randomized controlled trials showed that, in patients with moderate to severe TAO, RT 20 Gy
is a valid therapeutic option which improves lots of ocular symptoms. According to medical
literature the dose of 20 Gy can be considered the optimal dose for orbital RT of TAO. The
cumulative dose is usually fractionated in 10 daily doses over a 2-week period to reduce the
cataractogenic effect [221]. Higher cumulative doses of RT does not improve the effectiveness
of treatment [222]. Combined use of GCs and orbital RT was found to be more effective than
using either one alone (140). Orbital RT is usually well tolerated. It may be associated with a
transient exacerbation of inflammatory eye signs and symptoms, but this is unlikely to occur
if GCs are concomitantly administered. Cataract is a possible complication of irradiation to the
lens. Radiation retinopathy is an extremely rare complication of RT. Systemic microvascular
disease due to diabetes mellitus (DM) or to previous chemotherapy may increase the risk for
radiation retinopathy [221].
A major concern about orbital RT is carcinogenecity. In a small cohort of patients treated with
RT for  TAO, there  was no significant  evidence of  radiation-induced cancer  death [224].
Wakelkamp et al. evaluated the frequency of long-term complications of orbital RT for TAO
(radiation-induced tumors, cataract, and retinopathy) in comparison with GCs. Mortality has
obtained similarly in the irradiated and nonirradiated patients [225]. Haenssle et al. reported
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term treatment results seem to be satisfactory. But long-term follow up studies with greater
numbers of patients are necessary to examine the risks and benefits more precisely. Orbital
radiotherapy, when properly performed, appears to be a safe procedure with limited side effects.
3.12. Plasmapheresis
In the first report by Dandona et al., a patient with Graves's disease with acute progressive
exophthalmos was treated with plasmapheresis. Their results has suggested that plasmaphe‐
resis could be a useful treatment option in acute and rapidly progressive ophthalmopathy
[227]. Glinoer et al. observed significant clinical improvement immediately after plasmaphe‐
resis. The most significant effects were on soft tissue involvement, proptosis, intraocular
pressure, and visual acuity [228]. In contrast to these, unfavorable effects of plasmapheresis
have been reported [229,230]. Trials involving plasmapheresis provided conflicting results.
We need RCTs to assess the efficacy and safety of plasmapharesis.
3.13. Total thyroid ablation
According to "shared" antigen(s) theory hypothesis; autoreactive T-lymphocytes which can
recognize and interact with one or more antigens shared by the thyroid and the orbital tissue,
trigger the event [231]. If this hypothesis is correct, in patients with appropriate genetic
background and exposed to relevant environmental risk factors, the presence of thyroid tissue
could be related with the development and progression of the ophthalmopathy [232,233]. A
progressive decrease and disappearance of circulating auto-antibodies in initially antibody-
positive thyroid cancer patients was demonstrated. This observation supports the theory that
total thyroid ablation reduces thyroid autoimmunity [234]. Spinelli et al. reported major
efficacy in the ophthalmopathy by total thyroidectomy(TT) [235]. De Bellis et al. evaluated the
effect of TT alone or followed by post-surgical 131Iodine with respect to methimazole treatment
on the activity and severity of TAO. Patients in TT and 131Iodine showed an early significant
decrease and a further progressive reduction of the activity and severity of TAO during the
follow-up, without statistically significant differences. These studies suggest that TT alone
could be an appropriate alternative to improve TAO with a reduction of the cost/benefit ratio
[236]. In conclusion, Total Thyroid Ablation (TTA) could be a possible treatment strategy for
TAO. Its advantages are; better outcomes in the short term and a shorter period for the
improvement of TAO. Because of its costs and risks TTA can not be recommended as a first-
line treatment option in TAO.
3.14. Surgical therapy
Orbital decompression
The goal of orbital decompression is to provide increased space for the increased orbital tissue,
by removing the bony or fatty components of the orbit. In this way it is effective on proptosis
and on the other ocular manifestations. This treatment could not act on the pathogenesis of
the diesease. Several techniques have been used to remove portions of one to four walls of the
orbit. The decision for which surgical techniques could be used, depends on the experience of
the orbit surgeon and the clinical situation of the patient [237].
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The studies in the medical literature could not make any meaningful comparisons between
the surgical techniques. In the previous studies because of the risks of surgery, orbital
decompression has been used in patients with marked proptosis and optic nerve compression,
especially if no beneficial effect was obtained with other treatments. But in recent years the
indications of orbital decompression has expanded. Garrity et al. reviewed the records of 428
consecutive eye surgery patients at the Mayo Clinic. These were; optic neuropathy, severe
orbital inflammation, proptosis, and glucocorticoid side effects [238]. According to the
EUGOGO consensus statement on TAO; orbital decompression for exophthalmos (rehabilita‐
tive surgery) could be delayed for at least 6 months, until the orbitopathy has been inactive
for a period, because surgery yields the best results when TAO is inactive. But in patients with
TAO who are intolerant or non-responsive to GCs, orbital decompression can be considered
in the active phase. In conclusion, orbital decompression seems to be an effective and safe
treatment for patients with TAO [116].
3.15. Medical and surgical recommendations
Bartalena et al. within the EUGOGO consensus statement on TAO, published the set of medical
and surgical recommendations shown in Figure 2.
All patients with TAO
Restore euthyroidism ,urge smoking withdrawal,
refer to specialist centers (except for the mildest cases)
local mesures

























Commentary: Rehabilitative surgery includes orbital decompression, squint surgery, lid lengthening, and blepharo‐
plasty/browplasty. I.V.GCs: intravenous glucocorticoids; OR: orbital radiotherapy; DON: dysthyroid optic neuropathy.
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Commentary: Rehabilitative surgery includes orbital decompression, squint surgery, lid lengthening, and blepharo‐
plasty/browplasty. I.V.GCs: intravenous glucocorticoids; OR: orbital radiotherapy; DON: dysthyroid optic neuropathy.




4. Hyperthyroidism and bone
In 1891 Von Recklinghausen firstly described reduced bone mass in untreated hyperthyroid‐
ism. Thyroid hormones (3,3',5-triiodothyronine [T3] and 3,3',5,5'-tetra iodothyronine [T4]) act
on normal bone growth, development and turnover in both children and adults [239,240].
Hyperthyroidism increases bone turnover, acting mainly on bone resorption, but also on
osteoblast activity [241,242] [Figure-3]. As a result, hyperthyroidism is an important etiology

























Net loss of trabecular thickness
(Data adapted from reference 252).
Figure 3. Trabecular Bone Remoelling Cycle in (a) Hyperthyroid and (b) Normal Subjects
4.1. Mechanism
Direct stimulation of thyroid hormones on bone resorption in organ cultures have been
demonstrated [244]. This action may be mediated by a nuclear T3 receptor [245,246]. Thyroid
hormones may also affect bone calcium metabolism by a direct action on osteoclasts [247].
Besides the hormones of calcium metabolism, locally produced factors are important in
maintaining normal bone metabolism. Serum interleukin-6 (IL-6) concentration increases in
hyperthyroid patients and stimulates osteoclast production. Therefore, IL-6 may be an effector
of the action of PTH on bone [248]. Thyroid hormones may influence the IGF-I/IGFBP system
in vivo in hyperthyroidism. The anabolic effects of increased levels of IGF-I may be limited in
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hyperthyroidism due to the increases of inhibitory IGFBPs that can counteract the anabolic
effects and contribute to the observed net bone loss [249]. T3 activates fibroblast growth factor
receptor-1 (FGFR1) in bone and this can be related with the pathogenesis of skeletal disorders
resulting from thyroid disease [250].
4.2. Changes in hyperthyroidism
Histological changes in hyperthyroidism
Thyroid hormones increase the activation of new remodeling cycles. These effects include
predominantly increased osteoclastic activity. Although; excess osteoblastic activity, osteoid
deposition (osteomalacia) and rarefaction (osteoporosis) were also described. These changes
were observed both in trabecular and cortical bone ([51]. In 1978 Mosekilde & Melsen dem‐
onstrated a unique histomorphometric pattern; with evidence of both increased osteoblast and
osteoclast activity in hyperthyroidism. These changes have given rise to a net loss of bone
volume and were evident in both cortical and trabecular bone. But cortical bone has been rather
more influenced (Figure-4) [252]. An in-vitro organ culture of fetal rat bone, demonstrated a
direct stimulation of bone resorption by prolonged treatment with T4 or T3 [244].
Biochemical changes in hyperthyroidism
a. Calcium homeostasis in hyperthyroidism
The majority of patients with hyperthyroidism have normal or near normal total serum
calcium levels. However, ionized serum calcium levels are elevated in most of the patients.
Changes in serum calcium levels correlate with serum T3 levels [253,254]. Generally hyper‐
calcemia in hyperthyroidism tends to be mild or asymptomatic. Severe (>15 mg/dl) and
symptomatic hypercalcemia is rare [255]. Hypercalcemia usually resolves after attainment of
euthyroid state by all therapeutic modalities, i.e. subtotal thyroid resection, antithyroid drugs
and radioiodine therapy. Symptomatic hypercalcemia can be treated by rehydration, use of
corticosteroids, calcitonin and phosphate therapy. Reduced renal tubular and intestinal
calcium reabsorption leads to increased urinary and fecal calcium [241]. The hyperadrenergic
state of hyperthyroidism contributes hypercalcemia [256]. These changes correlate positively
with thyroid hormone levels and cortical osteoclastic activity. Hypercalcemia in hyperthyr‐
oidism is unrelated to the parathyroid hormone (PTH) levels [253,254].
b. Phosphorous homeostasis in hyperthyroidism
Most of the patients have increased serum phosphorous levels. But some studies have shown
normal or low levels of serum phosphorous. Increased bone and tissue catabolisms which lead
to excess input of phosphorous to the plasma, lower clearance and increased renal tubular
reabsorption of phosphorous may lead to hyperphosphatemia in hyperthyroidism. These
changes are related to suppressed PTH levels and direct effects of thyroid hormones. Antithy‐
roid treatment normalizes serum phosphorous concentration [253].
c. Parathyroid hormone secretion in hyperthyroidism
The reduction of serum PTH levels has been reported for the first time by Bouillon and DeMoor




4. Hyperthyroidism and bone
In 1891 Von Recklinghausen firstly described reduced bone mass in untreated hyperthyroid‐
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Figure 3. Trabecular Bone Remoelling Cycle in (a) Hyperthyroid and (b) Normal Subjects
4.1. Mechanism
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hyperthyroidism due to the increases of inhibitory IGFBPs that can counteract the anabolic
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resulting from thyroid disease [250].
4.2. Changes in hyperthyroidism
Histological changes in hyperthyroidism
Thyroid hormones increase the activation of new remodeling cycles. These effects include
predominantly increased osteoclastic activity. Although; excess osteoblastic activity, osteoid
deposition (osteomalacia) and rarefaction (osteoporosis) were also described. These changes
were observed both in trabecular and cortical bone ([51]. In 1978 Mosekilde & Melsen dem‐
onstrated a unique histomorphometric pattern; with evidence of both increased osteoblast and
osteoclast activity in hyperthyroidism. These changes have given rise to a net loss of bone
volume and were evident in both cortical and trabecular bone. But cortical bone has been rather
more influenced (Figure-4) [252]. An in-vitro organ culture of fetal rat bone, demonstrated a
direct stimulation of bone resorption by prolonged treatment with T4 or T3 [244].
Biochemical changes in hyperthyroidism
a. Calcium homeostasis in hyperthyroidism
The majority of patients with hyperthyroidism have normal or near normal total serum
calcium levels. However, ionized serum calcium levels are elevated in most of the patients.
Changes in serum calcium levels correlate with serum T3 levels [253,254]. Generally hyper‐
calcemia in hyperthyroidism tends to be mild or asymptomatic. Severe (>15 mg/dl) and
symptomatic hypercalcemia is rare [255]. Hypercalcemia usually resolves after attainment of
euthyroid state by all therapeutic modalities, i.e. subtotal thyroid resection, antithyroid drugs
and radioiodine therapy. Symptomatic hypercalcemia can be treated by rehydration, use of
corticosteroids, calcitonin and phosphate therapy. Reduced renal tubular and intestinal
calcium reabsorption leads to increased urinary and fecal calcium [241]. The hyperadrenergic
state of hyperthyroidism contributes hypercalcemia [256]. These changes correlate positively
with thyroid hormone levels and cortical osteoclastic activity. Hypercalcemia in hyperthyr‐
oidism is unrelated to the parathyroid hormone (PTH) levels [253,254].
b. Phosphorous homeostasis in hyperthyroidism
Most of the patients have increased serum phosphorous levels. But some studies have shown
normal or low levels of serum phosphorous. Increased bone and tissue catabolisms which lead
to excess input of phosphorous to the plasma, lower clearance and increased renal tubular
reabsorption of phosphorous may lead to hyperphosphatemia in hyperthyroidism. These
changes are related to suppressed PTH levels and direct effects of thyroid hormones. Antithy‐
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PTH secretion, so there is an inverse relationship between serum PTH and calcium levels.
Additionally, serum parathyroid hormone-related peptide (PTH-rP) levels increase in
hyperthyroidism. In hyperthyroid patients, a significant elevation in PTH-rP levels was
obtained when compared with healthy controls. After treatment, levels of PTH-rP declined.
PTH-rP could be a factor in the pathogenesis of hypercalcemia in hyperthyroid patients [258].
d. Vitamin D in hyperthyroidism
Serum concentrations of 25-hydroxyvitamin D3 (25(OH)D3)and 1,25-dihydroxyvitamin D3
(1,25(OH)2D3) in hyperthyroidism have been evaluated in many clinical trials. In most studies,
serum 25(OH)D3 levels were normal [255,259]. However, few studies in medical literature
obtained lower serum 25(OH)D3 levels in patients with hyperthyroidism than control subjects
[260,261]. Karsenty et al. found a higher metabolic clearance rate of 1,25(OH)2D3 in hyperthy‐
roid patients than in control subjects [262]. These changes in serum concentrations of
25(OH)D3 and 1,25(OH)2D3 are probably unrelated with the direct effects of thyroid hormones
on bone metabolism. It is postulated that lower levels of serum 25(OH)D3 and 1,25(OH)2D3,
can be related with reduced intestinal absorption [261]. Biochemical changes in hyperthyr‐
oidism are shown in Figure-2.
4.3. Evaluation of bone turnover in hyperthyroid patients and serum markers
Alkaline phosphatase (ALP)
Patients with hyperthyroidism have elevated levels of serum [263]. Total, liver, and bone
ALP activities obtained significantly higher in hyperthyroid patients. Bone ALP level are
more markedly elevated than liver ALP. Intestinal ALP does not differ significantly between
hyperthyroid and normal subjects. These changes correlate positively with thyroid hormone
levels. After a euthyroid state is achieved, serum ALP level remains elevated for a prolonged
time. This means increased bone turnover continues even after restoration of hyperthyroid‐
ism [264].
Other serum markers
Serum pyridinoline (PYD) and deoxypyridinoline (DPD) [265,266]., osteocalcin [267].,
carboxy-terminal propeptide of type 1 procollagen (P1CP) and carboxy-terminal telopeptide
of type 1 collagen (1CTP) [268]., serum bone Gla protein (BGP) [269]. and serum osteoprote‐
gerin (OPG) [270]. levels were obtained significantly higher in hyperthyroid patients than in
control subjects. These laboratory parameters can be considered as reliable non-invasive
markers of bone turnover in hyperthyroid patients. All markers were correlated with serum
thyroid function tests and were normalized after a eutyhyroid state was achieved.
4.4. Clinical implications
Hyperthyroidism causes reduction in bone mineral density (BMD) assessed by the measure‐
ment of lumbar vertebrae and femur by dual energy X-ray absorptiometry (DEXA) [271].
Hyperthyroidism affects bone mineralization especially during the early post-menopausal
period and the effect is mainly at the cortical bone [272]. However, hyperthyroidism could be
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associated with bone loss and may be a risk factor for the development of osteoporosis in pre-
menopausal women [273]. It has been well established that hyperthyroidism leads to reduced
BMD in female patients, but there is lack of acceptable data in male patients. Majima et al.
evaluated BMD and bone metabolism in male patients with hyperthyroidism. The study
demonstrated a high prevalence of cortical bone loss in male patients with hyperthyroidism,
especially in elderly patients [274].
Also, endogenous subclinical hyperthyroidism can be a risk factor for osteoporosis. In several
cross-sectional studies, BMD was decreased at multiple sites in pre-and post-menopausal
women with endogenous subclinical hyperthyroidism [275-277]. This finding, however, was
not confirmed in other cross-sectional observations in endogenous conditions [278]. Földes et
al. demonstrated that numbers of pre-menopausal patients with endogenous sub-clinical
hyperthyroidism BMD of the lumbar spine, femoral neck and the midshaft of the radius were
not significantly decreased. But in post-menopausal women with long-lasting endogenous
sub-clinical hyperthyroidism mean densitometric values were slightly, but significantly, lower
[279]. Whether endogenous sub-clinical hyperthyroidism significantly affects bone metabo‐
lism and increases the risk of fractures remains controversial.
Prolonged hyperthyroidism due to L-thyroxine(L-T4) treatment has been associated with
reduced bone mass and thus with the potential risk of premature development of osteoporosis.
The effects of L-T4 treatment have been evaluated in many clinical trials. In several studies,
bone mineral density was decreased at multiple sites in pre-and post-menopausal women
treated with L-T4 [280,281]. In a study by Giannini et al. post-menopausal thyroidectomized
patients showed significantly lower bone mass than pre-menopausal patients. A negative
correlation between time since menopause and bone mass were obtained in post-menopausal
L-T4 treated patients [282]. There is lack of acceptable data about the effects of L-T4 treatment
on bone metabolism in male patients. A mild deleterious effect of thyroid hormone excess in
the axial bone mass from male subjects obtained. Male patients with chronic TSH suppression
by L-T4 or history of hyperthyroidism should be assessed by BMD [283]. However, several
recent studies have failed to show such a harmful effect of L-T4 treatment on BMD [284-286].
It should be noted that other risk factors may affect BMD in hyperthyroid patients. These
include a relative deficiency of insulin-like growth factor type I, dehydroepiandrosterone
sulfate [287], vitamin D receptor (VDR) polymorphisms [288] and estrogen [289]. The question
as to whether prolonged hyperthyroidism due to L-T4 treatment increases the risk of fractures
also remains controversial.
4.5. Diagnosis
BMD measuring by DEXA scan is one of the best techniques to obtain the extent of bone
changes in hyperthyroidism. DEXA scan offers monitoring for response to therapy and with
little radiation it gives very reliable measurements [290]. Quantitative ultrasound (QUS) might
give information about bone mass and also on bone elasticity and structure. Advantages are
the lower expense, portability, and lack of radiation exposure [291]. Acotto et al. reported
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[292]. For practical use, the development of quality standards and criteria for diagnosing
osteoporosis are necessary.
Prevention and treatment of reduced bone density
Patients with a history of hyperthyroidism and who are treated with L-T4 replacement/
supressive therapy should be considered at higher risk of reducing BMD and developing
clinically significant osteoporosis. These patients should be encouraged to modify other risk
factors for osteoporosis such as smoking, drinking excessive alcohol, low Ca+² intake and lack
of exercise [293]. In these patients adequate daily calcium intake should be provided. Kung et
al. found that 1,000 mg. daily calcium supplementation prevents bone loss in post-menopausal
women taking suppressive doses of L-T4 compared with a placebo [294]. Estrogen replacement
therapy prevents a decrease of BMD in postmenopausal women with previous hyperthyroid‐
ism and subsequent L-T4 therapy [295,296]. These potentially beneficial effects of estrogen
replacement on BMD in postmenopausal women with a history of thyroid disease suggests
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Abbreviations are as follows: calcium (Ca), alkaline phosphatase (ALP), 25 hydroxy vitamin D3 (25 OH D), 1,25 dihy‐
droxy vitamin D3 (1,25 (OH)2D3), 24,25 dihydroxy vitamin D3 (S-24,25 (OH)2D), parathyroid hormone (PTH), phosphate
(PO4), urinary calcium (U-Ca), urinary hydroxyproline (U-OHP), urinary phosphate (U-PO4), urinary pyridinium and de‐
oxypyrodinoline (U-PYD/DPD). (Data adapted from reference 292).
Figure 4. Biochemical Changes in Hyperthyroidism.
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Titration of suppressive therapy to maintain serum TSH concentration between a slightly low
(e.g. between 0.1-0.5 mU/l) range may prevent bone loss [297]. Guo et al demonstrated a
reduction of L-T4 dose in post-menopausal women with suppressed serum TSH levels related
with deceleration of bone turn over (serum osteocalcin and urinary excretion of bone collagen-
derived pyridinium cross-links decreased) and increased BMD (lumbar/femoral) [298]. Careful
titration of L-T4 dosage to maintain biochemical euthyroidism is the most important way to
prevent the adverse effect of T4 on bone.
The major question is whether the decrease in BMD caused by hyperthyroidism can be
reversible. Many clinical trials have obtained that there is some reversibilty of bone mass after
treatment of hyperthyroidism [293,299-301]. Another question is whether antiresorptive
treatment is effective on hyperthyroidism related osteoporosis. Two clinical trials evaluated
the increase of BMD in osteoporotic/osteopenic hyperthyroid patients treated with only anti-
thyroid drugs versus patients treated with anti-thyroid drugs and alendronate. The combina‐
tion of anti-thyroid drugs and alendronate was found to be more efficacious than anti-thyroid
therapy alone [302,303]. Majima et al. evaluated the efficacy of risedronate for the treatment
of osteoporosis/osteopenia in patients with Graves' disease. The percentage increases in BMD
at the lumbar spine and distal radius were significantly greater in patients treated with an anti-
thyroid drug and risedronate than treated with an anti-thyroid drug only [304]. These findings
conclude that bisphosphonates can be considered as a treatment option in decreased bone mass
cases associated with hyperthyroidism. Kung et al. demonstrated intranasal calcitonin with
calcium supplements was not more effective than calcium supplements alone in preventing
bone loss induced by thyroxine suppressive therapy in post-menopausal women [305]. Jódar
et al. designed a prospective study to evaluate the effects of antiresorptive therapy with nasal
salmon calcitonin (CT) in hyperthyroid patients receiving standard medical treatment. They
showed that treatment with nasal CT has no additional beneficial effect compared with the
attainment of the euthyroid state [306]. But in another study by Akçay et al. the addition of
intranasal calcitonin to the anti-thyroid drugs was found to be effective in preventing the
degradation of bone [307]. More prospective, randomized and controlled trials, which include
large series of patients, are required to obtain more accurate results about antiresorptive
treatment in hyperthyroidism.
5. Thyroid storm
Thyroid storm (TS) [thyrotoxic crisis] is an uncommon, life-threatening condition reflecting
the augmentation of the manifestations of thyrotoxicosis. Mortality rates are high (10-20%) and
occur in less than 10% of patients hospitalized for thyrotoxicosis. TS occurs nine to ten times
more commonly in women than in men, and the most common aetiology is Graves’ hyper‐
thyroidism. However, any aetiology of thyrotoxicosis can cause TS. This situation can be
precipitated by a number of factors shown in Table-3 [308-312].
The pathophysiology of thyroid storm is not fully understood. The current theory is that;
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Titration of suppressive therapy to maintain serum TSH concentration between a slightly low
(e.g. between 0.1-0.5 mU/l) range may prevent bone loss [297]. Guo et al demonstrated a
reduction of L-T4 dose in post-menopausal women with suppressed serum TSH levels related
with deceleration of bone turn over (serum osteocalcin and urinary excretion of bone collagen-
derived pyridinium cross-links decreased) and increased BMD (lumbar/femoral) [298]. Careful
titration of L-T4 dosage to maintain biochemical euthyroidism is the most important way to
prevent the adverse effect of T4 on bone.
The major question is whether the decrease in BMD caused by hyperthyroidism can be
reversible. Many clinical trials have obtained that there is some reversibilty of bone mass after
treatment of hyperthyroidism [293,299-301]. Another question is whether antiresorptive
treatment is effective on hyperthyroidism related osteoporosis. Two clinical trials evaluated
the increase of BMD in osteoporotic/osteopenic hyperthyroid patients treated with only anti-
thyroid drugs versus patients treated with anti-thyroid drugs and alendronate. The combina‐
tion of anti-thyroid drugs and alendronate was found to be more efficacious than anti-thyroid
therapy alone [302,303]. Majima et al. evaluated the efficacy of risedronate for the treatment
of osteoporosis/osteopenia in patients with Graves' disease. The percentage increases in BMD
at the lumbar spine and distal radius were significantly greater in patients treated with an anti-
thyroid drug and risedronate than treated with an anti-thyroid drug only [304]. These findings
conclude that bisphosphonates can be considered as a treatment option in decreased bone mass
cases associated with hyperthyroidism. Kung et al. demonstrated intranasal calcitonin with
calcium supplements was not more effective than calcium supplements alone in preventing
bone loss induced by thyroxine suppressive therapy in post-menopausal women [305]. Jódar
et al. designed a prospective study to evaluate the effects of antiresorptive therapy with nasal
salmon calcitonin (CT) in hyperthyroid patients receiving standard medical treatment. They
showed that treatment with nasal CT has no additional beneficial effect compared with the
attainment of the euthyroid state [306]. But in another study by Akçay et al. the addition of
intranasal calcitonin to the anti-thyroid drugs was found to be effective in preventing the
degradation of bone [307]. More prospective, randomized and controlled trials, which include
large series of patients, are required to obtain more accurate results about antiresorptive
treatment in hyperthyroidism.
5. Thyroid storm
Thyroid storm (TS) [thyrotoxic crisis] is an uncommon, life-threatening condition reflecting
the augmentation of the manifestations of thyrotoxicosis. Mortality rates are high (10-20%) and
occur in less than 10% of patients hospitalized for thyrotoxicosis. TS occurs nine to ten times
more commonly in women than in men, and the most common aetiology is Graves’ hyper‐
thyroidism. However, any aetiology of thyrotoxicosis can cause TS. This situation can be
precipitated by a number of factors shown in Table-3 [308-312].
The pathophysiology of thyroid storm is not fully understood. The current theory is that;




levels in states of stress. Decreased binding to thyroxine-binding globulin (TBG), markedly
increase in free thyroid hormone levels may also play an important role [313].
∙ Severe infections (pulmonary) ∙ Direct trauma or surgical manipulation of the thyroid gland
∙ Diabetic ketoacidosis (DKA) ∙ Biological agents such as interleukin-2 and α-interferon
∙ Surgery ∙ Discontinuation of anti-thyroid medications or poor patient
adherence to the treatment
∙ Trauma ∙ Cerebrovascular disease
∙ Pulmonary thrombo-embolism ∙ Myocardial infarction (MI)
∙ Salicylates * ∙ Exogenous thyroid hormone intake
∙ Administration of large quantities of exogenous
iodine **
∙ Pregnancy
∙ Radioactive iodine therapy ∙ Unknown factors
*They increase the concentration of circulating free thyroid hormones to critical levels
**Such as iodinated contrast agents or amiodarone
Table 3. Precipitating Factors for Thyroid Storm
Clinical presentation of thyroid storm
Symptoms of thyroid storm are similar to those of hyperthyroidism, but they are more sudden,
severe and extreme. The main findings are high fever (38-41° C) accompanied by excessive
sweating and flushing. Other common symptoms include; altered mental status (confusion,
agitation, overt psychosis, and in extreme cases, even coma), cardiovascular complications
[tachycardia, cardiac arrhythmias (including atrial fibrillation), high systolic bood pressure,
low diastolic bood pressure and congestive heart failure], diffuse muscle weakness, tremor or
fasciculations and neuropsychiatric syndromes. Gastrointestinal involvement presents with
nausea, vomiting, diarrhoea and abdominal pain. Liver dysfunction (cardiac failure with
hepatic congestion or hypoperfusion, direct effect of the excess thyroid hormones) could be
present with jaundice [309,314]. Elderly patients often present with apathy, stupor, cardiac
failure, coma and minimal signs of thyrotoxicosis so-called apathetic thyroid storm [313].
The scoring system suggested by Burch and Wartofsky (Table 4) illustrates the typical features
of thyroid storm [315]. The clinical symptomatology is sometimes difficult to distinguish from
other medical emergencies [308]. Differential diagnosis of TS is shown in Table-5.
5.1. Diagnosis
Diagnosis depends on primarily clinical findings. There are no specific laboratory tests
available. Serum thyroid hormone levels (i.e. free T3 [FT3] and free T4 [FT4]) are elevated with
suppressed TSH levels (with the rare exceptions being states of thyroid hormone resistance or
TSH secreting pituitary adenomas). An immediate search should begin for precipitating
factors. Pregnancy should be excluded urgently in any woman of childbearing age with
urinary or plasma assessment of human chorionic gonadotropin (HCG) levels. Routine
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∙ Congestive heart failure
Absent 0
Mild (Pedal oedema) 5
Moderate (Bibasal rales or crackles) 10




3. Central nervous system dysfunction
Absent 0
Mild (Agitation) 10
Moderate (Delirium, psychosis, extreme lethargy) 20
Severe (Seizures, coma) 30
4. Gastrointestinal-hepatic dysfunction
Absent 0
Moderate (Diarrhoea, nausea/vomiting, abdominal pain) 10
Severe (Jaundice) 20




>45 Highly likely thyroid storm
25-44 Suggestive of impending storm
<25 Unlikely to represent storm
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[tachycardia, cardiac arrhythmias (including atrial fibrillation), high systolic bood pressure,
low diastolic bood pressure and congestive heart failure], diffuse muscle weakness, tremor or
fasciculations and neuropsychiatric syndromes. Gastrointestinal involvement presents with
nausea, vomiting, diarrhoea and abdominal pain. Liver dysfunction (cardiac failure with
hepatic congestion or hypoperfusion, direct effect of the excess thyroid hormones) could be
present with jaundice [309,314]. Elderly patients often present with apathy, stupor, cardiac
failure, coma and minimal signs of thyrotoxicosis so-called apathetic thyroid storm [313].
The scoring system suggested by Burch and Wartofsky (Table 4) illustrates the typical features
of thyroid storm [315]. The clinical symptomatology is sometimes difficult to distinguish from
other medical emergencies [308]. Differential diagnosis of TS is shown in Table-5.
5.1. Diagnosis
Diagnosis depends on primarily clinical findings. There are no specific laboratory tests
available. Serum thyroid hormone levels (i.e. free T3 [FT3] and free T4 [FT4]) are elevated with
suppressed TSH levels (with the rare exceptions being states of thyroid hormone resistance or
TSH secreting pituitary adenomas). An immediate search should begin for precipitating
factors. Pregnancy should be excluded urgently in any woman of childbearing age with
urinary or plasma assessment of human chorionic gonadotropin (HCG) levels. Routine
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∙ Congestive heart failure
Absent 0
Mild (Pedal oedema) 5
Moderate (Bibasal rales or crackles) 10




3. Central nervous system dysfunction
Absent 0
Mild (Agitation) 10
Moderate (Delirium, psychosis, extreme lethargy) 20
Severe (Seizures, coma) 30
4. Gastrointestinal-hepatic dysfunction
Absent 0
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>45 Highly likely thyroid storm
25-44 Suggestive of impending storm
<25 Unlikely to represent storm




biochemical tests, urinalysis, urine sediment, complete blood count, chest X-ray and related
cultures should be made, to exclude infectious diseases. Electrocardiography (ECG) and
cardiac enzymes should be procured, to exclude arrhythmia and myocardial infarction (MI)
[313]. Leukocytosis, increased transaminase-bilirubin levels, hypoglycemia and lactic acidosis
can be seen in laboratory evaluation [316,317].
Neurolept malignant syndrome Hypertensive encephalopathy
Malignant hyperthermia Alcohol withdrawal
Phaeochromocytoma Benzodiazepine / barbiturate withdrawal
Hypoglycemia Opioid withdrawal
Hypoxia Heat stroke
Sepsis Encephalitis / meningitis
Table 5. Differential Diagnosis of Thyroid Storm
5.2. Management
The patient should be managed in an intensive care unit. ABCDEs (i.e. airway; breathing;
circulation; disability, i.e. conscious level; and examination) should be provided as soon as
possible. Precipitant factors such as infection, trauma, MI, DKA, and other underlying
processes should be managed as per standard care [313].
General supportive care
First of all haemodynamic stability should be provided. Supportive care includes cooling
measures, intravenous (IV) fluid-electrolyte replacement and nutritional support. In order to
control profound pyrexia cooling blankets and acetaminophen can be used. Salicylates should
be avoided (increase the concentration of circulating free thyroid hormones). Tachyarrhyth‐
mias, which cause haemodynamic instability should be managed with cardioversion by
defibrillation. Otherwise, tachyarrhythmias can be managed with appropriate anti-arrhythmic
therapy. Diuretics, ACE inhibitors and digitalis can be used carefully for heart failure. Based
on arterial blood gas (ABG) analysis and other assessments; ventilatory support, either with
non-invasive positive pressure ventilation (NIPPV) or intubated ventilation, could be per‐
formed. In patients with severe agitation, medical intervention could be difficult. Sedatives
such as haloperidol or a benzodiazepine can be used in this situation. Phenobarbital increases
peripheral metabolism and inactivation of FT3-FT4. Chlorpromazine has the additional benefit
of reducing body temperature through effects on central thermoregulation. However, these
agents should be monitored for respiratory side effects. Nutritional support is important. This
includes vitamin (e.g. thiamine) and glucose replacement (as liver glycogen stores are depleted
during a thyroid storm) [313].
Thyroid-specific therapy
Thyriod-specific therapy includes; decreasing thyroid hormone synthesis, prevention of
thyroid hormone release and decreasing peripheral action of circulating thyroid hormones
[318]. In the treatment of thyroid storm, the five B’s should be kept in mind. This includes ‘Bs’:
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Block synthesis (i.e. antithyroid drugs); Block release (i.e. iodine); Block T4 into T3 conversion
(i.e. highdose propylthiouracil [PTU], propranolol, corticosteroid and, rarely, amiodarone);
Betablocker; and Block enterohepatic circulation (i.e. cholestyramine) [313].
Anti-thyroid drugs include PTU or carbimazole (or methimazole). PTU was preferred because
of its more rapid onset of action, short half-life and inhibition of peripheral deiodinase enzyme-
mediated conversion of T4 into T3. PTU could be administered orally or via a nasogastric (NG)
tube, if the patient is not suitable for oral administration, both PTU and methimazole can be
given as a rectal suppository or enema. PTU is administered with a loading dose of 600mg
followed by a dose of 200-250 mg every 4-6 hours. Carbimazole (or methimazole) is adminis‐
tered at a dose of 20-30mg every 4-6 hours [318]. The major concern about PTU is hepatoxicity.
In the thyroid storm management, there are not any comparative trials showing superiority
of PTU over either carbimazole or methimazole. It’s now recommended that using either
carbimazole or methimazole in thyroid storm (unless there is a contra-indication such as
pregnancy), and achieving T4 into T3 conversion inhibition just with beta-blockers and
corticosteroids [319].
Iodine should be administered at least 1 hour after PTU or carbimazole (or methimazole)
administration. In this way undesired tyrosine residue iodination and enrichment of thyroid
hormone stores could be prevented. Iodine could be administered in various formulations
(Table-6) [313].
In order to block the adrenergic effects of thyroid hormones betablockers should be adminis‐
tered immediately. A non-cardiac specific betablocker; propranolol can be used for this
purpose. Propranolol has the advantages of being suitable for IV administration and of
inhibition of peripheral T4-T3 conversion at high doses. Decompensated cardiac function,
triggered with tachycardia, can be treated with beta-blockers. However, beta-blockers should
be used with caution in patients with a history of heart failure. Cardioselective beta-blockers
such as metoprolol or atenolol could be used in patients with asthma and chronic obstructive
pulmonary disease, which are contra-indications for non-cardiac specific betablockers. If
unfavorable cardiac effects are expected, a short-acting beta-blocker; esmolol, can be used as
an alternative drug. Diltiazem, a calcium-channel blocker, can be used when there is absolute
contra-indication for beta-blockers (Table-6) [313].
Thyroid hormones accelerate cortisol metabolism and may trigger an adrenal crisis. Thyroid
crisis give rise to low plasma levels of ACTH and cortisol. Therefore, against a possible adrenal
insufficiency, exogenous corticosteroid therapy should be administered [320]. Furthermore,
corticosteroids inhibit peripheral conversion of T4 into T3 and have been shown to improve
outcomes in patients with thyroid storm [318]. Hydrocortisone or an equivalent corticosteroid
can be used for this purpose (Table-6). Then, the treatment should be withdrawn gradually,
based on the required duration of steroid therapy.
Other possible treatment options are lithium carbonate, potassium perchlorate and cholestyr‐
amine. Lithium inhibits thyroid hormone release from the gland and reduces iodination of
tyrosine residues. Lithium carbonate can be an alternative treatment option when there is a
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lithium carbonate is it’s toxicity. Potassium perchlorat inhibits iodide transport into the
thyrocyte [313]. Erdogan et al. demonstrated that the combination of thionamides, corticoste‐
roids and potassium perchlorat for a short period could be effective in the treatment of
amiodarone-induced thyrotoxicosis [321]. The most important side effects of potassium
perchlorat are aplastic anaemia and nephritic syndrome. To inhibit the enterohepatic circula‐
tion of thyroid hormones, a T4 and T3 binding resin, cholestyramine can be used [322].
Emerging treatments
In spite of all treatment approaches, clinical improvement could not be obtained. In this
situation, different treatment approaches can be tried in order to remove thyroid hormones
from the circulation.
Plasmapheresis should be considered as a treatment option, especially when patients have
failed or cannot tolerate conventional therapy. Plasmapheresis leads to amelioration of
symptoms and a significant decline in thyroid hormone levels, providing a window to treat
definitively with thyroidectomy [323,324]. In each session only small amounts of thyroid
hormones can be removed from the circulation, therefore plasmapharesis can be repeated.
Koball et al. reported a case of thyrotoxic crisis treated with plasmapheresis and single pass
albumin dialysis. Thyroxine can be bound by albumin and removed by extracorporeal single-
pass albumin dialysis (SPAD). The patient underwent two sessions of plasmapheresis without
clinical response. After four SPAD treatments clinical status of the patient improved. Accord‐
ing to this report SPAD represents a safe and efficient alternative to plasmapheresis [325].
Charcoal haemoperfusion has also been demonstrated to be effective in thyrotoxic states [326].
6. Thyrotoxic hypokalaemic periodic paralysis
Hyperthyroidism can be related with muscular disorders such as acute and chronic thyrotoxic
myopathies, exophthalmic ophthalmoplegia, myasthenia gravis, and periodic paralysis [327].
The association between thyrotoxicosis and periodic paralysis was first described by Rosenfeld
in 1902. Thyrotoxic hypokalaemic periodic paralysis (THPP) is a rare condition which occurs
in 2% of patients with thyrotoxicosis. THPP is generally sporadic, but autosomal recessive or
autosomal dominant cases have been reported and may be associated with certain HLA
haplotypes [HLA-Bw46 / B5 / DRw8 / CW7] [328-330]. THPP has been reported in many ethnic
groups such as Asian populations and Caucasians [331]. THPP appears almost exclusively
(85%) in young men between the ages of 20-39 [327].
Many aetiological factors that can lead to hyperthyroidism may be associated with THPP. It
has been reported that the most important aetiologic factor is Graves’ disease according to
large case series [332,333]. Other possible aetiological factors are subacute thyroiditis, silent
thyroiditis [334], autonomously functioning thyroid nodules [335], thyrotropin-secreting
pituitary adenomas [336,337], ingestion of excessive thyroxine [338], thyroxine-containing
herbal and dietary supplements [339], iodine induced thyrotoxicosis with inadvertent use of
iodine or with drugs containing iodine such as iodinate contrast agents or amiodarone
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Medication Dose Notes
Inhibition of hormone synthesis
Propylthiouracil (PTU)




recent warning from FDA regarding
severe liver toxicity with PTU makes
either carbimazole or methimazole
first-choice thionamide
Carbimazole (or methimazole) 20-30mg PO q4-6h
Inhibition of hormone release
Potassium Iodide 5 drops PO q6-8h
Administer at least 1 hour
after thionamide
Lugol’s Solution 5-10 drops PO q6-8h
Administer at least 1 hour
after thionamide
Iapanoic Acid
1000mg IV q8h for 24 h, followed by
500mg bd
Administer at least 1 hour after
thionamide, infrequently available
Inhibition of peripheral effects of excess thyroid hormone
Propranolol
1-2 mg/min IV q15min up to
max 10mg 40-80mg PO q4-6h
IV dose initially if haemodynamically
unstable
Esmolol
50 mg/kg/min IV -may increase by
50 mg/kg/min q4min as required to a
max of 300 mg/kg/min.
Short acting
Metoprolol 100mg PO q6h
Cardioselective; use if known airways
disease
Diltiazem 60-90mg PO q6-8h
Use if beta-blockers contraindicated IV
formulation available
Supplementary management
Hydrocortisone 100mg IV q6h
Dexamethasone 2mg IV q6h Care if significant hepatic dysfunction
Acetaminophen 1 g PO q6h
Additional therapies
Lithium Carbonate Carbonate 300mg PO q8h Monitor for toxicity
Potassium perchlorate 1 g PO od Associated with aplastic anaemia
Cholestyramine 4 g PO q6-12h and nephritic syndrome
PO, oral; IV, intravenous; q4-6h, every 4_6 hours; q6h, every 6 hours; q8h, every 8 hours; q4min, every 4 minutes; q15min,
every 15 minutes;od, once daily; bd, twice daily.
(Data adapted from reference 313)
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Upper respiratory tract infection
Trauma
Insulin
Table 7. Precipitating factors
The pathophysiology of THPP is not certain. However, it can be explained by some mecha‐
nisms (Figure-5). A quick shift of potassium from the extracellular compartment to the
intracellular compartment causes hypokalemia. This especially occurs in the muscles. Excess
thyroid hormone and insulin levels, increased sensitivity of beta-receptors to catecholamines
in thyrotoxicosis causes an increase in sodium/potassium-adenosine triphosphatase (Na/K-
ATPase) pump activity [347,348]. This mechanism explains insulin and epinephrine induced
paralytic attacks. Factors related with an increased insulin and epinephrine levels, such as
carbohydrate rich meals, emotional stress, cold, trauma and infection trigger THPP. During
exercise K releases from the skeletal muscles, but in the resting process K again returns to the
intracellular compartment. Because of this transport of the potassium, periodic and paralytic
attacks usually occur during resting time [349].
6.1. Clinical features
THPP attacks mostly occur in the late night or early morning and last from a few hours
up to several days. Prodromal symptoms such as aches, cramps and stiffness can be seen
[334]. The typical motor involvement in THPP begins from the lower limbs and ascends to
the upper limbs. The muscles affected may be asymmetrical. The severity of attacks range
from mild weakness to flaccid paralysis. Clinical improvement starts from the most recently
affected muscles. Sensory function is not affected and deterioration of mental functions has
never been seen [327]. Paralysis of respiratory, bulbar, and ocular muscles has been rarely
reported in severe attacks of THPP. Respiratory muscle involvement can be fatal [350]. Deep
tendon reflexes are markedly diminished or absent. Patients completely recover between
the attacks [348].
6.2. Laboratory features
The cardinal laboratory finding in THPP is hypokalaemia. But normokalaemic TPP have been
reported in some cases [351,352]. Severe hypokalaemia may trigger life-threatening arrhyth‐
mias and the severity of paralysis correlates with the degree of hypokalemia but not with the
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thyroid hormone level. Therefore the degree of hypokalaemia is important [353,354]. Hypo‐
phosphataemia and hypomagnesaemia could be obtained in THPP [332]. Hypokalemia can
cause vasoconstriction in muscle arterioles and may lead to ischemic changes in sarcolemma.
Thus hypokalaemia causes rhabdomyolysis [355]. Besides hypokalaemia, hypophosphatae‐
mia [356] and hyperthyroidism alone may cause rhabdomyolysis [357]. As a result of rhabdo‐
myolysis, serum creatine phosphokinase (CPK) level increases [332,358]. ECG changes in
THPP vary from nondiagnostic to those showing typical features of hypokalaemia and serious
ventricular arrhythmias. Other possible ECG changes include rapid heart rate, high QRS
voltage, and first-degree atrioventricular block [359,360].
6.3. Management
In cases of acute attacks of THPP immediate restoration and close monitoring of serum
potassium is important. Potassium replacement can be done in two ways; oral or intravenous.
Intravenous potassium has significant superiority to the oral route in the improvement of the
clinical findings and it is the major choice if the patient shows signs of cardiac dysrhythmia,
respiratory distress or is unable to take oral medications. Potassium replacement should not
exceed 90 mEq/24h because of the possibility of rebound hyperkalemia [327,344,361]. A non-
selective beta-blocker, propranolol, increases serum potassium and phosphate concentrations
and ameliorates paralysis [362].
THPP does not disappear completely unless patients become euthyroid. Thus, the manage‐
ment of hyperthyroidism is the mainstay of therapy. Permanent treatment is so important and
could be done by antithyroid drugs, radioiodine therapy or surgery [348]. Although gluco‐
corticoids (GCs) have been used to treat hyperthyroidism, they have detrimental effects on
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Figure-5: Pathophysiology of THPP 
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Figure-5: Pathophysiology of THPP 




should be aware of the risk of triggering THPP when using high-dose GCs in the thyrotoxic
phase [363]. To prevent recurrence of attacks, precipitating factors should be avoided.
The use of propranolol is important during early treatment with anti-thyroid drugs or after
radioactive iodine when the euthyroid status is not yet achieved. Propranolol also reduces the
frequency and severity of attacks. If the patient's serum potassium level is between normal
ranges, prophylactic potassium supplementation is not effective to prevent the attacks.
Acetazolamide may worsen the attacks in THPP and should be avoided [364,365].
7. Thyrotoxicosis related psychosis and convulsion
7.1. Hyperthyroidism and central nervous system
The brain, particularly the limbic system (amygdala and hippocampus), has a large number
of Tri-iodothyronine (T3) receptors. These receptors affect a variety of functions such as
emotion, behavior, and long term memory [366]. Excess thyroid hormones affect neurotrans‐
mitters such as serotonin, dopamine, or second messengers. This could be a possible explan‐
ation for the relation between neuropsychiatric symptoms and hyperthyroidism [367].
Evidence suggests that the modulation of the beta-adrenergic receptor response to catechola‐
mines in the central nervous system by thyroid hormones in thyrotoxic patients, may contrib‐
ute to psychotic behavior [368].
As a result, people with thyroid dysfunction could be presented with a wide variety of
neuropsychiatric symptoms such as anxiety, irritability, unstable mood, fatigue, insomnia,
dementia, confusion state, depression, thyrotoxic crisis, seizures, pyramidal signs, chorea,
attention deficit-hyperactivity disorder, sleepwalking (somnambulism)and Hashimoto's
encephalopathy. “Apathetic thyrotoxicosis” is an unusual presentation of hyperthyroidism,
characterised by depression, psychomotor slowing and apathy and occurring mostly in the
elderly [369-371].
7.2. Psychosis
More than 150 years ago, von Basedow first described a psychotic illness, probably mania, in
a patient with exophthalmic goitre [372]. More recent case reports have emphasised depressive
[373], manic [374], paranoid [375] and schizophreniform features [372]. But psychotic reactions
as the presenting feature of thyrotoxicosis is extremely rare, it was reported in 1% of cases and
most patients who develop psychosis have been previously diagnosed with mania and/or
delirium [376]. The occurrence of psychosis depends on the severity and duration of thyroid
disease and the underlying predisposition of the individual to psychiatric instability [377].
Most of the cases caused by thyrotoxicosis or hyperthyroidism have been described in patients
with Graves’ disease or toxic multinodular goiter. Therefore, transient thyroiditis or factitious
thyrotoxicosis can be related with neuropsychiatric symptoms, including organic psychosis
[378]. Only one case each of postpartum thyroiditis [379] and subacute thyroiditis [377] have
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been reported related with psychosis. The relations between thyroid autoimmunity and
anxiety disorders have been reported [380].
But it should be noted that psychiatric disorders can trigger hyperthyroxinemia [381].
Differential diagnosis between the two conditions is important. In such cases the TSH level is
usually in the upper “normal” range and free thyroxine elevation is modest and transient and
is usually seen within 1 week. This entity has not been established clearly, but may be
considered a form of non-thyroidal illness [382].
7.3. Management
Treatment of hyperthyroidism by standard anti-thyroid drugs (propylthiouracil, methima‐
zole, carbimazole) results with improvement in mental and cognitive symptoms. Psychiatric
improvements parallel with improvements in endocrine symptoms. Trzepacz et a.l also
showed that a similar improvement both in psychiatric and endocrine symptoms by two weeks
of propranolol treatment could be obtained [383,384].
Because of their slow onset of action and potential toxicity, psychotropic drugs (lithium,
benzodiazepines, antidepressants and antipsychotics) are not recommended as the primary
treatment option for neuropsychiatric symptoms caused by hyperthyroidism. Dopamine
receptor blockade with an antipsychotic such as haloperidol can be used in patients with severe
neuropsychiatric symptoms. If there is an exhibited psychiatric disease before hyperthyroid‐
ism, β-adrenoceptor antagonists may not be effective and neuropsychiatric symptoms may
remain after euthyroidism has been achieved, in which case psychotropic drug treatment
should be given. Selective serotonin reuptake inhibitors, lithium and benzodiazepines can be
used for the treatment of neuropsychiatric symptoms [366].
If therapy fails with the above-mentioned options, more radical approaches such as radioactive
iodine ablation and thyroidectomy should be considered [377,385].
7.4. Convulsion
Seizures in hyperthyroidism have rarely been reported in medical literature. Most of the cases
were related with Graves’ hyperthyroidism [386-388]. Other aetiologic factors were massive
levothyroxine ingestion [389], L-thyroxine treatment for hypothyroidism [390,391], subclinical
hyperthyroidism [392] and Hashimoto’s encephalopathy (HE) [393,394]. The pathophysiology
of HE is not clear but increased antithyroid antibodies in all affected patients supports an
autoimmune etiology. Generally, patients in medical literaure were euthyroid or hypothyroid.
But Sakurai et al reported a case of HE associated with Basedow's disease presented with
hyperthyroidism. Another possible aetiologic factor for seizures in hyperthyroidism may be
superior sagittal sinus (SSS) thrombosis. Hyperthyroidism may cause hypercoagulabilty,
venous stasis and could be related with thrombosis. All cases of seizures in SSS thrombosis in
medical literature were known cases of hyperthyroidism [395-397].
The certain incidence of seizures in hyperthyroidism is still unknown. Song et al. recently
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in women than in men, but no differences in the pattern of clinical seizures or electroence‐
phalography (EEG) were demonstrated between the two gender [399]. Most of the reports are
for generations of childhood and young adults.
Hyperthroidism can exacerbate seizures and paroxysmal EEG abnormalities in patients with
a diagnosis of epilepsy [390,400] or focal/generalized seizures only during thyrotoxicosis in
patients without established epilepsy [401]. The mechanisms of seizure induction by thyroid
hormones are not clear, but there are some possible explanations. Thyroid hormones may
influence the activity of sodium potassium adenosine–triphosphatase, leading to severely
altered concentrations of sodium in cerebral cells. In this way thyroid hormones trigger
seizures by lowering the seizure threshold [402-405].
To confirm the diagnosis patients should be evaluated for the other causes of seizures. Any
epileptic focus or organic lesion should not be obtained with EEG, CT or MRI. Hypoglycemia,
hypoxemia, serum electrolyte imbalance, acid-base imbalance or possible central nervous
system infections should be excluded [406]. Hyperthyroidism should be confirmed by low
serum thyroid-stimulating hormone (TSH) and high concentrations of T4, T3, or both. EEG
can be used as another diagnostic tool. Severity of hyperthyroidism correlates with EEG
parameters [399]. Generally EEG abnormalities regress after a euthyroid state achieved. Thus
EEG can be used to assess response to treatment [406]. The reversibility of EEG findings
demontrates that seizures in hyperthyroidism are functional, not organic [407]. But EEG may
not be positive in all cases of hyperthyroidism with seizures, and also positive EEGs in all cases
of hyperthyroidism may not manifest clinical seizures [399].
7.5. Management
Treatment of hyperthyroidism with standard medical approaches (propylthiouracil, lugols
iodine, propanolol and dexamethasone with additional vitamin B complex) have been shown
to be effective in patients with seizures. Anti-epileptic drugs may have been useful when
standard medical approaches were not adequate to control seizures. Thus, various anti-
epileptic drugs (carbamazepine, phenytoin, sodium valproate, diazepam, or clonazepam)
were used to treat seizures in the acute phase [399,408]. HE responds to glucocorticoids,
immunosuppressive therapy and plasmapheresis which supports the autoimmune etiology.
Seizure exacerbations usually remit when patients become euthyroid with treatment [409,410].
8. Thyrotoxicosis related diabetes mellitus
Glucose metabolism disorders can be seen in thyroid disorders, especially in hyperthyroidism.
Hyperthyroid patients have a higher risk of developing diabetes mellitus. The pathogenesis
is complex and there is lack of data about prevalence and severity in the literature [411].
8.1. Epidemiology
In young individuals with an autoimmune thyroid disease (as Graves’ disease) it is common
to develop type 1 diabetes. It is due to the alteration of the immune system which leads to a
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pathological reaction against self-antigens. In fact other autoimmune diseases like celiac
disease can also occur. Thyroid auto-immunity is common in type 1 diabetic patients, with up
to 27% of them having detectable titers of anti-thyroid peroxidase antibodies [412]. A preva‐
lence study by Greco et al. confirmed the frequent association between Graves' disease and
type 1 diabetes. Graves' disease often preceded diagnosis of type 1 diabetes, particularly in
female subjects with a high age at diabetes onset [413].
In older patients, hyperthyroidism can be associated with type 2 diabetes. The pathogenetic
mechanism can be explained by insulin resistance and metabolic derangement [414]. A study
showed that patients on treatment for hyperthyroid Graves’ disease were almost twice as likely
to develop type 2 diabetes than the general population, although they were less likely to be
overweight and were less likely to have family history. This suggests an association between
Graves' disease and type 2 diabetes [415].
8.2. Genetic predisposition
Studies have been performed for HLA-DR3, HLA-DR4 CTLA-4, and PTPN22. These studies
suggest that abnormalities in antigen presentation and T cell activation might play a significant
role in the shared genetic etiology of type 1 diabetes and auto-immune thyroid disease [416].
8.3. Hyperthyroidism and glucose homeostasis
The effect of hyperthyroidism on glucose homeostasis is complex [417]. Hyperthyroidism
stimulates increased metabolism in many tissues, leading to an increased demand for glucose
[418]. Altough having insulin resistance, as long as pancreatic beta cell functions remain
normal, overt diabetes does not develop in a hyperthyroidism.
Gastric emptying and intestinal absorption
It has been suggested that rapid gastric emptying and increased rates of intestinal absorption
of glucose could be responsible for altered glucose tolerance in hyperthyroidism [419]. In
contrast to this, recent studies found that gastric emptying has been decreased [420,421] or
unchanged [422,423] in hyperthyroidism.
Liver
Hyperthyroidism can cause insulin resistance with direct and indirect effects on the liver. The
direct effect is to increase basal hepatic glucose output by promoting gluconeogenesis and
glycogenolysis [424]. A sympathetic pathway from the hypothalamic paraventricular nucleus
to the liver has been proposed as a central pathway for modulation of hepatic glucose
metabolism by thyroid hormone, which forms the indirect effect [425].
Peripheral tissues
Glucose uptake in peripheral tissues especially in the skeletal muscle have been found to be
increased in hyperthyroisdism [426-429]. This increased uptake is mainly related with an
increase in insulin-stimulated glucose oxidation rates [430-433]. Furthermore, reduced
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intracellular glucose being redirected towards glycolysis and lactate formation [428,429,434].
The release of lactate from peripheral tissues back to the liver contributes to the Cori cycle
where more hepatic glucose is being produced [434-436]. In the adipose tissue, lipolysis
increases in the fasting state. This results with an increased production of glycerol and
nonesterified fatty acids (NEFA). Increased glycerol generated by lipolysis and increased
amino acids generated by proteolysis are used for gluconeogenesis. NEFA stimulate gluco‐
neogenesis and provide substrate to other tissues such as muscle, for oxidation [437].
Cytokines
There is an interaction between thyroid hormones and adipose tissue derived cytokines. Effects
of thyroid hormones on production rates and plasma levels of these cytokines could be used
to explain mechanisms of insulin resistance in hyperthyroidism. Adipose tissue derived
cytokines are adiponectin, leptin, interleukin-6, tumor necrosis factor-α, resistin and visfatin.
There are conflicting reports about the role of these cytokines to insulin resistance in hyper‐
thyroidism [418].
Insulin and glucagon secretion
Decreased [438-442], normal, or even increased [437,443] levels of plasma insulin have been
reported in hyperthyroidism. There are conflicting reports about insulin secretion in hyper‐
thyroidism. But it is more consistent that insulin degradation increases. Hyperthyroidism
augments renal clearance of insulin [428,444,445]. Another important pathologic change
induced by long-term hyperthyroidism has been shown to be irreversible pancreatic damage
[446-448]. Secretion and metabolic clearance rates of glucagon have been found increased in
hyperthyroidism [449]. Increased levels of growth hormone and catecholamines that accom‐
pany hyperthyroidism may further contribute to insulin resistance. Interorgan communication
in hyperthyroidism are shown in Figure-6 [418].
8.4. Subclinical hyperthyroidism and glucose homeostasis
Subclinical hyperthyroidism could be endogenous and exogenous. Both of them have also
been associated with insulin resistance in some studies [450,451]. But there are conflicting
reports in the literaure about insulin resistance in exogenous subclinical hyperthyroidism.
Yavuz et  al.  have reported reduced insulin  sentivity  in  these  patients  [452,453].  In  con‐
trast  to  this  Heemstra  et  al.  have reported that  insulin  sensitivty  was not  altered [454].
According to  its  cronicity  and higher  T3 levels  endogenous subclinical  hyperthyroidism
may have a larger impact on glucose homeostasis when compared to exogenous subclini‐
cal hyperthyroidism [451].
8.5. Impact of hyperthyroidism on diabetes
In some young women with Type 1 diabetes, glucose control may fluctuate following child‐
birth due to post-partum thyroiditis, when a state of hyperthyroidism is followed by hypo‐
thyroidism. Routine screening of TSH is recommended in such patients 6-8 weeks following
delivery [455]. Thyrotoxicosis and diabetic ketoacidosis can occur simultaneously. In this
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instance the combination could be fulminant and potentially life threatening. The first goal of
treatment is to maintain electrolyte balance to avoid cardiac arrest [456].
As far as hyperthyroidism affects glucose homeostasis and causes insulin resistance,  the
patients need more insulin administration for glycemic control. Moon et al. reported a case
of hyperglycemic hyperosmolar state (HHS) associated with Graves' hyperthyroidism. HHS
rarely  associates  with  Graves’  hyperthyroidism  but  this  unusual  relation  should  be
considered [457].
9. Conclusion
In conclusion all types of thyrotoxicosis may induce severe systemic complications which may
affect morbidity, even mortality of the disease. Prompt and effective treatment of the compli‐
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1. Introduction
Graves’ ophthalmopathy (GO), known as Graves’ orbitopathy or thyroid eye disease (TED),
is an autoimmune disorder and the main extrathyroidal expression of Graves' disease (GD).
GO occurs mainly, but not exclusively, in patients with Graves’ disease (up to 50% of GD
patients have clinically apparent ophthalmopathy). The major clinical risk factor for develop‐
ing thyroid eye disease is smoking. Moreover, radioactive iodine used to treat hyperthyroidism
can worsen GO. There is an age-specific and gender-related distribution of GO, and the annual
incidence is 0.4% for women and 0.1% for men but this largely reflects the increased incidence
of GD in women [1]. In addition to GD, thyroid eye disease can also be seen in chronic
autoimmune thyroiditis, albeit is far less common and occurs in 2–5% of these patients [2].
Although the link between GD and GO is still not totally clear, the close association between
onset of GD and the development of GO suggests that both disorders would have common
pathogenic mechanisms [3]. The ocular involvement of GD is explained by the expression of
receptor for thyroid-stimulating hormone (TSH-R) present not only in the thyroid follicular
cells but also in adipocytes, and fibroblasts located in the orbit, and lymphocytes infiltrating
orbit tissues [3]. Likewise, the signs and symptoms of GO occur due to inflammatory reaction
and subsequent fibrosis of the orbital components, including orbital connective tissue, and the
extraocular muscles [4]. Inflammatory cell infiltration of extraocular muscles is associated with
increased secretion of glycosaminoglycans and osmotic retention of water. The muscles
become enlarged, sometimes up to eight times their normal size, and may compress the optic
nerve. Subsequent degeneration of muscle fibers eventually leads to fibrosis, which exerts a
tethering effect on the involved muscle resulting in the muscle dysfunction and ophthalmo‐
plegia. Infiltration of interstitial tissues, orbital fat and lacrimal glands with lymphocytes,
plasma cells, macrophages and mast cells along with accumulation of glycosaminoglycans and
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retention of fluid cause an increase in the volume of orbital content and secondary elevation
of intraorbital pressure, which may itself cause further fluid retention within the orbit [4].
In general, GO can be divided into two clinical stages: the earlier inflammatory (congestive)
stage and the late fibrotic (quiescent) stage. The inflammatory stage is marked by edema and
deposition of glycosaminoglycans in the extraocular muscles. This results in the clinical
manifestations of orbital swelling, proptosis (exophthalmos), diplopia due to restricted ocular
motility, periorbital edema, and lid retraction. At this stage the eyes are red and painful. This
tends to remit within 3 years and only 10% of patients develop serious long-term ocular
problems. The fibrotic stage is a convalescent phase and may result in further restrictive
myopathy and lid retraction. The most serious complication of GO is optic neuropathy, caused
by compression of the optic nerve or its blood supply at the orbital apex by the congested and
enlarged recti. Such compression, which may occur in the absence of significant proptosis, may
lead to severe but preventable visual impairment.
The first step in diagnosis of thyroid-associated ophthalmopathy in an individual patient is
the ophthalmological examination performed by ophthalmologist. Then, dedicated special‐
ized imaging methods need to be employed in selected clinical situations in GO patients. For
example, muscle enlargement, and not retrobulbar fat accumulation, is associated with an
increased risk for development of dysthyroid optic neuropathy, which may lead to partial/
total loss of vision [5]. As shown by computer tomography (CT) and magnetic resonance
imaging (MRI), the swelling of extraocular muscles and disappearance of adipose tissue in the
apex of the orbit is suggestive for active development of dysthyroid optic neuropathy [6]. Also,
a stretched optic nerve is associated with an increased risk for visual loss [6], thus it should be
confirmed with particular imaging modality and the therapy should be immediately provided.
In principle, thyroid-associated ophthalmopathy is a bilateral condition, but it can occur
unilaterally in about 20% of all GO patients [7]. Indeed, Graves’ disease is the most common
cause (20–30%) of unilateral exophthalmos [8]. Since a variety of other neuro-ophthalmic
disorders require consideration when the unilateral proptosis or malposition of the eyelid are
detected, including a retrobulbar tumors, myasthenia gravis, myositis, lymphoma, metastasis,
arterio-venous malformation, carotid-sinus cavernous fistula, infection, diffuse or focal
idiopathic orbital inflammation with mass effect, or illusory ptosis of the opposite eyelid, the
comprehensive neuroimaging should be implicated. Therefore, all patients with unilateral eye
disease suspected to GO development should undergo broad orbital imaging, involving
several diagnostic methods, to exclude an alternative diagnosis. Apart from the comprehensive
diagnosing of GO, clinical imaging is also indicated for the control checkup in the course of
the thyroid-associated ophthalmopathy, especially for examination of the disease activity,
what may predict the onset and response to therapy.
In this chapter, we will highlight the use of different imaging techniques, such as ultrasonog‐
raphy, computer tomography, magnetic resonance, and nuclear medicine-based examinations
in the assessment of patients with Graves’ ophthalmopathy for diagnostic purposes and to
provide information about the optimal indications for use of each imaging method in the
clinical setting.
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2. Orbital imaging evaluation in Graves’ ophthalmopathy
Radiological neuroimaging of Graves’ ophthalmopathy plays an important role in the
differential diagnosis and interdisciplinary management of patients with GO. Orbital imaging
especially can be helpful in establishing the diagnosis of GO, because it objectively describes
the morphological abnormalities of the orbital structures. Likewise, it is estimated that orbital
imaging reveals anomalies in 90% of patients with Graves’ disease [9]. Based on the selected
imaging techniques, it is possible to establish the degree of extraocular muscle and orbital fat
enlargement, exclude other coexisting orbital pathology, clarify a confusing clinical set of
symptoms, and perform surgical planning [10]. Importantly, the signs and symptoms of
thyroid ophthalmopathy usually develop within one year after the thyroid gland dysfunction
onset, but up to 20% of subjects with exophthalmos may exhibit euthyroidism [11]. Moreover,
the widespread availability of CT and MRI have made early detection of exophthalmos
possible, and the imaging presentation of GO may even precede clinical signs of hyperthyr‐
oidism and significant changes in related laboratory tests. Therefore, it is postulated that
abnormal imaging findings may be a sign of early thyroid disease that subsequently need to
be diagnosed in detail [12-13]. Consequently, it is important to provide accurate diagnosis
based on specific radiological findings and to propose the following testing to rule out the
thyroid dysfunction in yet euthyroid patients.
Certainly, the commonly used imaging modalities posses the selected advantages and
disadvantages for their use in specific clinical situations in case of GO patients. Some selected
techniques have been reserved for patient examination in different phases of the disease
activity. For example, the assessing of vascularity around extraocular muscles is achieved with
the contrast-based CT and MR imaging techniques. On the contrary, the assessment of local
tissue edema is accomplished with the dedicated MRI sequences, and quantitative monitoring
of inflammation activity may require the radionuclide scintigraphy. Nevertheless, the search
for optimal method to characterize the selected GO features necessary for different diagnostic
and therapeutic purposes is not yet completed.
2.1. Ultrasound-based imaging evaluation of Graves’ ophthalmopathy
Ultrasonography (US) is a non-invasive, well-established imaging modality, that is widely
used in clinical practice and it enables the evaluation and measurement of extraocular muscles,
general assessment of the optic nerve status, detection of the existing gross edema or the
enlargement of lacrimal glands [14-16]. Especially, US may be conveniently used to investigate
some of the orbital muscle parameters. First ultrasonography-based evidence that extraocular
muscle enlargement can be documented directly by US was given by Werner and coworkers
in 1974 [17]. From this time, several groups have proposed selected methods for detection and
analysis of the thickness of the extraocular muscles and it was determined that their thickness
expands with increasing disease severity [18]. However, this technique has also been found
by several groups to have limited accuracy and not to be as effective as CT and MRI studies
[19-22]. Especially, ultrasound investigation do not include all the extraocular muscles, thus
sensitivity and specificity of this imaging modality is getting lower. Moreover, US examination
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In principle, thyroid-associated ophthalmopathy is a bilateral condition, but it can occur
unilaterally in about 20% of all GO patients [7]. Indeed, Graves’ disease is the most common
cause (20–30%) of unilateral exophthalmos [8]. Since a variety of other neuro-ophthalmic
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several diagnostic methods, to exclude an alternative diagnosis. Apart from the comprehensive
diagnosing of GO, clinical imaging is also indicated for the control checkup in the course of
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clinical setting.
Thyroid Disorders - Focus on Hyperthyroidism142
2. Orbital imaging evaluation in Graves’ ophthalmopathy
Radiological neuroimaging of Graves’ ophthalmopathy plays an important role in the
differential diagnosis and interdisciplinary management of patients with GO. Orbital imaging
especially can be helpful in establishing the diagnosis of GO, because it objectively describes
the morphological abnormalities of the orbital structures. Likewise, it is estimated that orbital
imaging reveals anomalies in 90% of patients with Graves’ disease [9]. Based on the selected
imaging techniques, it is possible to establish the degree of extraocular muscle and orbital fat
enlargement, exclude other coexisting orbital pathology, clarify a confusing clinical set of
symptoms, and perform surgical planning [10]. Importantly, the signs and symptoms of
thyroid ophthalmopathy usually develop within one year after the thyroid gland dysfunction
onset, but up to 20% of subjects with exophthalmos may exhibit euthyroidism [11]. Moreover,
the widespread availability of CT and MRI have made early detection of exophthalmos
possible, and the imaging presentation of GO may even precede clinical signs of hyperthyr‐
oidism and significant changes in related laboratory tests. Therefore, it is postulated that
abnormal imaging findings may be a sign of early thyroid disease that subsequently need to
be diagnosed in detail [12-13]. Consequently, it is important to provide accurate diagnosis
based on specific radiological findings and to propose the following testing to rule out the
thyroid dysfunction in yet euthyroid patients.
Certainly, the commonly used imaging modalities posses the selected advantages and
disadvantages for their use in specific clinical situations in case of GO patients. Some selected
techniques have been reserved for patient examination in different phases of the disease
activity. For example, the assessing of vascularity around extraocular muscles is achieved with
the contrast-based CT and MR imaging techniques. On the contrary, the assessment of local
tissue edema is accomplished with the dedicated MRI sequences, and quantitative monitoring
of inflammation activity may require the radionuclide scintigraphy. Nevertheless, the search
for optimal method to characterize the selected GO features necessary for different diagnostic
and therapeutic purposes is not yet completed.
2.1. Ultrasound-based imaging evaluation of Graves’ ophthalmopathy
Ultrasonography (US) is a non-invasive, well-established imaging modality, that is widely
used in clinical practice and it enables the evaluation and measurement of extraocular muscles,
general assessment of the optic nerve status, detection of the existing gross edema or the
enlargement of lacrimal glands [14-16]. Especially, US may be conveniently used to investigate
some of the orbital muscle parameters. First ultrasonography-based evidence that extraocular
muscle enlargement can be documented directly by US was given by Werner and coworkers
in 1974 [17]. From this time, several groups have proposed selected methods for detection and
analysis of the thickness of the extraocular muscles and it was determined that their thickness
expands with increasing disease severity [18]. However, this technique has also been found
by several groups to have limited accuracy and not to be as effective as CT and MRI studies
[19-22]. Especially, ultrasound investigation do not include all the extraocular muscles, thus
sensitivity and specificity of this imaging modality is getting lower. Moreover, US examination
Graves’ Ophthalmopathy Imaging Evaluation 143
of the orbit is not enough detailed in delineating the relationship of orbital pathology with
soft-tissue structures located in the orbits, nor is it reliable in imaging lesions of the posterior
part of the orbit, where compression of the optic nerve often occurs. Likewise, US has strong
limitations in imaging of the bone elements of the orbit. In addition, the accuracy of measure‐
ments in US examination is strongly dependent on investigator’s experience and qualifications.
In the concise analysis of differences between orbital MRI and US imaging that was performed
in 43 patients with orbitopathy and developed diplopia, the US has not provided sufficient
degree of information on muscles and connective tissue that, in contrast, was obtainable by
MRI [21]. Nevertheless, US permits to some extent for differential diagnosis of proptosis due
to the high degree of similarity between the right and left eye, and the diagnosis of symmetric
muscle enlargement is valuable in distinguishing the GO from other similar but often unilateral
ophthalmologic disorders [18].
Changes in ocular blood flow may alter the functions of the retina and retinal pigment
epithelium and may affect the prognosis of different ophthalmological disorders, including
TED. Ocular hemodynamic changes have been reported in GO by several authors using
different techniques, including Heidelberg retina flowmeter, ocular blood flow tonography,
and oculodynamometry [23-25]. In general, the numerous factors may cause alterations in
ocular blood flow in patients with Graves’ disease. It is assumed that in hyperthyroidism,
increased systemic blood pressure, increased intraocular pressure, and orbital inflammation
may affect ocular blood flow [26]. Color Doppler imaging (CDI) is a sonographic imaging
technique that permits for non-invasive assessment of blood flow velocity in orbital vessels,
and thus, it has been used to study the ocular blood flow in patients with GO. Importantly, it
allows for simultaneous imaging of the anatomic structures by B-mode ultrasonography with
superimposed color-coded vascular flow. The orbital venous congestion and decreased flow
velocity in the superior ophthalmic vein measured with CDI have been found in GO subjects
by several groups [26-28]. Similarly, Li et al. and Alp et al. found independently the signifi‐
cantly lower value of the peak systolic velocity (PSV) of blood flow in the central retinal artery
in GO patients compared to controls [26,29]. Additionally, Li et al. observed in the same vessel
the decreased end diastolic velocity (EDV) of blood flow and the resistance indexes (RIs)
significantly increased [29]. Besides, Perez-Lopez et al. measured the changes in retrobulbar
blood flow parameters in 14 GO patients before and after decompression surgery and found
that in inactive moderate-to-severe GO, the RIs of central retinal artery and ophthalmic artery
were preoperatively significantly higher compared to healthy subjects. After decompression
surgery, the authors observed a significant decrease of calculable US parameters, such as
resistive index (RI), which occurred in both ocular arteries mentioned above. These results
may indicate that increased RI of inactive GO might be due to orbital extrinsic compression of
vascular structures and decompression surgery leads to significant decreases of the RIs of
different orbital arteries [30]. Moreover, Doppler ultrasound parameters of the retrobulbar
arteries have been related to the clinical activity score, suggesting increased arterial blood flow
velocity in patients with active GO due to inflammation of the orbital tissues [31]. Some studies
have showed that evaluation of the impaired arterial vascularization of the orbit and the optic
nerve in inactive GO may indicate the necessity of performing the earlier decompression
surgery to prevent dysthyroid optic neuropathy in these patients. Altogether, these findings
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raise the possibility that CDI measurements represent a clinically useful tool in adjunction to
basic ultrasonography for diagnosis and follow-up of GO and, to some extent, for the evalu‐
ation of its activity. However, it is necessary to take into account that there are certain limita‐
tions that need to be recognized, when interpreting data obtained by retrobulbar CDI
measurements. As expected, there is a high intraobserver variability, and even higher the
interobserver variability, when the consecutive measurements are performed by two observers
in one patient. Therefore, the adequate training is mandatory to allow reproducible CDI
measurements. In addition, another limitation of retrobulbar CDI measurements is that it can
be influenced by proximal carotid artery stenosis and this abnormality should be excluded
prior to retrobulbar CDI. Finally, the resolution of CDI is insufficient up until today to provide
reliable volumetric vascular flow measurements. Hence, a high flow velocity in an artery
supplying the eyeball does not necessarily reflect the high flow, but may also reflect a stenosis
or constriction at the site of measurement. Despite the mentioned limitations, CDI has an
important advantage over the other imaging techniques as it is noninvasive, it requires no
contrast or radiation, and is available in almost every hospital setting. Nevertheless, according
to authors of the recent report on the use of colour Doppler imaging for assessment of
retrobulbar blood flow, it is not relevant for routine use in current clinical practice [32].
2.2. Computer tomography-based imaging evaluation of Graves’ ophthalmopathy
Computer tomography imaging can distinguish abnormal structures of different tissue density
based on their differing X-ray absorption properties. Generally, CT is the preferred imaging
modality for the diagnosis of patients with GO because of its ability to visualize bone and soft
tissues of the orbit. The orbital fat that acts as a natural contrast medium allows for good spatial
and density resolution of orbital structures [33]. As analyzed on the large GO patient cohort,
the extraocular muscles most frequently affected are the medial and inferior recti followed by
superior and lateral recti, which were involved less frequently and less severely. Importantly,
the two or more muscles were enlarged in 70% of patients with ocular involvement [34-35].
The extraocular muscles affected by GO appear to be enlarged in a fusiform fashion with sharp
borders [36]. The attempts to establish normative measurements of thickness of the extraocular
muscles have been performed by several groups based on national and international cohorts
of patients [37-39]. However, the assessment of muscle enlargement is often subjective and
requires comparison with the opposite orbit and prior qualitative experience in CT imaging
analysis.
Clinical symptoms of GO derive from the discrepancy between limited space of the orbit and
expansion of pathologically affected orbital tissues. CT permits to evaluate the differences in
orbital soft tissue volumes and densities that are different in GO patients compared to healthy
controls. For example, studies using three dimensional CT showed the increase in volume of
extra-ocular muscles alone in 20% of 40 subjects with GO, and 28% of GO patients presented
only the increased orbital fat tissue volume, however, almost half of the patients had aug‐
mented volume of both analyzed structures of the orbit, i.e. muscles and fat [40]. These results
indicate that orbital changes might be presented separately as the myogenic and the lipogenic
abnormal forms. Furthermore, Regensburg et al. determined by CT imaging that orbital fat
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muscles have been performed by several groups based on national and international cohorts
of patients [37-39]. However, the assessment of muscle enlargement is often subjective and
requires comparison with the opposite orbit and prior qualitative experience in CT imaging
analysis.
Clinical symptoms of GO derive from the discrepancy between limited space of the orbit and
expansion of pathologically affected orbital tissues. CT permits to evaluate the differences in
orbital soft tissue volumes and densities that are different in GO patients compared to healthy
controls. For example, studies using three dimensional CT showed the increase in volume of
extra-ocular muscles alone in 20% of 40 subjects with GO, and 28% of GO patients presented
only the increased orbital fat tissue volume, however, almost half of the patients had aug‐
mented volume of both analyzed structures of the orbit, i.e. muscles and fat [40]. These results
indicate that orbital changes might be presented separately as the myogenic and the lipogenic
abnormal forms. Furthermore, Regensburg et al. determined by CT imaging that orbital fat
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density was significantly higher in GO patients than in the normal population and it negatively
correlated to orbital fat volume. They also found a positive correlation between orbital fat
density and muscle volume or muscle density [38]. The same group proposed the useful
method for calculating orbital soft tissue volume using a manual segmentation technique for
CT scans. Based on their results, this technique seems to be reliable and might be an accurate
tool for diagnostic follow-up evaluation of GO patients [41]. A decade ago, Nishida et al.
hypothesized that orbital fat volume has larger influence on proptosis induction than increased
extraocular muscle volume [42]. Recently, Fang et al. observed in CT imaging that orbital fat
changes were more important in mild proptosis than in severe one [11]. Imaging-based studies
are not only important for the diagnosis of GO, but they can aid in the evaluation of disease
activity. Changes observed in sequential measurements of the extraocular muscles obtained
with CT may be related to clinical activity of the disease as muscular involvement occurs early
in GO and it may correlate with other clinical signs [43]. Other abnormal findings in the orbits
that may be determined by CT are a dilated superior ophthalmic vein and abrupt angulations
of the posterior muscle belly [44].
Computer tomography is also valuable for the evaluation of the orbital bone wall structures
and their remodeling. For example, in long-lasting GO a spontaneous bony orbit decompres‐
sion could be noted with an impression of the normally parallel laminae papyraceae, which
create the medial orbital walls, and then leading to the so-called “Coca Cola sign”, when GO
has bilateral occurrence and forms the shape typical for internationally-known bottle of Coca-
Cola [45]. Orbital CT is the modality of choice to particularly examine the osseous structures
of the orbital apex, the sinus, and the intra-orbital elements for the orbital decompression
surgery planning. In this notion, CT imaging is recommended pre-and postoperatively in order
to define the site and extent of the bony decompression.
Compressive optic neuropathy, which occurs in approximately 5% of patients with thyroid
eye disease, is caused by direct compression of the optic nerve at the orbital apex. Such
compression in general occurs due to enlarged extraocular muscles [46]. However, optic nerve
function in thyroid eye disease may be also compromised by other mechanisms. There have
been described several cases of dysthyroid optic neuropathy without apparent orbital apex
congestion in which the combination of increased orbital fat volume, shallow orbits, and/or
outbowing of the medial orbital wall caused sufficient anterior ocular displacement to allow
linear antero-posterior stretching of the optic nerve [47]. As the CT-based examination in
patients with dysthyroid optic neuropathy often reveals crowding of the optic nerve at the
orbital apex by enlarged extraocular muscles [46], thus several methods have been proposed
to delineate the degree of crowding of the optic nerve at the orbital apex using CT imaging
that comprised the radiologist-based subjective judgment of the appearance of the apex,
quantization of the total extraocular muscle volume by using an image analyzer [48], or just
the linear measurements of the amount of orbital height or width occupied by the extraocular
muscles at a selected point in the orbit (e.g. the middle between the posterior surface of the
globe and the orbital apex) [49]. As a result, every of the above-mentioned methods has shown
independently that optic nerve dysfunction is more common in crowded orbit and less
common in uncrowded orbit. Birchall et al. described an additional CT sign that has a high
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correlation with the presence of optic nerve dysfunction in patients with dysthyroid optic
neuropathy, which is the hernia of orbital fat raising out 2-4 mm from the superior orbital
fissure [50].
The muscles are usually involved bilaterally in GO and they present a “fusiform” appearance
due to characteristic sparing of the muscle tendons. The enlarged muscles produce not only
the apical crowding in the orbit, but also venous congestion what can be clearly noticeable in
the CT scans performed with intravenous contrast enhancement. As the inflammation starts
naturally in the extraocular muscles, it has a crisp, well-defined border within the affected
muscle, and thus can be distinguished from pseudotumors. The another characteristic sign,
helping in differential diagnosis of Graves’ orbitopathy versus orbital myositis, is lack of the
involvement of the muscle tendon into the inflammatory process. In the later, the tendon
should present swelling and enlargement. Consequently, the inflammatory process leaks from
the intramuscular tissue into the intraorbital fat and produces streaking within the fat giving
a characteristic ‘dirty fat’ sign inside the orbit. Concurrently, the medial rectus muscle
enlargement may produce the deformation or even the breakage of delicate lamina papyracea
of the orbital bony wall. These imaging features are efficiently diagnosed and monitored with
CT, especially obtained in the coronal plane [51]. However, the apical crowding is assessed
better on coronal planes of MRI scans.
Altogether, CT scanning of the orbits is non-invasive, simple, fast, and cost-effective imaging
technique. Findings such as spindle-shaped thickness >4 mm of more than one of the extraoc‐
ular muscles without involvement of the corresponding tendon, with preferential involvement
of the inferior and medial rectus, followed by the superior and lateral rectus muscles, apparent
increase in orbital fat volume and the compression of the optic nerve at the orbital apex
(“crowded orbital apex syndrome”) are the most important morphological diagnostic criteria
of GO, when analyzing the axial and coronal CT scans [52]. For the above reasons, and
especially because of lower costs and better availability than the MR equipment, the CT
imaging should be considered first imaging step in diagnostic evaluation of GO and other
thyroid-associated diseases. Moreover, CT provides precise imaging of the osseous periorbital
structures, therefore this is the method of choice to plan CT-guided orbital decompression
surgery in the inactive phase of GO. To the limitations of this imaging modality belong the
radiation exposure to the organism, and especially to the eye lenses. Moreover, CT does not
reveal information on the disease activity in most cases. It is also important to be aware that
there is a risk for thyrotoxicosis development due to the performance of CT with commonly
used iodinated contrast agents.
2.3. Magnetic resonance-based imaging evaluation of Graves’ ophthalmopathy
The main advantages of MRI are the excellent soft-tissue contrast, obtainable with a great
spatial tissue resolution, compared even to a high-resolution CT imaging and absence of
ionizing radiation during the examination. Therefore, MRI is the preferred modality for soft
tissue imaging. In orbital MR imaging, slices ranging from 3 to 5 mm are used, normally
oriented in the transverse and coronal direction and, along to the optic nerve, in the parasagittal
plane. One of the neuroimaging protocols proposed in the literature for examination of the
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density was significantly higher in GO patients than in the normal population and it negatively
correlated to orbital fat volume. They also found a positive correlation between orbital fat
density and muscle volume or muscle density [38]. The same group proposed the useful
method for calculating orbital soft tissue volume using a manual segmentation technique for
CT scans. Based on their results, this technique seems to be reliable and might be an accurate
tool for diagnostic follow-up evaluation of GO patients [41]. A decade ago, Nishida et al.
hypothesized that orbital fat volume has larger influence on proptosis induction than increased
extraocular muscle volume [42]. Recently, Fang et al. observed in CT imaging that orbital fat
changes were more important in mild proptosis than in severe one [11]. Imaging-based studies
are not only important for the diagnosis of GO, but they can aid in the evaluation of disease
activity. Changes observed in sequential measurements of the extraocular muscles obtained
with CT may be related to clinical activity of the disease as muscular involvement occurs early
in GO and it may correlate with other clinical signs [43]. Other abnormal findings in the orbits
that may be determined by CT are a dilated superior ophthalmic vein and abrupt angulations
of the posterior muscle belly [44].
Computer tomography is also valuable for the evaluation of the orbital bone wall structures
and their remodeling. For example, in long-lasting GO a spontaneous bony orbit decompres‐
sion could be noted with an impression of the normally parallel laminae papyraceae, which
create the medial orbital walls, and then leading to the so-called “Coca Cola sign”, when GO
has bilateral occurrence and forms the shape typical for internationally-known bottle of Coca-
Cola [45]. Orbital CT is the modality of choice to particularly examine the osseous structures
of the orbital apex, the sinus, and the intra-orbital elements for the orbital decompression
surgery planning. In this notion, CT imaging is recommended pre-and postoperatively in order
to define the site and extent of the bony decompression.
Compressive optic neuropathy, which occurs in approximately 5% of patients with thyroid
eye disease, is caused by direct compression of the optic nerve at the orbital apex. Such
compression in general occurs due to enlarged extraocular muscles [46]. However, optic nerve
function in thyroid eye disease may be also compromised by other mechanisms. There have
been described several cases of dysthyroid optic neuropathy without apparent orbital apex
congestion in which the combination of increased orbital fat volume, shallow orbits, and/or
outbowing of the medial orbital wall caused sufficient anterior ocular displacement to allow
linear antero-posterior stretching of the optic nerve [47]. As the CT-based examination in
patients with dysthyroid optic neuropathy often reveals crowding of the optic nerve at the
orbital apex by enlarged extraocular muscles [46], thus several methods have been proposed
to delineate the degree of crowding of the optic nerve at the orbital apex using CT imaging
that comprised the radiologist-based subjective judgment of the appearance of the apex,
quantization of the total extraocular muscle volume by using an image analyzer [48], or just
the linear measurements of the amount of orbital height or width occupied by the extraocular
muscles at a selected point in the orbit (e.g. the middle between the posterior surface of the
globe and the orbital apex) [49]. As a result, every of the above-mentioned methods has shown
independently that optic nerve dysfunction is more common in crowded orbit and less
common in uncrowded orbit. Birchall et al. described an additional CT sign that has a high
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correlation with the presence of optic nerve dysfunction in patients with dysthyroid optic
neuropathy, which is the hernia of orbital fat raising out 2-4 mm from the superior orbital
fissure [50].
The muscles are usually involved bilaterally in GO and they present a “fusiform” appearance
due to characteristic sparing of the muscle tendons. The enlarged muscles produce not only
the apical crowding in the orbit, but also venous congestion what can be clearly noticeable in
the CT scans performed with intravenous contrast enhancement. As the inflammation starts
naturally in the extraocular muscles, it has a crisp, well-defined border within the affected
muscle, and thus can be distinguished from pseudotumors. The another characteristic sign,
helping in differential diagnosis of Graves’ orbitopathy versus orbital myositis, is lack of the
involvement of the muscle tendon into the inflammatory process. In the later, the tendon
should present swelling and enlargement. Consequently, the inflammatory process leaks from
the intramuscular tissue into the intraorbital fat and produces streaking within the fat giving
a characteristic ‘dirty fat’ sign inside the orbit. Concurrently, the medial rectus muscle
enlargement may produce the deformation or even the breakage of delicate lamina papyracea
of the orbital bony wall. These imaging features are efficiently diagnosed and monitored with
CT, especially obtained in the coronal plane [51]. However, the apical crowding is assessed
better on coronal planes of MRI scans.
Altogether, CT scanning of the orbits is non-invasive, simple, fast, and cost-effective imaging
technique. Findings such as spindle-shaped thickness >4 mm of more than one of the extraoc‐
ular muscles without involvement of the corresponding tendon, with preferential involvement
of the inferior and medial rectus, followed by the superior and lateral rectus muscles, apparent
increase in orbital fat volume and the compression of the optic nerve at the orbital apex
(“crowded orbital apex syndrome”) are the most important morphological diagnostic criteria
of GO, when analyzing the axial and coronal CT scans [52]. For the above reasons, and
especially because of lower costs and better availability than the MR equipment, the CT
imaging should be considered first imaging step in diagnostic evaluation of GO and other
thyroid-associated diseases. Moreover, CT provides precise imaging of the osseous periorbital
structures, therefore this is the method of choice to plan CT-guided orbital decompression
surgery in the inactive phase of GO. To the limitations of this imaging modality belong the
radiation exposure to the organism, and especially to the eye lenses. Moreover, CT does not
reveal information on the disease activity in most cases. It is also important to be aware that
there is a risk for thyrotoxicosis development due to the performance of CT with commonly
used iodinated contrast agents.
2.3. Magnetic resonance-based imaging evaluation of Graves’ ophthalmopathy
The main advantages of MRI are the excellent soft-tissue contrast, obtainable with a great
spatial tissue resolution, compared even to a high-resolution CT imaging and absence of
ionizing radiation during the examination. Therefore, MRI is the preferred modality for soft
tissue imaging. In orbital MR imaging, slices ranging from 3 to 5 mm are used, normally
oriented in the transverse and coronal direction and, along to the optic nerve, in the parasagittal
plane. One of the neuroimaging protocols proposed in the literature for examination of the
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orbits with MRI is comprised of spin-echo T1-weighted sequences in the axial and coronal
planes with 3-mm-slice thickness, multi-echoes T2-weighted sequence in the coronal plane,
and short time inversion recovery (STIR) sequence in the coronal plane. Paramagnetic contrast-
enhanced images are acquired with T1-weighted sequence with fat-suppression in the axial,
coronal and sagittal oblique planes [53]. Our currently used MRI protocol for examination of
GO patients is given in Table 1.
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2975 ms / 68
ms
512 × 512 3 0.3 14.0 No
Table 1. MR-imaging protocol used in GE Signa HDxt MR apparatus with 8-channel HR head coil for patients with
thyroid-associated ophthalmopathy.
Importantly, the T1-weighted MRI sequence offers a better contrast resolution for evaluating
the orbit structures and measurement of the thickness of the intra-orbital muscles [54]. In
contrast, the pathophysiological conditions of the muscles could be better evaluated on T2-
weighted MRI sequences [55]. Moreover, the STIR sequences suppress the fatty signal and
allow a more adequate assessment of pathological tissues. Not affected extraocular muscles
are defined with a low signal intensity on T1-weighted sequences and low to intermediate
signal intensity on T2-weighted sequences, with evident and clear edges. Due to the immense
vascular supply of the orbital muscles the strong contrast enhancement is observed during the
examination with paramagnetic contrast mediums (e.g. gadolinium containing agents).
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Morphological imaging criteria, suggestive for GO on MRI are a bilateral, spindle-like
thickening of normally multiple extraocular recti muscles over 5 mm and an increase of intra-
and extra-conal fat, both leading to exophthalmos (Figure 1A-C). MRI imaging is specifically
advantageous for clinical diagnosis of exophthalmos, because it depicts a clear outline of the
eye globe that allows precise measurements. In the clinical setting, exophthalmos is usually
measured manually with a Hertel exophthalmometer. The average measurement is around
13.5 mm, and the difference between bilateral eye protrusions should be within 2 mm.
However, this manual diagnostic method has poor reproducibility due to the orbital interval,
variance of eye diameter as a result of ametropia, exophthalmometer variance and instrument
operator bias. In contrast, on axial T1-weighted sequences, the level of proptosis can be
measured very precisely, compared to the clinically measured Hertel-index [56]. On imaging,
a interzygomatic line is drawn between the right and left ventral zygomatic border. From there,
a perpendicular line, representing the value of Hertel-index in mm, is taken to the apex of each
globe, thus depicting the measurement of proptosis. Physiologically, 1⁄3 of the globe is located
behind the interzygomatic line and a Hertel-index of ≥ 22 mm is pathological and indicates
exophthalmos (Figure 1A).
Although changes in extraocular muscle size and increased amounts of orbital fat can be
assessed with CT, the orbital soft tissue edema and water content changes in the extraocular
muscles can be only assessed by MRI imaging. There are several studies indicating the specific
applications of MRI imaging in establishing of the disease phase due to the ability to estimate
the water content in orbital tissues. Especially, the images from strong T2-weighted and fat
suppressed sequences have been found to be useful in detecting tissue edema [44]. Inflamma‐
tory process of the extra-ocular muscles can be detected in MRI independently from the size
of the muscles [21]. Young and colleagues proposed to employ in GO patients the MRI turbo
inversion recovery magnitude (TIRM) sequences used with short inversion times (80–150 ms).
These strong T2-weighted and fat-suppressed images have been found to be useful in detecting
edema and therefore, TIRM sequences can be used to define inflammation in extra-ocular
muscles [57]. Specifically, the STIR signal intensity, which is directly related to the raise of
relaxation in T2 time caused by increased abnormal content in the analyzed tissue, correlates
with the inflammatory activity in GO [58]. STIR-sequence MRI may also detect peri-muscular
inflammation [59]. Importantly, Kirsch et al. reported that the difference in T2-STIR versus T1-
STIR would be helpful to distinguish inflammatory edema of the extra-ocular muscles from
intra-orbital congestion due to reduced venous outflow [60]. Therefore, the results of MRI
examination have a great therapeutic impact, identifying inflammatory and edematous
alterations in orbital muscles that are critical to achieve a good outcome of the anti-inflamma‐
tory treatment, which is effective only in the active phase of the disease. Likewise, increase in
the signal intensity on T2-weighted sequences was associated with a good response to
methylprednisolone pulse therapy [61]. Also, longer T2 relaxation times in the extraocular
muscles before treatment were associated with a good response to orbital irradiation [62].
Moreover, individual STIR imaging was useful for predicting the outcome of immunosup‐
pressive therapy [61]. On the other hand, the T1-weighted images with contrast enhancement
and in combination with fat saturation are helpful to detect intense signal enhancement of the
eyelid, which is also affected in the inflammatory GO stage [63]. Interestingly, the decrease of
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orbits with MRI is comprised of spin-echo T1-weighted sequences in the axial and coronal
planes with 3-mm-slice thickness, multi-echoes T2-weighted sequence in the coronal plane,
and short time inversion recovery (STIR) sequence in the coronal plane. Paramagnetic contrast-
enhanced images are acquired with T1-weighted sequence with fat-suppression in the axial,
coronal and sagittal oblique planes [53]. Our currently used MRI protocol for examination of
GO patients is given in Table 1.
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Table 1. MR-imaging protocol used in GE Signa HDxt MR apparatus with 8-channel HR head coil for patients with
thyroid-associated ophthalmopathy.
Importantly, the T1-weighted MRI sequence offers a better contrast resolution for evaluating
the orbit structures and measurement of the thickness of the intra-orbital muscles [54]. In
contrast, the pathophysiological conditions of the muscles could be better evaluated on T2-
weighted MRI sequences [55]. Moreover, the STIR sequences suppress the fatty signal and
allow a more adequate assessment of pathological tissues. Not affected extraocular muscles
are defined with a low signal intensity on T1-weighted sequences and low to intermediate
signal intensity on T2-weighted sequences, with evident and clear edges. Due to the immense
vascular supply of the orbital muscles the strong contrast enhancement is observed during the
examination with paramagnetic contrast mediums (e.g. gadolinium containing agents).
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Morphological imaging criteria, suggestive for GO on MRI are a bilateral, spindle-like
thickening of normally multiple extraocular recti muscles over 5 mm and an increase of intra-
and extra-conal fat, both leading to exophthalmos (Figure 1A-C). MRI imaging is specifically
advantageous for clinical diagnosis of exophthalmos, because it depicts a clear outline of the
eye globe that allows precise measurements. In the clinical setting, exophthalmos is usually
measured manually with a Hertel exophthalmometer. The average measurement is around
13.5 mm, and the difference between bilateral eye protrusions should be within 2 mm.
However, this manual diagnostic method has poor reproducibility due to the orbital interval,
variance of eye diameter as a result of ametropia, exophthalmometer variance and instrument
operator bias. In contrast, on axial T1-weighted sequences, the level of proptosis can be
measured very precisely, compared to the clinically measured Hertel-index [56]. On imaging,
a interzygomatic line is drawn between the right and left ventral zygomatic border. From there,
a perpendicular line, representing the value of Hertel-index in mm, is taken to the apex of each
globe, thus depicting the measurement of proptosis. Physiologically, 1⁄3 of the globe is located
behind the interzygomatic line and a Hertel-index of ≥ 22 mm is pathological and indicates
exophthalmos (Figure 1A).
Although changes in extraocular muscle size and increased amounts of orbital fat can be
assessed with CT, the orbital soft tissue edema and water content changes in the extraocular
muscles can be only assessed by MRI imaging. There are several studies indicating the specific
applications of MRI imaging in establishing of the disease phase due to the ability to estimate
the water content in orbital tissues. Especially, the images from strong T2-weighted and fat
suppressed sequences have been found to be useful in detecting tissue edema [44]. Inflamma‐
tory process of the extra-ocular muscles can be detected in MRI independently from the size
of the muscles [21]. Young and colleagues proposed to employ in GO patients the MRI turbo
inversion recovery magnitude (TIRM) sequences used with short inversion times (80–150 ms).
These strong T2-weighted and fat-suppressed images have been found to be useful in detecting
edema and therefore, TIRM sequences can be used to define inflammation in extra-ocular
muscles [57]. Specifically, the STIR signal intensity, which is directly related to the raise of
relaxation in T2 time caused by increased abnormal content in the analyzed tissue, correlates
with the inflammatory activity in GO [58]. STIR-sequence MRI may also detect peri-muscular
inflammation [59]. Importantly, Kirsch et al. reported that the difference in T2-STIR versus T1-
STIR would be helpful to distinguish inflammatory edema of the extra-ocular muscles from
intra-orbital congestion due to reduced venous outflow [60]. Therefore, the results of MRI
examination have a great therapeutic impact, identifying inflammatory and edematous
alterations in orbital muscles that are critical to achieve a good outcome of the anti-inflamma‐
tory treatment, which is effective only in the active phase of the disease. Likewise, increase in
the signal intensity on T2-weighted sequences was associated with a good response to
methylprednisolone pulse therapy [61]. Also, longer T2 relaxation times in the extraocular
muscles before treatment were associated with a good response to orbital irradiation [62].
Moreover, individual STIR imaging was useful for predicting the outcome of immunosup‐
pressive therapy [61]. On the other hand, the T1-weighted images with contrast enhancement
and in combination with fat saturation are helpful to detect intense signal enhancement of the
eyelid, which is also affected in the inflammatory GO stage [63]. Interestingly, the decrease of
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Figure 1. 59-year-old female patient with diagnosis of clinically active Graves’ orbitopathy. (A) Axial T2 FRFSE MR im‐
age of orbits without contrast shows marked bilateral exophthalmos as indicated by interzygomatic line (blue line)
and Hertel-index (perpendicular white lines). This image shows also the largest diameters (yellow lines) perpendicular
to long axis of medial and lateral rectus muscles in both orbits. (B) Unenhanced T1 FSE coronal image of orbits shows
the transverse sections of the thickest extraocular muscles in both orbits (arrows). (C) and (D) Unenhanced T1 FSE sag‐
ittal images parallel to optic nerve show corresponding maximal diameters (yellow lines) for inferior rectus muscle and
for superior muscle group of right (C) and left (D) orbit.
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T2 relaxation times of the extraocular muscles in response to immunosuppressive therapy
occurs even in spite of unchanged laboratory markers during and after the treatment [64].
Nagy et al. found that T2 relaxation times on MRI provided more diagnostic and prognostic
information than other applied eleven clinical and laboratory factors [21]. In summary, the
major result of the above studies is the relationship between response to therapy and pre-
therapeutic value of the T2 times of relaxation in MRI sequences. Consequently, the measure‐
ment of T2 before giving the therapy might play a role in the prediction of the reversibility of
orbital tissue abnormalities (e.g. muscle thickening, increased fat volume), and favors the
choice of anti-inflammatory therapy regimens in GO patients.
MRI is also a valuable tool that can be used to detect other features of the active inflammatory
phase of the disease that include lacrimal gland hypertrophy, palpebral edema, anterior
displacement of the orbital septum and optic nerve stretching. On the contrary, gradual
decreasing of signal intensity of intra-orbital muscles on T1-and T2-weighted sequences
suggests the presence of chronic fibrotic alterations that clinically correspond to chronic phase
at the Rundle’s curve of disease activity [65]. Hyper-intense intramuscular foci on T1-and T2-
weighted sequences are suggestive of chronic fat degeneration [66]. Of note, chronic fat
degeneration may also be identified at CT imaging through hypodense areas corresponding
to fat infiltration of muscle tissue [53]. The above-mentioned findings indicate the presence of
the non-congestive phase of the disease with restricted ocular motion secondary to extraocular
muscle fibrosis and subsequent loss of elasticity in association with volume reduction of the
muscles [66]. Recently, the dynamic contrast-enhanced MRI (DCE-MRI) technique that is used
for assessment of microcirculation was able to establish the correlation between disease activity
and the microcirculation characteristics of extraocular muscles in patients with GO [63, 67-68].
The natural consequence of the pressure at the orbital apex by increased volume of orbital
contents, and resulting overcrowding and stretching of the optic nerve is the compressive optic
neuropathy, in which the nerve diameter at the orbital apex has been found to be significantly
reduced in MRI imaging. The high-resolution volume acquisition (T1-w-3D) with curved
multiplanar reformatting process can be used to measure the optic nerve diameter along its
entire length, and thus it can be used to predict possible optic nerve compression. The group
of Dodds et al. has demonstrated in MRI modality a reproducible decrease in mean nerve
diameter as it extends posterior from the globe in patients with chronic GO [69]. Importantly,
this situation may occur even in orbits without increased muscle indices but with clinical signs
of optic neuropathy. An additional sign of nerve compression is intracranial fat prolapse in
the orbital apex [44].
In conclusion, MRI remains a valuable tool in the care of patients with GO, despite its limited
usage due to the time-consuming and a relatively high cost, as well as the still reduced
availability, and magnetism contraindicated in patients with certain types of implants. MRI
offers extraordinary images of orbital anatomy, except for bony structures, and has an ability
to quantify muscle enlargement that outperforms the results obtained from other modalities
such as the US and CT imaging. MRI modality is the most effective tool not only in establishing
the initial diagnosis but also in diagnosing of the disease stage and immune activity of GO for
predicting therapeutic efficacy and of the potential harmful disease complications (damage to
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Figure 1. 59-year-old female patient with diagnosis of clinically active Graves’ orbitopathy. (A) Axial T2 FRFSE MR im‐
age of orbits without contrast shows marked bilateral exophthalmos as indicated by interzygomatic line (blue line)
and Hertel-index (perpendicular white lines). This image shows also the largest diameters (yellow lines) perpendicular
to long axis of medial and lateral rectus muscles in both orbits. (B) Unenhanced T1 FSE coronal image of orbits shows
the transverse sections of the thickest extraocular muscles in both orbits (arrows). (C) and (D) Unenhanced T1 FSE sag‐
ittal images parallel to optic nerve show corresponding maximal diameters (yellow lines) for inferior rectus muscle and
for superior muscle group of right (C) and left (D) orbit.
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T2 relaxation times of the extraocular muscles in response to immunosuppressive therapy
occurs even in spite of unchanged laboratory markers during and after the treatment [64].
Nagy et al. found that T2 relaxation times on MRI provided more diagnostic and prognostic
information than other applied eleven clinical and laboratory factors [21]. In summary, the
major result of the above studies is the relationship between response to therapy and pre-
therapeutic value of the T2 times of relaxation in MRI sequences. Consequently, the measure‐
ment of T2 before giving the therapy might play a role in the prediction of the reversibility of
orbital tissue abnormalities (e.g. muscle thickening, increased fat volume), and favors the
choice of anti-inflammatory therapy regimens in GO patients.
MRI is also a valuable tool that can be used to detect other features of the active inflammatory
phase of the disease that include lacrimal gland hypertrophy, palpebral edema, anterior
displacement of the orbital septum and optic nerve stretching. On the contrary, gradual
decreasing of signal intensity of intra-orbital muscles on T1-and T2-weighted sequences
suggests the presence of chronic fibrotic alterations that clinically correspond to chronic phase
at the Rundle’s curve of disease activity [65]. Hyper-intense intramuscular foci on T1-and T2-
weighted sequences are suggestive of chronic fat degeneration [66]. Of note, chronic fat
degeneration may also be identified at CT imaging through hypodense areas corresponding
to fat infiltration of muscle tissue [53]. The above-mentioned findings indicate the presence of
the non-congestive phase of the disease with restricted ocular motion secondary to extraocular
muscle fibrosis and subsequent loss of elasticity in association with volume reduction of the
muscles [66]. Recently, the dynamic contrast-enhanced MRI (DCE-MRI) technique that is used
for assessment of microcirculation was able to establish the correlation between disease activity
and the microcirculation characteristics of extraocular muscles in patients with GO [63, 67-68].
The natural consequence of the pressure at the orbital apex by increased volume of orbital
contents, and resulting overcrowding and stretching of the optic nerve is the compressive optic
neuropathy, in which the nerve diameter at the orbital apex has been found to be significantly
reduced in MRI imaging. The high-resolution volume acquisition (T1-w-3D) with curved
multiplanar reformatting process can be used to measure the optic nerve diameter along its
entire length, and thus it can be used to predict possible optic nerve compression. The group
of Dodds et al. has demonstrated in MRI modality a reproducible decrease in mean nerve
diameter as it extends posterior from the globe in patients with chronic GO [69]. Importantly,
this situation may occur even in orbits without increased muscle indices but with clinical signs
of optic neuropathy. An additional sign of nerve compression is intracranial fat prolapse in
the orbital apex [44].
In conclusion, MRI remains a valuable tool in the care of patients with GO, despite its limited
usage due to the time-consuming and a relatively high cost, as well as the still reduced
availability, and magnetism contraindicated in patients with certain types of implants. MRI
offers extraordinary images of orbital anatomy, except for bony structures, and has an ability
to quantify muscle enlargement that outperforms the results obtained from other modalities
such as the US and CT imaging. MRI modality is the most effective tool not only in establishing
the initial diagnosis but also in diagnosing of the disease stage and immune activity of GO for
predicting therapeutic efficacy and of the potential harmful disease complications (damage to
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the optic nerve), what makes it a unique instrument in determining the proper treatment and
monitoring of the therapeutic response.
2.4. Radionuclide-based imaging evaluation of Graves’ ophthalmopathy
Direct neuroimaging methods (US, CT and MRI) play currently a significant role as an aid in
the diagnostic process and clinical evaluation of patients with endocrine ophthalmopathy,
however, there is no sufficient imaging modality that could be applied to determine with a
high sensitivity and specificity the GO activity. It is suggested that intervention using immu‐
nosuppressive drugs will be most successful, if applied in the phase of active inflammation.
Therefore, to decide, when the treatment should be given, it is important to determine the
phase of the disease in an individual patient. One of such imaging possibilities gives octreotide
scintigraphy so-called “octreoscan”. Previously, it was observed that accumulation of octreo‐
tide, a somatostatin analogue labelled with radioisotope indium-111, binds in the thyroid and
the orbit to the somatostatin receptor in patients with active GO [70]. Octreotide uptake was
significantly higher in patients with active GO compared to those with non-active GO, and the
observed high orbital radionuclide activity decreased after therapy. Postema and colleagues
have also performed thyroid octreoscan in patients with confirmed Graves' disease and in
controls [71]. In this study, the thyroidal octreotide accumulation was increased in thyrotoxi‐
cosis, and was almost absent after radioiodine-induced hypothyroidism. The cause of specific
orbital and thyroid uptake of octreotide is not well known yet. Most probably, the orbital
uptake of octreotide in GO is caused by the expression of somatostatin receptors on the surface
of both activated T lymphocytes and fibroblasts, which infiltrate the orbital and thyroid tissues
in patients with GO [72-73]. Radio-labeled octreotide accumulated within the orbits can be
detected via single-photon emission CT (SPECT), and may serve as a marker of disease activity
[70]. On the other hand, the octreoscan does not provide information on inactive patients nor
gives any anatomical and morphologic information on the orbit. Importantly, although several
studies have found a relation between octreoscan uptake and severity of GO [74-76], the others
did not find such a correlation [77-78]. Due to the above-mentioned results indicating sub‐
stantial limitations of octreoscan (i.e. high demand of the technique in terms of accuracy needed
for prediction, inter-observer variance, significant price, modest availability, a non-negligible
radiation burden of patients, long acquisition protocol and relative lack of specificity), it is not
recommended by some specialists to use it as a routine imaging procedure in a regular clinical
practice with GO patients [79-80].
In contrast to octreotide labeled with In-111, the orbital SPECT with other radionuclide tracers
has been proposed as clinically suitable protocols for activity evaluation of Graves’ ophthalm‐
opathy and differential diagnosis of GO cases sensitive or resistant to the immune suppressive
therapy. Indeed, the diethylenetriamine pentaacetic acid labeled with technetium-99 (Tc-99m
DTPA) has been indicated as suitable radiopharmaceutical for such examination [81]. The
theoretical basis of this method is that the high capillarisation in the orbit and edematous
swelling of orbital tissues may be reflected on SPECT images, as the Tc-99m DTPA uptake has
been reported as related to the inflammatory process, and signal disappearing with the
resolution of the inflammation. The Tc-99m DTPA complex (molecular weight 492 Da),
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administered intravenously, marks the high capillarization of inflammation sites leaving the
vascular bed through damaged capillary walls. It goes out into the interstitial fluid and binds
to polypeptides present in the extracellular fluid at inflammation sites [82]. This may explain
the high DTPA uptake in GO since the orbital inflammation is a basic pathophysiological
process in GO. The determination of periorbital inflammation tissue by testing with intrave‐
nously given Tc-99m DTPA may identify the patients that will benefit from anti-inflammatory
treatment. This protocol was clinically tested by Galuska et al., who was able to visualize the
active retrobulbar inflammation in GO patient by Tc-99m DTPA SPECT [83]. Moreover, Ujhelyi
et al. found that the mean retrobulbar Tc-99m DTPA uptake is useful to estimate GO activity
and may predict the effectiveness of immunosuppressive therapy with corticosteroids in GO
patients [84]. Especially, patients included in this study with Tc-99m DTPA uptake score above
12.28MBq/cm3 were more likely to respond to corticosteroid treatment. Another promising
method for the diagnosis of inflammatory state is SPECT technique, which uses polyclonal
and monoclonal antibodies labeled with technetium-99 (Tc-99m). This technique was previ‐
ously reported to allow the use of polyclonal human immunoglobulin gamma labeled with
Tc-99m (Tc-99m HIG) as a radiopharmaceutical tool in the evaluation of the disease activity
in GO [85]. Recently, Lopes and colleagues proposed Tc-99m anti-TNF-alpha scintigraphy
based on labeling of a human monoclonal antibody directed against TNF-alpha molecule,
commercially known as adalimumab, with technetium-99, as a promising method for the
diagnosis of active ocular disease [86]. This method is based on the demonstration of TNF-
alpha as one of the cytokines involved in the initial active phase of GO development. They
reported the successful use of Tc-99m-anti-TNF-alpha scintigraphy in case of unilateral
exophthalmos in which intense uptake of anti-TNF-alpha antibody was observed, indicating
the development of active retrobulbar inflammation that may be related with active phase of
GO.
Concurrently, the positron emission tomography (PET) appears also as promising tool for
diagnosing of active phase of GO. PET is a noninvasive diagnostic method that has been used
as a mean for differential diagnosis of inflammatory and malignant processes and it offers the
ability to perform functional and metabolic assessment in cases of the absence of any tissue
structural alteration [87]. One of its main advantages over other methods is its ability to detect
early inflammatory stages prior to structural changes in the tissue [88]. Recently, García-Rojas
et al. demonstrated in PET combined with CT (PET/CT) imaging a significant correlation
between extraocular muscle uptake of 18-fluorodeoxyglucose (18-FDG) radiotracer and GO
developed in hyperthyroid patients [89]. These studies indicate that modern PET/CT imaging
modality may provide the valuable clinical information and may be a helpful tool in detecting,
localizing, and quantifying the GO inflammation. Ultimately, in the same line of work, Pichler
et al. reported the case of subclinical hyperthyroidism due to Graves’ disease without pre‐
senting exophthalmos in a 53-year-old woman. Application of specific radiotracer Ga-68-
DOTA-NOC for high-resolution hybrid PET/CT imaging comprised of gallium-68
radionuclide demonstrated marked accumulation at the thyroid and the right rectus inferior
muscle in this patient. Therefore, this specific imaging modality revealed active Graves’
orbitopathy in a single extraorbital muscle. The authors concluded that the Ga-68 labeled PET
tracers may provide the possibility to evaluate the status of activity in any single extraorbital
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the optic nerve), what makes it a unique instrument in determining the proper treatment and
monitoring of the therapeutic response.
2.4. Radionuclide-based imaging evaluation of Graves’ ophthalmopathy
Direct neuroimaging methods (US, CT and MRI) play currently a significant role as an aid in
the diagnostic process and clinical evaluation of patients with endocrine ophthalmopathy,
however, there is no sufficient imaging modality that could be applied to determine with a
high sensitivity and specificity the GO activity. It is suggested that intervention using immu‐
nosuppressive drugs will be most successful, if applied in the phase of active inflammation.
Therefore, to decide, when the treatment should be given, it is important to determine the
phase of the disease in an individual patient. One of such imaging possibilities gives octreotide
scintigraphy so-called “octreoscan”. Previously, it was observed that accumulation of octreo‐
tide, a somatostatin analogue labelled with radioisotope indium-111, binds in the thyroid and
the orbit to the somatostatin receptor in patients with active GO [70]. Octreotide uptake was
significantly higher in patients with active GO compared to those with non-active GO, and the
observed high orbital radionuclide activity decreased after therapy. Postema and colleagues
have also performed thyroid octreoscan in patients with confirmed Graves' disease and in
controls [71]. In this study, the thyroidal octreotide accumulation was increased in thyrotoxi‐
cosis, and was almost absent after radioiodine-induced hypothyroidism. The cause of specific
orbital and thyroid uptake of octreotide is not well known yet. Most probably, the orbital
uptake of octreotide in GO is caused by the expression of somatostatin receptors on the surface
of both activated T lymphocytes and fibroblasts, which infiltrate the orbital and thyroid tissues
in patients with GO [72-73]. Radio-labeled octreotide accumulated within the orbits can be
detected via single-photon emission CT (SPECT), and may serve as a marker of disease activity
[70]. On the other hand, the octreoscan does not provide information on inactive patients nor
gives any anatomical and morphologic information on the orbit. Importantly, although several
studies have found a relation between octreoscan uptake and severity of GO [74-76], the others
did not find such a correlation [77-78]. Due to the above-mentioned results indicating sub‐
stantial limitations of octreoscan (i.e. high demand of the technique in terms of accuracy needed
for prediction, inter-observer variance, significant price, modest availability, a non-negligible
radiation burden of patients, long acquisition protocol and relative lack of specificity), it is not
recommended by some specialists to use it as a routine imaging procedure in a regular clinical
practice with GO patients [79-80].
In contrast to octreotide labeled with In-111, the orbital SPECT with other radionuclide tracers
has been proposed as clinically suitable protocols for activity evaluation of Graves’ ophthalm‐
opathy and differential diagnosis of GO cases sensitive or resistant to the immune suppressive
therapy. Indeed, the diethylenetriamine pentaacetic acid labeled with technetium-99 (Tc-99m
DTPA) has been indicated as suitable radiopharmaceutical for such examination [81]. The
theoretical basis of this method is that the high capillarisation in the orbit and edematous
swelling of orbital tissues may be reflected on SPECT images, as the Tc-99m DTPA uptake has
been reported as related to the inflammatory process, and signal disappearing with the
resolution of the inflammation. The Tc-99m DTPA complex (molecular weight 492 Da),
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administered intravenously, marks the high capillarization of inflammation sites leaving the
vascular bed through damaged capillary walls. It goes out into the interstitial fluid and binds
to polypeptides present in the extracellular fluid at inflammation sites [82]. This may explain
the high DTPA uptake in GO since the orbital inflammation is a basic pathophysiological
process in GO. The determination of periorbital inflammation tissue by testing with intrave‐
nously given Tc-99m DTPA may identify the patients that will benefit from anti-inflammatory
treatment. This protocol was clinically tested by Galuska et al., who was able to visualize the
active retrobulbar inflammation in GO patient by Tc-99m DTPA SPECT [83]. Moreover, Ujhelyi
et al. found that the mean retrobulbar Tc-99m DTPA uptake is useful to estimate GO activity
and may predict the effectiveness of immunosuppressive therapy with corticosteroids in GO
patients [84]. Especially, patients included in this study with Tc-99m DTPA uptake score above
12.28MBq/cm3 were more likely to respond to corticosteroid treatment. Another promising
method for the diagnosis of inflammatory state is SPECT technique, which uses polyclonal
and monoclonal antibodies labeled with technetium-99 (Tc-99m). This technique was previ‐
ously reported to allow the use of polyclonal human immunoglobulin gamma labeled with
Tc-99m (Tc-99m HIG) as a radiopharmaceutical tool in the evaluation of the disease activity
in GO [85]. Recently, Lopes and colleagues proposed Tc-99m anti-TNF-alpha scintigraphy
based on labeling of a human monoclonal antibody directed against TNF-alpha molecule,
commercially known as adalimumab, with technetium-99, as a promising method for the
diagnosis of active ocular disease [86]. This method is based on the demonstration of TNF-
alpha as one of the cytokines involved in the initial active phase of GO development. They
reported the successful use of Tc-99m-anti-TNF-alpha scintigraphy in case of unilateral
exophthalmos in which intense uptake of anti-TNF-alpha antibody was observed, indicating
the development of active retrobulbar inflammation that may be related with active phase of
GO.
Concurrently, the positron emission tomography (PET) appears also as promising tool for
diagnosing of active phase of GO. PET is a noninvasive diagnostic method that has been used
as a mean for differential diagnosis of inflammatory and malignant processes and it offers the
ability to perform functional and metabolic assessment in cases of the absence of any tissue
structural alteration [87]. One of its main advantages over other methods is its ability to detect
early inflammatory stages prior to structural changes in the tissue [88]. Recently, García-Rojas
et al. demonstrated in PET combined with CT (PET/CT) imaging a significant correlation
between extraocular muscle uptake of 18-fluorodeoxyglucose (18-FDG) radiotracer and GO
developed in hyperthyroid patients [89]. These studies indicate that modern PET/CT imaging
modality may provide the valuable clinical information and may be a helpful tool in detecting,
localizing, and quantifying the GO inflammation. Ultimately, in the same line of work, Pichler
et al. reported the case of subclinical hyperthyroidism due to Graves’ disease without pre‐
senting exophthalmos in a 53-year-old woman. Application of specific radiotracer Ga-68-
DOTA-NOC for high-resolution hybrid PET/CT imaging comprised of gallium-68
radionuclide demonstrated marked accumulation at the thyroid and the right rectus inferior
muscle in this patient. Therefore, this specific imaging modality revealed active Graves’
orbitopathy in a single extraorbital muscle. The authors concluded that the Ga-68 labeled PET
tracers may provide the possibility to evaluate the status of activity in any single extraorbital
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muscle in hybrid imaging of PET with CT [90]. Whether novel radiopharmaceutical, such as
Ga-68-DOTA-NOC, which has a stronger discriminative capability for detecting active
endocrine orbitopathy than octreotide will achieve clinical applicability similar to techneti‐
um-99-labelled tracers, it remains to be demonstrated in the future.
In conclusion, the nuclear medicine-based imaging continues to be important in the diagnosis
and management of thyroid-associated ophthalmopathy. Although, the previously used
SPECT technique known as octreoscan presents nowadays the restricted clinical application
[91] due to its high costs, relative lack of specificity (i.e., the number of false positives in other
inflammatory or non-inflammatory orbital disorders), and a non-negligible radiation burden,
some other SPECT-based methods including technetium-related scintigraphy with the new
target-based modalities (i.e. antibodies against selected pro-inflammatory molecules), can be
used in the reliable evaluation of patients with unilateral/bilateral active GO. Particularly, the
better image quality due to the high energy of technetium, the lower radiation dose for patients
and personnel, and the short acquisition protocol favor scintigraphy with Tc-99m-over In-111-
labeled compounds [92]. In the near future, the modern PET/CT imaging technique may still
improve significantly the process of the treatment selection and the outcome in patient with
GO. The results of the currently reported studies demonstrated that PET/CT imaging modal‐
ities are able to recognize the early active phase from the late stable stage of the disease and to
predict the response to anti-inflammatory treatment in majority of GO patients. Especially, the
hybrid PET/CT imaging modality provides valuable and useful information for the diagnosis,
characterization, and therapeutic decision in cases, where clinical doubts and uncertainties
exist.
3. Predicting therapeutic efficacy and disease activity based on orbital
neuroimaging
The activity and severity are important pathophysiological characteristics in Graves’ orbitop‐
athy and have implications for the treatment, although the biologic activity of ophthalmopathy
is neither synonymous nor coincident with the clinical severity of the eye disease. Severity of
GO is defined by the functional impairment and should be categorized using an examination
form and a photographic color atlas, which includes the clinical signs of the disease [5]. The
European Group of Graves’ Orbitopathy (EUGOGO) suggests classifying the GO severity,
based on subjective symptoms and objective signs, into three categories: sight-threatening,
moderate-to-severe, and mild GO [93]. On the other hand, the activity of GO is related to the
presence of inflammatory signs in the orbits. It can be measured using the Clinical Activity
Score (CAS) classification that is based on the classical features of inflammation (pain, redness,
swelling, and impaired function). In the CAS ten-point scoring system, which was developed
by Mourits et al., one point is given for each of the following 10 items: painful, oppressive
feeling on and behind the globe during the past 4 weeks; pain attempted up, side, or down
gaze during the past 4 weeks; redness of the eyelid; diffuse redness of conjunctiva covering at
least one quadrant; swelling of the eyelid; chemosis; swollen caruncle; increase of proptosis of
≥ 2 mm during a period of 1–3 months; decrease of eye movements in any direction ≥ 5o during
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a period of 1–3 months; and decrease of visual acuity of ≥ 1 line(s) on the Snellen chart during
a period of 1–3 months. A score ≥ 3 defines an active GO [94]. The second classification,
NOSPECS mnemonic, is a useful alternative reminder of what should be assessed in patients
with Graves’ orbitopathy regarding severity, but it is of lesser practical value [5]. Importantly,
the clinical problem in GO is not the establishing of the diagnosis of the disease, because this
is quite obvious from the clinical presentation, but the treatment of the eye symptoms in an
individual patient. Patients with the immunologically-active ophthalmopathy need the anti-
inflammatory treatment, and patients with inactive disease require a completely different
treatment course, including rehabilitative surgery (strabismus surgery, eyelid surgery, etc.).
In general, the decision for anti-inflammatory treatment with steroids or irradiation is based
on objective findings of detailed ophthalmological examination. However, it is important to
be able to predict, if the patient will benefit from immunosuppression, as some patients might
improve without such therapy, whereas in some patients with a severe course of the disease
the initial choice of immunosuppressive steroid dosage may be too low. In contrast, patients
with the immunologically inactive orbit will only suffer from the serious adverse reactions of
otherwise ineffective immunosuppressive therapy given to them. Furthermore, there are
always the questions demanding the rapid answer that include the decision whether to
continue or to stop the anti-inflammatory therapy in patients with mild but persisting
inflammation, and when is the right moment for surgical rehabilitation, which should not be
done in patients at risk for further deterioration due to the high disease activity. The clinical
decisions in GO patients are often difficult, and it is extremely important for the clinicians to
be able to distinguish the specific phases of Graves’ orbitopathy. Of note, in the last decade as
many as one-third of patients did not respond to given immunosuppressive treatment [95].
Most of these cases were due to lack of the active stage of disease in the course of the therapy.
In such scenarios, more discriminative information of better quality is needed to establish the
activity phase of the disease and to make the best treatment decision. For this reason, several
groups have assessed the predictive value of several potential activity parameters to predict
response to therapy including duration of the eye disease, the CAS score, urinary glycosami‐
noglycan (GAG) excretion, serum cytokine levels, serum levels of TSH-receptor autoantibodies
[91,94,96-98]. Lastly, even genetic factors might influence treatment outcome as several HLA
markers have been shown to indicate good or bad response to immune therapy [99]. Notwith‐
standing, some of these parameters could predict a response to treatment only to some extent,
while others could predict to some extent a lack of the therapeutic response. This means that
probably a combination of different parameters may be necessary to accurately predict the
response to the treatment in the particular patient. In this notion, several recent clinical and
experimental studies have found evidences that the selected neuroimaging modalities would
be valuable in measuring the disease activity to predict therapeutic outcomes in GO patients.
Especially, there are two imaging modalities that seem to be highly supportive to detect disease
activity, including MRI and radionuclide-based imaging.
MRI has currently emerged as a valuable tool in the evaluation of disease activity in patients
with GO as it can illustrate in detail the inflamed regions of orbits. More than two decades ago,
Just et al. described that in MRI sequences an increased T2 time in the eye muscles before
treatment was associated with a good response to orbital irradiation [62]. This first report was
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muscle in hybrid imaging of PET with CT [90]. Whether novel radiopharmaceutical, such as
Ga-68-DOTA-NOC, which has a stronger discriminative capability for detecting active
endocrine orbitopathy than octreotide will achieve clinical applicability similar to techneti‐
um-99-labelled tracers, it remains to be demonstrated in the future.
In conclusion, the nuclear medicine-based imaging continues to be important in the diagnosis
and management of thyroid-associated ophthalmopathy. Although, the previously used
SPECT technique known as octreoscan presents nowadays the restricted clinical application
[91] due to its high costs, relative lack of specificity (i.e., the number of false positives in other
inflammatory or non-inflammatory orbital disorders), and a non-negligible radiation burden,
some other SPECT-based methods including technetium-related scintigraphy with the new
target-based modalities (i.e. antibodies against selected pro-inflammatory molecules), can be
used in the reliable evaluation of patients with unilateral/bilateral active GO. Particularly, the
better image quality due to the high energy of technetium, the lower radiation dose for patients
and personnel, and the short acquisition protocol favor scintigraphy with Tc-99m-over In-111-
labeled compounds [92]. In the near future, the modern PET/CT imaging technique may still
improve significantly the process of the treatment selection and the outcome in patient with
GO. The results of the currently reported studies demonstrated that PET/CT imaging modal‐
ities are able to recognize the early active phase from the late stable stage of the disease and to
predict the response to anti-inflammatory treatment in majority of GO patients. Especially, the
hybrid PET/CT imaging modality provides valuable and useful information for the diagnosis,
characterization, and therapeutic decision in cases, where clinical doubts and uncertainties
exist.
3. Predicting therapeutic efficacy and disease activity based on orbital
neuroimaging
The activity and severity are important pathophysiological characteristics in Graves’ orbitop‐
athy and have implications for the treatment, although the biologic activity of ophthalmopathy
is neither synonymous nor coincident with the clinical severity of the eye disease. Severity of
GO is defined by the functional impairment and should be categorized using an examination
form and a photographic color atlas, which includes the clinical signs of the disease [5]. The
European Group of Graves’ Orbitopathy (EUGOGO) suggests classifying the GO severity,
based on subjective symptoms and objective signs, into three categories: sight-threatening,
moderate-to-severe, and mild GO [93]. On the other hand, the activity of GO is related to the
presence of inflammatory signs in the orbits. It can be measured using the Clinical Activity
Score (CAS) classification that is based on the classical features of inflammation (pain, redness,
swelling, and impaired function). In the CAS ten-point scoring system, which was developed
by Mourits et al., one point is given for each of the following 10 items: painful, oppressive
feeling on and behind the globe during the past 4 weeks; pain attempted up, side, or down
gaze during the past 4 weeks; redness of the eyelid; diffuse redness of conjunctiva covering at
least one quadrant; swelling of the eyelid; chemosis; swollen caruncle; increase of proptosis of
≥ 2 mm during a period of 1–3 months; decrease of eye movements in any direction ≥ 5o during
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a period of 1–3 months; and decrease of visual acuity of ≥ 1 line(s) on the Snellen chart during
a period of 1–3 months. A score ≥ 3 defines an active GO [94]. The second classification,
NOSPECS mnemonic, is a useful alternative reminder of what should be assessed in patients
with Graves’ orbitopathy regarding severity, but it is of lesser practical value [5]. Importantly,
the clinical problem in GO is not the establishing of the diagnosis of the disease, because this
is quite obvious from the clinical presentation, but the treatment of the eye symptoms in an
individual patient. Patients with the immunologically-active ophthalmopathy need the anti-
inflammatory treatment, and patients with inactive disease require a completely different
treatment course, including rehabilitative surgery (strabismus surgery, eyelid surgery, etc.).
In general, the decision for anti-inflammatory treatment with steroids or irradiation is based
on objective findings of detailed ophthalmological examination. However, it is important to
be able to predict, if the patient will benefit from immunosuppression, as some patients might
improve without such therapy, whereas in some patients with a severe course of the disease
the initial choice of immunosuppressive steroid dosage may be too low. In contrast, patients
with the immunologically inactive orbit will only suffer from the serious adverse reactions of
otherwise ineffective immunosuppressive therapy given to them. Furthermore, there are
always the questions demanding the rapid answer that include the decision whether to
continue or to stop the anti-inflammatory therapy in patients with mild but persisting
inflammation, and when is the right moment for surgical rehabilitation, which should not be
done in patients at risk for further deterioration due to the high disease activity. The clinical
decisions in GO patients are often difficult, and it is extremely important for the clinicians to
be able to distinguish the specific phases of Graves’ orbitopathy. Of note, in the last decade as
many as one-third of patients did not respond to given immunosuppressive treatment [95].
Most of these cases were due to lack of the active stage of disease in the course of the therapy.
In such scenarios, more discriminative information of better quality is needed to establish the
activity phase of the disease and to make the best treatment decision. For this reason, several
groups have assessed the predictive value of several potential activity parameters to predict
response to therapy including duration of the eye disease, the CAS score, urinary glycosami‐
noglycan (GAG) excretion, serum cytokine levels, serum levels of TSH-receptor autoantibodies
[91,94,96-98]. Lastly, even genetic factors might influence treatment outcome as several HLA
markers have been shown to indicate good or bad response to immune therapy [99]. Notwith‐
standing, some of these parameters could predict a response to treatment only to some extent,
while others could predict to some extent a lack of the therapeutic response. This means that
probably a combination of different parameters may be necessary to accurately predict the
response to the treatment in the particular patient. In this notion, several recent clinical and
experimental studies have found evidences that the selected neuroimaging modalities would
be valuable in measuring the disease activity to predict therapeutic outcomes in GO patients.
Especially, there are two imaging modalities that seem to be highly supportive to detect disease
activity, including MRI and radionuclide-based imaging.
MRI has currently emerged as a valuable tool in the evaluation of disease activity in patients
with GO as it can illustrate in detail the inflamed regions of orbits. More than two decades ago,
Just et al. described that in MRI sequences an increased T2 time in the eye muscles before
treatment was associated with a good response to orbital irradiation [62]. This first report was
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confirmed by two others indicating that the T2 time decreases after immunosuppressive
therapy, what suggests a transition from an edematous and inflammatory state into a fibrotic
chronic stage [100]. In particular, there was established strong positive correlation between the
clinical activity score of GO and the T2 relaxation time and ratio of signal intensity in STIR
sequences in T2-weighted and fat suppressed images [61]. Moreover, Mayer et al. found, that
the area of highest signal intensity within the most inflamed extra-ocular muscle, and the
average cross-sectional signal intensity of the most inflamed extra-ocular muscle reliably
correlated with CAS, and this was maintained as disease activity changed over time [59].
Recently, the correlation between disease activity and the microcirculation characteristics of
extraocular muscles has been demonstrated in GO using sophisticated dynamic contrast-
enhanced MR imaging [68]. This novel technique is based on the hypothesis that the patho‐
logical changes occurring at different stages of GO might impact the microcirculatory status
of extraocular muscles differently, and therefore induce distinct contrast-enhancement
characteristics on DCE-MRI images, which might serve as indicators for activity estimation.
Furthermore, to improve the sensitivity of detection of active phase of the disease and therefore
the prediction of the response to immunosuppressive therapy, over CAS alone, the combina‐
tion of the orbital MR imaging and CAS estimation was proposed by Tachibana et al. [101].
They reported that the orbital MR imaging combined with CAS could improve the sensitivity
of differentiation between the active and inactive GO form and especially the CAS and the
maximum of T2 relaxation times of extraocular muscles (maxT2RT) showed significant
positive correlation. Interestingly, 40% of GO patients included in this study were positive by
only MR imaging and all these GO patients presented significant improvement after intrave‐
nous immunosuppressive therapy due to active GO diagnosis by MRI classification, what
indicates the importance of the orbital MR imaging for the diagnosis of active GO. Recently,
Le Moli et al. determined positive correlation between CAS score and ratio of extraocular
muscles area to the total orbit area measured in CT imaging modality [43].
Similarly, several radionuclide-based imaging methods have been proposed recently to
evaluate disease activity in GO. Importantly, the obtained image evaluation and orbital uptake
fraction calculation of the selected radiotracers could provide the qualitative (image-based)
and quantitative (numerical) information on disease activity. Historically, the imaging of
orbital uptake of In-111-labeled octreotide detected by scintigraphy was presented as a
sensitive method to estimate immunologic disease activity in GO patients [70]. However,
further studies indicated the low specificity for this method, therefore, its clinical applicability
is strongly limited nowadays [33,40]. Subsequently, SPECT imaging of the orbits using Tc-99m-
labeled DTPA have been proposed by several reports [102-103]. This method has been accepted
for evaluation of GO disease activity allowing a rapid imaging at an acceptable cost, and in
addition, the successful management of GO has been associated with the decrease in orbital
uptake of radiotracer [84]. In addition, to improve the sensitivity of detection of active GO
phase, and therefore the prediction of the response to immunosuppressive therapy, over
clinical activity score (CAS) alone, the combination of Tc-99m DTPA SPECT imaging and CAS
estimation was proposed by Galuska et al. [104]. They reported that Tc-99m DTPA SPECT
imaging provides essential supplementary information to traditional CAS evaluation in
assessing GO activity. Likewise, Szabados et al. reported recently the results of the study in
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which they measured the inflammatory activity in the retrobulbar region using Tc-99m DTPA
SPECT before and after external radiation to determine whether this method is suitable for
predicting the effectiveness of the anti-inflammatory therapy [105]. They found in the group
comprised of thirty-two patients with suspected active GO that a high initial DTPA uptake
may predict the response to orbital radiation therapy, therefore the orbital SPECT with Tc-99m
DTPA may be a suitable technique for the selection of GO patients for radiation therapy [105].
Furthermore, the different imaging methods, which were developed recently, applying
scintigraphy of Tc-99m-labeled compounds, including polyclonal and monoclonal antibodies
against inflammatory-related molecules (e.g. TNF-alpha), gave a new perspective in the
diagnostic approach of active GO, which could be diagnosed with high sensitivity and
specificity [85-86]. The preliminary results obtained from the group of 25 GO patients with
different CAS score suggest that scintigraphy with Tc-99m-labeled anti-TNF-alpha might be
a promising procedure for the evaluation of active orbital inflammation in GO [106]. Lately,
the high-resolution PET/CT have been introduced to clinical practice for improved detection,
disease grading, and follow-up of patients with GO in order to optimize the treatment in the
inflammatory GO phase. Several novel radiotracers have been employed in PET/CT imaging,
including gallium-68 and fluor-18 to supply valuable information on localizing and quantify‐
ing of GO-related inflammation in retrobulbar tissues [89-90]. Importantly, the availability of
novel PET tracers for high-resolution and hybrid imaging in PET/CT enables to evaluate
selectively the actual status of immune activity in any single extraorbital muscle.
Altogether, the precise quantitative evaluation of clinical disease activity and prediction of the
outcome of immunosuppressive therapy in GO are reserved nowadays for only selected orbital
neuroimaging modalities such as MRI and nuclear medicine-based imaging using gallium or
technetium scintigraphy. Importantly, there are some limitations to the imaging studies of GO
activity. For example, as the histological validation by extraocular muscle biopsy, which is the
“golden standard” in diagnosis evaluation, is not available on regular basis in case of the orbits,
the discussion about morphology-related changes observed in images obtained by different
imaging modalities are speculative to some extent. Moreover, although MRI and radionuclide-
based imaging may show increased edema in the muscles and inflammatory process in the
orbital tissues during the active phase, however both modalities tend to be less helpful in
therapeutic surgical planning since no detail about bone architecture is provided in these
techniques.
4. Conclusion
Diagnosis  of  Graves’  orbitopathy is  usually given by careful  ophthalmological  examina‐
tion when clinical manifestations occur. The main symptoms of the orbitopathy derive from
the discrepancy between limited space of the orbit and expansion of pathologically affected
orbital tissues. Therefore, in most patients, CT and MRI of the orbit confirm diagnosis by
showing enlarged extraocular muscles (without involvement of the tendon) and/or increased
orbital fibroadipose tissue. Although extra-ocular muscle enlargement can be documented
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confirmed by two others indicating that the T2 time decreases after immunosuppressive
therapy, what suggests a transition from an edematous and inflammatory state into a fibrotic
chronic stage [100]. In particular, there was established strong positive correlation between the
clinical activity score of GO and the T2 relaxation time and ratio of signal intensity in STIR
sequences in T2-weighted and fat suppressed images [61]. Moreover, Mayer et al. found, that
the area of highest signal intensity within the most inflamed extra-ocular muscle, and the
average cross-sectional signal intensity of the most inflamed extra-ocular muscle reliably
correlated with CAS, and this was maintained as disease activity changed over time [59].
Recently, the correlation between disease activity and the microcirculation characteristics of
extraocular muscles has been demonstrated in GO using sophisticated dynamic contrast-
enhanced MR imaging [68]. This novel technique is based on the hypothesis that the patho‐
logical changes occurring at different stages of GO might impact the microcirculatory status
of extraocular muscles differently, and therefore induce distinct contrast-enhancement
characteristics on DCE-MRI images, which might serve as indicators for activity estimation.
Furthermore, to improve the sensitivity of detection of active phase of the disease and therefore
the prediction of the response to immunosuppressive therapy, over CAS alone, the combina‐
tion of the orbital MR imaging and CAS estimation was proposed by Tachibana et al. [101].
They reported that the orbital MR imaging combined with CAS could improve the sensitivity
of differentiation between the active and inactive GO form and especially the CAS and the
maximum of T2 relaxation times of extraocular muscles (maxT2RT) showed significant
positive correlation. Interestingly, 40% of GO patients included in this study were positive by
only MR imaging and all these GO patients presented significant improvement after intrave‐
nous immunosuppressive therapy due to active GO diagnosis by MRI classification, what
indicates the importance of the orbital MR imaging for the diagnosis of active GO. Recently,
Le Moli et al. determined positive correlation between CAS score and ratio of extraocular
muscles area to the total orbit area measured in CT imaging modality [43].
Similarly, several radionuclide-based imaging methods have been proposed recently to
evaluate disease activity in GO. Importantly, the obtained image evaluation and orbital uptake
fraction calculation of the selected radiotracers could provide the qualitative (image-based)
and quantitative (numerical) information on disease activity. Historically, the imaging of
orbital uptake of In-111-labeled octreotide detected by scintigraphy was presented as a
sensitive method to estimate immunologic disease activity in GO patients [70]. However,
further studies indicated the low specificity for this method, therefore, its clinical applicability
is strongly limited nowadays [33,40]. Subsequently, SPECT imaging of the orbits using Tc-99m-
labeled DTPA have been proposed by several reports [102-103]. This method has been accepted
for evaluation of GO disease activity allowing a rapid imaging at an acceptable cost, and in
addition, the successful management of GO has been associated with the decrease in orbital
uptake of radiotracer [84]. In addition, to improve the sensitivity of detection of active GO
phase, and therefore the prediction of the response to immunosuppressive therapy, over
clinical activity score (CAS) alone, the combination of Tc-99m DTPA SPECT imaging and CAS
estimation was proposed by Galuska et al. [104]. They reported that Tc-99m DTPA SPECT
imaging provides essential supplementary information to traditional CAS evaluation in
assessing GO activity. Likewise, Szabados et al. reported recently the results of the study in
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which they measured the inflammatory activity in the retrobulbar region using Tc-99m DTPA
SPECT before and after external radiation to determine whether this method is suitable for
predicting the effectiveness of the anti-inflammatory therapy [105]. They found in the group
comprised of thirty-two patients with suspected active GO that a high initial DTPA uptake
may predict the response to orbital radiation therapy, therefore the orbital SPECT with Tc-99m
DTPA may be a suitable technique for the selection of GO patients for radiation therapy [105].
Furthermore, the different imaging methods, which were developed recently, applying
scintigraphy of Tc-99m-labeled compounds, including polyclonal and monoclonal antibodies
against inflammatory-related molecules (e.g. TNF-alpha), gave a new perspective in the
diagnostic approach of active GO, which could be diagnosed with high sensitivity and
specificity [85-86]. The preliminary results obtained from the group of 25 GO patients with
different CAS score suggest that scintigraphy with Tc-99m-labeled anti-TNF-alpha might be
a promising procedure for the evaluation of active orbital inflammation in GO [106]. Lately,
the high-resolution PET/CT have been introduced to clinical practice for improved detection,
disease grading, and follow-up of patients with GO in order to optimize the treatment in the
inflammatory GO phase. Several novel radiotracers have been employed in PET/CT imaging,
including gallium-68 and fluor-18 to supply valuable information on localizing and quantify‐
ing of GO-related inflammation in retrobulbar tissues [89-90]. Importantly, the availability of
novel PET tracers for high-resolution and hybrid imaging in PET/CT enables to evaluate
selectively the actual status of immune activity in any single extraorbital muscle.
Altogether, the precise quantitative evaluation of clinical disease activity and prediction of the
outcome of immunosuppressive therapy in GO are reserved nowadays for only selected orbital
neuroimaging modalities such as MRI and nuclear medicine-based imaging using gallium or
technetium scintigraphy. Importantly, there are some limitations to the imaging studies of GO
activity. For example, as the histological validation by extraocular muscle biopsy, which is the
“golden standard” in diagnosis evaluation, is not available on regular basis in case of the orbits,
the discussion about morphology-related changes observed in images obtained by different
imaging modalities are speculative to some extent. Moreover, although MRI and radionuclide-
based imaging may show increased edema in the muscles and inflammatory process in the
orbital tissues during the active phase, however both modalities tend to be less helpful in
therapeutic surgical planning since no detail about bone architecture is provided in these
techniques.
4. Conclusion
Diagnosis  of  Graves’  orbitopathy is  usually given by careful  ophthalmological  examina‐
tion when clinical manifestations occur. The main symptoms of the orbitopathy derive from
the discrepancy between limited space of the orbit and expansion of pathologically affected
orbital tissues. Therefore, in most patients, CT and MRI of the orbit confirm diagnosis by
showing enlarged extraocular muscles (without involvement of the tendon) and/or increased
orbital fibroadipose tissue. Although extra-ocular muscle enlargement can be documented
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directly by ultrasonography, the CT scan or MRI highly improve the measurements (i.e.
thickness and volume) by direct visualizing the retro-bulbar muscles in their entire length
and at the apex of the orbit, where their augmentation is responsible for dysthyroid optic
neuropathy. The orbital neuroimaging is especially required in asymmetrical or, particular‐
ly,  unilateral  forms of  GO, to rule out that  exophthalmos,  swelling of  periorbital  tissue,
inflammation, or diplopia exist due to disorders other than GO. The MRI is the preferred
modality for soft tissue imaging. As a basic rule, T1-weighted images are best for anatom‐
ic details, while T2 images give more information about the different tissue composition.
Compared with MRI, computer tomography is less expensive, more available in the national
health system and faster to perform, however, is less efficient in the evaluation of soft tissue
changes  and might  not  reveal  details  that  could be important  in  the  assessment  of  dis‐
ease activity. In addition, the iodinated contrast medium usage for CT imaging should be
limited  in  patients  with  Graves’  disease.  On  the  other  hand,  MRI  provides  a  precise
quantitative evaluation of clinical disease activity and may predict the outcome of immuno‐
suppressive therapy for GO. As a consequence, there is potential for MRI in the evalua‐
tion of the therapeutic outcomes of new drugs for GO [45].
The history of the disease, physical examination, and neuroimaging findings can all provide
important data on the actual phase of the disease process. But they can also be equivocal or
confusing. The orbital cavity is a particularly difficult area for quantitative analysis. It contains
various anatomical structures, which are small in size and have significantly different densi‐
ties, structures, and shapes as well as complicated spatial relationships. This leads to various
artifacts that can significantly affect the final results of applied neuroimaging. In addition to
this, individual variability strongly affects the established range of standard parameters
important for correct disease diagnosis [55]. Diagnostic uncertainties have to be weighed
against the benefits and risks of therapy with systemic immunosuppressive treatment,
radiation, or surgical orbital decompression.
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directly by ultrasonography, the CT scan or MRI highly improve the measurements (i.e.
thickness and volume) by direct visualizing the retro-bulbar muscles in their entire length
and at the apex of the orbit, where their augmentation is responsible for dysthyroid optic
neuropathy. The orbital neuroimaging is especially required in asymmetrical or, particular‐
ly,  unilateral  forms of  GO, to rule out that  exophthalmos,  swelling of  periorbital  tissue,
inflammation, or diplopia exist due to disorders other than GO. The MRI is the preferred
modality for soft tissue imaging. As a basic rule, T1-weighted images are best for anatom‐
ic details, while T2 images give more information about the different tissue composition.
Compared with MRI, computer tomography is less expensive, more available in the national
health system and faster to perform, however, is less efficient in the evaluation of soft tissue
changes  and might  not  reveal  details  that  could be important  in  the  assessment  of  dis‐
ease activity. In addition, the iodinated contrast medium usage for CT imaging should be
limited  in  patients  with  Graves’  disease.  On  the  other  hand,  MRI  provides  a  precise
quantitative evaluation of clinical disease activity and may predict the outcome of immuno‐
suppressive therapy for GO. As a consequence, there is potential for MRI in the evalua‐
tion of the therapeutic outcomes of new drugs for GO [45].
The history of the disease, physical examination, and neuroimaging findings can all provide
important data on the actual phase of the disease process. But they can also be equivocal or
confusing. The orbital cavity is a particularly difficult area for quantitative analysis. It contains
various anatomical structures, which are small in size and have significantly different densi‐
ties, structures, and shapes as well as complicated spatial relationships. This leads to various
artifacts that can significantly affect the final results of applied neuroimaging. In addition to
this, individual variability strongly affects the established range of standard parameters
important for correct disease diagnosis [55]. Diagnostic uncertainties have to be weighed
against the benefits and risks of therapy with systemic immunosuppressive treatment,
radiation, or surgical orbital decompression.
Author details
Miłosz P. Kawa1*, Anna Machalińska2, Grażyna Wilk3 and Bogusław Machaliński1
*Address all correspondence to: kawamilosz@gmail.com
1 Department of General Pathology, Pomeranian Medical University of Szczecin, Szczecin,
Poland
2 Department of Ophthalmology, Pomeranian Medical University of Szczecin, Szczecin,
Poland
3 Department of General and Dental Radiology, Pomeranian Medical University of Szczecin,
Szczecin, Poland
Thyroid Disorders - Focus on Hyperthyroidism158
References
[1] Bahn RS Graves' ophthalmopathy. N Engl J Med. 2010;362(8):726-38.
[2] Lazarus JH, Marino M. Orbit–thyroid relationship. In: W.M. Wiersinga, G.J. Kahaly
(Eds.), Graves’ orbitopathy: a multidisciplinary approach – questions and answers
(2nd ed.). Basel: Karger AG; 2010. p26–32.
[3] Khoo TK, Bahn RS. Pathogenesis of Graves' ophthalmopathy: the role of autoanti‐
bodies. Thyroid. 2007;17(10):1013-8.
[4] Eckstein AK, Johnson KT, Thanos M, Esser J, Ludgate M. Current insights into the
pathogenesis of Graves' orbitopathy. Horm Metab Res. 2009;41(6):456-64.
[5] Dickinson AJ, Perros P. Controversies in the clinical evaluation of active thyroid-as‐
sociated orbitopathy: use of a detailed protocol with comparative photographs for
objective assessment. Clin Endocrinol (Oxf). 2001;55(3):283-303.
[6] Regensburg NI, Wiersinga WM, Berendschot TT, Potgieser P, Mourits MP Do sub‐
types of graves' orbitopathy exist? Ophthalmology. 2011;118(1):191-6.
[7] Pitz S. Orbital Imaging. In: Wiersinga WM, Kahaly GJ (eds): Graves’ Orbitopathy: A
Multidisciplinary Approach. Basel: Karger AG; 2007. p57-65.
[8] von Arx G. Atypical manifestations. In: Wiersinga WM, Kahaly GJ, eds. Graves’ Or‐
bitopathy. A multidisciplinary approach. Basel: Karger AG; 2007. p212–220.
[9] Müller-Forell W, Pitz S, Mann W, Kahaly GJ. Neuroradiological diagnosis in thyroid-
associated orbitopathy. Exp Clin Endocrinol Diabetes. 1999;107 Suppl 5:S177-83.
[10] Kazim M, Trokel SL, Acaroglu G, Elliott A. Reversal of dysthyroid optic neuropathy
following orbital fat decompression. Br J Ophthalmol. 2000;84(6):600-5.
[11] Fang ZJ, Zhang JY, He WM. CT features of exophthalmos in Chinese subjects with
thyroid-associated ophthalmopathy. Int J Ophthalmol. 2013;6(2):146-149.
[12] Salvi M, Zhang ZG, Haegert D, Woo M, Liberman A, Cadarso L, Wall JR Patients
with endocrine ophthalmopathy not associated with overt thyroid disease have mul‐
tiple thyroid immunological abnormalities. J Clin Endocrinol Metab. 1990;70(1):89-94.
[13] Barbesino G, Tomer Y Clinical review: Clinical utility of TSH receptor antibodies. J
Clin Endocrinol Metab. 2013;98(6):2247-55.
[14] Prummel MF, Suttorp-Schulten MS, Wiersinga WM, Verbeek AM, Mourits MP,
Koornneef L. A new ultrasonographic method to detect disease activity and predict
response to immunosuppressive treatment in Graves ophthalmopathy. Ophthalmol‐
ogy. 1993;100(4):556-61.
Graves’ Ophthalmopathy Imaging Evaluation 159
[15] Sabetti L, Toscano A, Specchia G, Balestrazzi E. Alterations of the internal reflectivity
of extra-ocular muscles associated with several clinical stages of Graves' ophthalm‐
opathy. Ophthalmologica 1998;212 Suppl 1:107-9.
[16] Gerding MN, Prummel MF, Wiersinga WM Assessment of disease activity in Graves'
ophthalmopathy by orbital ultrasonography and clinical parameters. Clin Endocrinol
(Oxf). 2000;52(5):641-6.
[17] Werner SC, Coleman DJ, Franzen LA. Ultrasonographic evidence of a consistent orbi‐
tal involvement in Graves's disease. N Engl J Med. 1974;290(26):1447-50.
[18] Willinsky RA, Arenson AM, Hurwitz JJ, Szalai J. Ultrasonic B-scan measurement of
the extra-ocular muscles in Graves' orbitopathy. J Can Assoc Radiol. 1984;35(2):171-3.
[19] Demer JL, Kerman BM. Comparison of standardized echography with magnetic res‐
onance imaging to measure extraocular muscle size. American Journal of Ophthal‐
mology 1994;118:351-361
[20] Villadolid MC, Yokoyama N, Izumi M, Nishikawa T, Kimura H, Ashizawa K, Kiriya‐
ma T, Uetani M, Nagataki S. Untreated Graves' disease patients without clinical oph‐
thalmopathy demonstrate a high frequency of extraocular muscle (EOM)
enlargement by magnetic resonance. J Clin Endocrinol Metab. 1995;80(9):2830-3.
[21] Nagy EV, Toth J, Kaldi I, Damjanovich J, Mezosi E, Lenkey A, Toth L, Szabo J, Kara‐
nyi Z, Leovey A. Graves' ophthalmopathy: eye muscle involvement in patients with
diplopia. Eur J Endocrinol. 2000;142(6):591-7.
[22] Imbrasienė D, Jankauskienė J, Stanislovaitienė D. Ultrasonic measurement of ocular
rectus muscle thickness in patients with Graves' ophthalmopathy. Medicina (Kau‐
nas). 2010;46(7):472-6.
[23] Perri P, Campa C, Costagliola C, Incorvaia C, D'Angelo S, Sebastiani A. Increased ret‐
inal blood flow in patients with active Graves' ophthalmopathy. Curr Eye Res.
2007;32(11):985-90.
[24] Alimgil ML, Benian O, Esgin H, Erda S. Ocular pulse amplitude in patients with
Graves' disease: a preliminary study. Acta Ophthalmol Scand. 1999;77(6):694-6.
[25] Hartmann K, Meyer-Schwickerath R. Measurement of venous outflow pressure in
the central retinal vein to evaluate intraorbital pressure in Graves' ophthalmopathy: a
preliminary report. Strabismus. 2000;8:187-93.
[26] Alp MN, Ozgen A, Can I, Cakar P, Gunalp I Colour Doppler imaging of the orbital
vasculature in Graves' disease with computed tomographic correlation. Br J Ophthal‐
mol. 2000;84(9):1027-30.
[27] Monteiro ML, Angotti-Neto H, Benabou JE, Betinjane AJ Color Doppler imaging of
the superior ophthalmic vein in different clinical forms of Graves' orbitopathy. Jpn J
Ophthalmol. 2008;52(6):483-8.
Thyroid Disorders - Focus on Hyperthyroidism160
[28] Konuk O, Onaran Z, Ozhan Oktar S, Yucel C, Unal M. Intraocular pressure and supe‐
rior ophthalmic vein blood flow velocity in Graves' orbitopathy: relation with the
clinical features. Graefes Arch Clin Exp Ophthalmol. 2009;247(11):1555-9.
[29] Li H, Liu YH, Li DH, Zhang Y. Value of measurements of blood flow velocity in cen‐
tral retinal artery in thyroid-associated ophthalmopathy. Zhongguo Yi Xue Ke Xue
Yuan Xue Bao. 2004;26:460–462.
[30] Pérez-López M, Sales-Sanz M, Rebolleda G, Casas-Llera P, González-Gordaliza C,
Jarrín E, Muñoz-Negrete FJ. Retrobulbar ocular blood flow changes after orbital de‐
compression in Graves' ophthalmopathy measured by color Doppler imaging. Invest
Ophthalmol Vis Sci. 2011;52(8):5612-7.
[31] Yanik B, Conkbayir I, Acaroglu G, Hekimoglu B. Graves' ophthalmopathy: compari‐
son of the Doppler sonography parameters with the clinical activity score. J Clin Ul‐
trasound. 2005;33(8):375-80.
[32] Stalmans I, Vandewalle E, Anderson DR, Costa VP, Frenkel RE, Garhofer G, Grun‐
wald J, Gugleta K, Harris A, Hudson C, Januleviciene I, Kagemann L, Kergoat H,
Lovasik JV, Lanzl I, Martinez A, Nguyen QD, Plange N, Reitsamer HA, Sehi M, Sies‐
ky B, Zeitz O, Orgül S, Schmetterer L. Use of colour Doppler imaging in ocular blood
flow research. Acta Ophthalmol. 2011;89(8):e609-30.
[33] Kirsch E, von Arx G, Hammer B. Imaging in Graves' orbitopathy. Orbit. 2009;28(4):
219-25.
[34] Enzmann DR, Donaldson SS, Kriss JP. Appearance of Graves' disease on orbital com‐
puted tomography. J Comput Assist Tomogr. 1979;3(6):815-9.
[35] Yoshikawa K, Higashide T, Nakase Y, Inoue T, Inoue Y, Shiga H. Role of rectus mus‐
cle enlargement in clinical profile of dysthyroid ophthalmopathy. Jpn J Ophthalmol.
1991;35(2):175-81.
[36] Dabbs CB, Kline LB. Big muscles and big nerves. Surv Ophthalmol. 1997;42(3):247-54.
[37] Ozgen A, Ariyurek M. Normative measurements of orbital structures using CT. AJR
Am J Roentgenol. 1998;170(4):1093-6.
[38] Regensburg NI, Wiersinga WM, Berendschot TT, Saeed P, Mourits MP. Densities of
orbital fat and extraocular muscles in graves orbitopathy patients and controls. Oph‐
thal Plast Reconstr Surg. 2011;27(4):236-40.
[39] Regensburg NI, Wiersinga WM, van Velthoven ME, Berendschot TT, Zonneveld FW,
Baldeschi L, Saeed P, Mourits MP. Age and gender-specific reference values of orbi‐
tal fat and muscle volumes in Caucasians. Br J Ophthalmol. 2011;95(12):1660-3.
[40] Prummel MF. Graves' ophthalmopathy: diagnosis and management. Eur J Nucl Med.
2000 Apr;27(4):373-6.
Graves’ Ophthalmopathy Imaging Evaluation 161
[15] Sabetti L, Toscano A, Specchia G, Balestrazzi E. Alterations of the internal reflectivity
of extra-ocular muscles associated with several clinical stages of Graves' ophthalm‐
opathy. Ophthalmologica 1998;212 Suppl 1:107-9.
[16] Gerding MN, Prummel MF, Wiersinga WM Assessment of disease activity in Graves'
ophthalmopathy by orbital ultrasonography and clinical parameters. Clin Endocrinol
(Oxf). 2000;52(5):641-6.
[17] Werner SC, Coleman DJ, Franzen LA. Ultrasonographic evidence of a consistent orbi‐
tal involvement in Graves's disease. N Engl J Med. 1974;290(26):1447-50.
[18] Willinsky RA, Arenson AM, Hurwitz JJ, Szalai J. Ultrasonic B-scan measurement of
the extra-ocular muscles in Graves' orbitopathy. J Can Assoc Radiol. 1984;35(2):171-3.
[19] Demer JL, Kerman BM. Comparison of standardized echography with magnetic res‐
onance imaging to measure extraocular muscle size. American Journal of Ophthal‐
mology 1994;118:351-361
[20] Villadolid MC, Yokoyama N, Izumi M, Nishikawa T, Kimura H, Ashizawa K, Kiriya‐
ma T, Uetani M, Nagataki S. Untreated Graves' disease patients without clinical oph‐
thalmopathy demonstrate a high frequency of extraocular muscle (EOM)
enlargement by magnetic resonance. J Clin Endocrinol Metab. 1995;80(9):2830-3.
[21] Nagy EV, Toth J, Kaldi I, Damjanovich J, Mezosi E, Lenkey A, Toth L, Szabo J, Kara‐
nyi Z, Leovey A. Graves' ophthalmopathy: eye muscle involvement in patients with
diplopia. Eur J Endocrinol. 2000;142(6):591-7.
[22] Imbrasienė D, Jankauskienė J, Stanislovaitienė D. Ultrasonic measurement of ocular
rectus muscle thickness in patients with Graves' ophthalmopathy. Medicina (Kau‐
nas). 2010;46(7):472-6.
[23] Perri P, Campa C, Costagliola C, Incorvaia C, D'Angelo S, Sebastiani A. Increased ret‐
inal blood flow in patients with active Graves' ophthalmopathy. Curr Eye Res.
2007;32(11):985-90.
[24] Alimgil ML, Benian O, Esgin H, Erda S. Ocular pulse amplitude in patients with
Graves' disease: a preliminary study. Acta Ophthalmol Scand. 1999;77(6):694-6.
[25] Hartmann K, Meyer-Schwickerath R. Measurement of venous outflow pressure in
the central retinal vein to evaluate intraorbital pressure in Graves' ophthalmopathy: a
preliminary report. Strabismus. 2000;8:187-93.
[26] Alp MN, Ozgen A, Can I, Cakar P, Gunalp I Colour Doppler imaging of the orbital
vasculature in Graves' disease with computed tomographic correlation. Br J Ophthal‐
mol. 2000;84(9):1027-30.
[27] Monteiro ML, Angotti-Neto H, Benabou JE, Betinjane AJ Color Doppler imaging of
the superior ophthalmic vein in different clinical forms of Graves' orbitopathy. Jpn J
Ophthalmol. 2008;52(6):483-8.
Thyroid Disorders - Focus on Hyperthyroidism160
[28] Konuk O, Onaran Z, Ozhan Oktar S, Yucel C, Unal M. Intraocular pressure and supe‐
rior ophthalmic vein blood flow velocity in Graves' orbitopathy: relation with the
clinical features. Graefes Arch Clin Exp Ophthalmol. 2009;247(11):1555-9.
[29] Li H, Liu YH, Li DH, Zhang Y. Value of measurements of blood flow velocity in cen‐
tral retinal artery in thyroid-associated ophthalmopathy. Zhongguo Yi Xue Ke Xue
Yuan Xue Bao. 2004;26:460–462.
[30] Pérez-López M, Sales-Sanz M, Rebolleda G, Casas-Llera P, González-Gordaliza C,
Jarrín E, Muñoz-Negrete FJ. Retrobulbar ocular blood flow changes after orbital de‐
compression in Graves' ophthalmopathy measured by color Doppler imaging. Invest
Ophthalmol Vis Sci. 2011;52(8):5612-7.
[31] Yanik B, Conkbayir I, Acaroglu G, Hekimoglu B. Graves' ophthalmopathy: compari‐
son of the Doppler sonography parameters with the clinical activity score. J Clin Ul‐
trasound. 2005;33(8):375-80.
[32] Stalmans I, Vandewalle E, Anderson DR, Costa VP, Frenkel RE, Garhofer G, Grun‐
wald J, Gugleta K, Harris A, Hudson C, Januleviciene I, Kagemann L, Kergoat H,
Lovasik JV, Lanzl I, Martinez A, Nguyen QD, Plange N, Reitsamer HA, Sehi M, Sies‐
ky B, Zeitz O, Orgül S, Schmetterer L. Use of colour Doppler imaging in ocular blood
flow research. Acta Ophthalmol. 2011;89(8):e609-30.
[33] Kirsch E, von Arx G, Hammer B. Imaging in Graves' orbitopathy. Orbit. 2009;28(4):
219-25.
[34] Enzmann DR, Donaldson SS, Kriss JP. Appearance of Graves' disease on orbital com‐
puted tomography. J Comput Assist Tomogr. 1979;3(6):815-9.
[35] Yoshikawa K, Higashide T, Nakase Y, Inoue T, Inoue Y, Shiga H. Role of rectus mus‐
cle enlargement in clinical profile of dysthyroid ophthalmopathy. Jpn J Ophthalmol.
1991;35(2):175-81.
[36] Dabbs CB, Kline LB. Big muscles and big nerves. Surv Ophthalmol. 1997;42(3):247-54.
[37] Ozgen A, Ariyurek M. Normative measurements of orbital structures using CT. AJR
Am J Roentgenol. 1998;170(4):1093-6.
[38] Regensburg NI, Wiersinga WM, Berendschot TT, Saeed P, Mourits MP. Densities of
orbital fat and extraocular muscles in graves orbitopathy patients and controls. Oph‐
thal Plast Reconstr Surg. 2011;27(4):236-40.
[39] Regensburg NI, Wiersinga WM, van Velthoven ME, Berendschot TT, Zonneveld FW,
Baldeschi L, Saeed P, Mourits MP. Age and gender-specific reference values of orbi‐
tal fat and muscle volumes in Caucasians. Br J Ophthalmol. 2011;95(12):1660-3.
[40] Prummel MF. Graves' ophthalmopathy: diagnosis and management. Eur J Nucl Med.
2000 Apr;27(4):373-6.
Graves’ Ophthalmopathy Imaging Evaluation 161
[41] Regensburg NI, Kok PH, Zonneveld FW, Baldeschi L, Saeed P, Wiersinga WM,
Mourits MP. A new and validated CT-based method for the calculation of orbital soft
tissue volumes. Invest Ophthalmol Vis Sci. 2008;49(5):1758-62.
[42] Nishida Y, Tian S, Isberg B, Hayashi O, Tallstedt L, Lennerstrand G. Significance of
orbital fatty tissue for exophthalmos in thyroid-associated ophthalmopathy. Graefes
Arch Clin Exp Ophthalmol. 2002;240(7):515-20.
[43] Le Moli R, Pluchino A, Muscia V, Regalbuto C, Luciani B, Squatrito S, Vigneri R.
Graves' orbitopathy: extraocular muscle/total orbit area ratio is positively related to
the Clinical Activity Score. Eur J Ophthalmol. 2012;22(3):301-8.
[44] Kahaly GJ. Imaging in thyroid-associated orbitopathy. Eur J Endocrinol. 2001;145(2):
107-18.
[45] Müller-Forell W, Kahaly GJ Neuroimaging of Graves' orbitopathy. Best Pract Res
Clin Endocrinol Metab. 2012;26(3):259-71.
[46] Nugent RA, Belkin RI, Neigel JM, Rootman J, Robertson WD, Spinelli J, Graeb DA.
Graves orbitopathy: correlation of CT and clinical findings. Radiology. 1990;177(3):
675-82.
[47] Anderson RL, Tweeten JP, Patrinely JR, Garland PE, Thiese SM Dysthyroid optic
neuropathy without extraocular muscle involvement. Ophthalmic Surg. 1989;20(8):
568-74.
[48] Feldon SE, Lee CP, Muramatsu SK, Weiner JM. Quantitative computed tomography
of Graves' ophthalmopathy. Extraocular muscle and orbital fat in development of op‐
tic neuropathy. Arch Ophthalmol. 1985;103(2):213-5.
[49] Barrett L, Glatt HJ, Burde RM, Gado MH. Optic nerve dysfunction in thyroid eye dis‐
ease: CT. Radiology. 1988;167(2):503-7.
[50] Birchall D, Goodall KL, Noble JL, Jackson A. Graves ophthalmopathy: intracranial fat
prolapse on CT images as an indicator of optic nerve compression. Radiology.
1996;200(1):123-7.
[51] Aviv RI, Miszkiel K. Orbital imaging: Part 2. Intraorbital pathology. Clin Radiol.
2005;60(3):288-307.
[52] Neigel JM, Rootman J, Belkin RI, Nugent RA, Drance SM, Beattie CW, Spinelli JA.
Dysthyroid optic neuropathy. The crowded orbital apex syndrome. Ophthalmology.
1988;95(11):1515-21.
[53] Machado KFS, Garcia MM. Thyroid ophthalmopathy revisited. Radiol Bras.
2009;42(4):261-266.
[54] Lennerstrand G, Tian S, Isberg B, Landau Högbeck I, Bolzani R, Tallstedt L, Schworm
H. Magnetic resonance imaging and ultrasound measurements of extraocular mus‐
Thyroid Disorders - Focus on Hyperthyroidism162
cles in thyroid-associated ophthalmopathy at different stages of the disease. Acta
Ophthalmol Scand. 2007;85(2):192-201.
[55] Majos A, Pajak M, Grzelak P, Stefańczyk L Magnetic Resonance evaluation of disease
activity in Graves' ophthalmopathy: T2-time and signal intensity of extraocular mus‐
cles. Med Sci Monit. 2007;13 Suppl 1:44-8.
[56] Kirsch E, Hammer B, von Arx G. Graves' orbitopathy: current imaging procedures.
Swiss Med Wkly. 2009;139(43-44):618-23.
[57] Young IR, Bydder GM, Hajnal JV Contrast properties of the inversion recovery se‐
quence. In: Bradley WG Jr, Bydder GM (eds) Advanced MR Imaging Techniques.
London: Martin Dunitz Ltd; 1997. p143–162.
[58] Mayer E, Herdman G, Burnett C, Kabala J, Goddard P, Potts MJ. Serial STIR magnet‐
ic resonance imaging correlates with clinical score of activity in thyroid eye disease.
Eye 2001;15:313–8.
[59] Mayer E, Fox DL, Herdman G, Hsuan J, Kabala J, Goddard P, Potts MJ, Lee RW. Sig‐
nal intensity, clinical activity and cross-sectional areas on MRI scans in thyroid eye
disease. Eur J Radiol. 2005;56(1):20-4.
[60] Kirsch E, Kaim A, Gregorio De Oliveira M, von Arx G Correlation of signal intensity
ratio on orbital MRI-TIRM and clinical activity score as a possible predictor of thera‐
py response in Graves’ orbitopathy—a pilot study at 1.5 T. Neuroradiology
2010;52:91–97.
[61] Hiromatsu Y, Kojima K, Ishisaka N, Tanaka K, Sato M, Nonaka K, Nishimura H,
Nishida H. Role of magnetic resonance imaging in thyroid-associated ophthalmop‐
athy: its predictive value for therapeutic outcome of immunosuppressive therapy.
Thyroid. 1992;2(4):299-305.
[62] Just M, Kahaly G, Higer HP, Rösler HP, Kutzner J, Beyer J, Thelen M. Graves oph‐
thalmopathy: role of MR imaging in radiation therapy. Radiology. 1991;179(1):187-90.
[63] Cakirer S, Cakirer D, Basak M, Durmaz S, Altuntas Y, Yigit U. Evaluation of extraoc‐
ular muscles in the edematous phase of Graves ophthalmopathy on contrast-en‐
hanced fat-suppressed magnetic resonance imaging. J Comput Assist Tomogr.
2004;28(1):80-6.
[64] Utech CI, Khatibnia U, Winter PF, Wulle KG. MR T2 relaxation time for the assess‐
ment of retrobulbar inflammation in Graves' ophthalmopathy. Thyroid. 1995;5(3):
185-93.
[65] Dolman PJ. Evaluating Graves' orbitopathy. Best Pract Res Clin Endocrinol Metab.
2012 Jun;26(3):229-48.
Graves’ Ophthalmopathy Imaging Evaluation 163
[41] Regensburg NI, Kok PH, Zonneveld FW, Baldeschi L, Saeed P, Wiersinga WM,
Mourits MP. A new and validated CT-based method for the calculation of orbital soft
tissue volumes. Invest Ophthalmol Vis Sci. 2008;49(5):1758-62.
[42] Nishida Y, Tian S, Isberg B, Hayashi O, Tallstedt L, Lennerstrand G. Significance of
orbital fatty tissue for exophthalmos in thyroid-associated ophthalmopathy. Graefes
Arch Clin Exp Ophthalmol. 2002;240(7):515-20.
[43] Le Moli R, Pluchino A, Muscia V, Regalbuto C, Luciani B, Squatrito S, Vigneri R.
Graves' orbitopathy: extraocular muscle/total orbit area ratio is positively related to
the Clinical Activity Score. Eur J Ophthalmol. 2012;22(3):301-8.
[44] Kahaly GJ. Imaging in thyroid-associated orbitopathy. Eur J Endocrinol. 2001;145(2):
107-18.
[45] Müller-Forell W, Kahaly GJ Neuroimaging of Graves' orbitopathy. Best Pract Res
Clin Endocrinol Metab. 2012;26(3):259-71.
[46] Nugent RA, Belkin RI, Neigel JM, Rootman J, Robertson WD, Spinelli J, Graeb DA.
Graves orbitopathy: correlation of CT and clinical findings. Radiology. 1990;177(3):
675-82.
[47] Anderson RL, Tweeten JP, Patrinely JR, Garland PE, Thiese SM Dysthyroid optic
neuropathy without extraocular muscle involvement. Ophthalmic Surg. 1989;20(8):
568-74.
[48] Feldon SE, Lee CP, Muramatsu SK, Weiner JM. Quantitative computed tomography
of Graves' ophthalmopathy. Extraocular muscle and orbital fat in development of op‐
tic neuropathy. Arch Ophthalmol. 1985;103(2):213-5.
[49] Barrett L, Glatt HJ, Burde RM, Gado MH. Optic nerve dysfunction in thyroid eye dis‐
ease: CT. Radiology. 1988;167(2):503-7.
[50] Birchall D, Goodall KL, Noble JL, Jackson A. Graves ophthalmopathy: intracranial fat
prolapse on CT images as an indicator of optic nerve compression. Radiology.
1996;200(1):123-7.
[51] Aviv RI, Miszkiel K. Orbital imaging: Part 2. Intraorbital pathology. Clin Radiol.
2005;60(3):288-307.
[52] Neigel JM, Rootman J, Belkin RI, Nugent RA, Drance SM, Beattie CW, Spinelli JA.
Dysthyroid optic neuropathy. The crowded orbital apex syndrome. Ophthalmology.
1988;95(11):1515-21.
[53] Machado KFS, Garcia MM. Thyroid ophthalmopathy revisited. Radiol Bras.
2009;42(4):261-266.
[54] Lennerstrand G, Tian S, Isberg B, Landau Högbeck I, Bolzani R, Tallstedt L, Schworm
H. Magnetic resonance imaging and ultrasound measurements of extraocular mus‐
Thyroid Disorders - Focus on Hyperthyroidism162
cles in thyroid-associated ophthalmopathy at different stages of the disease. Acta
Ophthalmol Scand. 2007;85(2):192-201.
[55] Majos A, Pajak M, Grzelak P, Stefańczyk L Magnetic Resonance evaluation of disease
activity in Graves' ophthalmopathy: T2-time and signal intensity of extraocular mus‐
cles. Med Sci Monit. 2007;13 Suppl 1:44-8.
[56] Kirsch E, Hammer B, von Arx G. Graves' orbitopathy: current imaging procedures.
Swiss Med Wkly. 2009;139(43-44):618-23.
[57] Young IR, Bydder GM, Hajnal JV Contrast properties of the inversion recovery se‐
quence. In: Bradley WG Jr, Bydder GM (eds) Advanced MR Imaging Techniques.
London: Martin Dunitz Ltd; 1997. p143–162.
[58] Mayer E, Herdman G, Burnett C, Kabala J, Goddard P, Potts MJ. Serial STIR magnet‐
ic resonance imaging correlates with clinical score of activity in thyroid eye disease.
Eye 2001;15:313–8.
[59] Mayer E, Fox DL, Herdman G, Hsuan J, Kabala J, Goddard P, Potts MJ, Lee RW. Sig‐
nal intensity, clinical activity and cross-sectional areas on MRI scans in thyroid eye
disease. Eur J Radiol. 2005;56(1):20-4.
[60] Kirsch E, Kaim A, Gregorio De Oliveira M, von Arx G Correlation of signal intensity
ratio on orbital MRI-TIRM and clinical activity score as a possible predictor of thera‐
py response in Graves’ orbitopathy—a pilot study at 1.5 T. Neuroradiology
2010;52:91–97.
[61] Hiromatsu Y, Kojima K, Ishisaka N, Tanaka K, Sato M, Nonaka K, Nishimura H,
Nishida H. Role of magnetic resonance imaging in thyroid-associated ophthalmop‐
athy: its predictive value for therapeutic outcome of immunosuppressive therapy.
Thyroid. 1992;2(4):299-305.
[62] Just M, Kahaly G, Higer HP, Rösler HP, Kutzner J, Beyer J, Thelen M. Graves oph‐
thalmopathy: role of MR imaging in radiation therapy. Radiology. 1991;179(1):187-90.
[63] Cakirer S, Cakirer D, Basak M, Durmaz S, Altuntas Y, Yigit U. Evaluation of extraoc‐
ular muscles in the edematous phase of Graves ophthalmopathy on contrast-en‐
hanced fat-suppressed magnetic resonance imaging. J Comput Assist Tomogr.
2004;28(1):80-6.
[64] Utech CI, Khatibnia U, Winter PF, Wulle KG. MR T2 relaxation time for the assess‐
ment of retrobulbar inflammation in Graves' ophthalmopathy. Thyroid. 1995;5(3):
185-93.
[65] Dolman PJ. Evaluating Graves' orbitopathy. Best Pract Res Clin Endocrinol Metab.
2012 Jun;26(3):229-48.
Graves’ Ophthalmopathy Imaging Evaluation 163
[66] Yokoyama N, Nagataki S, Uetani M, Ashizawa K, Eguchi K.Role of magnetic reso‐
nance imaging in the assessment of disease activity in thyroid-associated ophthalm‐
opathy. Thyroid. 2002;12(3):223-7.
[67] Taoka T, Sakamoto M, Nakagawa H, Fukusumi A, Iwasaki S, Taoka K, Kichikawa K.
Evaluation of extraocular muscles using dynamic contrast enhanced MRI in patients
with chronic thyroid orbitopathy. J Comput Assist Tomogr. 2005;29(1):115-20
[68] Jiang H, Wang Z, Xian J, Li J, Chen Q, Ai L. Evaluation of rectus extraocular muscles
using dynamic contrast-enhanced MR imaging in patients with Graves' ophthalmop‐
athy for assessment of disease activity. Acta Radiol. 2012;53(1):87-94.
[69] Dodds NI, Atcha AW, Birchall D, Jackson A. Use of high-resolution MRI of the optic
nerve in Graves' ophthalmopathy. Br J Radiol. 2009;82(979):541-4.
[70] Krassas GE, Kahaly GJ. The role of octreoscan in thyroid eye disease. Eur J Endocri‐
nol. 1999;140(5):373-5.
[71] Postema PT, Krenning EP, Wijngaarde R, Kooy PP, Oei HY, van den Bosch WA, Reu‐
bi JC, Wiersinga WM, Hooijkaas H, van der Loos T [111-In-DTPA-D-Phe1] octreotide
scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activi‐
ty? J Clin Endocrinol Metab. 1994;79(6):1845-51.
[72] Pasquali D, Vassallo P, Esposito D, Bonavolontà G, Bellastella A, Sinisi AA Somatos‐
tatin receptor gene expression and inhibitory effects of octreotide on primary cul‐
tures of orbital fibroblasts from Graves’ ophthalmopathy. J Mol Endocrinol
2000;25:63-71.
[73] Pasquali D, Notaro A, Bonavolontà G, Vassallo P, Bellastella A, Sinisi AA Somatosta‐
tin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves’
disease. J Clin Endocrinol Metab 2002;87:5125-5129.
[74] Krassas GE, Dumas A, Pontikides N, Kaltsas T. Somatostatin receptor scintigraphy
and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol (Oxf).
1995;42(6):571-80.
[75] Kahaly G, Görges R, Diaz M, Hommel G, Bockisch A. Indium-111-pentetreotide in
Graves' disease. J Nucl Med. 1998;39(3):533-6.
[76] Gerding MN, van der Zant FM, van Royen EA, Koornneef L, Krenning EP, Wiersinga
WM, Prummel MF. Octreotide-scintigraphy is a disease-activity parameter in Graves'
ophthalmopathy. Clin Endocrinol (Oxf). 1999;50(3):373-9.
[77] Durak I, Durak H, Ergin M, Yürekli Y, Kaynak S. Somatostatin receptors in the or‐
bits. Clin Nucl Med. 1995;20(3):237-42.
[78] Moncayo R, Baldissera I, Decristoforo C, Kendler D, Donnemiller E. Evaluation of
immunological mechanisms mediating thyroid-associated ophthalmopathy by radio‐
Thyroid Disorders - Focus on Hyperthyroidism164
nuclide imaging using the somatostatin analog 111In-octreotide. Thyroid. 1997;7(1):
21-9.
[79] Kirsch E, von Arx G, Hammer B. Graves' ophthalmopathy: diagnosis and manage‐
ment. Eur J Nucl Med. 2000;27(4):373-6
[80] Prummel MF. Imaging in Graves' orbitopathy. Orbit. 2009;28(4):219-25.
[81] Piciu D. Orbital Single Photon Emission Computed Tomography (SPECT) with
Tc-99m DTPA for the Evaluation of Graves’ Ophthalmopathy. In: Piciu D., Nuclear
Endocrinology. Berlin, Heidelberg: Springer-Verlag; 2012. p122-123.
[82] Rinderknecht J, Shapiro L, Krauthammer M, Taplin G, Wasserman K, Uszler JM, Ef‐
fros RM. Accelerated clearance of small solutes from the lungs in interstitial lung dis‐
ease. Am Rev Respir Dis. 1980;121(1):105-17.
[83] Galuska L, Varga J, Szucs Farkas Z, Garai I, Boda J, Szabo J, Leovey A, Nagy EV. Ac‐
tive retrobulbar inflammation in Graves ophthalmopathy visualized by Tc-99m
DTPA SPECT. Clin Nucl Med. 2003;28(6):515-6.
[84] Ujhelyi B, Erdei A, Galuska L, Varga J, Szabados L, Balazs E, Bodor M, Cseke B, Kar‐
anyi Z, Leovey A, Mezosi E, Burman KD, Berta A, Nagy EV. Retrobulbar 99mTc-di‐
ethylenetriamine-pentaacetic-acid uptake may predict the effectiveness of
immunosuppressive therapy in Graves' ophthalmopathy. Thyroid. 2009;19(4):375-80.
[85] Ortapamuk H, Hoşal B, Naldöken S. The role of Tc-99m polyclonal human immuno‐
globulin G scintigraphy in Graves' ophthalmopathy. Ann Nucl Med. 2002;16(7):
461-5.
[86] Lopes FP, de Souza SA, Dos Santos Teixeira Pde F, Rebelo Pinho Edos S, da Fonseca
LM, Vaisman M, Gutfilen B 99mTc-Anti-TNF-α scintigraphy: a new perspective
within different methods in the diagnostic approach of active Graves ophthalmop‐
athy. Clin Nucl Med. 2012;37(11):1097-101.
[87] Alavi A, Kung JW, Zhuang H. Implications of PET based molecular imaging on the
current and future practice of medicine. Semin Nucl Med. 2004;34(1):56-69.
[88] Gotthardt M, Bleeker-Rovers CP, Boerman OC, Oyen WJ. Imaging of inflammation
by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med.
2010;51(12):1937-49
[89] García-Rojas L, Adame-Ocampo G, Alexánderson E, Tovilla-Canales JL 18-Fluoro‐
deoxyglucose Uptake by Positron Emission Tomography in Extraocular Muscles of
Patients with and without Graves’ Ophthalmology. Journal of Ophthalmology
2013;e529187:1-4.
[90] Pichler R, Sonnberger M, Dorninger C, Assar H, Stojakovic T. Ga-68-DOTA-NOC
PET/CT reveals active Graves' orbitopathy in a single extraorbital muscle. Clin Nucl
Med. 2011;36(10):910-1.
Graves’ Ophthalmopathy Imaging Evaluation 165
[66] Yokoyama N, Nagataki S, Uetani M, Ashizawa K, Eguchi K.Role of magnetic reso‐
nance imaging in the assessment of disease activity in thyroid-associated ophthalm‐
opathy. Thyroid. 2002;12(3):223-7.
[67] Taoka T, Sakamoto M, Nakagawa H, Fukusumi A, Iwasaki S, Taoka K, Kichikawa K.
Evaluation of extraocular muscles using dynamic contrast enhanced MRI in patients
with chronic thyroid orbitopathy. J Comput Assist Tomogr. 2005;29(1):115-20
[68] Jiang H, Wang Z, Xian J, Li J, Chen Q, Ai L. Evaluation of rectus extraocular muscles
using dynamic contrast-enhanced MR imaging in patients with Graves' ophthalmop‐
athy for assessment of disease activity. Acta Radiol. 2012;53(1):87-94.
[69] Dodds NI, Atcha AW, Birchall D, Jackson A. Use of high-resolution MRI of the optic
nerve in Graves' ophthalmopathy. Br J Radiol. 2009;82(979):541-4.
[70] Krassas GE, Kahaly GJ. The role of octreoscan in thyroid eye disease. Eur J Endocri‐
nol. 1999;140(5):373-5.
[71] Postema PT, Krenning EP, Wijngaarde R, Kooy PP, Oei HY, van den Bosch WA, Reu‐
bi JC, Wiersinga WM, Hooijkaas H, van der Loos T [111-In-DTPA-D-Phe1] octreotide
scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activi‐
ty? J Clin Endocrinol Metab. 1994;79(6):1845-51.
[72] Pasquali D, Vassallo P, Esposito D, Bonavolontà G, Bellastella A, Sinisi AA Somatos‐
tatin receptor gene expression and inhibitory effects of octreotide on primary cul‐
tures of orbital fibroblasts from Graves’ ophthalmopathy. J Mol Endocrinol
2000;25:63-71.
[73] Pasquali D, Notaro A, Bonavolontà G, Vassallo P, Bellastella A, Sinisi AA Somatosta‐
tin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves’
disease. J Clin Endocrinol Metab 2002;87:5125-5129.
[74] Krassas GE, Dumas A, Pontikides N, Kaltsas T. Somatostatin receptor scintigraphy
and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol (Oxf).
1995;42(6):571-80.
[75] Kahaly G, Görges R, Diaz M, Hommel G, Bockisch A. Indium-111-pentetreotide in
Graves' disease. J Nucl Med. 1998;39(3):533-6.
[76] Gerding MN, van der Zant FM, van Royen EA, Koornneef L, Krenning EP, Wiersinga
WM, Prummel MF. Octreotide-scintigraphy is a disease-activity parameter in Graves'
ophthalmopathy. Clin Endocrinol (Oxf). 1999;50(3):373-9.
[77] Durak I, Durak H, Ergin M, Yürekli Y, Kaynak S. Somatostatin receptors in the or‐
bits. Clin Nucl Med. 1995;20(3):237-42.
[78] Moncayo R, Baldissera I, Decristoforo C, Kendler D, Donnemiller E. Evaluation of
immunological mechanisms mediating thyroid-associated ophthalmopathy by radio‐
Thyroid Disorders - Focus on Hyperthyroidism164
nuclide imaging using the somatostatin analog 111In-octreotide. Thyroid. 1997;7(1):
21-9.
[79] Kirsch E, von Arx G, Hammer B. Graves' ophthalmopathy: diagnosis and manage‐
ment. Eur J Nucl Med. 2000;27(4):373-6
[80] Prummel MF. Imaging in Graves' orbitopathy. Orbit. 2009;28(4):219-25.
[81] Piciu D. Orbital Single Photon Emission Computed Tomography (SPECT) with
Tc-99m DTPA for the Evaluation of Graves’ Ophthalmopathy. In: Piciu D., Nuclear
Endocrinology. Berlin, Heidelberg: Springer-Verlag; 2012. p122-123.
[82] Rinderknecht J, Shapiro L, Krauthammer M, Taplin G, Wasserman K, Uszler JM, Ef‐
fros RM. Accelerated clearance of small solutes from the lungs in interstitial lung dis‐
ease. Am Rev Respir Dis. 1980;121(1):105-17.
[83] Galuska L, Varga J, Szucs Farkas Z, Garai I, Boda J, Szabo J, Leovey A, Nagy EV. Ac‐
tive retrobulbar inflammation in Graves ophthalmopathy visualized by Tc-99m
DTPA SPECT. Clin Nucl Med. 2003;28(6):515-6.
[84] Ujhelyi B, Erdei A, Galuska L, Varga J, Szabados L, Balazs E, Bodor M, Cseke B, Kar‐
anyi Z, Leovey A, Mezosi E, Burman KD, Berta A, Nagy EV. Retrobulbar 99mTc-di‐
ethylenetriamine-pentaacetic-acid uptake may predict the effectiveness of
immunosuppressive therapy in Graves' ophthalmopathy. Thyroid. 2009;19(4):375-80.
[85] Ortapamuk H, Hoşal B, Naldöken S. The role of Tc-99m polyclonal human immuno‐
globulin G scintigraphy in Graves' ophthalmopathy. Ann Nucl Med. 2002;16(7):
461-5.
[86] Lopes FP, de Souza SA, Dos Santos Teixeira Pde F, Rebelo Pinho Edos S, da Fonseca
LM, Vaisman M, Gutfilen B 99mTc-Anti-TNF-α scintigraphy: a new perspective
within different methods in the diagnostic approach of active Graves ophthalmop‐
athy. Clin Nucl Med. 2012;37(11):1097-101.
[87] Alavi A, Kung JW, Zhuang H. Implications of PET based molecular imaging on the
current and future practice of medicine. Semin Nucl Med. 2004;34(1):56-69.
[88] Gotthardt M, Bleeker-Rovers CP, Boerman OC, Oyen WJ. Imaging of inflammation
by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med.
2010;51(12):1937-49
[89] García-Rojas L, Adame-Ocampo G, Alexánderson E, Tovilla-Canales JL 18-Fluoro‐
deoxyglucose Uptake by Positron Emission Tomography in Extraocular Muscles of
Patients with and without Graves’ Ophthalmology. Journal of Ophthalmology
2013;e529187:1-4.
[90] Pichler R, Sonnberger M, Dorninger C, Assar H, Stojakovic T. Ga-68-DOTA-NOC
PET/CT reveals active Graves' orbitopathy in a single extraorbital muscle. Clin Nucl
Med. 2011;36(10):910-1.
Graves’ Ophthalmopathy Imaging Evaluation 165
[91] Prummel MF, Wiersinga WM, Mourits, MP Assessment of disease activity of Graves’
ophthalmopathy. In: M.F. Prummel ed. Recent Developments in Graves’ Ophthalm‐
opathy. Boston: Kluwer; 2000. p59–80.
[92] Burggasser G, Hurtl I, Hauff W, Lukas J, Greifeneder M, Heydari B, Thaler A, We‐
drich A, Virgolini I. Orbital scintigraphy with the somatostatin receptor tracer
99mTc-P829 in patients with Graves' disease. J Nucl Med. 2003;44(10):1547-55.
[93] Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C,
Mourits M, et al. European Group on Graves' Orbitopathy (EUGOGO). Consensus
statement of the European Group on Graves' orbitopathy (EUGOGO) on manage‐
ment of GO. Eur J Endocrinol. 2008;158(3):273-85.
[94] Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a
guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol
(Oxf). 1997;47(1):9-14.
[95] Terwee CB, Prummel MF, Gerding MN, Kahaly GJ, Dekker FW, Wiersinga WM.
Measuring disease activity to predict therapeutic outcome in Graves' ophthalmop‐
athy. Clin Endocrinol (Oxf). 2005;62(2):145-55.
[96] Kahaly G, Förster G, Hansen C. Glycosaminoglycans in thyroid eye disease. Thyroid.
1998;8(5):429-32.
[97] Wakelkamp IM, Gerding MN, Van Der Meer JW, Prummel MF, Wiersinga WM Both
Th1-and Th2-derived cytokines in serum are elevated in Graves' ophthalmopathy.C
lin Exp Immunol. 2000;121(3):453-7.
[98] Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel
MF. Association of thyrotrophin receptor antibodies with the clinical features of
Graves' ophthalmopathy. Clin Endocrinol (Oxf). 2000;52(3):267-71.
[99] van der Gaag R, Wiersinga WM, Koornneef L, Mourits MP, Prummel MF, Berghout
A, de Vries RR, Schreuder GM, D'Amaro J. HLA-DR4 associated response to cortico‐
steroids in Graves' ophthalmopathy patients. J Endocrinol Invest. 1990;13(6):489-92.
[100] Nakahara H, Noguchi S, Murakami N, Morita M, Tamaru M, Ohnishi T, Hoshi H,
Jinnouchi S, Nagamachi S, Futami S, Graves ophthalmopathy: MR evaluation of 10-
Gy versus 24-Gy irradiation combined with systemic corticosteroids. Radiology.
1995;196(3):857-62.
[101] Tachibana S, Murakami T, Noguchi H, Noguchi Y, Nakashima A, Ohyabu Y, Nogu‐
chi S. Orbital magnetic resonance imaging combined with clinical activity score can
improve the sensitivity of detection of disease activity and prediction of response to
immunosuppressive therapy for Graves' ophthalmopathy. Endocr J. 2010;57(10):
853-61.
Thyroid Disorders - Focus on Hyperthyroidism166
[102] Galuska L, Leovey A, Szucs-Farkas Z, Garai I, Szabo J, Varga J, Nagy EV. SPECT us‐
ing 99mTc-DTPA for the assessment of disease activity in Graves' ophthalmopathy: a
comparison with the results from MRI. Nucl Med Commun. 2002;23(12):1211-6.
[103] Galuska L, Varga J, Szucs Farkas Z, Garai I, Boda J, Szabo J, Leovey A, Nagy EV. Ac‐
tive retrobulbar inflammation in Graves' ophthalmopathy visualized by Tc-99m
DTPA SPECT. Clin Nucl Med. 2003;28(6):515-6.
[104] Galuska L, Leovey A, Szucs-Farkas Z, Szabados L, Garai I, Berta A, Balazs E, Varga J,
Nagy EV. Imaging of disease activity in Graves' orbitopathy with different methods:
comparison of (99m)Tc-DTPA and (99m)Tc-depreotide single photon emission to‐
mography, magnetic resonance imaging and clinical activity scores. Nucl Med Com‐
mun. 2005;26(5):407-14.
[105] Szabados L, Nagy EV, Ujhelyi B, Urbancsek H, Varga J, Nagy E, Galuska L. The im‐
pact of 99mTc-DTPA orbital SPECT in patient selection for external radiation therapy
in Graves' ophthalmopathy. Nucl Med Commun. 2013;34(2):108-12.
[106] Rebelo Pinto E, Lopes FP, de Souza SA, da Fonseca LM, Vaisman M, Gutfilen B, dos
Santos PF. A pilot study evaluating 99mTc-anti-TNF-alpha scintigraphy in graves'
ophtalmopathy patients with different clinical activity score. Horm Metab Res.
2013;45(10):765-8.
Graves’ Ophthalmopathy Imaging Evaluation 167
[91] Prummel MF, Wiersinga WM, Mourits, MP Assessment of disease activity of Graves’
ophthalmopathy. In: M.F. Prummel ed. Recent Developments in Graves’ Ophthalm‐
opathy. Boston: Kluwer; 2000. p59–80.
[92] Burggasser G, Hurtl I, Hauff W, Lukas J, Greifeneder M, Heydari B, Thaler A, We‐
drich A, Virgolini I. Orbital scintigraphy with the somatostatin receptor tracer
99mTc-P829 in patients with Graves' disease. J Nucl Med. 2003;44(10):1547-55.
[93] Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C,
Mourits M, et al. European Group on Graves' Orbitopathy (EUGOGO). Consensus
statement of the European Group on Graves' orbitopathy (EUGOGO) on manage‐
ment of GO. Eur J Endocrinol. 2008;158(3):273-85.
[94] Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a
guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol
(Oxf). 1997;47(1):9-14.
[95] Terwee CB, Prummel MF, Gerding MN, Kahaly GJ, Dekker FW, Wiersinga WM.
Measuring disease activity to predict therapeutic outcome in Graves' ophthalmop‐
athy. Clin Endocrinol (Oxf). 2005;62(2):145-55.
[96] Kahaly G, Förster G, Hansen C. Glycosaminoglycans in thyroid eye disease. Thyroid.
1998;8(5):429-32.
[97] Wakelkamp IM, Gerding MN, Van Der Meer JW, Prummel MF, Wiersinga WM Both
Th1-and Th2-derived cytokines in serum are elevated in Graves' ophthalmopathy.C
lin Exp Immunol. 2000;121(3):453-7.
[98] Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel
MF. Association of thyrotrophin receptor antibodies with the clinical features of
Graves' ophthalmopathy. Clin Endocrinol (Oxf). 2000;52(3):267-71.
[99] van der Gaag R, Wiersinga WM, Koornneef L, Mourits MP, Prummel MF, Berghout
A, de Vries RR, Schreuder GM, D'Amaro J. HLA-DR4 associated response to cortico‐
steroids in Graves' ophthalmopathy patients. J Endocrinol Invest. 1990;13(6):489-92.
[100] Nakahara H, Noguchi S, Murakami N, Morita M, Tamaru M, Ohnishi T, Hoshi H,
Jinnouchi S, Nagamachi S, Futami S, Graves ophthalmopathy: MR evaluation of 10-
Gy versus 24-Gy irradiation combined with systemic corticosteroids. Radiology.
1995;196(3):857-62.
[101] Tachibana S, Murakami T, Noguchi H, Noguchi Y, Nakashima A, Ohyabu Y, Nogu‐
chi S. Orbital magnetic resonance imaging combined with clinical activity score can
improve the sensitivity of detection of disease activity and prediction of response to
immunosuppressive therapy for Graves' ophthalmopathy. Endocr J. 2010;57(10):
853-61.
Thyroid Disorders - Focus on Hyperthyroidism166
[102] Galuska L, Leovey A, Szucs-Farkas Z, Garai I, Szabo J, Varga J, Nagy EV. SPECT us‐
ing 99mTc-DTPA for the assessment of disease activity in Graves' ophthalmopathy: a
comparison with the results from MRI. Nucl Med Commun. 2002;23(12):1211-6.
[103] Galuska L, Varga J, Szucs Farkas Z, Garai I, Boda J, Szabo J, Leovey A, Nagy EV. Ac‐
tive retrobulbar inflammation in Graves' ophthalmopathy visualized by Tc-99m
DTPA SPECT. Clin Nucl Med. 2003;28(6):515-6.
[104] Galuska L, Leovey A, Szucs-Farkas Z, Szabados L, Garai I, Berta A, Balazs E, Varga J,
Nagy EV. Imaging of disease activity in Graves' orbitopathy with different methods:
comparison of (99m)Tc-DTPA and (99m)Tc-depreotide single photon emission to‐
mography, magnetic resonance imaging and clinical activity scores. Nucl Med Com‐
mun. 2005;26(5):407-14.
[105] Szabados L, Nagy EV, Ujhelyi B, Urbancsek H, Varga J, Nagy E, Galuska L. The im‐
pact of 99mTc-DTPA orbital SPECT in patient selection for external radiation therapy
in Graves' ophthalmopathy. Nucl Med Commun. 2013;34(2):108-12.
[106] Rebelo Pinto E, Lopes FP, de Souza SA, da Fonseca LM, Vaisman M, Gutfilen B, dos
Santos PF. A pilot study evaluating 99mTc-anti-TNF-alpha scintigraphy in graves'
ophtalmopathy patients with different clinical activity score. Horm Metab Res.
2013;45(10):765-8.
Graves’ Ophthalmopathy Imaging Evaluation 167
Chapter 6
Thyrotoxic Periodic Paralysis – Clinical Diagnosis and
Management
Ana Luiza R. Rolim and Magnus R. Dias da Silva




Periodic paralysis comprises a group of neuromuscular diseases in which the patients present
with paroxysmal muscle weakness of the limbs. [1] The most common causes are thyrotoxic
hypokalemic periodic paralysis (TPP) and familial hypokalemic periodic paralysis (FPP). [1]
Thyrotoxic periodic paralysis (TPP) is a medical emergency characterized by an acute and
reversible attack of muscle weakness associated with the hypokalemia. [1, 2] TPP is the most
common form of acquired flaccid paralysis in adults with hyperthyroidism and can occur in
patients of any ethnicity, [3, 4] although it is more frequent in Asian populations. [5] TPP is
the newest form of endocrine channelopathy included in the large group of periodic paralysis
and should be included in the differential diagnosis of acute muscle weakness in patients
seeking emergency care.
2. Epidemiology
The association of loss of limb muscle strength and Graves’ disease was first published by
Rosenfeld in the German literature at the beginning of the last century. [6] In English, the first
report was made by Dunlap and Kepler in 1931, describing four patients. [7] In 1968, the first
case of TPP diagnosed in Brazil was described by Pereira et al. [8]
TPP is more frequently described in Asian descendants, [5] but it can occur in patients of other
ancestries. [3, 4] This aspect is particularly important because TPP should not be excluded in
the differential diagnosis of paralysis based only on the patient’s ethnicity. Although thyro‐
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toxicosis has a higher incidence in women, the paralysis affects predominantly men, with a
male:female ratio of approximately 30:1. [2]
TPP symptoms occur in young adults, in contrast to FPP, in which the paralysis crises begin
at an earlier age, usually before puberty. [1] TPP is more common between the third and fifth
decades of life, which coincides with the peak incidence of thyrotoxicosis [9]. In a study
performed with 35 Brazilian patients, the age at diagnosis ranged from 19 to 51 years, [2] similar
to the international literature. [9, 10] Unlike the familial form, TPP appears as a sporadic
disease. [11] However, rare cases of TPP with a family history of paralysis and thyrotoxicosis
have been reported. [12, 13]
3. Etiology and genetic susceptibility
The paralysis crises occur only in the presence of the thyrotoxic state, regardless of its etiology.
Several causes of thyrotoxicosis with paralysis have been reported, including Graves’ disease
(GD), toxic adenoma, toxic multinodular goiter, amiodarone-induced thyrotoxicosis, TSH-
producing pituitary tumor, lymphocytic thyroiditis, and factitious thyrotoxicosis. [2] In most
of the cases, TPP is associated with the hyperthyroidism in GD, [9, 14] and the paralysis crisis
may be an atypical form of initial presentation of the disease. In our studies, there are also a
report of TPP in a patient who used formulations containing levothyroxine to lose weight. [2]
The methodological approach to determining the genetic susceptibility to TPP is difficult. This
is due in part to the absence of a familial pattern of inheritance that allows linkage analysis by
polymorphic allele markers, as almost all of the cases described in the literature are sporadic.
Second, the number of cases is relatively small, making an association study to identify genetic
susceptibility difficult. Thus, the first genes to be studied were the ones most commonly related
to FPP (CACN1AS and SCN4A) [15], a clinical condition physiopathologically similar to the
TPP. However, the investigation of these genes revealed that patients with TPP were negative
for these mutations [17, 18]. Several other genes were subsequently studied, and although there
were reports of patients bearing the KCNE3 mutation [18, 19], these patients were later proven
to have only a polymorphic variant. [20]
More recently, after the study of Plaster et al. [21] on a familial paralysis form associated with
facial dysmorphism and arrhythmias called Andersen-Twail Syndrome, a new group of
candidate genes arose. Thus, the KCNJ12 gene (potassium channel Kir2.2) was included in the
screening for TPP mutations. Kir2.2 became the candidate of greatest interest because of its
expression in the skeletal muscle and the presence of the consensus elements (cis), the Thyroid
Response Elements (TRE), in its regulatory region. Although no mutation has been found in
this group of genes in TPP, during the study of the KCNJ12 gene, a novel paralog gene was
discovered and called KCNJ18 (Kir2.6). [22] Four different mutations were identified, including
two missense (T354M & K366R) and two nonsense (R399X & Q407X) mutations that combined
are present in 33% of patients with TPP. [22] These mutations result in a defect in muscle
repolarization. The high K+levels in the muscular system keep the cell in a partially depolarized
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state, and the membrane becomes unable to trigger a new muscle excitation-contraction
coupling, resulting in flaccid paralysis. [22]
4. Physiopathology
The physiopathology of TPP remains incompletely understood. Evidence suggests that TPP
results from a combination of three factors: genetic, environmental, and thyrotoxicosis [1].
From this association, we hypothesized that the interaction of these factors would alter the
channel dynamics of the cell membrane at the neuromuscular junction, triggering the paralysis
crises only in patients genetically susceptible. [2] There are reports of a patient with history of
TPP who suffered a paralysis crisis after taking excessive doses of thyroid hormone, [23, 24]
which supports this hypothesis. [25]
In  Figure  1,  we described a  theoretical  model  of  multifactorial  interactions  in  TPP.  The
genetic  factors  could include a defect  in one of  the ion channels  involved in excitation-
contraction  coupling  (Ca2+,  Na+,  and  K+)  or  a  defect  in  one  of  the  channel’s  regulatory
subunits (ß, ∂, or SUR, for example). Alterations in one of these genes would be responsi‐
ble for the generation of non-functional ion channels, which would define the TPP as an
endocrine channelopathy. [26, 27]
The environmental factors include the excessive consumption of carbohydrate-rich foods,
alcohol, or resting after intense exercise. Thyrotoxicosis would be the limiting factor and
essential for the paralysis crisis. [1] In addition, several other studies have demonstrated that
the activity of the Na+/K+-ATPase pump is increased in thyrotoxicosis and is more exacerbated
in patients with TPP. [28, 29] The hypokalemia observed in these cases is due to the increased
K+influx into a cell secondary to the increase in the activity of the Na+/K+-ATPase pump and
by the hyperinsulinemic response to carbohydrate intake in patients susceptible to TPP. [25,
Figure 1. Theoretical model of multifactorial interaction in TPP. Modified from Ref. [1]
Thyrotoxic Periodic Paralysis – Clinical Diagnosis and Management
http://dx.doi.org/10.5772/58475
171
toxicosis has a higher incidence in women, the paralysis affects predominantly men, with a
male:female ratio of approximately 30:1. [2]
TPP symptoms occur in young adults, in contrast to FPP, in which the paralysis crises begin
at an earlier age, usually before puberty. [1] TPP is more common between the third and fifth
decades of life, which coincides with the peak incidence of thyrotoxicosis [9]. In a study
performed with 35 Brazilian patients, the age at diagnosis ranged from 19 to 51 years, [2] similar
to the international literature. [9, 10] Unlike the familial form, TPP appears as a sporadic
disease. [11] However, rare cases of TPP with a family history of paralysis and thyrotoxicosis
have been reported. [12, 13]
3. Etiology and genetic susceptibility
The paralysis crises occur only in the presence of the thyrotoxic state, regardless of its etiology.
Several causes of thyrotoxicosis with paralysis have been reported, including Graves’ disease
(GD), toxic adenoma, toxic multinodular goiter, amiodarone-induced thyrotoxicosis, TSH-
producing pituitary tumor, lymphocytic thyroiditis, and factitious thyrotoxicosis. [2] In most
of the cases, TPP is associated with the hyperthyroidism in GD, [9, 14] and the paralysis crisis
may be an atypical form of initial presentation of the disease. In our studies, there are also a
report of TPP in a patient who used formulations containing levothyroxine to lose weight. [2]
The methodological approach to determining the genetic susceptibility to TPP is difficult. This
is due in part to the absence of a familial pattern of inheritance that allows linkage analysis by
polymorphic allele markers, as almost all of the cases described in the literature are sporadic.
Second, the number of cases is relatively small, making an association study to identify genetic
susceptibility difficult. Thus, the first genes to be studied were the ones most commonly related
to FPP (CACN1AS and SCN4A) [15], a clinical condition physiopathologically similar to the
TPP. However, the investigation of these genes revealed that patients with TPP were negative
for these mutations [17, 18]. Several other genes were subsequently studied, and although there
were reports of patients bearing the KCNE3 mutation [18, 19], these patients were later proven
to have only a polymorphic variant. [20]
More recently, after the study of Plaster et al. [21] on a familial paralysis form associated with
facial dysmorphism and arrhythmias called Andersen-Twail Syndrome, a new group of
candidate genes arose. Thus, the KCNJ12 gene (potassium channel Kir2.2) was included in the
screening for TPP mutations. Kir2.2 became the candidate of greatest interest because of its
expression in the skeletal muscle and the presence of the consensus elements (cis), the Thyroid
Response Elements (TRE), in its regulatory region. Although no mutation has been found in
this group of genes in TPP, during the study of the KCNJ12 gene, a novel paralog gene was
discovered and called KCNJ18 (Kir2.6). [22] Four different mutations were identified, including
two missense (T354M & K366R) and two nonsense (R399X & Q407X) mutations that combined
are present in 33% of patients with TPP. [22] These mutations result in a defect in muscle
repolarization. The high K+levels in the muscular system keep the cell in a partially depolarized
Thyroid Disorders - Focus on Hyperthyroidism170
state, and the membrane becomes unable to trigger a new muscle excitation-contraction
coupling, resulting in flaccid paralysis. [22]
4. Physiopathology
The physiopathology of TPP remains incompletely understood. Evidence suggests that TPP
results from a combination of three factors: genetic, environmental, and thyrotoxicosis [1].
From this association, we hypothesized that the interaction of these factors would alter the
channel dynamics of the cell membrane at the neuromuscular junction, triggering the paralysis
crises only in patients genetically susceptible. [2] There are reports of a patient with history of
TPP who suffered a paralysis crisis after taking excessive doses of thyroid hormone, [23, 24]
which supports this hypothesis. [25]
In  Figure  1,  we described a  theoretical  model  of  multifactorial  interactions  in  TPP.  The
genetic  factors  could include a defect  in one of  the ion channels  involved in excitation-
contraction  coupling  (Ca2+,  Na+,  and  K+)  or  a  defect  in  one  of  the  channel’s  regulatory
subunits (ß, ∂, or SUR, for example). Alterations in one of these genes would be responsi‐
ble for the generation of non-functional ion channels, which would define the TPP as an
endocrine channelopathy. [26, 27]
The environmental factors include the excessive consumption of carbohydrate-rich foods,
alcohol, or resting after intense exercise. Thyrotoxicosis would be the limiting factor and
essential for the paralysis crisis. [1] In addition, several other studies have demonstrated that
the activity of the Na+/K+-ATPase pump is increased in thyrotoxicosis and is more exacerbated
in patients with TPP. [28, 29] The hypokalemia observed in these cases is due to the increased
K+influx into a cell secondary to the increase in the activity of the Na+/K+-ATPase pump and
by the hyperinsulinemic response to carbohydrate intake in patients susceptible to TPP. [25,
Figure 1. Theoretical model of multifactorial interaction in TPP. Modified from Ref. [1]
Thyrotoxic Periodic Paralysis – Clinical Diagnosis and Management
http://dx.doi.org/10.5772/58475
171
30] Androgens also can increase the activity of the Na+/K+-ATPase pump, which explains the
higher incidence of the disease in young males. [30]
According to the mechanism illustrated in the Figure 2, we believe that during the TPP crisis,
the mutated Kir2.6 potassium channel retains potassium in the sarcolemma, causing hypoka‐
lemia and flaccid paralysis.
Figure 2. Physiological regulation of Kir2.6 by thyroid hormone and when mutated.
5. Clinical presentation
Illustrative case report of TPP:
A 32-year-old mulatto male patient was brought to the emergency room at 5:00 am by relatives
in a wheelchair. He reported being healthy until six months prior to presentation when
episodes of muscle weakness in his lower limbs began to develop and kept him from getting
out of bed and walking. He also complained of weakness of lower intensity in upper limbs.
He denied pain or loss of sensation. All episodes spontaneously resolved without motor
sequelae. During physical examination, a decreased in strength, especially in the lower limbs,
and hypoactive deep tendon reflexes were noted. In addition, the patient also exhibited diffuse
goiter, ocular proptosis, and thyrotoxicosis symptoms (tachycardia, excessive sweating,
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tremor of the extremities, and 10 kg weight loss). Eating several slices of pizza and soda in a
restaurant was identified by the patient as the triggering factor for the crisis the following the
next day.
The laboratory tests at the time of the crisis demonstrated hypokalemia (K=1.9 mEq/L; Normal
Range: 3.5 to 5.1 mEq/L). The ECG demonstrated the presence of “U” waves and decreased
amplitude of the T wave, and oral and intravenous potassium replacement was initiated. The
paralysis crisis was resolved after the medication, and the patient was referred to the clinic for
the etiologic diagnosis. During the investigation, Graves’ disease was diagnosed with TSH
<0.05 mUI/L (Normal range: 0.5-4.5 mUI/L), free T4 >6.0 ng/dL (Normal range: 0.6-1.5 ng/dL),
and total T3=535 ng/dL (Normal range: 30-200 ng/dL). The ultrasound revealed diffuse
enlargement of the thyroid gland and increased vascularization detected by Doppler. [1, 31] I
scintigraphy revealed an uptake of 21% over 2 hours (normal range from 1 to 8%) and 50%
over 24 hours (normal range from 3 to 23%). Methimazole and propranolol treatments were
initiated followed by the definitive hyperthyroidism therapy with radioactive iodine.
The case above illustrates the importance of a proper diagnosis to determine the specific
treatment. Many patients already exhibit signs of hyperthyroidism due to Graves’ disease
(goiter and exophthalmia) or thyrotoxicosis symptoms at the time of the paralysis crisis, but
often the thyroid alteration is not recognized at the time and may be confused with hysteria
or neuro-anxiety. Often, patients are erroneously classified as psychiatric and consequently
treated with benzodiazepines.
The paralysis crises are transient and remit spontaneously, and their frequency, duration and
intensity vary. [1] Because of this variability in the clinical presentation, the delayed diagnosis
is not uncommon. Many patients report multiple visits to the emergency department with a
sudden onset of muscle weakness of the limbs before the diagnosis.
Muscle weakness typically affects the proximal muscles of the lower limbs and is usually
symmetric. [31] Some patients may present with tetraparesis or tetraplegia, which can be
confused with Guillain-Barre syndrome, transverse myelitis, myasthenia gravis, or an acute
spinal cord compression. However, in TPP, there is no urinary incontinence or intestinal
dysfunction, nor is there a history of infection or trauma. [32] Although rare, there are reports
of respiratory muscle paralysis that requires mechanical ventilation. [1, 33] It is important to
distinguish TPP from other neuromuscular disorders that also presents with proximal muscle
weakness inherent to thyrotoxic myopathy. In these other disease, the patients exhibit muscle
atrophy and increased tendon reflexes, and the symptoms are proportional to the severity of
the thyrotoxic state. [34]
TPP may be preceded by prodromal symptoms such as muscle pain, cramps, and/or stiffness
of muscles of the affected limbs. [32] Frequently, the patients report that crises occur when
they get up during the night or early in the morning after a day of intensive exercise and/or
consumption of a large amount of food.
Sensitivity is preserved in the physical-neurological examination. However, as shown in
Figure 3, the tendon reflexes are decreased or absent in the majority of the patients, [32] in
contrast to the expected hyperreflexia in a thyrotoxic patient without paralysis. The duration
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of the crisis is variable, lasting up to 72 hours. [31] In a recently published study, the average
duration of most cases was two to six hours. [2]
Figure 3. Patellar tendon reflex in patients with TPP, normal individuals, and individuals with thyrotoxicosis.
6. Laboratory and differential diagnosis
The confirmation of thyrotoxicosis, i.e., TSH suppressed in the presence of high levels of
thyroid hormones (total and free T3 and T4), is essential for the definitive diagnosis of TPP.
Hypokalemia is the primary laboratory alteration at the time of crisis. [9, 35] There are some
reports of normokalemia, [36, 37] but we believe that these reports are due to errors during
data collection, i.e., data collection in a late stage of the crisis after the serum concentrations of
potassium have already recovered, [9] or due to improper storage of the samples, predisposing
them to hemolysis. [2]
Hypokalemia results from the influx of ion into the intracellular compartment and does not
indicate total depletion of the body potassium. [28] Calcium levels are normal, and creatine
phosphokinase (CPK) might be elevated. [2] Some patients exhibit hypophosphatemia and
hypomagnesemia, [9] both without need for replacement.
Other complementary exams, such as ultrasound, thyroid scintigraphy, and antibody meas‐
urements (anti-thyroglobulin, anti-peroxidase, and anti-TSH receptors (TRAb), may be
necessary to define the etiology of hyperthyroidism. During the paralysis crisis, some patients
exhibit a myopathic pattern on electromyography, which disappears in the remission period.
[38] Muscle biopsy demonstrates nonspecific histological findings, and the study of the
cerebrospinal fluid does not add any information to the diagnosis, both being dispensable
during the investigation of TPP. [2]
We present a table 1 summarizing the major clues for differential diagnosis of acquired
muscular disorders in young adults, including clinical and analytical features.
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them to hemolysis. [2]
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indicate total depletion of the body potassium. [28] Calcium levels are normal, and creatine
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hypomagnesemia, [9] both without need for replacement.
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We present a table 1 summarizing the major clues for differential diagnosis of acquired
muscular disorders in young adults, including clinical and analytical features.
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Table 1. Clues for differential diagnosis of acquired muscular disorders in young adults
7. Treatment and follow-up
The administration of oral and/or intravenous (IV) potassium is recommended during the
paralysis crisis to accelerate the recovery and prevent a possible cardiac arrhythmia. [2] The
oral use of potassium should be preferred, [39] but if a faster recovery is necessary, potassium
may be slowly IV infused, usually over 2 hours. The main concern about potassium replace‐
ment is rebound hyperkalemia [40] because the potassium abnormality is not due to total
potassium depletion but intracellular ion trapping. Therefore, monitoring the serum K levels
during the treatment and suspending the infusion at the first sign of the muscular force
recovery is recommended. [2]
Non-selective beta blockers, especially oral propranolol (80-240 mg/day), [2] may be useful in
TPP treatment, especially when awaiting the FT4 and TSH results, by limiting the time of the
crisis without inducing rebound hyperkalemia. [41, 42] These drugs block the adrenergic
stimulation of the Na+/K+-ATPase pump activity, resulting in lower K influx to skeletal muscle.
Early treatment for the underlying cause of thyrotoxicosis is the most important procedure in
patients with TPP. When euthyroidism is reached, the paralysis crises remits definitively. [34]
Triggering factors such as high intake of carbohydrates, alcohol, and intense physical exercise
should be avoided until the resolution of the thyroid disease. [43] In cases of thyrotoxicosis
caused by excessive intake of thyroid hormones, the drug is suspended. In hyperthyroidism
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associated with Graves’ disease, toxic multinodular goiter, or toxic adenoma, the definitive
treatment with radioactive iodine or thyroidectomy should be established immediately. Anti-
thyroid drugs (methimazole or propylthiouracil) should be prescribed as adjuvant while the
patient waits for the definitive therapy.
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1. Introduction
Thyroid hormones (THs), the only known iodine-containing compounds with biological
activity, are important for normal development of human organism, affecting the function of
virtually all systems [1]. The thyroid gland releases primarily thyroxine (T4), which is con‐
verted in peripheral tissues by the enzyme thyroxine 5’-deiodinase to the active TH form, 3,3',
5-triiodo-L-thyronine (T3) [1]. Thyroid hormone action is predominantly the result of T3
binding to high-affinity nuclear TH receptors (TRs) that have different tissue distribution and
metabolic targets. TRs subsequently interact with specific DNA sequences, called thyroid
hormone response elements (TREs), located in the regulatory region of different target genes
[2]. Although both T3 and T4 enter the cells, only T3 is the ligand for TRs. When T3 binds to
TR, specific co-factors are recruited and transmit signals to basal transcriptional machinery,
thus inducing conformational changes of the chromatin, and making the selected genes
accessible to the transcription process [3]. Accordingly, the transcription of the target genes is
regulated by T3 and, in this way triiodothyronine exerts its biological effects through the
chosen products of the transcription process. There are two thyroid hormone receptor genes,
TRα and TRβ, located in humans on chromosomes 17 and 3, respectively. Although various
TR isoforms have been reported, these isoforms can be categorized into TRα1, TRα2, TRβ1,
which are widely distributed in the body, and a form with more limited expression, TRβ2 [4].
TRα1 and TRβ1 are the major products of TRα and TRβ genes, respectively. Alternative
splicing of the 3'-most exon of TRα1 results in the generation of TRα2. Since the discovery of
these TR isoforms, many studies have attempted to demonstrate their relative contribution to
mediate thyroid hormone action in various tissues. However, a number of tissues that are well
known targets of THs, is so far limited, and include the pituitary, bones, liver, skeletal and
cardiac muscle, fat tissue and developing brain [1]. In addition to the variable expression of
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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TRs in different tissues, the role of TH can vary in particular tissues. Likewise, the numerous
effects by a single hormone on so many distinct tissues is surprising and underscores the vital
role of thyroid hormones in cellular function. Therefore, the interpretation of studies on action
of biological TH/TRs axis is dependent on understanding the complex nature of thyroid
hormone action. It was found that TRs are a multi-functional proteins: they act as transcrip‐
tional repressors in the absence of ligand and as transcriptional activators in the presence of
T3 [5]. Of note, there are reports that TRα2 reveals an inhibitory action against other active TRs
[6]. Importantly, the majority of thyroid hormone actions are thought to be mediated by nuclear
receptors, although a wide range of nongenomic effects of TH at the cellular level have been
recognized in the last decade [7]. Cellular uptake of iodothyronines and the nuclear TRs are
not implicated in the nongenomic actions of thyroid hormones. These specific TH activities
have been described to be present in the cell membrane, various organelles, the cytoskeleton,
and in cytoplasm. Plasma membrane-initiated actions of TH begin at αvβ3 receptor for
integrin,which activates ERK1/2-dependant cascade of kinases and culminate in local mem‐
brane processes, like a modulation of ion transport systems or in complex intracellular events,
such as cell proliferation [8].
The objective of this chapter is to provide a current overview of the impact of hyperthyroidism
on physiological hematopoiesis in humans and experimental animals. The molecular mecha‐
nisms involved in thyroid-dependent regulation of hematopoietic cell growth and develop‐
ment, with insight on the effects of hyperthyroidism on hematopoietic stem cell proliferation,
apoptosis and cell cycle have been described. Moreover, the potential direct role of thyroid
hormones in regulating the development of main hematopoietic lineages, erythropoiesis and
leukopoiesis, are discussed. Finally, a summary on hyperthyroidism and its correlation with
thrombocytopoiesis and platelet counts in circulating blood is also given.
2. Hyperthyroidism and hematopoiesis
Thyroid hormones significantly affect the cell cycle, proliferation, apoptosis as well as
differentiation and metabolism in different types of human cells throughout the entire life [9].
THs also play an important role in specific tissues during their growth and development. THs
have been known to be important regulators of bone development and metabolism [10-12]. In
this notion, thyroid hormones may also regulate a wide array of hematological parameters of
peripheral blood due to their potential influence on cell functions of hematopoietic system.
The association of thyroid disorders and abnormalities in hematological parameters is well
known, however, evidence for a role of THs/TRs in hematopoiesis is unclear so far and mostly
indirect. In 1881, Charcot showed for the first time that Graves’ disease is associated with
anemia. Two years later, Kocher observed a decreased number of red blood cells (RBCs) in the
peripheral blood (PB) of patients after thyroidectomy. Likewise, direct and indirect effects of
excessive or insufficient thyroid hormones on hematopoietic cell maturation and function, on
the synthesis and action of hematogenous humoral factors, and on changes in established
blood composition may play a role in the pathogenesis of abnormal functions of hematopoietic
system that accompany different thyroid diseases. Moreover, various abnormalities in
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hematological status that occur in patients with thyroid diseases may range from subclinical
laboratory abnormalities to clinically significant disorders that might strongly complicate the
clinical course of particular thyroid disease. Indeed, erythrocytosis is fairly common in the
course of hyperthyroidism [13-14], and importantly, all parameters involved in erythropoiesis
return to normal, when an euthyroid state is obtained [15]. However, also anemia is present
in 10 to 25 percent of these patients. With regard to white blood cells, elevated, normal, but
also depressed, total leukocyte counts have been reported in hyperthyroid patients. Observing
the specific types of leukocytes in circulating blood, only the slight decrease in the number of
neutrophils and relative increase in the number of eosinophils and mononuclear cells have
been recorded in hyperthyroid patients. Nevertheless, the hyperplasia of all myeloid lineages
in the bone marrow has been described in several cases of hyperthyroidism [16]. Interestingly,
treatment with thyroid hormones has been suggested to improve reconstitution of the immune
system after hematopoietic stem cell transplantation [17]. Besides, the clinical relationship
between thyroid diseases and the hemostatic system was first defined in 1913 by Kaliebe and
coworkers [18]. At that time authors have reported an episode of central vein thrombosis in a
thyrotoxic patient. Different overt thyroid dysfunctions may cause thrombosis or hemorrhage
by affecting primary and secondary physiologic hemostasis as this system requires careful
regulation, also hormonal, in order to work properly [19].
Altogether, according to recent knowledge, the relationship between thyroid diseases and
hematopoiesis is more complex than assumed and there are several molecular and patient-
based studies on this subject in the scientific literature. Nevertheless, appropriate and adequate
studies of high quality are lacking. In most of the reported studies, there are important
methodological limitations, such as lack of control groups, small number of cases, and
heterogeneity in etiology of the diseases, the severity of thyroid dysfunction and the usage of
different laboratory methods. We review here some of the major advances in this area by
initially focusing on what is known about molecular mechanisms of TH action on hemato‐
poietic cells, with the particular insight into hematopoietic stem and progenitor cells, and
discuss the implications of TH functioning in specific hematopoietic lineages. Although there
is a great body of evidence that TH affect early hematopoietic cells in the indirect manner, the
recent studies of our group suggested that THs may play a direct role in the regulation of the
growth and apoptosis of human early hematopoietic cells [20-21].
2.1. Thyroid hormone receptor expression in hematopoietic stem/progenitor cells
In order to prove that thyroid hormones can directly influence hematopoiesis it is necessary
to investigate in the first line the presence of the thyroid hormone receptor in hematopoietic
stem/progenitor cells (HSPC). The expression of different TRs has been documented in mature
cells of mouse bone marrow (BM), particularly in stromal cells [22], as well as in rat BM cells
[23]. Besides, expression of mRNA for TRα1 receptor was reported in mononuclear cells
isolated from human peripheral blood [17]. Recently, our group demonstrated for the first time
that TH receptors (TRα1 and TRβ1) are expressed at mRNA and protein level in human
CD34+HSPCs that were derived from different sources such as bone marrow and peripheral
blood [20]. Importantly, we also analyzed TRα1 and TRβ1 expression in HSPC circulating in
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TRs in different tissues, the role of TH can vary in particular tissues. Likewise, the numerous
effects by a single hormone on so many distinct tissues is surprising and underscores the vital
role of thyroid hormones in cellular function. Therefore, the interpretation of studies on action
of biological TH/TRs axis is dependent on understanding the complex nature of thyroid
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recognized in the last decade [7]. Cellular uptake of iodothyronines and the nuclear TRs are
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have been described to be present in the cell membrane, various organelles, the cytoskeleton,
and in cytoplasm. Plasma membrane-initiated actions of TH begin at αvβ3 receptor for
integrin,which activates ERK1/2-dependant cascade of kinases and culminate in local mem‐
brane processes, like a modulation of ion transport systems or in complex intracellular events,
such as cell proliferation [8].
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blood composition may play a role in the pathogenesis of abnormal functions of hematopoietic
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return to normal, when an euthyroid state is obtained [15]. However, also anemia is present
in 10 to 25 percent of these patients. With regard to white blood cells, elevated, normal, but
also depressed, total leukocyte counts have been reported in hyperthyroid patients. Observing
the specific types of leukocytes in circulating blood, only the slight decrease in the number of
neutrophils and relative increase in the number of eosinophils and mononuclear cells have
been recorded in hyperthyroid patients. Nevertheless, the hyperplasia of all myeloid lineages
in the bone marrow has been described in several cases of hyperthyroidism [16]. Interestingly,
treatment with thyroid hormones has been suggested to improve reconstitution of the immune
system after hematopoietic stem cell transplantation [17]. Besides, the clinical relationship
between thyroid diseases and the hemostatic system was first defined in 1913 by Kaliebe and
coworkers [18]. At that time authors have reported an episode of central vein thrombosis in a
thyrotoxic patient. Different overt thyroid dysfunctions may cause thrombosis or hemorrhage
by affecting primary and secondary physiologic hemostasis as this system requires careful
regulation, also hormonal, in order to work properly [19].
Altogether, according to recent knowledge, the relationship between thyroid diseases and
hematopoiesis is more complex than assumed and there are several molecular and patient-
based studies on this subject in the scientific literature. Nevertheless, appropriate and adequate
studies of high quality are lacking. In most of the reported studies, there are important
methodological limitations, such as lack of control groups, small number of cases, and
heterogeneity in etiology of the diseases, the severity of thyroid dysfunction and the usage of
different laboratory methods. We review here some of the major advances in this area by
initially focusing on what is known about molecular mechanisms of TH action on hemato‐
poietic cells, with the particular insight into hematopoietic stem and progenitor cells, and
discuss the implications of TH functioning in specific hematopoietic lineages. Although there
is a great body of evidence that TH affect early hematopoietic cells in the indirect manner, the
recent studies of our group suggested that THs may play a direct role in the regulation of the
growth and apoptosis of human early hematopoietic cells [20-21].
2.1. Thyroid hormone receptor expression in hematopoietic stem/progenitor cells
In order to prove that thyroid hormones can directly influence hematopoiesis it is necessary
to investigate in the first line the presence of the thyroid hormone receptor in hematopoietic
stem/progenitor cells (HSPC). The expression of different TRs has been documented in mature
cells of mouse bone marrow (BM), particularly in stromal cells [22], as well as in rat BM cells
[23]. Besides, expression of mRNA for TRα1 receptor was reported in mononuclear cells
isolated from human peripheral blood [17]. Recently, our group demonstrated for the first time
that TH receptors (TRα1 and TRβ1) are expressed at mRNA and protein level in human
CD34+HSPCs that were derived from different sources such as bone marrow and peripheral
blood [20]. Importantly, we also analyzed TRα1 and TRβ1 expression in HSPC circulating in
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human umbilical cord blood and we found that TRα1 was expressed in both mRNA and
protein form, however, TRβ1 gene had only the expression at the mRNA and not at the protein
level [20]. The presence of different TRs in human early CD34+hematopoietic cells is summar‐
ized in Figure 1.
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Figure 1. Analysis of TRα1 and TRβ1 expression at transcriptomic and translational level in 
human CD34+-enriched hematopoietic stem/progenitor cells. Left panel: expression of mRNA for 
β-actin (A), TRα1 (B) and TRβ1 (C) in CD34+ human cells obtained from cord blood (CB), peripheral 
blood (PB), and bone marrow (BM). Right panel: expression of protein for TRα1 (D) and TRβ1 (E) in 
CD34+ human cells obtained from bone marrow (BM), cord blood (CB), and peripheral blood (PB). 
M - molecular marker of DNA weight. Modified from: [20]. 
























Figure 1. Analysis of TRα1 and TRβ1 expression at transcriptomic and translational level in human CD34+-enriched
hematopoietic stem/progenitor cells. Left panel: expression of mRNA for β-actin (A), TRα1 (B) and TRβ1 (C) in
CD34+human cells obtained from cord blood (CB), peripheral blood (PB), and bone marrow (BM). Right panel: expres‐
sion of protein for TRα1 (D) and TRβ1 (E) in CD34+human cells obtained from bone marrow (BM), cord blood (CB), and
peripheral blood (PB). M-molecular marker of DNA weight. Modified from: [20].
Interestingly, we recently observed that the abnormal concentrations of thyroid hormones may
influence the rate of expression of different TRs in hematopoietic cells. To investigate the
molecular changes underlying the enhanced influence of THs on circulatory HSPCs, we
analyzed the expression of TRα-1 gene in CD34+-enriched HSPCs isolated from the PB of
healthy subjects. When HSPC population was subjected for period of 72 hours to triiodothyr‐
onine at concentration ten times higher than normal physiological concentration (equal to 3.7
pg/mL), which quite resemble the natural conditions of hyperthyroid state in human patients,
the expression of mRNA for TRα-1 gene was down-regulated in the majority of analyzed blood
samples as shown in Figure 2 [21].
Furthermore, our group found that in patients with hyperthyroidism the levels of mRNA for
TRα-1 expressed by CD34+-enriched HSPCs were significantly decreased by around 37%
compared to HSPCs isolated from control healthy subjects (254.9 vs. 398.3, respectively;
amount of the transcript given in arbitrary units; P<0.01) as determined by real-time PCR [21].
Additionally, the results indicating the direct influence of THs on TR expression were
qualitatively corroborated by the immunocytofluorescence analysis of TRα-1 protein expres‐
sion in PB-derived CD34+-enriched HSPCs obtained from patients with overt thyroid dys‐
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function. Here, the fluorescence signal of cells from hyperthyroid patients was much weaker
than signal of equal cell population from healthy donors. Interestingly, HSPCs from hypo‐
thyroid patients presented the most intense fluorescence signal in this analysis performed in
the established and fixed conditions. The summary of data obtained from in vitro investigation
using immunofluorescence to detect TRα-1 protein expression is presented in Figure 3.
Altogether, the above findings may indicate that T3 at high concentration might reduce the
expression of TRα-1 in circulating CD34+-enriched HSPCs due to active trafficking of protein
receptors and possible intense biodegradation after terminating its role in cell signaling. The
process of shuttling of TR between cytoplasm and nucleus directly after TH stimulation was
also observed [24]. Alternatively, a biologically controlled ligand-negative loop that form
homeostatic mechanism regulating cell activity may prevent the possibility that more ligand
binding to specific receptors could actively induce different cellular processes in TR-expressing
cells. Therefore, the active reduction of mRNA expression or inhibition of TR protein produc‐
tion would result in prevention against cellular hyperactivity in the hyperthyroid state of the
organism, also in the hematopoietic cells of patients with hyperthyroidism. Similar data were
obtained by Meier–Heusler et al., who documented a decreased expression of TRβ-1 in
mononuclear cells of peripheral blood from hyperthyroid patients and they noted that the
levels of mRNA for TRβ-1 were about 40% lower than in euthyroid subjects [25]. Correspond‐
ingly, previous observations by Rao et al. suggested a significant trend towards a down-
regulation of TRα-1 mRNA levels in the other tissues under the hyperthyroid state, such as rat
testes [26]. These data suggest that specific cellular TR expression is sensitive to the patholog‐
ical conditions related to hyperthyroidism developed in the affected organism.
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Figure 2. Expression of mRNA for TRα-1 in human CD34+-enriched hematopoietic 
stem/progenitor cells incubated with increased concentration of T3. Gene expression of TRα-1 
was assessed by real-time RT-PCR in CD34+ cells collected from healthy donors and incubated 
through 72 hours with serum saline (Control) or with ten times higher than normal concentration of 
T3 (T3 10xN). The amount of the transcript is expressed in the arbitrary units. Each line represents 
TRα-1 expression in cells collected from particular subject [21]. 
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2.2. Hyperthyroidism and lineage-specific clonogenic growth of hematopoietic cells
The hematopoietic system is very sensitive to thyroid hormones and hyperthyroidism may
induce significant alterations in growth of hematopoietic stem/progenitor cells, originally
located in bone marrow as well as constantly circulating in peripheral blood, and thus
significantly exposed to biologic activity of free THs. Unfortunately, our current knowledge
concerning the influence of THs on clonogenicity of human HSPCs is very limited and mostly
based on studies performed in animal models or human tissues cultured ex vivo. However,
such studies, performed in part also by our group, expanded the understanding of the role of
thyroid disorders in normal human hematopoiesis and could show a direct pathophysiological
influence of T3 on this process.
2.2.1. Erythropoiesis
Erythropoiesis is the physiologic process in which red blood cells (RBCs) are produced.
Hematopoietic development within the erythroid lineage requires a delicate balance between
the opposing effects of proliferation-promoting factors that maintain the renewal capacity of
immature erythroid progenitors and differentiation-inducing factors required for successful
terminal maturation of erythroid progenitors into mature erythrocytes [27]. In vivo, both the
renewal and maturation of human erythroid progenitors proceed in the bone marrow in
Figure 3. Immunocytofluorescence of TRα-1 protein in human CD34+-enriched hematopoietic stem/progenitor
cells. CD34+cells from healthy donors (B), hyperthyroid patients (C), and hypothyroid patients (D) were stained with
anti-TRα-1 antibody (pseudo-colored red). Cell nuclei (A-D) are visualized with DAPI (pseudo-colored blue) [21].
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parallel. Although thyroid hormones are required for normal development and differentiation
of many cell types, little is known about their role in physiologic erythropoiesis, especially in
humans [4]. On one side, hyperthyroidism induced in experimental laboratory animals or in
humans, generates increased RBC number and total RBC mass through stimulation of
erythropoiesis [28-29], however, it has been postulated that this effect would be indirect and
involves modulating function of biologically active substances important for erythropoiesis,
such as kidney-derived erythropoietin (EPO) or other hematogenous humoral factors, which
production by non-erythroid cells is also increased in hyperthyroid state [30-31]. Besides, there
are evidences that THs may increase the concentration of 2,3-diphosphoglycerate in erythro‐
cytes, which serves to enhance the delivery of oxygen to tissues, and thus affects steady-state
levels of circulating EPO [32-33]. Interestingly, in vitro studies confirmed that both T4 and T3
stimulate EPO synthesis in the human liver cell line HepG2 and this stimulating effect could
persist for 24 hours after the removal of THs from the cell culture [34]. However, in the
established model of HSPCs cultures in vitro with standard amount of EPO performed for
analysis of differential clonogenic growth of hematopoietic cells, we observed that prolifera‐
tive potential of burst-forming units of erythrocytes (BFU-E) was increased only in the samples
collected from the patients with hyperthyroidism and, in contrast, it was decreased in case of
samples collected from the hypothyroid subjects [21]. Therefore, it seems that THs can induce
signal transduction pathways implicated in proliferation of hematopoietic progenitors for
erythroid lineage other than EPO-dependent mechanisms. Data from in the available literature
corroborate our discovery indicating the direct role of THs in normal erythroid differentiation
of human and animal origin [35-38]. For example, daily administration of thyroxine into mice
stimulated the increase of indices significant for RBC production, such as packed red blood
cell volume, total circulating RBC count and mass, and reticulocyte count [39]. Likewise,
Malgor et al. have studied the TH role on modulation of erythropoiesis using the in vitro
cultures of cells collected from bone marrow of normal rats in the absence of EPO [37]. They
found that T3 produced a direct and significant stimulation of clonogenic growth of late
colony-forming erythroid units (CFU-E) and a moderate increase of early erythroid burst-
forming units (BFU-E) indicating an enhanced proliferative activity of committed erythroid
progenitors in response to this hormone. In contrast, the addition of T3 to in vitro cultures of
avian BM cells activates the TRα receptor in avian erythroblasts, blocks their self-renewal, and
induces synchronous, terminal differentiation of erythroid lineage from hematopoietic
progenitor cells [40]. Notwithstanding, Kendrick et al. recently verified the essential function
of TRα in regulating erythropoiesis in mammals by characterizing the phenotype of TRα−/−
mice deficient for TRα. These transgenic mice had significantly reduced numbers of erythroid
progenitor cells in the fetal liver, decreased hematocrit in adult organism, and a diminished
erythroid stress response to hemolytic anemia [41]. Similar results of direct TH influence on
erythroid lineage growth were taken from observations of human erythropoiesis developed
in vitro in established conditions. In pioneer studies of human BM-derived cells and THs action
Golde et al. showed that THs do not shift the requirement for EPO in the course of human
erythropoiesis, but both substances have synergistic effects in increasing the number of
erythroid colonies growing in vitro [35]. These data were corroborated by Leberbauer et al.,
who recently demonstrated that terminal erythroid maturation in course of development of
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2.2. Hyperthyroidism and lineage-specific clonogenic growth of hematopoietic cells
The hematopoietic system is very sensitive to thyroid hormones and hyperthyroidism may
induce significant alterations in growth of hematopoietic stem/progenitor cells, originally
located in bone marrow as well as constantly circulating in peripheral blood, and thus
significantly exposed to biologic activity of free THs. Unfortunately, our current knowledge
concerning the influence of THs on clonogenicity of human HSPCs is very limited and mostly
based on studies performed in animal models or human tissues cultured ex vivo. However,
such studies, performed in part also by our group, expanded the understanding of the role of
thyroid disorders in normal human hematopoiesis and could show a direct pathophysiological
influence of T3 on this process.
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Erythropoiesis is the physiologic process in which red blood cells (RBCs) are produced.
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the opposing effects of proliferation-promoting factors that maintain the renewal capacity of
immature erythroid progenitors and differentiation-inducing factors required for successful
terminal maturation of erythroid progenitors into mature erythrocytes [27]. In vivo, both the
renewal and maturation of human erythroid progenitors proceed in the bone marrow in
Figure 3. Immunocytofluorescence of TRα-1 protein in human CD34+-enriched hematopoietic stem/progenitor
cells. CD34+cells from healthy donors (B), hyperthyroid patients (C), and hypothyroid patients (D) were stained with
anti-TRα-1 antibody (pseudo-colored red). Cell nuclei (A-D) are visualized with DAPI (pseudo-colored blue) [21].
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parallel. Although thyroid hormones are required for normal development and differentiation
of many cell types, little is known about their role in physiologic erythropoiesis, especially in
humans [4]. On one side, hyperthyroidism induced in experimental laboratory animals or in
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are evidences that THs may increase the concentration of 2,3-diphosphoglycerate in erythro‐
cytes, which serves to enhance the delivery of oxygen to tissues, and thus affects steady-state
levels of circulating EPO [32-33]. Interestingly, in vitro studies confirmed that both T4 and T3
stimulate EPO synthesis in the human liver cell line HepG2 and this stimulating effect could
persist for 24 hours after the removal of THs from the cell culture [34]. However, in the
established model of HSPCs cultures in vitro with standard amount of EPO performed for
analysis of differential clonogenic growth of hematopoietic cells, we observed that prolifera‐
tive potential of burst-forming units of erythrocytes (BFU-E) was increased only in the samples
collected from the patients with hyperthyroidism and, in contrast, it was decreased in case of
samples collected from the hypothyroid subjects [21]. Therefore, it seems that THs can induce
signal transduction pathways implicated in proliferation of hematopoietic progenitors for
erythroid lineage other than EPO-dependent mechanisms. Data from in the available literature
corroborate our discovery indicating the direct role of THs in normal erythroid differentiation
of human and animal origin [35-38]. For example, daily administration of thyroxine into mice
stimulated the increase of indices significant for RBC production, such as packed red blood
cell volume, total circulating RBC count and mass, and reticulocyte count [39]. Likewise,
Malgor et al. have studied the TH role on modulation of erythropoiesis using the in vitro
cultures of cells collected from bone marrow of normal rats in the absence of EPO [37]. They
found that T3 produced a direct and significant stimulation of clonogenic growth of late
colony-forming erythroid units (CFU-E) and a moderate increase of early erythroid burst-
forming units (BFU-E) indicating an enhanced proliferative activity of committed erythroid
progenitors in response to this hormone. In contrast, the addition of T3 to in vitro cultures of
avian BM cells activates the TRα receptor in avian erythroblasts, blocks their self-renewal, and
induces synchronous, terminal differentiation of erythroid lineage from hematopoietic
progenitor cells [40]. Notwithstanding, Kendrick et al. recently verified the essential function
of TRα in regulating erythropoiesis in mammals by characterizing the phenotype of TRα−/−
mice deficient for TRα. These transgenic mice had significantly reduced numbers of erythroid
progenitor cells in the fetal liver, decreased hematocrit in adult organism, and a diminished
erythroid stress response to hemolytic anemia [41]. Similar results of direct TH influence on
erythroid lineage growth were taken from observations of human erythropoiesis developed
in vitro in established conditions. In pioneer studies of human BM-derived cells and THs action
Golde et al. showed that THs do not shift the requirement for EPO in the course of human
erythropoiesis, but both substances have synergistic effects in increasing the number of
erythroid colonies growing in vitro [35]. These data were corroborated by Leberbauer et al.,
who recently demonstrated that terminal erythroid maturation in course of development of
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human erythroblasts obtained from umbilical cord blood is significantly improved by
supplementation of T3 to the defined culture medium [42]. Likewise, we performed a quan‐
titative molecular analysis of hematopoietic stem/progenitor cell proliferation based on the
expression levels of mRNA for the Cyclin D1 and PCNA genes, which are concerned to be
important for the cell cycle regulation. We found in our study, the nearly 100% increase in
expression of mRNA for both analyzed genes in PB-derived CD34+-enriched HSPCs collected
from subjects with hyperthyroidism (Figure 4), thus indicating that THs significantly stimu‐
lates up-regulation of genes involved in the induction of hematopoietic cell proliferation [21].
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time RT-PCR in CD34+cells isolated from PB of patients with hyperthyroidism and healthy donors (Control). The mean
amount of the selected gene transcript (± SD) is expressed in the arbitrary units. P < 0.05. [21]
These molecular data correlate strongly with increased potential of erythroid progenitor cell
growth observed in our study performed on CD34+-enriched HSPCs from PB of patients with
thyroid dysfunction using in vitro proliferation assays [21]. Erythroid BFU-E c lonies culti‐
vated from CD34+cells that were collected from circulating blood of patients with hyperthyr‐
oidism exhibi ed in average a 40% increase f their clonogenic gr wth compared to the healthy
control group (P<0.05). Importantly, in the group of patients with hyperthyroidism comprised
of 25 persons of whom 52% were p tients ith Graves’ d seas  and 48% with toxic nodular
goiter, we also observed a significant increase in the number of mature RBCs in the PB.
Furthermore, RBCs from our cohort possessed increased mean corpuscular volume, but
reduced mean corpuscular hemoglobin concentration and mean hemoglobin mass. These
findings together might indicate that erythroid progenitors that are overproduced in BM of
hyperthyroid patients under the abnormal T3 stimulation would generate mature RBCs
circulating in excess in peripheral blood. However, cellular structure and composition of
circulating RBCs was also affected. Of note, our study group presented the mild increase in
free T3 concentration compared to healthy volunteers who served as control group (2.71±1.14
vs. 6.95±3.13 pg/mL of T3, respectively).
However, there is a few studies with contradictory results investigating the functional effect
of thyroid abnormalities on the RBC counts in peripheral blood. Gianoukakis et al. have
measured the RBCs in 87 hyperthyroid patients with Graves’ disease and 19 healthy subjects.
The average number of RBCs was found to be lower in the 36% of recruited hyperthyroid
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subjects compared to the healthy individuals. Nevertheless, in the group of selected patients
with anemia, the mean EPO levels were significantly higher (P=0.004) than those of the non-
anemic controls [43]. According to other authors, anemia is present in 10 to 25 percent of
patients with hyperthyroidism [15, 44]. This finding may be the result of increased plasma
volume, as reported effect of increased T3 concentration in humans [45] and animal model [39],
but also the result of autoimmune processes leading to anemia in Graves’ disease, such as
pernicious anemia and autoimmune hemolytic anemia, which concurrently may develop [46].
In addition, decreased RBC survival and ineffective erythropoiesis in course of hyperthyroid‐
ism have been described [47-48]. Pancytopenia in the setting of hyperthyroidism has also been
reported in the literature. Most cases of pancytopenia have been associated with Graves’
disease and one case with toxic adenoma, and TH-related stem cell dysfunction has been
suggested there as one possible mechanism among others [49-51]. Likewise, our group
observed that heavily non-physiological concentrations of T3, such as ten times higher or fifty
times higher than physiological concentration of free T3 significantly negatively influenced
the in vitro growth of erythroid BFU-E colonies in proliferation assays derived from human
CD34+HSPCs circulating in peripheral blood. This effect was even more noticeable after
prolonged exposure to increased non-physiological T3 amounts [20]. This may explain the
abnormalities in RBC counts observed in some patients with hyperthyroidism, especially those
with advanced and chronic disease. In contrast, the in vitro clonogenic potential of erythroid
BFU-E progenitors was considerably increased in physiological concentration of free T3 as well
as in mildly increased concentration of T3 such as five times higher than normal physiological
one [21]. The mean numbers of the colonies of erythroid BFU-E obtained in our study are
presented in Table 1.
Free T3 concentration N 5xN 10xN 50xN
Parameter Incubation % % % %
Growth of BFU-E from BM 24 hours 100.00 103.5 ± 30.7 85.6 ± 29.1 70.6 ± 54.4
72 hours 100.00 108.9 ± 43.9 88.25 ± 46,9 49.2 ± 18.2*
Growth of BFU-E from PB 24 hours 100.00 114.0 ± 42.9* 104.0 ± 20.2 65.0 ± 12.2*
72 hours 100.00 101.0 ± 50.3 63.0 ± 36.2 59.0 ± 13.9*
Growth of BFU-E from CB 24 hours 100.00 94.9 ± 32.2 88.8 ± 39.2 58.0 ± 31.9
72 hours 100.00 90.5 ± 18.9 66.5 ± 11.6* 46.9 ± 14.5*
Table 1. Influence of T3 on clonogenicity of human BFU-E after 24-and 72-hour incubation with increasing free T3
concentrations. Cells (n=5) incubated with: N=physiological dose of T3 (3.7 pg/mL); 5×N=five times higher than N;
10×N=10 times higher than N; 50×N=50 times higher than N. Results are expressed as mean percentage (± SD) of the
control value obtained with established physiological dose of T3 taken as 100%. P < 0.05 [20].
2.2.2. Leukopoiesis
Leukopoiesis is the process of white blood cells (WBCs) formation from hematopoietic stem
cells placed in hematopoietic organs. Leukocytes are a heterogeneous group of blood cells that
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human erythroblasts obtained from umbilical cord blood is significantly improved by
supplementation of T3 to the defined culture medium [42]. Likewise, we performed a quan‐
titative molecular analysis of hematopoietic stem/progenitor cell proliferation based on the
expression levels of mRNA for the Cyclin D1 and PCNA genes, which are concerned to be
important for the cell cycle regulation. We found in our study, the nearly 100% increase in
expression of mRNA for both analyzed genes in PB-derived CD34+-enriched HSPCs collected
from subjects with hyperthyroidism (Figure 4), thus indicating that THs significantly stimu‐
lates up-regulation of genes involved in the induction of hematopoietic cell proliferation [21].
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These molecular data correlate strongly with increased potential of erythroid progenitor cell
growth observed in our study performed on CD34+-enriched HSPCs from PB of patients with
thyroid dysfunction using in vitro proliferation assays [21]. Erythroid BFU-E c lonies culti‐
vated from CD34+cells that were collected from circulating blood of patients with hyperthyr‐
oidism exhibi ed in average a 40% increase f their clonogenic gr wth compared to the healthy
control group (P<0.05). Importantly, in the group of patients with hyperthyroidism comprised
of 25 persons of whom 52% were p tients ith Graves’ d seas  and 48% with toxic nodular
goiter, we also observed a significant increase in the number of mature RBCs in the PB.
Furthermore, RBCs from our cohort possessed increased mean corpuscular volume, but
reduced mean corpuscular hemoglobin concentration and mean hemoglobin mass. These
findings together might indicate that erythroid progenitors that are overproduced in BM of
hyperthyroid patients under the abnormal T3 stimulation would generate mature RBCs
circulating in excess in peripheral blood. However, cellular structure and composition of
circulating RBCs was also affected. Of note, our study group presented the mild increase in
free T3 concentration compared to healthy volunteers who served as control group (2.71±1.14
vs. 6.95±3.13 pg/mL of T3, respectively).
However, there is a few studies with contradictory results investigating the functional effect
of thyroid abnormalities on the RBC counts in peripheral blood. Gianoukakis et al. have
measured the RBCs in 87 hyperthyroid patients with Graves’ disease and 19 healthy subjects.
The average number of RBCs was found to be lower in the 36% of recruited hyperthyroid
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subjects compared to the healthy individuals. Nevertheless, in the group of selected patients
with anemia, the mean EPO levels were significantly higher (P=0.004) than those of the non-
anemic controls [43]. According to other authors, anemia is present in 10 to 25 percent of
patients with hyperthyroidism [15, 44]. This finding may be the result of increased plasma
volume, as reported effect of increased T3 concentration in humans [45] and animal model [39],
but also the result of autoimmune processes leading to anemia in Graves’ disease, such as
pernicious anemia and autoimmune hemolytic anemia, which concurrently may develop [46].
In addition, decreased RBC survival and ineffective erythropoiesis in course of hyperthyroid‐
ism have been described [47-48]. Pancytopenia in the setting of hyperthyroidism has also been
reported in the literature. Most cases of pancytopenia have been associated with Graves’
disease and one case with toxic adenoma, and TH-related stem cell dysfunction has been
suggested there as one possible mechanism among others [49-51]. Likewise, our group
observed that heavily non-physiological concentrations of T3, such as ten times higher or fifty
times higher than physiological concentration of free T3 significantly negatively influenced
the in vitro growth of erythroid BFU-E colonies in proliferation assays derived from human
CD34+HSPCs circulating in peripheral blood. This effect was even more noticeable after
prolonged exposure to increased non-physiological T3 amounts [20]. This may explain the
abnormalities in RBC counts observed in some patients with hyperthyroidism, especially those
with advanced and chronic disease. In contrast, the in vitro clonogenic potential of erythroid
BFU-E progenitors was considerably increased in physiological concentration of free T3 as well
as in mildly increased concentration of T3 such as five times higher than normal physiological
one [21]. The mean numbers of the colonies of erythroid BFU-E obtained in our study are
presented in Table 1.
Free T3 concentration N 5xN 10xN 50xN
Parameter Incubation % % % %
Growth of BFU-E from BM 24 hours 100.00 103.5 ± 30.7 85.6 ± 29.1 70.6 ± 54.4
72 hours 100.00 108.9 ± 43.9 88.25 ± 46,9 49.2 ± 18.2*
Growth of BFU-E from PB 24 hours 100.00 114.0 ± 42.9* 104.0 ± 20.2 65.0 ± 12.2*
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Growth of BFU-E from CB 24 hours 100.00 94.9 ± 32.2 88.8 ± 39.2 58.0 ± 31.9
72 hours 100.00 90.5 ± 18.9 66.5 ± 11.6* 46.9 ± 14.5*
Table 1. Influence of T3 on clonogenicity of human BFU-E after 24-and 72-hour incubation with increasing free T3
concentrations. Cells (n=5) incubated with: N=physiological dose of T3 (3.7 pg/mL); 5×N=five times higher than N;
10×N=10 times higher than N; 50×N=50 times higher than N. Results are expressed as mean percentage (± SD) of the
control value obtained with established physiological dose of T3 taken as 100%. P < 0.05 [20].
2.2.2. Leukopoiesis
Leukopoiesis is the process of white blood cells (WBCs) formation from hematopoietic stem
cells placed in hematopoietic organs. Leukocytes are a heterogeneous group of blood cells that
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all have nuclei and include granulocytes (i.e. neutrophils, eosinophils, and basophils),
monocytes, lymphocytes T and B, as well as natural killer cells. Leukopoiesis is stimulated by
different cytokines, interleukins, colony-stimulating factors and several hormones. The body
of information on the relationship between thyroid hormones and WBC biology is relatively
large and describes contribution of thyroid hormones to the modulation of physiological
leukocyte activities such as chemotaxis, phagocytosis, respiratory burst, cytolytic activity, and
cytokine synthesis in monocytes/macrophages and different types of lymphocytes. Neverthe‐
less, the data available are frequently difficult to interpret or even contradictory, when related
to growth and proliferation of specific leukocyte types. This situation is even more complicated
by the fact, that WBCs are able to produce several hormones or hormone-like molecules [52],
and the expression of thyroid hormones has been reported in several WBCs, like monocytes,
granulocytes, natural killer cells, mast cells, and lymphocytes [53-54]. It is also known that T3
is able to modulate functions of immune-related cells either via nuclear receptors that are
responsible for genomic TH activities, and by interactions with other membrane receptors for
THs that conduct non-genomic actions of THs [1].
In general, it was found that physiological concentrations of thyroid hormones positively
correlates with the immune cell parameters/functions, such as cell counts and induction of
different physiological activities of particular WBC populations. Few reports analyzing the in
vitro actions of THs showed modifications in lymphocyte reactivity [55-56]. However, the
direction and magnitude of these alterations might depend on the type and concentration of
the TH encountered by the responding cells, and the species source of lymphoid cells. For
example, it was found that THs within the normal physiological range may increase a mitogen-
induced normal T lymphocytes proliferation through both the genomic and non-genomic
mechanisms [57]. Furthermore, Hodkinson et al. measured plasma thyroid hormone levels in
93 late-middle aged healthy euthyroid subjects, and calculated the mean T3/T4 ratio, and next
used these numbers to distinguish between low-and high-thyroid hormones concentration,
but still within the normal physiological range, and found a significant positive association
between thyroid hormones concentration and natural killer T-cell percentage and monocytes
count [58]. In addition, in the same study there was also a significant inverse association of
THs levels with the expression of early lymphocyte apoptosis markers [58]. Recently, it has
been proposed that thyroid hormones are significant for leukopoesis as highly involved in
maintaining immune system homeostasis in response to environmental changes or stress-
mediated immunosuppression [59]. Further evidences from studies on mammals indicate that
thyroid hormones have important immunomodulatory effects. Likewise, T3 enhances
phytohaemagglutinin stimulation of human lymphocytes [60]. Concurrently, El-Shaikh et al.
have shown that the daily subcutaneous supplementation of T4 in BALB/c mice for one month
induces an increase in the total number of peripheral blood leukocytes, as well as augments
cellularity of thymus and spleen parenchyma, and peripheral lymph nodes [61]. In general,
developed hyperthyroid state induces the increase in the immune system functions related to
the antibody production, immune cell migration, and reactive oxygen species production,
whereas it decreases the proinflammatory markers expression, the antioxidant enzymes
production, and their cellular activity [62]. Notwithstanding, in other in vivo study performed
Thyroid Disorders - Focus on Hyperthyroidism190
in rats, the induction of hyperthyroidism did not affect the ratio of helper to suppressor T
lymphocytes in the examined immune system [63].
Due to the contrasting results revealed in some previous reports, it is quite difficult to establish
a clear correlation between hyperthyroidism and immune functions [62]. These discrepancies
may be largely attributed to differences in the duration of disease, age and gender of animal
and human subjects and hyperthyroidism origin, or even the treatment mode given to the
patients with thyroid disease. Especially, previous studies on human different WBC popula‐
tion counts and function during hypo-and hyperthyroid states produced conflicting results.
Indeed, a significant decrease in the lymphocyte and increase in monocyte count were
observed in patients with autoimmune thyroiditis [64], however, similar changes in the
number of lymphocytes were also observed in autoimmune hyperthyroidism [65]. Thus, it is
supposed that the changes in number of lymphocytes in different thyroid autoimmune
dysfunctions are due to the autoimmune process alone, and not due to the direct influence of
thyroid hormones specifically on lymphopoiesis. Possibly, the elevated number of lympho‐
cytes in autoimmune-related thyroid disorders may demonstrate a nonspecific activation of
the immune system as it is found in some other autoimmune-derived diseases in humans
[66-67]. Our own results performed in the selected group of patients with hyperthyroidism
showed a tendency to decrease the general WBC number in circulating peripheral blood. Thus,
we were mostly interested in biology of hematopoietic stem and progenitor cells of myelo‐
monocytic lineage from these subjects, as appeared that this lineage may be clearly independ‐
ent from autoimmune responses developed in this patient group and might be affected by
abnormal THs concentration. It appears from the available literature that the relationship
between thyroid hormones and myelopoiesis has been studied mainly based on hematopoietic
cells collected from peripheral blood of healthy subjects. Unfortunately, the current knowledge
concerning the influence of THs on clonogenicity of progenitors for granulocytes and mono‐
cytes that grown as colony forming units of granulocytes and monocytes (CFU-GM) is very
limited. There are only few reports on the influence of physiological T3 concentration on
clonogenic potential of human CFU-GM cells. For example, Notario et al. observed that both
thyroid hormones, T3 and T4, are able to enhance the colony growth of CFU-GM obtained
from normal PB, and interestingly, the response is more evident for T4 than T3 [68]. Moreover,
the second report of this group revealed that there is a synergistic effect of THs and different
hematopoietic growth factors, like G-CSF, GM-CSF, and IL-3, which are substantial for
proliferation of progenitors for myelomonocytic lineage [69]. In contrast, Ponassi et al. reported
an abnormal granulopoiesis in nearly 50 percent of patients with untreated Graves' disease,
based on the pharmacological test with mobilization of the marrow granulocyte reserve by
hydrocortisone [70]. However, no data on clonogenic potential of hematopoietic progenitor
cells in the presence of different nonphysiological concentrations of thyroid hormones were
reported in either of these studies. Therefore, our group recently analyzed the in vitro growth
of myeloid CFU-GM colonies derived from human CD34+HSPCs in proliferation assays with
growing non-physiological concentrations of free T3. We observed that clonogenic potential
of CFU-GM colonies from CD34+HSPCs of healthy subjects was considerably increased in
concentration of T3 only moderately higher (5x) than the physiological T3 concentration [20].
In contrast, the much higher non-physiological concentrations of T3, such as ten times higher
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In general, it was found that physiological concentrations of thyroid hormones positively
correlates with the immune cell parameters/functions, such as cell counts and induction of
different physiological activities of particular WBC populations. Few reports analyzing the in
vitro actions of THs showed modifications in lymphocyte reactivity [55-56]. However, the
direction and magnitude of these alterations might depend on the type and concentration of
the TH encountered by the responding cells, and the species source of lymphoid cells. For
example, it was found that THs within the normal physiological range may increase a mitogen-
induced normal T lymphocytes proliferation through both the genomic and non-genomic
mechanisms [57]. Furthermore, Hodkinson et al. measured plasma thyroid hormone levels in
93 late-middle aged healthy euthyroid subjects, and calculated the mean T3/T4 ratio, and next
used these numbers to distinguish between low-and high-thyroid hormones concentration,
but still within the normal physiological range, and found a significant positive association
between thyroid hormones concentration and natural killer T-cell percentage and monocytes
count [58]. In addition, in the same study there was also a significant inverse association of
THs levels with the expression of early lymphocyte apoptosis markers [58]. Recently, it has
been proposed that thyroid hormones are significant for leukopoesis as highly involved in
maintaining immune system homeostasis in response to environmental changes or stress-
mediated immunosuppression [59]. Further evidences from studies on mammals indicate that
thyroid hormones have important immunomodulatory effects. Likewise, T3 enhances
phytohaemagglutinin stimulation of human lymphocytes [60]. Concurrently, El-Shaikh et al.
have shown that the daily subcutaneous supplementation of T4 in BALB/c mice for one month
induces an increase in the total number of peripheral blood leukocytes, as well as augments
cellularity of thymus and spleen parenchyma, and peripheral lymph nodes [61]. In general,
developed hyperthyroid state induces the increase in the immune system functions related to
the antibody production, immune cell migration, and reactive oxygen species production,
whereas it decreases the proinflammatory markers expression, the antioxidant enzymes
production, and their cellular activity [62]. Notwithstanding, in other in vivo study performed
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in rats, the induction of hyperthyroidism did not affect the ratio of helper to suppressor T
lymphocytes in the examined immune system [63].
Due to the contrasting results revealed in some previous reports, it is quite difficult to establish
a clear correlation between hyperthyroidism and immune functions [62]. These discrepancies
may be largely attributed to differences in the duration of disease, age and gender of animal
and human subjects and hyperthyroidism origin, or even the treatment mode given to the
patients with thyroid disease. Especially, previous studies on human different WBC popula‐
tion counts and function during hypo-and hyperthyroid states produced conflicting results.
Indeed, a significant decrease in the lymphocyte and increase in monocyte count were
observed in patients with autoimmune thyroiditis [64], however, similar changes in the
number of lymphocytes were also observed in autoimmune hyperthyroidism [65]. Thus, it is
supposed that the changes in number of lymphocytes in different thyroid autoimmune
dysfunctions are due to the autoimmune process alone, and not due to the direct influence of
thyroid hormones specifically on lymphopoiesis. Possibly, the elevated number of lympho‐
cytes in autoimmune-related thyroid disorders may demonstrate a nonspecific activation of
the immune system as it is found in some other autoimmune-derived diseases in humans
[66-67]. Our own results performed in the selected group of patients with hyperthyroidism
showed a tendency to decrease the general WBC number in circulating peripheral blood. Thus,
we were mostly interested in biology of hematopoietic stem and progenitor cells of myelo‐
monocytic lineage from these subjects, as appeared that this lineage may be clearly independ‐
ent from autoimmune responses developed in this patient group and might be affected by
abnormal THs concentration. It appears from the available literature that the relationship
between thyroid hormones and myelopoiesis has been studied mainly based on hematopoietic
cells collected from peripheral blood of healthy subjects. Unfortunately, the current knowledge
concerning the influence of THs on clonogenicity of progenitors for granulocytes and mono‐
cytes that grown as colony forming units of granulocytes and monocytes (CFU-GM) is very
limited. There are only few reports on the influence of physiological T3 concentration on
clonogenic potential of human CFU-GM cells. For example, Notario et al. observed that both
thyroid hormones, T3 and T4, are able to enhance the colony growth of CFU-GM obtained
from normal PB, and interestingly, the response is more evident for T4 than T3 [68]. Moreover,
the second report of this group revealed that there is a synergistic effect of THs and different
hematopoietic growth factors, like G-CSF, GM-CSF, and IL-3, which are substantial for
proliferation of progenitors for myelomonocytic lineage [69]. In contrast, Ponassi et al. reported
an abnormal granulopoiesis in nearly 50 percent of patients with untreated Graves' disease,
based on the pharmacological test with mobilization of the marrow granulocyte reserve by
hydrocortisone [70]. However, no data on clonogenic potential of hematopoietic progenitor
cells in the presence of different nonphysiological concentrations of thyroid hormones were
reported in either of these studies. Therefore, our group recently analyzed the in vitro growth
of myeloid CFU-GM colonies derived from human CD34+HSPCs in proliferation assays with
growing non-physiological concentrations of free T3. We observed that clonogenic potential
of CFU-GM colonies from CD34+HSPCs of healthy subjects was considerably increased in
concentration of T3 only moderately higher (5x) than the physiological T3 concentration [20].
In contrast, the much higher non-physiological concentrations of T3, such as ten times higher
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or fifty times higher than physiological T3 concentration significantly negatively influenced
the growth of myeloid CFU-GM colonies derived from CD34+HSPCs collected from peripheral
blood as well as umbilical cord blood. This effect was even more significant in case of myeloid
CFU-GM colonies derived from CD34+HSPCs harvested from the bone marrow of healthy
donors [20]. In addition, we noticed an enhanced negative effects of non-physiological
concentrations of T3 in the case of prolonged in vitro exposure to the triiodothyronine (72-
hour-period). The mean numbers of the colonies of myeloid CFU-GM obtained in our study
are presented in Table 2.
Free T3 concentration N 5xN 10xN 50xN
Parameter Incubation % % % %
Growth of CFU-GM from BM 24 hours 100.00 77.8 ± 19.6* 72.6 ± 18.7* 50.1 ± 8.7
72 hours 100.00 91.0 ± 36.7 97.2 ± 47,7 49.2 ± 18.2*
Growth of CFU-GM from PB 24 hours 100.00 154.0 ± 18.7* 101.0 ± 14.5 90.0 ± 35.8*
72 hours 100.00 292.0 ± 26.6* 205.0 ± 17.5* 141.0 ± 29.4*
Growth of CFU-GM from CB 24 hours 100.00 106.3 ± 28.4 92.7 ± 11.6 93.8 ± 35.7
72 hours 100.00 96.1 ± 16.2 65.1 ± 9.9 55.9 ± 7.5
Table 2. Influence of T3 on clonogenicity of human CFU-GM after 24-and 72-hour incubation with increasing free T3
concentrations. Cells (n=5) incubated with: N=physiological dose of T3 (3.7 pg/mL); 5×N=five times higher than N;
10×N=10 times higher than N; 50×N=50 times higher than N. Results are expressed as mean percentage (± SD) of the
control value obtained with established physiological dose of T3 taken as 100%. P < 0.05 [20].
The abovementioned results clearly correlated with clonogenic potential of CD34+-enriched
HSPCs collected from subjects with diagnosed thyroid dysfunction [21]. In our clinical study,
we examined the clonogenicity of CD34+HSPCs harvested from PB of hyperthyroid patients
using the in vitro proliferation assays, and we found that the number of CD34+-expanded CFU-
GM colonies was significantly lower in this group than that observed in healthy euthyroid
subjects (66 vs. 100% respectively; P < 0.05).
One of the possible explanations for the diminished clonogenic growth of CFU-GM derived
from hyperthyroid patients might be the TH-dependent cell death induced in circulating
and BM residual HSPCs. Cell death has been broadly classified into two categories, necrosis
and apoptosis. Of note, there is ongoing debate as to the mutually exclusive nature of these
two  categories  of  cell  death,  and  it  seems  possible  that  there  are  many  intermediate
subcategories.  However,  necrotic  cell  death  is  always  a  pathological  event  occurring  in
response to strong cell/tissue injury or environmental  insult.  In contrast,  apoptosis is  an
energy-requiring process that often involves altered expression of key cell proliferation and
death-inducing  genes.  It  is  known that  THs,  like  many other  hormones  acting  through
nuclear receptors, are important regulators of cellular proliferation and apoptosis [71-72].
At the cellular level, both T3 and T4 induce apoptosis in different cell types, like rat pituitary
cell lines [73-74], rat cardiomyocytes [75], and human breast cancer cells [76], when exposed
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to THs in vitro or in vivo. It was observed that in HeLa cervix cancer cell line T3 indu‐
ces caspase activity, which plays a key role in the execution of apoptosis [77]. In contrast,
the  physiological  concentrations  of  both  T3  and  T4  inhibited  apoptosis  in  rat  brain-
derived  endothelial  cells  in  vitro  through  alterations  in  the  mRNA levels  of  apoptosis-
related genes, such as BCL-2 and BAD [78]. T4 was able to inhibit the resveratrol-induced
apoptosis  in  glioma cells  in  vitro  through nongenomic  mechanisms,  employing integrin
receptor  and ERK-mediated cascade [79].  Alike,  previously  mentioned Hodkinson et  al.
observed that under normal physiological conditions T3 reduced incidence of lymphocyte
apoptosis in healthy older individuals [58]. Similarly, Barreiro Arcos et al. observed, that
TH treatment augments the mitogen-induced proliferation of normal T lymphocytes [80].
Altogether, TH-mediated effects on cellular apoptosis depend on the type and developmen‐
tal or pathophysiological state of the selected cells and tissues. Importantly, there are many
compounds and circumstances that can induce cell apoptosis. It is known that a particu‐
lar agent may produce apoptosis in a given cell or tissue, but may not in another, or in a
given cell at one period of the cell cycle, but not at another. Whether a cell responds to
such an agent by induction of  programmed cell  death,  it  must therefore depend on the
specific array of interactive molecular regulatory systems active in that cell at that time [81].
In  case  of  cells  related  to  hematopoietic  system,  the  pro-apoptotic  actions  of  THs were
defined in normal and tumor-derived lymphocytes. In this notion, Mihara et al. demonstrat‐
ed that T lymphoma cells from the human Jurkat cell line, cultured in vitro for 2 weeks
with addition of T3 and T4, showed their enhanced apoptosis [82]. This group also showed
that T lymphocytes from healthy volunteers cultured with T3,  but not T4,  for five days
exhibited an increase in the percent of spontaneous apoptosis,  thus indicating that long-
term exposure to T3 induces accelerated lymphocyte apoptosis in vitro [82]. Indeed, Mihara
and coworkers found also significantly higher percentage of apoptotic T lymphocytes in
vivo  from patients  with  chronic  Graves’  disease  than from healthy  subjects  [82].  More‐
over, Gandrillon et al. determined that THs increased apoptosis rate in early erythrocytic
progenitor cells [83], and similar effect was observed by Hara et al. in hematopoietic HL-60
cells of promyeloleukemic lineage [84]. To put the light on the possible pathophysiologi‐
cal  mechanisms  of  such  decreased  proliferative  potential  of  CD34+HSPCs  in  high  non-
physiological  T3  concentrations  reported  by  our  group,  we  analyzed  the  process  of
apoptosis in HSPCs collected from different compartments of human hematopoietic system,
such as  bone  marrow,  peripheral  blood or  umbilical  cord blood [20].  In  our  study,  we
performed the analysis of potential influence of T3 on the apoptosis induction in human
CD34+-enriched hematopoietic progenitor cells collected from the above hematopoietic cell
sources of healthy subjects. Importantly, we analyzed the apoptosis in these cells employ‐
ing three different molecular techniques as, according to specialists in this field, it is crucial
for reliable detection of this phenomenon to confirm it by applying at least three distinct
laboratory methods. For this reason, we used the flow cytometry-based detection of annexin-
V, TUNEL technique detecting apoptosis-related abnormalities in cell genetic material, and
finally,  analysis of the expression level of pro-apoptotic Bax  and both anti-apoptotic Bcl-
xL and Bcl-2 genes in the CD34+HSPCs that were incubated with different non-physiologi‐
cal T3 concentrations (5×N; 10×N; and 50×N; where N is equal to established physiological
Hematopoiesis Dysfunction Associated with Abnormal Thyroid Hormones Production
http://dx.doi.org/10.5772/58531
193
or fifty times higher than physiological T3 concentration significantly negatively influenced
the growth of myeloid CFU-GM colonies derived from CD34+HSPCs collected from peripheral
blood as well as umbilical cord blood. This effect was even more significant in case of myeloid
CFU-GM colonies derived from CD34+HSPCs harvested from the bone marrow of healthy
donors [20]. In addition, we noticed an enhanced negative effects of non-physiological
concentrations of T3 in the case of prolonged in vitro exposure to the triiodothyronine (72-
hour-period). The mean numbers of the colonies of myeloid CFU-GM obtained in our study
are presented in Table 2.
Free T3 concentration N 5xN 10xN 50xN
Parameter Incubation % % % %
Growth of CFU-GM from BM 24 hours 100.00 77.8 ± 19.6* 72.6 ± 18.7* 50.1 ± 8.7
72 hours 100.00 91.0 ± 36.7 97.2 ± 47,7 49.2 ± 18.2*
Growth of CFU-GM from PB 24 hours 100.00 154.0 ± 18.7* 101.0 ± 14.5 90.0 ± 35.8*
72 hours 100.00 292.0 ± 26.6* 205.0 ± 17.5* 141.0 ± 29.4*
Growth of CFU-GM from CB 24 hours 100.00 106.3 ± 28.4 92.7 ± 11.6 93.8 ± 35.7
72 hours 100.00 96.1 ± 16.2 65.1 ± 9.9 55.9 ± 7.5
Table 2. Influence of T3 on clonogenicity of human CFU-GM after 24-and 72-hour incubation with increasing free T3
concentrations. Cells (n=5) incubated with: N=physiological dose of T3 (3.7 pg/mL); 5×N=five times higher than N;
10×N=10 times higher than N; 50×N=50 times higher than N. Results are expressed as mean percentage (± SD) of the
control value obtained with established physiological dose of T3 taken as 100%. P < 0.05 [20].
The abovementioned results clearly correlated with clonogenic potential of CD34+-enriched
HSPCs collected from subjects with diagnosed thyroid dysfunction [21]. In our clinical study,
we examined the clonogenicity of CD34+HSPCs harvested from PB of hyperthyroid patients
using the in vitro proliferation assays, and we found that the number of CD34+-expanded CFU-
GM colonies was significantly lower in this group than that observed in healthy euthyroid
subjects (66 vs. 100% respectively; P < 0.05).
One of the possible explanations for the diminished clonogenic growth of CFU-GM derived
from hyperthyroid patients might be the TH-dependent cell death induced in circulating
and BM residual HSPCs. Cell death has been broadly classified into two categories, necrosis
and apoptosis. Of note, there is ongoing debate as to the mutually exclusive nature of these
two  categories  of  cell  death,  and  it  seems  possible  that  there  are  many  intermediate
subcategories.  However,  necrotic  cell  death  is  always  a  pathological  event  occurring  in
response to strong cell/tissue injury or environmental  insult.  In contrast,  apoptosis is  an
energy-requiring process that often involves altered expression of key cell proliferation and
death-inducing  genes.  It  is  known that  THs,  like  many other  hormones  acting  through
nuclear receptors, are important regulators of cellular proliferation and apoptosis [71-72].
At the cellular level, both T3 and T4 induce apoptosis in different cell types, like rat pituitary
cell lines [73-74], rat cardiomyocytes [75], and human breast cancer cells [76], when exposed
Thyroid Disorders - Focus on Hyperthyroidism192
to THs in vitro or in vivo. It was observed that in HeLa cervix cancer cell line T3 indu‐
ces caspase activity, which plays a key role in the execution of apoptosis [77]. In contrast,
the  physiological  concentrations  of  both  T3  and  T4  inhibited  apoptosis  in  rat  brain-
derived  endothelial  cells  in  vitro  through  alterations  in  the  mRNA levels  of  apoptosis-
related genes, such as BCL-2 and BAD [78]. T4 was able to inhibit the resveratrol-induced
apoptosis  in  glioma cells  in  vitro  through nongenomic  mechanisms,  employing integrin
receptor  and ERK-mediated cascade [79].  Alike,  previously  mentioned Hodkinson et  al.
observed that under normal physiological conditions T3 reduced incidence of lymphocyte
apoptosis in healthy older individuals [58]. Similarly, Barreiro Arcos et al. observed, that
TH treatment augments the mitogen-induced proliferation of normal T lymphocytes [80].
Altogether, TH-mediated effects on cellular apoptosis depend on the type and developmen‐
tal or pathophysiological state of the selected cells and tissues. Importantly, there are many
compounds and circumstances that can induce cell apoptosis. It is known that a particu‐
lar agent may produce apoptosis in a given cell or tissue, but may not in another, or in a
given cell at one period of the cell cycle, but not at another. Whether a cell responds to
such an agent by induction of  programmed cell  death,  it  must therefore depend on the
specific array of interactive molecular regulatory systems active in that cell at that time [81].
In  case  of  cells  related  to  hematopoietic  system,  the  pro-apoptotic  actions  of  THs were
defined in normal and tumor-derived lymphocytes. In this notion, Mihara et al. demonstrat‐
ed that T lymphoma cells from the human Jurkat cell line, cultured in vitro for 2 weeks
with addition of T3 and T4, showed their enhanced apoptosis [82]. This group also showed
that T lymphocytes from healthy volunteers cultured with T3,  but not T4,  for five days
exhibited an increase in the percent of spontaneous apoptosis,  thus indicating that long-
term exposure to T3 induces accelerated lymphocyte apoptosis in vitro [82]. Indeed, Mihara
and coworkers found also significantly higher percentage of apoptotic T lymphocytes in
vivo  from patients  with  chronic  Graves’  disease  than from healthy  subjects  [82].  More‐
over, Gandrillon et al. determined that THs increased apoptosis rate in early erythrocytic
progenitor cells [83], and similar effect was observed by Hara et al. in hematopoietic HL-60
cells of promyeloleukemic lineage [84]. To put the light on the possible pathophysiologi‐
cal  mechanisms  of  such  decreased  proliferative  potential  of  CD34+HSPCs  in  high  non-
physiological  T3  concentrations  reported  by  our  group,  we  analyzed  the  process  of
apoptosis in HSPCs collected from different compartments of human hematopoietic system,
such as  bone  marrow,  peripheral  blood or  umbilical  cord blood [20].  In  our  study,  we
performed the analysis of potential influence of T3 on the apoptosis induction in human
CD34+-enriched hematopoietic progenitor cells collected from the above hematopoietic cell
sources of healthy subjects. Importantly, we analyzed the apoptosis in these cells employ‐
ing three different molecular techniques as, according to specialists in this field, it is crucial
for reliable detection of this phenomenon to confirm it by applying at least three distinct
laboratory methods. For this reason, we used the flow cytometry-based detection of annexin-
V, TUNEL technique detecting apoptosis-related abnormalities in cell genetic material, and
finally,  analysis of the expression level of pro-apoptotic Bax  and both anti-apoptotic Bcl-
xL and Bcl-2 genes in the CD34+HSPCs that were incubated with different non-physiologi‐
cal T3 concentrations (5×N; 10×N; and 50×N; where N is equal to established physiological
Hematopoiesis Dysfunction Associated with Abnormal Thyroid Hormones Production
http://dx.doi.org/10.5772/58531
193
T3 dose) for period of 24 or 72 hours. We found that after 24 hours all  three used non-
physiological T3 concentrations markedly induced the apoptosis in analyzes hematopoiet‐
ic progenitors, however the percentage of apoptotic CD34+HSPCs was significantly higher
in samples collected from PB, CB and BM incubated with the highest dose [20].  Similar
results were obtained for longer incubation through 72-hour-period. It was especially clearly
noticeable in the detailed analysis of the apoptosis detected by TUNEL technique present‐
ed in Table 3. Correspondingly, when analyzing the mRNA expression for genes crucial
for  apoptosis  in  human  early  hematopoietic  CD34+cells  after  incubation  with  the  fixed
increasing T3 concentrations, we observed an augmented expression of pro-apoptotic BAX
gene and decreased expression of the anti-apoptotic genes: BCL-xL and BCL-2 in these cells
under  exposure  to  T3  amount  50  times  higher  than  the  established  physiological  T3
concentration [20].
Free T3 concentration N 5xN 10xN 50xN
Parameter Time % % % %
Apoptotic CD34+ HSPCs from BM 24 hours 100.00 144.5 ± 39.4* 94.3 ± 33.9 87.4 ± 47.6
72 hours 100.00 179.0 ± 25.5* 107.3 ± 9,6 119.1 ± 11.0*
Apoptotic CD34+ HSPCs from PB 24 hours 100.00 115.1 ± 20.5 166.6 ± 31.7* 98.8 ± 20.4
72 hours 100.00 105.3 ± 36.5 122.5 ± 17.8* 125.1 ± 16.1*
Apoptotic CD34+ HSPCs from CB 24 hours 100.00 105.3 ± 36.5 122.5 ± 47.8 105.1 ± 26.1
72 hours 100.00 167.8 ± 6.9* 177.4 ± 34.6* 213.6 ± 32.0*
Table 3. Percentage of apoptotic cells detected with the established TUNEL method after 24-and 72-hour incubation
of human CD34+cells with increasing free T3 concentrations. Cells (n=5) incubated with: N=physiological dose of T3
(3.7 pg/mL); 5×N=five times higher than N; 10×N=10 times higher than N; 50×N=50 times higher than N. Results are
expressed as mean percentage (± SD) of the control value obtained with established physiological dose of T3 taken as
100%. P < 0.05 [20].
Our group was also interested to assess the influence of THs on apoptosis rate in PB-derived
CD34+HSPCs circulating in peripheral blood of the patients with hyperthyroidism [21]. For
this analysis, we used combined annexin-V and propidium iodate staining of hematopoietic
cells detected by flow cytometry. This method especially provides the chance to assess
apoptosis in two distinct stages, the early and late phase of apoptosis. In fact, we observed a
significant increase in the percentage of cells undergoing the late, executive phase of apoptosis
in the group of patients with hyperthyroidism compared to euthyroid control subjects (1823.43
± 1334.15 vs. 100% of the control population, respectively; P<0.05). The results are displayed
in Figure 5. However, there were no differences between analyzed groups in percentage of
CD34+cells undergoing the early stage of apoptosis (103.1 ± 74.16 vs. 100% of the control
population, respectively).
Concurrently, expression of mRNA for BCL-2 and BCL-xL genes was assessed by real-time RT-
PCR in CD34+cells isolated from PB of patients with hyperthyroidism and healthy controls.
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We found that both examined anti-apoptotic genes, BCL-2 and BCL-xL, were significantly
down-regulated compared to healthy volunteers (40% and 67% vs. 100% respectively; P<0.05).
In the same manner the expression of BAX gene of pro-apoptotic activity was analyzed.
Interestingly, this gene was also significantly down-regulated compared to control subjects
(36% vs. 100% respectively; P<0.05). The above data strongly correlate with the previously
observed tendency to decrease the clonogenic potential of CD34+hematopoietic stem/progen‐
itor cells of myeloid lineage of hyperthyroid subjects and may indicate that THs at higher
concentrations negatively modulate the expression of genes important for hematopoietic cell
survival, such as anti-apoptotic BCL-2 and BCL-xL genes. On the other side, the parallel
decrease of expression level of pro-apoptotic BAX gene might be related with significant
augmentation of late, executive phase of apoptosis in circulating CD34+cells due to the chronic
exposure to elevated concentrations of T3 found in hyperthyroid patients (Fig. 5). Indeed, BAX
is expressed at high levels during the period when programmed cell death is activated by
intracellular or extracellular stimuli, and down-regulation of the gene expression occurs
thereafter, when signal transduction pathways triggered the performance of apoptotic protein
cascade inside the cell [21].
2.2.3. Thrombocytopoiesis
Thrombocytopoiesis is the process of thrombocyte generation from the cytoplasm of mega‐
karyocytes located in bone marrow hematopoietic niche. Megakaryocyte maturation comes to
completion with the release of thrombocytes, known as platelets, into the bloodstream and
each day an adult produces about 100 billion platelets. They are necessary for normal blood
clotting. Megakaryocytes normally account for 1 out of 10.000 bone marrow cells but their
*  
Figure 5. Percentage of human CD34+-enriched hematopoietic stem/progenitor cells in the late apoptotic stage col‐
lected from hyperthyroid patients. Apoptosis in hematopoietic progenitor cells collected from patients with hyper‐
thyroidism and healthy subjects (Controls) was scored by cytometric detection of annexin-V and propidium iodate.
Results are expressed as mean percentage (± SD) in relation to control values considered as 100%. *P<0.05 vs. con‐
trols. [21]
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T3 dose) for period of 24 or 72 hours. We found that after 24 hours all  three used non-
physiological T3 concentrations markedly induced the apoptosis in analyzes hematopoiet‐
ic progenitors, however the percentage of apoptotic CD34+HSPCs was significantly higher
in samples collected from PB, CB and BM incubated with the highest dose [20].  Similar
results were obtained for longer incubation through 72-hour-period. It was especially clearly
noticeable in the detailed analysis of the apoptosis detected by TUNEL technique present‐
ed in Table 3. Correspondingly, when analyzing the mRNA expression for genes crucial
for  apoptosis  in  human  early  hematopoietic  CD34+cells  after  incubation  with  the  fixed
increasing T3 concentrations, we observed an augmented expression of pro-apoptotic BAX
gene and decreased expression of the anti-apoptotic genes: BCL-xL and BCL-2 in these cells
under  exposure  to  T3  amount  50  times  higher  than  the  established  physiological  T3
concentration [20].
Free T3 concentration N 5xN 10xN 50xN
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Apoptotic CD34+ HSPCs from BM 24 hours 100.00 144.5 ± 39.4* 94.3 ± 33.9 87.4 ± 47.6
72 hours 100.00 179.0 ± 25.5* 107.3 ± 9,6 119.1 ± 11.0*
Apoptotic CD34+ HSPCs from PB 24 hours 100.00 115.1 ± 20.5 166.6 ± 31.7* 98.8 ± 20.4
72 hours 100.00 105.3 ± 36.5 122.5 ± 17.8* 125.1 ± 16.1*
Apoptotic CD34+ HSPCs from CB 24 hours 100.00 105.3 ± 36.5 122.5 ± 47.8 105.1 ± 26.1
72 hours 100.00 167.8 ± 6.9* 177.4 ± 34.6* 213.6 ± 32.0*
Table 3. Percentage of apoptotic cells detected with the established TUNEL method after 24-and 72-hour incubation
of human CD34+cells with increasing free T3 concentrations. Cells (n=5) incubated with: N=physiological dose of T3
(3.7 pg/mL); 5×N=five times higher than N; 10×N=10 times higher than N; 50×N=50 times higher than N. Results are
expressed as mean percentage (± SD) of the control value obtained with established physiological dose of T3 taken as
100%. P < 0.05 [20].
Our group was also interested to assess the influence of THs on apoptosis rate in PB-derived
CD34+HSPCs circulating in peripheral blood of the patients with hyperthyroidism [21]. For
this analysis, we used combined annexin-V and propidium iodate staining of hematopoietic
cells detected by flow cytometry. This method especially provides the chance to assess
apoptosis in two distinct stages, the early and late phase of apoptosis. In fact, we observed a
significant increase in the percentage of cells undergoing the late, executive phase of apoptosis
in the group of patients with hyperthyroidism compared to euthyroid control subjects (1823.43
± 1334.15 vs. 100% of the control population, respectively; P<0.05). The results are displayed
in Figure 5. However, there were no differences between analyzed groups in percentage of
CD34+cells undergoing the early stage of apoptosis (103.1 ± 74.16 vs. 100% of the control
population, respectively).
Concurrently, expression of mRNA for BCL-2 and BCL-xL genes was assessed by real-time RT-
PCR in CD34+cells isolated from PB of patients with hyperthyroidism and healthy controls.
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We found that both examined anti-apoptotic genes, BCL-2 and BCL-xL, were significantly
down-regulated compared to healthy volunteers (40% and 67% vs. 100% respectively; P<0.05).
In the same manner the expression of BAX gene of pro-apoptotic activity was analyzed.
Interestingly, this gene was also significantly down-regulated compared to control subjects
(36% vs. 100% respectively; P<0.05). The above data strongly correlate with the previously
observed tendency to decrease the clonogenic potential of CD34+hematopoietic stem/progen‐
itor cells of myeloid lineage of hyperthyroid subjects and may indicate that THs at higher
concentrations negatively modulate the expression of genes important for hematopoietic cell
survival, such as anti-apoptotic BCL-2 and BCL-xL genes. On the other side, the parallel
decrease of expression level of pro-apoptotic BAX gene might be related with significant
augmentation of late, executive phase of apoptosis in circulating CD34+cells due to the chronic
exposure to elevated concentrations of T3 found in hyperthyroid patients (Fig. 5). Indeed, BAX
is expressed at high levels during the period when programmed cell death is activated by
intracellular or extracellular stimuli, and down-regulation of the gene expression occurs
thereafter, when signal transduction pathways triggered the performance of apoptotic protein
cascade inside the cell [21].
2.2.3. Thrombocytopoiesis
Thrombocytopoiesis is the process of thrombocyte generation from the cytoplasm of mega‐
karyocytes located in bone marrow hematopoietic niche. Megakaryocyte maturation comes to
completion with the release of thrombocytes, known as platelets, into the bloodstream and
each day an adult produces about 100 billion platelets. They are necessary for normal blood
clotting. Megakaryocytes normally account for 1 out of 10.000 bone marrow cells but their
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number can increase or decrease in the course of certain diseases, thus resulting in abnormal
megakaryocyte function and abnormal platelet quantity or function, and this influences
hemostatic system in peripheral blood [85]. In the specialized microenvironment of the bone
marrow the megakaryocyte development and subsequent platelets production is regulated
through a complex crosstalk between many cell types and cytokines. Especially, thrombo‐
poietin was identified as the major regulator of platelet production, however, other biologically
active substances, such as hormones, may play an important role in the regulation of mega‐
karyocyte growth and proliferation [86].
Exactly, one century ago appeared the first report of Kaliebe et al. indicating the clinical
relationship between thyroid disease and the dysfunction in hemostatic system. In 1913 the
authors have described an episode of central vein thrombosis in a thyrotoxic patient and this
medical report was later summarized in 1927 by Doyle, who was studying a possible associ‐
ation between thyrotoxicosis and cerebral vein thrombosis in patients with neurological
symptoms [87]. Likewise, various diseases of hemostatic system, ranging from hemostasis
disorders, and rarely life-threatening hemorrhages to hypercoagulability and thrombotic
events, could be observed in parallel to thyroid gland dysfunctions. However, some contra‐
dictory results regarding hemostatic system functions have been obtained in clinical studies
of patients with thyroid disorders.
Several published reports have shown a hypercoagulable state in patients with hyperthyroid‐
ism [19, 88]. For certain, patients with hyperthyroidism showed a tendency toward thrombo-
embolic process (8–40%), including major emboli at cerebral vasculature, which accounts for
nearly 18% of all deaths associated with thyrotoxicosis [89]. Another systematic analysis also
supports an increased risk of venous thrombotic complications, including cerebral venous
thrombosis, deep vein thrombosis and pulmonary embolism in patients with hyperthyroidism
[90]. Hypercoagulability state that is observed in hyperthyroidism is produced by various
coagulation factor (e.g. clotting factors and their inhibitors) abnormalities that occur in patients
with hyperthyroidism and are not directly related to thrombocytes and thrombocytopoiesis.
Researchers hypothesized that THs may affect the synthesis of many proteins originating from
the liver and endothelium by altering the specific gene expression. Indeed, collected data have
specified that hyperthyroidism, regardless of its etiology, influences endothelial function by
up-regulating the expression levels of vascular adhesion molecules and endothelium-derived
proteins important for fibrinolysis, such as tissue-type plasminogen activator and plasmino‐
gen activator inhibitor-1 [91]. On the other hand, it is known that there is a general increase of
metabolism in hyperthyroid state, which may affect cell components of the peripheral blood
and bone marrow. Likewise, it was found that the life-span of platelets is shortened in patients
with hyperthyroidism resulting in thrombocytopenia [92]. Moreover, the same group ob‐
served that the platelet count increased upon reduction of the concentration of circulating
thyroid hormones [92]. Similar data were obtained by Kurata et al., who showed that the
platelets count are low and their lifespan shorter in almost one-half of 214 studied patients
with Graves’ disease [93]. Notwithstanding, thrombocytopenia in patients with hyperthyr‐
oidism may have several causes, such as autoimmunity against thromobocytes [94-95] in
parallel to nonspecific thyroid antibodies binding to platelets that augment their non-specific
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degradation or due to thrombocyte clearance from plasma by the enhanced phagocytic activity
of the reticuloendothelial system [96]. Finally, detected relative low platelet quantities could
be due to increased circulating blood volume observed in patients with hyperthyroidism, as
in case of other hematologic parameters of blood. Of note, patients with hyperthyroidism had
significantly higher risks of having co-morbidities such as hypertension, hyperlipidemia, and
diabetes that might affect the survival of platelets and their bone marrow progenitors.
Although the pathomechanism is still not well known, altered glucose and lipid metabolism
has been often reported in patients with hyperthyroidism [97]. Altogether, the above-men‐
tioned studies have indicated that hyperthyroidism is associated with either increased blood
coagulability and endothelial cell dysfunction based on examining the incidence of venous
thrombosis, or with thrombocytopenia and decreased life-span of platelets, however, only few
scientists attempted to explore the bone marrow-related mechanisms of abnormal functions
of hemostatic system among patients with hyperthyroidism. Even the recent development of
efficient megakaryocyte cultures in vitro that produce functional platelets has provided the
means to study the biology of megakaryopoesis in abnormal pathophysiological conditions,
such as hyperthyroid state, the number of reports covering this field is very scanty. In one
attempt, to check whether non-physiological THs concentration may directly affect platelet
production, it was necessary to determine the quantity of reticulated platelets (RP) circulating
in peripheral blood. RP represent young cells recently released from the bone marrow, and
according to some reports, their number in peripheral blood reflects thrombopoietic activity
[98]. Indeed, Stiegler et al. confirmed that hyperthyroidism was associated with an increased
marrow thrombocytopoiesis resulting in elevated RP counts. Moreover this finding was
corroborated by observation that RP increase in course of hyperthyroidism was reversible
upon achievement of euthyroid state [99]. Furthermore, to confirm the clinical reports
indicating that excessive THs exert depressive effects on platelets production, Sullivan et al.
used a mouse model to investigate the effects of the hyperthyroid state on thrombocytopoiesis
in vivo by administration of T4 into normal healthy mice. They observed that daily thyroxine
administration significantly decreased total circulating platelet count and platelet mass due to
decreased platelet production. This mechanism was confirmed using the most sensitive
methods of assessing platelet production, i.e. percentage of S-35 incorporation into platelets
and determination of megakaryocyte size and number [39]. Likewise, Sullivan and coworkers
observed that percentage of S-35 incorporation into platelets was reduced and megakaryocyte
size and number in bone marrow were considerably decreased [39]. These are only a few
available evidences that hyperthyroidism plays a direct role in the fine regulation of throm‐
bocytopoiesis in vivo.
3. Conclusion
In recent years there have been published several studies indicating that the thyroid dysfunc‐
tion could have important implications in human hematopoiesis, and thus might affect various
hematological parameters of circulating blood. This chapter demonstrates that hyperthyroid
state might be responsible for profound disturbances in functions of the hematopoietic system
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the liver and endothelium by altering the specific gene expression. Indeed, collected data have
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up-regulating the expression levels of vascular adhesion molecules and endothelium-derived
proteins important for fibrinolysis, such as tissue-type plasminogen activator and plasmino‐
gen activator inhibitor-1 [91]. On the other hand, it is known that there is a general increase of
metabolism in hyperthyroid state, which may affect cell components of the peripheral blood
and bone marrow. Likewise, it was found that the life-span of platelets is shortened in patients
with hyperthyroidism resulting in thrombocytopenia [92]. Moreover, the same group ob‐
served that the platelet count increased upon reduction of the concentration of circulating
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thrombosis, or with thrombocytopenia and decreased life-span of platelets, however, only few
scientists attempted to explore the bone marrow-related mechanisms of abnormal functions
of hemostatic system among patients with hyperthyroidism. Even the recent development of
efficient megakaryocyte cultures in vitro that produce functional platelets has provided the
means to study the biology of megakaryopoesis in abnormal pathophysiological conditions,
such as hyperthyroid state, the number of reports covering this field is very scanty. In one
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production, it was necessary to determine the quantity of reticulated platelets (RP) circulating
in peripheral blood. RP represent young cells recently released from the bone marrow, and
according to some reports, their number in peripheral blood reflects thrombopoietic activity
[98]. Indeed, Stiegler et al. confirmed that hyperthyroidism was associated with an increased
marrow thrombocytopoiesis resulting in elevated RP counts. Moreover this finding was
corroborated by observation that RP increase in course of hyperthyroidism was reversible
upon achievement of euthyroid state [99]. Furthermore, to confirm the clinical reports
indicating that excessive THs exert depressive effects on platelets production, Sullivan et al.
used a mouse model to investigate the effects of the hyperthyroid state on thrombocytopoiesis
in vivo by administration of T4 into normal healthy mice. They observed that daily thyroxine
administration significantly decreased total circulating platelet count and platelet mass due to
decreased platelet production. This mechanism was confirmed using the most sensitive
methods of assessing platelet production, i.e. percentage of S-35 incorporation into platelets
and determination of megakaryocyte size and number [39]. Likewise, Sullivan and coworkers
observed that percentage of S-35 incorporation into platelets was reduced and megakaryocyte
size and number in bone marrow were considerably decreased [39]. These are only a few
available evidences that hyperthyroidism plays a direct role in the fine regulation of throm‐
bocytopoiesis in vivo.
3. Conclusion
In recent years there have been published several studies indicating that the thyroid dysfunc‐
tion could have important implications in human hematopoiesis, and thus might affect various
hematological parameters of circulating blood. This chapter demonstrates that hyperthyroid
state might be responsible for profound disturbances in functions of the hematopoietic system
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due to the fact that THs modulate hematopoietic cell production in the bone marrow. The
hyperthyroidism-related symptoms in peripheral blood comprise increased plasma volume,
anemia (10-25%), leukopenia (10%), neutropenia, lymphopenia, thrombocytopenia, decreased
MCV, and reduced RBC survival, as well as general pancytopenia. Of note, erythrocytosis,
lymphocytosis and increased counts of monocytes are also fairly common. Potential molecular
mechanisms of reported hematologic symptoms has been explained in part in this paper.
Importantly, increased thyroid hormone concentrations influence the mechanisms of the
development of hematological abnormalities through both genomic and non-genomic actions.
As a result, in patients with different thyroid endocrinopathies, overt hyperthyroidism should
be also considered as a possible cause of clinically detectable abnormalities in peripheral blood
of these patients. Novel pathophysiological insights into the mechanisms of thyroid hormone
actions in the hematopoietic system may help to improve the understanding of the interactions
between THs and human hematopoiesis and offer a potential for the future development of
novel therapeutic interventions in thyroid diseases.
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1. Introduction
Hyperthyroidism is a syndrome characterised by the signs and symptoms of hyper-metabo‐
lism and excess sympathetic nervous system activity. It has an overall prevalence of 27 per
1000 women and 2.3 per 1000 men within the United Kingdom [1]. Hyperthyroidism occurs
as a result of either the excess synthesis or secretion of thyroid hormones by the thyroid gland
itself. It must be distinguished from thyrotoxicosis, in which excess thyroid hormone may
come from other sources, such as excess thyroid hormone ingestion, struma ovarii and
functional metastatic thyroid carcinoma[2,3].
Patients present with a variety of symptoms and clinical findings on physical examination. It
is important for clinicians to remember that these may be more subtle in the elderly population
who may present with fatigue or weakness, a condition known as apathetic hyperthyroidism,
or with predominantly cardiovascular signs such as atrial fibrillation, ischaemic heart disease
and congestive cardiac failure [4,5]. The routine use of serum thyrotropin (TSH) as a screening
investigation may allow earlier identification and treatment of the disease [6,7]. Radiological
imaging with iodine-123 uptake scanning and thyroid scintigraphy may aid in the identifica‐
tion of the underlying cause [6].
The management of hyperthyroidism is based on three treatment modalities, namely anti-
thyroid medication, radioactive iodine ablation or surgery. Patient, physician and geograph‐
ically preferences may dictate the choice of therapy. Given the overall healthcare costs of
hyperthyroidism, surgical intervention performed with minimal morbidity in high volume
centres may offer the highest chance of success with the lowest chance of recurrence [8].
The aim of this chapter is to discuss the role of surgical intervention in hyperthyroidism. Firstly,
to examine the evidence supporting surgical intervention in the management of Graves’
disease and that of toxic nodular goitres including toxic multi-nodular goitre and solitary toxic
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Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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nodule. Secondly, and perhaps more controversially, the evidence for the extent of surgical
intervention in hyperthyroidism will be discussed focusing specifically on the evidence for
total compared with subtotal thyroidectomy.
2. Surgical anatomy
The thyroid gland is derived from the median thyroid diverticulum at the floor of the pharynx.
The thyroglossal duct extends from the foramen caecum at the base of the tongue to the isthmus
and is derived from the stalk of the diverticulum, which is later obliterated, with the distal
portion forming the pyramidal lobe of the thyroid. The ultimobranchial bodies that arise from
the fourth pharyngeal pouch become related to the lateral aspect of the gland and constitute
the para-follicular and C cells, which produce calcitonin [9,10,11].
The thyroid gland consists of two lobes connected by an isthmus that is situated antero-lateral
to the trachea and cricothyroid muscle. The gland itself has a bi-lobed shape and weighs 15 –
25g often depending on age and sex. Superiorly, the pyramidal extension (lobe) of the gland
may be found on the anterior surface of the cricothyroid. Laterally, the tubercles of Zucker‐
kandl, which arise from median anlage and ultimobranchial fusion, may form significant
protrusions of thyroid tissue within the tracheo-esophageal groove. Inferior to the thyroid lie
the thyrothymic rests. These occur in up to 50% of individuals and are classified according to
their connection to the thyroid [12).
The blood supply to the thyroid is derived from two main arteries; the superior thyroid artery,
which is a branch of the external carotid artery, and the inferior thyroid artery, which is a
branch of the thyrocervical trunk that itself is a branch of the subclavian artery. The main
venous drainage is through the middle thyroid vein directly into the internal jugular vein.
Other venous drainage includes the paired superior thyroid veins and a plexus of veins
draining the inferior poles of the gland. The lymphatic drainage is to local lymph nodes
situated in the central neck compartment and subsequently to cervical nodes [10,11].
The recurrent laryngeal nerve (RLN) and the external branch of the superior laryngeal nerve
(EBSLN) are closely related to the thyroid gland and can be vulnerable to damage during
thyroid surgery. An intimate knowledge of their anatomy in the neck is crucial to safe thyroid
surgery. The recurrent laryngeal nerve (RLN) originates from the vagus (X Cranial nerve)
nerve. The right RLN branches from the vagus as it crosses the subclavian artery and loops
around it, while the left nerve arises at the level of the arch of aorta and loops under it. Both
nerves lie and ascend in the tracheo-oesophageal groove, where they pass deep to the postero-
medial surface of the thyroid lobes [10,11]. The angle of the nerve relative to the trachea is
usually more oblique on the right. The nerve subsequently enters the larynx by passing behind
the inferior constrictors, supplying all the intrinsic muscles of the larynx except the cricothy‐
roid and sensation to the mucosa below the vocal cords [10,11]. The right RLN may have a
non-recurring course (0.3%) and derive directly from the vagus, approaching the cricothyroid
directly without travelling in the tracheo-esophageal groove. This occurs as a consequence of
a displaced right subclavian arterial takeoff from the aortic arch and may be identified pre-
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operatively if cross-sectional imaging is performed. Both left and right RLNs may give multiple
branches to the oesophagus and trachea. The RLN may bifurcate prior to insertion into the
cricothyroid, with the majority of the motor fibres being carried in the anterior portion of the
nerve [9,10,11].
The superior laryngeal nerve (SLN) also emanates from the vagus and travels deep and medial
to the carotid arteries where it then divides into an internal and external branch above the
superior horn of hyoid [all books Grays]. The internal branch travels in relation to the superior
laryngeal vessels and supplies the mucosa to the level of the vocal cords. The external branch
supplies the cricothyroid muscle and lies deep to superior thyroid artery [10], where it can be
particularly vulnerable to damage. In an attempt to minimise trauma to the EBSLN numerous
classifications have been proposed, the most widely adopted being that devised by Cernea et
al [13,14]. Type 1 EBSLN is where the EBSLN crosses the superior thyroid artery (STA) greater
than 1cm above the upper pole of the thyroid. It is the commonest (40 – 62%) type and suggests
that the nerve may not be significantly at risk. In type 2a and b, the EBSLN crosses the artery
less than 1 cm above the upper pole and may therefore be at risk during dissection [13,14].
Kierner et al proposed that these be further divided into type 3 EBSLN where the nerve crosses
the STA under the cover of the thyroid gland and type 4 is where the EBSLN had descended
dorsal to the artery and only crosses the branches of the STA immediately above the upper
pole of the thyroid [14].
The paired inferior and superior parathyroid glands are derived from the third and fourth
pharyngeal  pouches  respectively  and are  closely  related to  the  thyroid  in  position.  The
majority of individuals (85%) will have four glands while approximately 13% will have five
glands and an even smaller proportion will have greater than this. The superior gland is
found in over 90% of cases within 1cm of the junction of the inferior thyroid artery and
the recurrent laryngeal  nerve on the posterior aspect  of  the middle third of  the thyroid
gland.  The  inferior  parathyroid  glands,  in  conjunction  with  the  thymus,  have  a  longer
migration path and their location is therefore more variable. The majority will be found on
the anterior or postero-lateral aspect of the thyroid lobe or within the thyrothymic tract and
are typically symmetrical in location [9,10,11].
3. Hyperthyroidism
Hyperthyroidism, a disorder of the thyroid gland, arises as a result of either excess hormone
synthesis or secretion [2,3]. It has a population prevalence of 2% for women and 0.2% for men
[1]. It is common with the incidence of new cases in the UK per year among women being
reported at 3 per 1000 [6]. The mean age of diagnosis is 48 years with an increasing incidence
with age [6,15]. Grave’s disease, being the most common cause of hyperthyroidism, accounts
for 60-80% of all cases [16]. Other causes include hyperthyroidism resulting from a toxic
nodular goitre (single or multiple nodule) and these constitute the remaining 5-15% of all
causes. [16].
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Hyperthyroidism must be distinguished from thyrotoxicosis, which is defined as the excess
of circulating thyroid hormones in the bloodstream [17]. Causes for thyrotoxicosis vary and
include excess thyroid hormone ingestion, struma ovarii and functional metastatic thyroid
carcinoma [18]. These will not be discussed further in this chapter
4. Clinical features
Hyperthyroidism has a multi-system effect on the body, giving rise to a range of classic signs
and symptoms which are caused by increased catabolism [19]. Patients present with nervous‐
ness, fatigue, palpitations, heat intolerance, polyphagia and weight loss [6,9]. It is important
to note that the elderly may present with a different range of symptoms and exhibit more subtle
signs [20]. Weight loss and anorexia are common symptoms in older patients and may be
mistaken for the presence of a neoplastic process which can lead to over investigation [21].
As a result of the increased basal metabolic rate patients often present with a persisting
tachycardia. This occurs characteristically during sleep and may be associated with palpita‐
tions [22]. In the elderly and in those with pre-morbid cardiac disease, cardiac arrhythmias
may develop on this background [22]. Atrial fibrillation is the commonest arrhythmia and is
present in up to 20% of patients [18]. Interestingly, up to 15% of new onset atrial fibrillation in
the elderly population is due to hyperthyroidism [23]. This may be resistant to medical
treatment and resolves only when the underlying hyperthyroidism itself is treated [24].
Cardiovascular mortality is increased in hypertoxic states primarily as a result of ischaemic
heart disease and congestive heart failure [25,26].
Increasing dyspnoea may occur in hyperthyroid patients, limiting exercise tolerance. This is
thought to be due to a reduction in respiratory muscle mass and strength with a corresponding
reduction in the vital capacity [18]. Bone turnover is also increased in the thyrotoxic state due
to the direct stimulation of osteoclasts and osteoblasts to increase bone resorption [27,28]. Low
TSH levels, of themselves, have also been implicated in the dysregulation of bone turnover
[29]. Longstanding thyrotoxicosis can lead to increase bone loss and subsequent osteoporosis.
Thyrotoxic patients can be emotionally labile and restless. Other less common complaints




Serum thyrotropin (TSH) is the most commonly used screening test to diagnose hyperthyr‐
oidism with levels being low or undetectable [2]. TSH levels are measured using immunora‐
diometric and chemiluminescent methods which have a high sensitivity (100%) and specificity
(99.1%) [30,31]. When an abnormally low TSH is detected, free Thyroxine (T4) and free Tri-
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iodothyronine (T3) levels are measured to determine the degree of hyperthyroidism. Indirect
assays measure the free T4 and T3 level while sensitive and specific radioimmunoassays are
used to measure total T4 and T3 levels [7]. The presence of a low TSH with normal T4 and T3
level is defined as sub-clinical hyperthyroidism [32]. Atrial fibrillation, other cardiac arrhyth‐
mias and cardiovascular mortality are all associated with prolonged sub-clinical hyperthyr‐
oidism, especially in the elderly [33,34]. The identification of a normal T4 but a high free T3 is
known as T3 Thyrotoxicosis and may be an early manifestation of Grave’s disease [3,35].
The measurement of auto antibodies, thyroglobulin, thyroxine peroxidase (TPO) and TSH
receptor (TSHR) antibodies, may help in elucidating the underlying aetiology [6]. More than
90% of patients with Graves’ disease have increased levels of circulating TSHR antibodies and
in the setting of thyrotoxicosis it can confirm the diagnosis [3]. Similarly, TPO antibodies are
also present in approximately 75% of patients with Graves’ disease [2].
5.2. Radiological imaging
Radionuclide scanning and radioactive iodine uptake assesses the activity within the thyroid
gland and may be used as an adjunct to biochemical analysis to identify the underlying
aetiology of hyperthyroidism. Lesions are classified into three main categories: hot, whereby
there is hyper-accumulation of radiotracer; warm, where there is increased uptake with
suppression of background thyroidal tissue; or cold where the thyroid nodule is non-func‐
tioning [36]. Warm and hot nodules represent an increase in thyroid tissue turnover and may
therefore suggest a benign toxic cause (Figure 1). Cold nodules, on the other hand are con‐
cerning for malignancy and should proceed to an ultrasound and FNAC [36,37]. Typically in
Graves’ disease, thyroid tissue is diffusely hyper-active with increased radio-tracer throughout
the gland. In toxic nodular goitres, the radioactive iodine is focally concentrated in the nodules
with suppression of the background tissue giving patchy uptake [38].
Early radionuclide scans were performed using radioactive iodine. This had been subsequent‐
ly replaced by technetium (Tc-99m) pertechnetate. This has been shown to mimic the behaviour
and uptake of iodine within the thyroid gland but involves a much lower dose of radioactivity
and is cheaper [39].
Thyroid ultrasound has a limited role in patients with hyperthyroidism. It has been recom‐
mended to assess thyroid nodules, palpable thyroid abnormalities, nodular goitres and lesions
found incidentally by other imaging modalities [37]. However, in the presence of a low TSH
and a discrete hot nodule fine needle aspiration cytology should be avoided. Suspicious
nodules on ultrasound or cold nodules should be subjected to a FNAC to allow for a cytological
diagnosis to be made pre-operatively [37,38].
Chest radiography, CT and MRI scans can help in surgical planning for patients with com‐
pressive or obstructive symptoms although it is rarely used. CT scanning may allow assess‐
ment of size and extent of the goitre, including the presence of a retro-sternal component but
predominantly aids in pre-operative assessment of the airway (narrowing and displacement)
and the need for an awake fiber-optic intubation (Figure 1). When undertaking cross-sectional
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ment of size and extent of the goitre, including the presence of a retro-sternal component but
predominantly aids in pre-operative assessment of the airway (narrowing and displacement)
and the need for an awake fiber-optic intubation (Figure 1). When undertaking cross-sectional
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imaging, contrast should be avoided due to the high iodine content, which may acutely worsen
or induce symptoms of hyperthyroidism [40].
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6. Aetiology of hyperthyroidism
6.1. Graves’ disease
Graves’ disease is an autoimmune disorder with a familial predisposition first described by
Robert James Grave in 1835 [41]. Overall the incidence of the disease is approximately 100-200
cases per 100,000 per year with a marked female predominance and accounts for approxi‐
mately 60–80% of all causes of hyperthyroidism [1,16]. A strong family history among affected
patients suggests a genetic predisposition however the incidence in monozygotic twins is
approximately 20% suggesting that penetrance is not 100% and other environmental causes
may play a role in pathogenesis [3,42]. It is typically associated with other autoimmune
conditions such as rheumatoid arthritis, SLE, Sjogrens, Type 1 Diabetes Mellitus and perni‐
cious anaemia [43]. Graves’ disease is also closely associated with myasthenia gravis occurring
in 3-5% of patients [18].
Graves’ disease classically consists of a triad of hyperthyroidism with diffuse goitre, oph‐
thalmopathy and pretibial myxoedema [44]. Each of these may run an independent course.
The clinical presentation includes signs and symptoms of thyrotoxicosis, a symmetrically
enlarged non tender goitre often with a palpable thrill or audible bruit [5]. However, it may
also present with a variable degree of extra-thyroidal manifestations such as ophthalmopathy,
pretibial myxoedema and acropachy [6]. Ophthalmopathy, proptoisis, extra-ocular muscle
involvement and rarely optic nerve compression, are thought to arise as a result of an immune
response to antigens within the retro-orbital tissues that are shared with the thyroid leading
to oedema and glycosaminoglycan deposition and fibrosis of the retro-orbital tissues [45,46].
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The diagnosis of Graves’ disease is made by establishing the presence of hyperthyroidism, the
presence of TSH auto-antibodies and diffuse increased symmetrical uptake on radio-iodine
scanning [47].
Treatment options include anti-thyroid medication, radioactive iodine ablation or surgical
intervention. The aim of treatment is to achieve a euthyroid state and in the presence of
ophthalmopathy to ensure overall stability. The ultimate decision regarding optimal manage‐
ment is tailored to an individual patient.
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(1) Toxic Nodular Goitre
Toxic nodular disease, resulting from either multiple or single adenomatous nodules was first described as a 
separate entity to Graves’ disease in 1913 by Henry Plummer [48].  Toxic nodular goitre includes two distinct 
entities, toxic multi-nodular goitre and a solitary toxic nodule, also known as Plummers’ Disease.  Both are 
characterised by abnormal thyroid function independent of TSH regulation.  Together, they account for the 
second commonest cause of hyperthyroidism but there are differences in their pathogenesis and treatment and 
therefore will be considered separately.
Toxic Multi-nodular Goitre
Toxic multinodular goitre is defined as a thyroid gland with two or more autonomously functioning nodules [49]. 
It’s incidence ranges from 5% of all hyperthyroid cases in iodine replete areas to 50% in iodine deficient areas 
and typically presents in older females [19].  Many aetiological factors are involved in the pathogenesis of toxic 
multi-nodular goitre including the functional heterogeneity of the thyroid follicles, the effects of growth factors and 
goitrogens, the presence or absence of iodine and genetic abnormalities. Concurrent autoimmune diseases are 
uncommon [50]. 
Patients present with less severe symptoms of hyperthyroidism and the onset may be more insidious [51]. 
Typically they have compressive symptoms from an enlarging multi-nodular goitre with retro-sternal extension [3]. 
The diagnosis is confirmed with a combination of biochemistry and radio-iodine scanning. Nuclear medicine 
scanning may show a heterogenous gland with mixed areas of hyper and hypo-activity [3,32]. Thyroid auto-
antibodies are negative. [32]. 
The treatment of multinodular goitres is aimed at eradication of all autonomously functioning thyroid tissue. Given 
the concurrent compressive symptoms surgery may provide the most definitive treatment.  Recurrence of disease 
is more common with either medical anti-thyroid medication or radio-iodine ablation [6,32]. 
Solitary Toxic Nodule
A solitary toxic nodule is an autonomously hyper-functioning nodule present within an otherwise normal thyroid 
gland.  Approximately 50% of solitary nodules are truly solitary, while typically it presents as part of a nodular 
gland constituting a dominant nodule [52]. The prevalence of palpable nodules in a population ages 30-59 years 
can be up to 4.2% [53]. 
Patients present with a neck lump, visible or palpable.  Appropriate investigation of a solitary nodule is crucial as 
the risk of malignancy is higher than in the presence of a multi-nodular goitre [37]. The incidence of malignancy in 
truly solitary nodules is 5-15%, but this figure would increase for solid or cold nodules to more than 25% [37].  
Surgery remains the treatment of choice for these patients although they may be observed if asymptomatic.   
Treatment Options
The management of hyperthyroidism is based on three different treatment modalities, namely anti-thyroid 
medication, radioactive iodine ablation or surgery.  Patient, physician and geographical preferences will dictate 
the choice of therapy.  The overall aim of treatment is to provide symptom relief, achieve a euthyroid state and to 
prevent recurrence.  Given the overall healthcare costs of hyperthyroidism, surgical intervention performed with 
minimal morbidity in high volume centres may offer the highest chance of success with the lowest chance of 
recurrence [8]. However, a prospective study by Torring et al examining such outcome measures as patient 
satisfaction, time to euthyroidism and rates of sick leave demonstrated equivalence between all three treatment 
modalities [54].  
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known as Plummers’ Disease. Both are characterised by abnormal thyroid function independ‐
ent of TSH regulation. Together, they account for the second commonest cause of hyperthyr‐
oidism but there are differences in their pathogenesis and treatment and therefore will be
considered separately.
Toxic Multi-nodular Goitre
Toxic multinodular goitre is defined as a thyroid gland with two or more auto omously
functioning nodules [49]. It’s incidence ranges from 5% of all hyperthyroid cases in iodine
replete areas to 50% in iodine deficient areas and typically presents in older females [19]. Many
aetiological factors are involved i  the pathogenesis of toxic multi- odular goitre including
the functional het rogeneity of the thyroid follicles, the eff cts of growth factors and goitro‐
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Patients present with less severe symptoms of hyperthyroidism and the onset may be more
insidious [51]. Typically they have compressive symptoms from an enlarging multi-nodular
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imaging, contrast should be avoided due to the high iodine content, which may acutely worsen
or induce symptoms of hyperthyroidism [40].
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6. Aetiology of hyperthyroidism
6.1. Graves’ disease
Graves’ disease is an autoimmune disorder with a familial predisposition first described by
Robert James Grave in 1835 [41]. Overall the incidence of the disease is approximately 100-200
cases per 100,000 per year with a marked female predominance and accounts for approxi‐
mately 60–80% of all causes of hyperthyroidism [1,16]. A strong family history among affected
patients suggests a genetic predisposition however the incidence in monozygotic twins is
approximately 20% suggesting that penetrance is not 100% and other environmental causes
may play a role in pathogenesis [3,42]. It is typically associated with other autoimmune
conditions such as rheumatoid arthritis, SLE, Sjogrens, Type 1 Diabetes Mellitus and perni‐
cious anaemia [43]. Graves’ disease is also closely associated with myasthenia gravis occurring
in 3-5% of patients [18].
Graves’ disease classically consists of a triad of hyperthyroidism with diffuse goitre, oph‐
thalmopathy and pretibial myxoedema [44]. Each of these may run an independent course.
The clinical presentation includes signs and symptoms of thyrotoxicosis, a symmetrically
enlarged non tender goitre often with a palpable thrill or audible bruit [5]. However, it may
also present with a variable degree of extra-thyroidal manifestations such as ophthalmopathy,
pretibial myxoedema and acropachy [6]. Ophthalmopathy, proptoisis, extra-ocular muscle
involvement and rarely optic nerve compression, are thought to arise as a result of an immune
response to antigens within the retro-orbital tissues that are shared with the thyroid leading
to oedema and glycosaminoglycan deposition and fibrosis of the retro-orbital tissues [45,46].
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and typically presents in older females [19].  Many aetiological factors are involved in the pathogenesis of toxic 
multi-nodular goitre including the functional heterogeneity of the thyroid follicles, the effects of growth factors and 
goitrogens, the presence or absence of iodine and genetic abnormalities. Concurrent autoimmune diseases are 
uncommon [50]. 
Patients present with less severe symptoms of hyperthyroidism and the onset may be more insidious [51]. 
Typically they have compressive symptoms from an enlarging multi-nodular goitre with retro-sternal extension [3]. 
The diagnosis is confirmed with a combination of biochemistry and radio-iodine scanning. Nuclear medicine 
scanning may show a heterogenous gland with mixed areas of hyper and hypo-activity [3,32]. Thyroid auto-
antibodies are negative. [32]. 
The treatment of multinodular goitres is aimed at eradication of all autonomously functioning thyroid tissue. Given 
the concurrent compressive symptoms surgery may provide the most definitive treatment.  Recurrence of disease 
is more common with either medical anti-thyroid medication or radio-iodine ablation [6,32]. 
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A solitary toxic nodule is an autonomously hyper-functioning nodule present within an otherwise normal thyroid 
gland.  Approximately 50% of solitary nodules are truly solitary, while typically it presents as part of a nodular 
gland constituting a dominant nodule [52]. The prevalence of palpable nodules in a population ages 30-59 years 
can be up to 4.2% [53]. 
Patients present with a neck lump, visible or palpable.  Appropriate investigation of a solitary nodule is crucial as 
the risk of malignancy is higher than in the presence of a multi-nodular goitre [37]. The incidence of malignancy in 
truly solitary nodules is 5-15%, but this figure would increase for solid or cold nodules to more than 25% [37].  
Surgery remains the treatment of choice for these patients although they may be observed if asymptomatic.   
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The management of hyperthyroidism is based on three different treatment modalities, namely anti-thyroid 
medication, radioactive iodine ablation or surgery.  Patient, physician and geographical preferences will dictate 
the choice of therapy.  The overall aim of treatment is to provide symptom relief, achieve a euthyroid state and to 
prevent recurrence.  Given the overall healthcare costs of hyperthyroidism, surgical intervention performed with 
minimal morbidity in high volume centres may offer the highest chance of success with the lowest chance of 
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Toxic nodular disease, resulting from either multiple or single adenomatous nodules was first
described as a separate entity to Graves’ disease in 1913 by Henry Plummer [48]. Toxic nodular
goitre incl des two distinct e tities, toxic multi-nodular g itre and a solitary toxic nodule, also
known as Plummers’ Disease. Both are characterised by abnormal thyroid function independ‐
ent of TSH regulation. Together, they account for the second commonest cause of hyperthyr‐
oidism but there are differences in their pathogenesis and treatment and therefore will be
considered separately.
Toxic Multi-nodular Goitre
Toxic multinodular goitre is defined as a thyroid gland with two or more auto omously
functioning nodules [49]. It’s incidence ranges from 5% of all hyperthyroid cases in iodine
replete areas to 50% in iodine deficient areas and typically presents in older females [19]. Many
aetiological factors are involved i  the pathogenesis of toxic multi- odular goitre including
the functional het rogeneity of the thyroid follicles, the eff cts of growth factors and goitro‐
gens, the presence or absence of iodine and genetic abnormalities. Concurrent autoimmune
diseases are uncommon [50].
Patients present with less severe symptoms of hyperthyroidism and the onset may be more
insidious [51]. Typically they have compressive symptoms from an enlarging multi-nodular
goitre with retro-sternal extension [3]. The diagnosis is confirmed with a combination of
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biochemistry and radio-iodine scanning. Nuclear medicine scanning may show a heteroge‐
nous gland with mixed areas of hyper and hypo-activity [3,32]. Thyroid auto-antibodies are
negative. [32].
The treatment of multinodular goitres is aimed at eradication of all autonomously functioning
thyroid tissue. Given the concurrent compressive symptoms surgery may provide the most
definitive treatment. Recurrence of disease is more common with either medical anti-thyroid
medication or radio-iodine ablation [6,32].
Solitary Toxic Nodule
A solitary toxic nodule is an autonomously hyper-functioning nodule present within an
otherwise normal thyroid gland. Approximately 50% of solitary nodules are truly solitary,
while typically it presents as part of a nodular gland constituting a dominant nodule [52]. The
prevalence of palpable nodules in a population ages 30-59 years can be up to 4.2% [53].
Patients present with a neck lump, visible or palpable. Appropriate investigation of a solitary
nodule is crucial as the risk of malignancy is higher than in the presence of a multi-nodular
goitre [37]. The incidence of malignancy in truly solitary nodules is 5-15%, but this figure would
increase for solid or cold nodules to more than 25% [37]. Surgery remains the treatment of
choice for these patients although they may be observed if asymptomatic.
Treatment Options
The management of hyperthyroidism is based on three different treatment modalities, namely
anti-thyroid medication, radioactive iodine ablation or surgery. Patient, physician and
geographical preferences will dictate the choice of therapy. The overall aim of treatment is to
provide symptom relief, achieve a euthyroid state and to prevent recurrence. Given the overall
healthcare costs of hyperthyroidism, surgical intervention performed with minimal morbidity
in high volume centres may offer the highest chance of success with the lowest chance of
recurrence [8]. However, a prospective study by Torring et al examining such outcome
measures as patient satisfaction, time to euthyroidism and rates of sick leave demonstrated
equivalence between all three treatment modalities [54].
6.3. Anti thyroid drugs
Anti-thyroid medication is used to render patients euthyroid to either induce long-term
remission or as preparation for definitive treatment with radioactive ablation or surgery [2].
The main thioamide agents used are Carbimazole, Methamimazole and Propylthiouracil
(PTU). By inhibiting thyroxine peroxidase and interfering with both the organification of
iodide and the coupling of iodo-thyryronines a reduction in hormone synthesis is achieved
[6,55]. Initial doses of medication are usually high and a euthyroid state can be achieved after
8-12 weeks of treatment whereupon doses can be titrated downwards to a maintenance dose
[2]. PTU is preferred in pregnancy as at it less likely to cross the placenta due to protein binding
[56,57]. Treatment may be discontinued after one year if sustained remission is achieved with
the patient being euthyroid and TSH-R antibodies undetectable [19]. Remission can be variable
with reported relapse rates of between 50% to 60% [19]. Factors influencing relapse include
Thyroid Disorders - Focus on Hyperthyroidism214
smoking, compliance with medication, the presence of a large goitres and the elevated TSH-
R antibodies at end of treatment [58]. Side effects range from mild symptoms of urticaria, fever
and rash to more serious neutropenia, hepatotoxicity and vascultitis [55,59,60]. Agranulocy‐
tocis occurs in approximately 0.1-0.5% of treated patients and the rate of development of
hypothyroidism is 0.6% per annum [61,62]..
6.4. Radio-iodine ablation
Radio-iodine (RAI) can be used as first line treatment or for patients who have either failed
medical management or present with recurrent disease following a sub-total thyroidectomy.
Within the USA RAI is the first line treatment for patients with Graves’ disease [55]. Iodine-131
is taken up by the thyroid cells causing local apopotosis and subsequent fibrosis of the gland
thereby reducing the overall functional thyroid mass [22]. RAI is most suitable for patients
with a small goitre in the absence of ophthalomopathy. A wide variety of dosages (200–
600MBq) can be used [22]. The dosage however depends on the size and activity of the gland,
associated failure rates with low doses and the increased rate of hypothyroidism when higher
doses are utilised [19,63]. Absolute contra-indications include pregnancy, breastfeeding and
coexisting differentiated thyroid cancer [55]. RAI is usually avoided in patients with severe
ophthalmopathy as in approximately 15% of patient symptoms may worsen following
treatment [64,65]. It may be used cautiously in patients with stable eye disease in combination
with high dose glucocorticoids. [65].
Anti-thyroid agents are given for four to six weeks prior to radio-ablation in an attempt to
render patients euthyroid and thus prevent the development of a thyrotoxic crisis during initial
treatment [2]. These are discontinued two to three days prior to treatment to ensure functional
thyroid tissue which is required to take up iodine [2,66]. The majority of patients (75%) require
only a single dose of radio-iodine [67]. The effects of the RAI are not immediate and continue
for months following treatment. Symptomatic improvement can take up to two months.
Immediate complications include thyroid gland tenderness [32]. Long-term complications
include the development of hypothyroidism in approximately 60% of patients at 1 year, and
therefore regular long-term surveillance is warranted with T4 replacement as necessary [68].
6.5. Surgery
Surgery provides high cure rates in hyperthyroidism with minimal morbidity in high volume
centres It gives almost immediate relief of the compressive symptoms of large goitres, achieves
euthyroidism rapidly and consistently, and avoids the long term risks of radioactive iodine
and anti-thyroid medications [69]. Surgical intervention is warranted where the disease has
proved refractory to medical management, including both anti-thyroid medication and radio-
active iodine. Other indications for surgery include large goitres with compressive symptoms,
where RAI is contra-indicated including pregnancy (usually performed in the 2nd trimester)
and severe ophthalomopathy, desire for pregnancy soon after treatment, suspicion or presence
of underlying thyroid malignancy, for children and patient preference [5]
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biochemistry and radio-iodine scanning. Nuclear medicine scanning may show a heteroge‐
nous gland with mixed areas of hyper and hypo-activity [3,32]. Thyroid auto-antibodies are
negative. [32].
The treatment of multinodular goitres is aimed at eradication of all autonomously functioning
thyroid tissue. Given the concurrent compressive symptoms surgery may provide the most
definitive treatment. Recurrence of disease is more common with either medical anti-thyroid
medication or radio-iodine ablation [6,32].
Solitary Toxic Nodule
A solitary toxic nodule is an autonomously hyper-functioning nodule present within an
otherwise normal thyroid gland. Approximately 50% of solitary nodules are truly solitary,
while typically it presents as part of a nodular gland constituting a dominant nodule [52]. The
prevalence of palpable nodules in a population ages 30-59 years can be up to 4.2% [53].
Patients present with a neck lump, visible or palpable. Appropriate investigation of a solitary
nodule is crucial as the risk of malignancy is higher than in the presence of a multi-nodular
goitre [37]. The incidence of malignancy in truly solitary nodules is 5-15%, but this figure would
increase for solid or cold nodules to more than 25% [37]. Surgery remains the treatment of
choice for these patients although they may be observed if asymptomatic.
Treatment Options
The management of hyperthyroidism is based on three different treatment modalities, namely
anti-thyroid medication, radioactive iodine ablation or surgery. Patient, physician and
geographical preferences will dictate the choice of therapy. The overall aim of treatment is to
provide symptom relief, achieve a euthyroid state and to prevent recurrence. Given the overall
healthcare costs of hyperthyroidism, surgical intervention performed with minimal morbidity
in high volume centres may offer the highest chance of success with the lowest chance of
recurrence [8]. However, a prospective study by Torring et al examining such outcome
measures as patient satisfaction, time to euthyroidism and rates of sick leave demonstrated
equivalence between all three treatment modalities [54].
6.3. Anti thyroid drugs
Anti-thyroid medication is used to render patients euthyroid to either induce long-term
remission or as preparation for definitive treatment with radioactive ablation or surgery [2].
The main thioamide agents used are Carbimazole, Methamimazole and Propylthiouracil
(PTU). By inhibiting thyroxine peroxidase and interfering with both the organification of
iodide and the coupling of iodo-thyryronines a reduction in hormone synthesis is achieved
[6,55]. Initial doses of medication are usually high and a euthyroid state can be achieved after
8-12 weeks of treatment whereupon doses can be titrated downwards to a maintenance dose
[2]. PTU is preferred in pregnancy as at it less likely to cross the placenta due to protein binding
[56,57]. Treatment may be discontinued after one year if sustained remission is achieved with
the patient being euthyroid and TSH-R antibodies undetectable [19]. Remission can be variable
with reported relapse rates of between 50% to 60% [19]. Factors influencing relapse include
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smoking, compliance with medication, the presence of a large goitres and the elevated TSH-
R antibodies at end of treatment [58]. Side effects range from mild symptoms of urticaria, fever
and rash to more serious neutropenia, hepatotoxicity and vascultitis [55,59,60]. Agranulocy‐
tocis occurs in approximately 0.1-0.5% of treated patients and the rate of development of
hypothyroidism is 0.6% per annum [61,62]..
6.4. Radio-iodine ablation
Radio-iodine (RAI) can be used as first line treatment or for patients who have either failed
medical management or present with recurrent disease following a sub-total thyroidectomy.
Within the USA RAI is the first line treatment for patients with Graves’ disease [55]. Iodine-131
is taken up by the thyroid cells causing local apopotosis and subsequent fibrosis of the gland
thereby reducing the overall functional thyroid mass [22]. RAI is most suitable for patients
with a small goitre in the absence of ophthalomopathy. A wide variety of dosages (200–
600MBq) can be used [22]. The dosage however depends on the size and activity of the gland,
associated failure rates with low doses and the increased rate of hypothyroidism when higher
doses are utilised [19,63]. Absolute contra-indications include pregnancy, breastfeeding and
coexisting differentiated thyroid cancer [55]. RAI is usually avoided in patients with severe
ophthalmopathy as in approximately 15% of patient symptoms may worsen following
treatment [64,65]. It may be used cautiously in patients with stable eye disease in combination
with high dose glucocorticoids. [65].
Anti-thyroid agents are given for four to six weeks prior to radio-ablation in an attempt to
render patients euthyroid and thus prevent the development of a thyrotoxic crisis during initial
treatment [2]. These are discontinued two to three days prior to treatment to ensure functional
thyroid tissue which is required to take up iodine [2,66]. The majority of patients (75%) require
only a single dose of radio-iodine [67]. The effects of the RAI are not immediate and continue
for months following treatment. Symptomatic improvement can take up to two months.
Immediate complications include thyroid gland tenderness [32]. Long-term complications
include the development of hypothyroidism in approximately 60% of patients at 1 year, and
therefore regular long-term surveillance is warranted with T4 replacement as necessary [68].
6.5. Surgery
Surgery provides high cure rates in hyperthyroidism with minimal morbidity in high volume
centres It gives almost immediate relief of the compressive symptoms of large goitres, achieves
euthyroidism rapidly and consistently, and avoids the long term risks of radioactive iodine
and anti-thyroid medications [69]. Surgical intervention is warranted where the disease has
proved refractory to medical management, including both anti-thyroid medication and radio-
active iodine. Other indications for surgery include large goitres with compressive symptoms,
where RAI is contra-indicated including pregnancy (usually performed in the 2nd trimester)
and severe ophthalomopathy, desire for pregnancy soon after treatment, suspicion or presence
of underlying thyroid malignancy, for children and patient preference [5]
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Historically thyroid surgery was rarely performed for indications other than cancer until the
last quarter of the twentieth century [70]. The high peri-operative and post-operative morbidity
and mortality made the procedure untenable and indeed in 1850 it was banned by the French
Academy of Medicine [71]. However improvements in anti-sepsis, anaesthesia and the
introduction of anti-thyroid medication to render patients euthyroid pre-operatively revolu‐
tionised thyroid surgery. It is now well established as an acceptable and efficacious form of
treatment and the controversy focuses on the extent of intervention; sub-total versus total
thyroidectomy.
Currently, total thyroidectomy is regarded as the surgical procedure of choice for Graves’
disease, multi-nodular toxic and non toxic nodules [70,72-74]. A study by Efermidou et al
reviewing 932 cases of total thyroidectomy for benign thyroid disease showed that surgery
is  safe  and  is  associated  with  minimal  morbidity.  Patients  achieved  immediate  and
permanent  cure  with  no  risk  of  disease  recurrent  or  repeated  surgery  [75].  This  was
supported by Ballentone et al who demonstrated in over 500 patietns a postoperative rates
of haemorrhage of 1.5%, a permanent RLN palsy of 0.4% and a permanent rate of hypocal‐
caemia of 3.4%[76]. There was no recurrences noted during ther follow-up of 44 months
(Ballintone). Another study by Pappalardo et al randomised 141 patients into receiving a
total thyroidectomy or subtotal thyroidectomy and patients were followed up for a median
of 14.5 months. The rate of goitre recurrence in the subtotal thyroidectomy group was higher
at 14% [77].
Finally, a meta-analysis which included 1402 patients from 5 continents demonstrated higher
relapse rates with anti-thyroid drugs than radioactive iodine (52.7% vs 15%) and with anti-
thyroid drugs than surgery (52.7% vs 10%). In addition, examination of 31 scohort studies
which included 5136 patinets found an adverse effect rate of 13% in patients treated with anti-
thyroid drugs [78].
It is now widely accepted that high surgical volume in specialised units provides better patient
outcome. A systematic review published in the British Journal of Surgery in 2007 examined
1075 studies and found that high volume surgeons had better outcomes in 75% of the studies
and that specialised surgeons had significantly better outcomes than general surgeons in 91%
of the studies [79]. The association between volume and outcome has also been demonstrated
in thyroid surgery. Boudourakis et al performed a cross sectional analyses of a number of
surgeries deemed to have demonstrated a volume-outcome relationship. There was a signifi‐
cant increased in number of procedures performed by high volume surgeons during the study
period (23% for thyroidectomies). Unadjusted mortality and length of stay was significantly
lower for high-volume surgeons compared with low-volume surgeons [80]. In a study by
Pieracci et al, substernal thyroidectomy was compared with cervical thyroidectomy, with the
main aim of assessing outcomes (all volume type hospitals were included). Increasing hospital
volume predicted a decreased likelihood of overall complications, post-operative bleeding,
blood transfusion, respiratory failure, mortality and length of stay [81].
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7. Extent of surgery
7.1. Graves
Historically, a subtotal thyroidectomy was the procedure of choice in Graves’ disease,
minimizing the complications of surgery with potential cure of the disease. However, a
randomized trial comparing anti-thyroid drugs, radioiodine treatment, and surgery in Graves’
disease found all are equally effective in normalizing serum thyroid hormone concentrations
within six weeks and over 95% of the patients were satisfied with their therapy [54].
The type of surgery in Graves’ disease remains controversial. A total thyroidectomy ensures
complete cure of symptoms but is obviously associated with surgical hypothyroidism and the
need for lifelong thyroxine treatment. Conversely, subtotal thyroidectomy, given that a
proportion of thyroid tissue is left in-situ is associated with a higher likelihood of recurrence
and may still be associated with hypothyroidism. In a randomized trial of subtotal versus total
thyroidectomy for Graves’ disease involving 191 patients followed over five years, recurrent
hyperthyroidism occurred in 4.7% of patients after subtotal versus 0% after total thyroidecto‐
my, while transient hypoparathyroidism was seen in 6.8% and 12.6% respectively, and
permanent hypoparathyroidism in 0% and 0.5% respectively confirming the advantages of
total thyroidectomy without adversely affecting morbidity [82]. A meta-analysis published by
Palit et al demonstrated in 35 studies with over 7241 patients that the rates of RLN injury and
permanent hypo-parathyroidism were similar between subtotal and total thyroidectomy.
More importantly they also demonstrated an 8% recurrence risk in those patients who had a
subtotal thyroidectomy versus none in the total thyroidectomy group [83]. A further rando‐
mised trial published in the same year added weight to the call for total thyroidectomy as it
failed to demonstrate a significant difference in the complication rates between a total or
subtotal thyroidectomy [84]. Therefore total thyroidecomy should be considered the gold
standard surgical intervention in Graves’ disease.
7.2. Toxic multinodular goitre
Surgical resection remains the treatment of choice especially in the presence of a large goitre
and compressive symptoms where surgery gives prompt relief [85]. The extent of surgical
intervention and the comparative results of performing a near total or total thyroidectomy
have been topical in the last decade. Attempts to perform more minimal surgery have been
proposed to minimise the complications, such as RLN damage and permanent hypoparathyr‐
oidism, of thyroid surgery but are typically associated with higher rates of recurrence and an
increased requirement for re-operative surgery. Stenmuller et al showed that a lobectomy plus
a contralateral subtotal resection (known as the Dunhill procedure) and bilateral subtotal
resection resulted in a low overall incidence of permanent hypoparathyroidism and RLN
injury [86]. Rayes et al perfomed a prospective randomised study on 200 patients and con‐
cluded both can be performed with similar complication rates [87]. Remnant size was found
to determine recurrence rates. Barczynski et al compared total thyroidectomy, Dunhill
procedure and bilateral subtotal resection in 570 patients. Recurrence rates were 0.5% 4.7%
and 11.6% respectively with recurrence highest in bilateral subtotal resection. However this
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study also shows that although recurrence rates differ, reoperation rates for these recurrences
are comparable showing that not all of these recurrences may be clinically significant and
require further surgery [88]. Several other papers have also supported the role for total
thyroidectomy for multinodular goitre showing that it completely eradicates the disease
process, lowers the local recurrence rate, allows for avoiding the substantial risk of reoperative
surgery, and involves only a minimal risk of morbidity [89,90-91].
7.3. Toxic solitary nodule
For patients with a solitary toxic adenoma without evidence of nodules in the contralateral
lobe, a thyroid lobectomy is adequate. For patients with toxic adenoma and a coexisting
nonfunctioning nodule in the contralateral lobe, total thyroidectomy may be warranted
especially if there is any suspicion regarding thyroid malignancy. The main advantages of
surgery include immediate resolution of hyperthyroidsim symptoms, relief from compressive
symptoms, avoidance of radiation exposure to normal tissue and confirmation of diagnosis in
rare cases of suspected carcinoma [40]. The reported incidence of hypothyroidism is low (14%
with surgery compared with 22% with radioiodine treatment [40].
8. Preparation for surgery
Historically the mortality and morbidity associated with thyroid surgery was extremely high,
not only from intra-operative complications but from post-operative hormonal dysregulation
[92,93]. Meticulous pre-operative preparation of hyperthyroid patients has reduced this to less
that 1% in high volume centres [92,94].
8.1. Anti-thyroid drugs
The aim of preoperative preparation as previously discussed is to render patients as close as
possible to being clinically and biochemically euthyroid [22]. Antithyroid drugs interfere with
the incorporation of iodine into tyrosine residues and prevent the coupling of iodotyrosines
into iodothyronines [55]. Anti thyroid agents such as Carbimazole and Propythiouracil are
prescribed to achieve a euthyroid state [93,95]. The last dose should be given the day prior to
surgery [22].
8.2. Beta-blockers
Many manifestations of hyperthyroidism relate to the cardiovascular system and to the
sensitisation of the B-adrenergic receptors to catecholamines in patients who are thyrotoxic.
Pre-operative treatment with a beta-blocker such as propranolol controls adrenergic effects
[93]. It has also been shown to reduce the peripheral conversion of T4 to T3 [96]. Beta-blockers
are used in combination with antithyroid drugs and play an important role in pre-operative
patient preparation [97]. It is crucial to note that this drug should not be omitted on the morning
of surgery and must be continued for at least 5 days postoperatively [22]. Beta-blockers are
contraindicated in asthmatics, where a cardio-selective B-blocker may be considered [3].
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8.3. Iodine treatment
The use of iodines in the pre-operative management of Graves disease was first documented
in 1923 and its introduction saw a significant reduction in the mortality associated with thyroid
surgery [98]. Iodines are now routinely used in the peri-operative management of hyperthy‐
roid patients [93]. It is prescribed in the form of oral Lugol’s iodine (drops) at a dose of 24mg
divided over three doses administered 7–10 days pre-operatively to reduce the vascularity of
the gland [93]. It has been postulated that organic iodide such as Lugol’s solution usage can
decrease the vascularity of the thyroid gland pre-operatively by inhibiting vascular endothelial
growth factor A expression in thyroid follicles [99]. A randomised control trial by Erbil et al
using colour flow Doppler ultrasonography, immunohistochemical and western blot analysis
to compare thyroid vascularity with or without preoperative Lugol’s solution in 36 patients.
It showed a decrease in rate of blood flow to thyroid, thyroid vascularity and intra-operative
blood loss in the preoperative Lugol solution treatment group. They concluded that preoper‐
ative Lugols treatment reduces intraoperative bleeding which in turn improves the safety
profile of the procedure [100].
Large doses of iodine act by producing a transient remission of hormone synthesis by ‘stun‐
ning’ the thyroid gland an effect known as the Wolff-Chaikoff effect. It is a phenomenon where
higher than normal doses of iodine inhibit organification of thyroid hormone resulting in a
decrease in hormone synthesis and release [101]. Onset of action begins 24 hours post admin‐
istration peaking at approximately 10 days [102]. This can be seen as an auto-regulatory system
in dealing with supra-physiologic levels of iodine [93]. In normal euthyroid subjects thyroid
synthesis normalises due to down-regulation of the sodium iodine symporter known as the
escape phenomenon [103].
However, in hyperthyroid patients the escape phenomenon does not occur and Jod-Basedow
phenomenon occurs instead [93]. The Jod Basedow effect occurs due to dysregulation of iodine
in hyperthyroid patients where excess iodine stimulates more hormone production by acting
as the substrate [104]. It can result in a temporary hyperthyroidism, worsening of existing
hyperthyroidism or rarely a permanent rise in thyroid hormone [93]. Therefore iodines should
be used cautiously and for a limited time period in conjunction with anit-thryoid medication
in the pre-operative period.
9. Surgical intervention
9.1. Anaesthesia
The majority of thyroid surgery is performed under general anaesthetic without neuromus‐
cular blockade using an endotracheal cuffed tube to allow for intra-operative neuromonitor‐
ing. Local anasethic is given pre-operatively along the incision to ensure minimal post-
operative discomfort. In selective patients with small thyroid nodules and favourable anatomy
local anaesthetic has been documented as being utilised. Local anesthetic techniques require
the use of cervical block anesthesia. The disadvantage of this is risk of bilateral paralysis of the
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recurrent laryngeal nerve resulting from blockade with the local anaeasthetic, with consequent
difficulty in breathing postoperatively [105].
9.2. Intra-operative nerve monitoring
The primary complication of thyroid surgery is damage to either the recurrent laryngeal nerve
or the external branch of the superior laryngeal nerve. Routine visual identification of the RLN
decreases the incidence of injury and is standard practice (Figure 3). However, a recent survey
of members of the American Association of Endocrine Surgeons found that 63% of respondents
do not use neuromonitoring, 14% of surgeons used it routinely and 23% were selective users
[106]. Non-users were in practice longer, reported a lower case volume, were less familiar with
the technology and had limited access to the equipment [106].
The main role for intra-operative monitoring is to identify the RLN nerve, to aid in safe
dissection once it is identified and for prognostication of neural function postoperatively [107].
The two main components of monitoring are stimulation of the RLN and assessment of the
vocal cord response to stimulation. Several techniques have been described and are in routine
use. The most common method is the use of a laryngeal surface electrode which is applied to
the surface of the endotracheal tube in a proximal location to the vocal cord [108,109]. An
attached probe is used to deliver the low voltage electric current. During thyroid resection an
auditory signal or visual EMG signal can be used to provide information about the presence
and course of the RLN.
A systematic review of the literature demonstrated that neuromonitoring of the RLN during
thyroid surgery reduced RLN injury compared with routine nerve identification [110]. Other
studies comparing intra-operative nerve monitoring have demonstrated a benefit for its use
although a statistically significant difference between the groups could not be identified [111,
112]. A randomized trial of 1000 patients showed a decrease in transient but not permanent
RLN paresis compared to visualization alone [113]. In addition, there are studies which show
low sensitivity and positive predictive value of intra-operative neuromonitoring for predicting
nerve injury [114]. Despite this evidence, monitoring, when used appropriately, has been
shown to be feasible, safe and reproducible and should be considered for all cases. It must be
noted that neuromonitoring does not replace adequate intra-operative visualization and
meticulous surgical technique.
10. Surgical procedures in hyperthyroidism
10.1. Dunhill and Holtz procedures
Hartely and Dunhill described the procedure of subtotal thyroidectomy where a total thyroid
lobectomy is performed on one side and a small remnant is left in situ (weighing approximately
4 grams) on the contralateral side [5]. However it has been consistently difficult to assess the
residual remnant thyroid size and it may vary between 2–12 gms. The surgery is performed
through a collar incision placed halfway between the sternal notch and the thyroid cartilage.
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As the thyroid gland is approached, the middle thyroid vein is identified and ligated. The
entire lobe and isthmus are excised on the diseased side. On the contralateral side, the superior
pole is freed by dividing the superior vessels and the remaining thyroid lobe is approached
from a postero-lateral plane through the thyroid tissue leaving a posterior remnant. This keeps
the dissection plane away from the parathyroid glands and the recurrent laryngeal nerve on
this sub-total operative side [115].
The Enderlen Holtz procedure involves performing a subtotal bilateral thyroidectomy. The
procedure is similar to the Dunhill procedure and involves mobilisation of the thyroid gland
supero-laterally. In this case remnant tissue of 2 grams or more are left on both sides. Disad‐
vantages of both these procedures, as previously discussed include the high risk of recurrence
as well as an increased rate of complications (RLN damage and permanent hypoparathyroid‐
ism) associated with re-operative surgery [115].
10.2. Total thyroidectomy
The patient is positioned supine on the operating table in a slight reverse Trendelenburg
position. A gel pad or sand bag is placed transversely under the shoulders and the neck is
extended  and  placed  in  a  head  ring.  This  allows  the  thyroid  gland  to  become  more
prominent and applies tension to the skin, platysma, and strap muscles aiding in dissec‐
tion. In a total thyroidectomy complete excision of the gland, including the pyramidal lobe
is performed [22,105].
A curved incision is made midway between the suprastenal notch and the thyroid cartilage.
The incision is deepened through the skin, subcutaneous tissue and platysma. Skin flaps are
then raised upwards to the thyroid notch and downwards to the suprasternal notch. The deep
cervical fascia is then divided in the midline down and in-between the strap muscles to the
plane of the thyroid gland. The strap muscles are then retracted laterally and mobilised off the
Figure 3. Nerve stimulator used for intra-operative recurrent laryngeal nerve monitoring
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recurrent laryngeal nerve resulting from blockade with the local anaeasthetic, with consequent
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4 grams) on the contralateral side [5]. However it has been consistently difficult to assess the
residual remnant thyroid size and it may vary between 2–12 gms. The surgery is performed
through a collar incision placed halfway between the sternal notch and the thyroid cartilage.
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thyroid gland using an advanced surgical sealing instrument, such as the Ligasure vessel
sealing device (Covidien) [22,105].
The middle thyroid vein is encountered laterally, and this drains directly into the internal
jugular vein. This is ligated and divided. The plane between the medial pole of the upper
lobe and the cricothyroid muscle is subsequently developed, ensuring close proximity to
the  thyroid  in  order  to  avoid  trauma  or  injury  to  the  external  branch  of  the  superior
laryngeal nerve.  The branches of the superior thyroid artery are then ligated and divid‐
ed,  allowing  downward  delivery  of  the  upper  pole.  Capsular  dissection  is  then  per‐
formed and this invovles commencing the lateral component of the dissection high on the
surface  of  the  thyroid  gland,  diviging only  the  tertiary  branches  of  the  inferior  thyroid
artery and progressing posteriorly. In this process, the vascular supply of the parathyroid
glands is often well preserved [22,105,117].
The recurrent laryngeal nerve is identified in its course in the tracheo-esophageal groove. This
is first identified and sought below the level of the inferior thyroid artery, where it passes
obliquely upwards and forwards. The tubercle of Zuckerkandl serves as a useful landmark in
the identification of the RLN. Situated on posterolateral aspect of the gland in the tracheo-
esphageal groove in proximity of the cricothryoid membrane it is a constant landmark for RLN
identification which is aided by further mobilisation of the thyroid. The nerve is followed
upwards until it passes into the larynx under the inferior border of the inferior constrictor
behind the inferior cornu of the thyroid cartilage. In cases where the right nerve is difficult to
Figure 4. Thryoid gland and pyramidal lobe [116]
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identify one must consider an anomalous (non-recurrent) nerve, which is pesent in 1 percent
of patients. A non-recurrent RLN passes behind the carotid sheath and curves medially,
forwards and upwards and can be mistaken for the inferior thyroid artery. It is important to
be careful with diathermy and newer advanced sealing devices as heat conduction may
damage the RLN, the blood supply to the parathyroid’s or to the delicate areas within the
larynx [22,105,117].
The parathyroid glands must be identified in all cases. This is done by careful inspection of
the common locations and by utilising capsular dissection they can be peeled away from the
thyroid gland itself. Care is taken not to damage the branches of the inferior thyroid artery
which supply the parathyroid glands. If a parathyroid gland is accidentally excised or
Figure 5. Marking of incision
Figure 6. Mobilisation of the thyroid
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devascularised inadvertantly then it should be fragmented into small pieces and auto-
transplanted immediately within the sternocleidomastoid muscle [22,105,117].
Figure 7. Postero-lateral aspect of the thyroid
The pretacheal and cercval fascia are closed using interrupted sutures. Routine drain place‐
ment after thyroid surgery is not necessary. A meta-analysis of 11 randomized clinical trials
showed no significant difference in the incidence of hematoma or seroma between routine
drainage and no drainage [118]. If the thyroid is very large with a significant retrosternal
component or the dissection is extensive,a closed-suction drain can be placed to prevent a
serous fluid collection [118]. This can be removed safely when the drain output is serous and
decreasing in volume.
10.3. Thyroid lobectomy
Thyroid lobectomy is predominantly the treatment of choice in the management of solitary
toxic nodules because it not only removes the stimulus of excess thyroid production, but it also
allows definitive histological assessment of the nodule.
The details of the procedure, patient positing and exposure are similar to that of a total
thyroidectomy, as described above. In a thyroid lobectomy, the isthmus is transected using a
haemostatic device such as the harmonic scalpel or Ligasure [22,105,116].
10.4. Subtotal thyroidectomy
The thyroid gland is exposed in a similar manner to a total thyroidectomy. The middle thyroid
vein is encountered upon retractionof the strap muscles and is ligated and divided. The
superior poles of the thyroid are then ligated taking care to avoid the EBSLN [22,105,116]. The
inferior thyroid artery is identified and ligated lateral to the recurrent laryngeal nerve. The
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procedure then entails dividing across each lobe of the thyroid from the lateral edge towards
the trachea, leaving intact a posterior capsule with the attached remnant of the thyroid. For
ease of closure the thicker remnant of the gland is left laterally and incised more on the medial
aspect. This allows the folding over of the remnant laterally to medially, allowing the capsular
edges to be sutured together using a Vicryl suture. As a general guide the remnant strip is
often recommended to be 3cm x 1cm on each side. This operation is rarely used in modern
surgical practice [22,105,116].
Figure 8. Identification of recurrent laryngeal nerve
10.5. Surgery in recurrent thyroid disease
Re-operative thyroid surgery is technically challenging due to the formation of adhesions and
scar tissue, and is associated with increased rates of recurrent laryngeal nerve injury and
hypoparathyroidism  [119,120,121].  Operative  intervention  for  recurrence  accounts  for
anywhere between 5–12% of all thyroidectomies performed [122,123]. However, the last twenty
years have seen a shift away from conservative primary operations such as bilateral subtotal
thyroidectomy and this should begin to be mirrored by declining recurrence rates [124].
The risks associated with reoperation should be carefully examined and balanced with the
options of medical management or observation [119,120,121]. The extent of the disease should
be assessed in addition to the location and possible complications such as nerve injury and
excision of the parathyroid glands [124].
The operation of choice in all cases of recurrent nodular goiter should be a completion total
thyroidectomy. The surgical approach is dependent on the extent of the initial operation and
the size and location of the recurrent goitre. Re-operation following a subtotal or total thyroi‐
dectomy is hazardous and requires a methodical and standardized operative approach [124].
The key is the initial identification of anatomical landmarks outside the original operative field.
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The dissection must commence laterally by mobilization of the sternocleidomastoid muscle to
expose the carotid sheath. The carotid sheath may however be displaced medially and lie
abutting both fibrous tissue and the thyroid remnant. Dissection continues until the lateral
aspect of the gland in encountered. It is important to ensure that the nerve is not encased within
the strap muscles prior to their division. Identification of standard landmarks is vital. Therefore
the esophagus posteriorly and the trachea anteriorly should be identified next. This helps to
narrow down the location of the recurrent laryngeal nerve, which should be lying within the
trachea-oesophageal groove. Protection of the recurrent laryngeal nerve is best achieved by
identifying it in virgin territory. Dissection should thus begin low down in the trachea-
esophageal groove, if necessary as low as the thoracic inlet, where the nerve can be safely
identified in an undisturbed, non-operated field. Once the nerve has been identified, its course
is traced through to the insertion into the cricothyroid muscle. The recurrent laryngeal nerve
should not be sought at the fibrosed upper pole, as the risk of subsequent damage is extremely
high. Mobilization of the thyroid is by capsular dissection. Sub-sternal recurrent goitre may
increase the difficulty of surgical management and may be associated with a significantly
higher rate of recurrent laryngeal nerve damage as it exits the thoracic inlet. A sternal split is
rarely required. However, where there is excessive local bleeding or where removal of the
gland is prevented by excessive fibrosis a partial sternal split provides adequate access [124].
10.6. Retrosternal thyroid extension
Given the embryological descent of the thyroid most extension of the thyroid gland is into the
anterior and superior mediastinum. In the majority of cases the retrosternal component of the
thyroid gland can be delivered into the neck with gentle traction upwards given the position
the patient on the operation table [105]. In the small number of cases where the thyroid extends
behind the trachea and enters into the posterior mediastinum, there is a risk of injury to major
vessels and structures within the chest and a median sternotomy in conjunction with the
cardio-thoracic surgeons should be performed [105].
10.7. Postoperative care
Post operative patients are monitored closely for complications. Typically, thyroid surgery is
performed as a 23 hour surgical stay but increasingly in smaller cases there has been a move
to day case surgery. Patients are observed for exclusion of a post-operative haematoma and
subsequent airway compromise as well as for signs and symptoms of hypocalcemia in the
immediate post-operative period. Close monitoring of calcium levels especially in sympto‐
matic patients is crucial. Clinical tests of hypocalcaemic, including Chvostek’s sign (tapping
of facial nerve causing facial muscles to twitch) and Trousseu’s sign (finger and wrist spasm
on insufflation of a sphygnomanomator cuff around arm), may be present [125]. Studies have
shown that oral calcium and vitamin D supplementation has been found to decrease the
development of hypocalcaemic symptoms. However, a randomized trial that included 143
patients undergoing a total thyroidectomy, showed that patients with a PTH level >10 pg/mL
obtained on post-operative day one could be safely discharged without routine calcium
supplementation [126]. Calcium levels need to be followed up as hypercalcaemia may occur.
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In addition short term courses are usually sufficient and supplementation may be discontinued
once levels are normalised.
It is recommended that thyroid hormone is started on the first post-operative day in patients
who have undergone a total thyroidectomy. Serum TSH and free T4 are tested 6 weeks
postoperatively and the dose of oral thyroxine adjusted accordingly. Anti-thyroid medications
are stopped following surgery and beta-blockers may be weaned.
11. Complications of surgery
The most important complications of thyroid surgery include recurrent laryngeal nerve injury,
external superior laryngeal nerve injury, hypoparathyroidism, laryngeal oedema, bleeding,
hypothyroidism/hyperthyroidism, wound infection and keloid scarring. Morbidity from
thyroid surgery is minimised with meticulous anatomical dissection and operating in a
bloodless field.
11.1. Airway obstruction
This complication, although rare, remains life-threatening. This can be due to sub-glottic and
laryngeal oedema caused by venous and lymphatic obstruction, post-operative haematoma
formation or bilateral recurrent laryngeal nerve damage. The identification of early signs of
airway obstruction are crucial. It is recognised by a distressed patient and the presence of
increasing stridor. Immediate suture removal and exploration of the wound is warranted. If
no haematoma is demonstrated then one may proceed with conservative treatment with
humidified oxygen and the administration of intravenous glucocorticoids. Anaesthetic input
is recommended as intubation may be necessary to secure the patient’s airway [22].
11.2. Haemorrhage
Haemostasis is paramount in thyroid surgery. Bleeding from the thyroid arteries and veins or
the thyroid remnant can lead to the development of a haematoma deep to the strap muscles.
A haematoma requires immediate decompression by opening all the layers of the wound and
return to the operating room to control the underlying bleeding. The airway must be secured
and sometimes a definitive airway is required although intubation for 24 hours with use of
glucocorticoids and subsequent trial of extubation may save the patient a tracheostomy [22].
11.3. Nerve damage
Recurrent laryngeal nerve injury is rare and has been reported to occur 0.3-3% of cases
permanently [127]. The incidence is increased in recurrent thyroid surgery and total thyroi‐
dectomy compared with thyroid lobectomy. The nerve can be typically injured or divided
during ligation of the inferior thyroid artery or as it enters the larynx at the ligament of Berry.
Mobilisation of large goitres can also stretch the nerve and make it more vulnerable to damage
[10]. Paresis or partial damage of RLN, which is more common than complete transection,
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results in the vocal cord on the affected side adopting a midline adducted position [10].
Transient paresis of the RLN can occur with rates of 1.8% at one month and 0.5% at 3 months
for first time operations suggesting improvement with time [22]. Symptoms of unilateral RLN
damage include hoarseness, inability to speak loudly, fatiguable of the voice and an increased
risk of aspiration [128]. In bilateral RLN damage both cords adopt a midline position and
symptoms include total loss of voice, stridor and airway compromise requiring tracheostomy
[10]. Measures to reduce RLN injury include pre-operative laryngoscopy to assess vocal cord
function, direct identification of RLN and use of vocal cord stimulator intra-operatively.
The external branch of the superior laryngeal nerves lies close to the superior thyroid artery
and can be damaged as the vessels are ligated and divided. Damage to the SLN causes the
inability of the cricothyroid to tighten the vocal cords resulting in a weakness in phonation
and a change in pitch of the voice [10]. These findings are more subtle than damage to the RLN
and may be overlooked unless patients are specifically asked regarding symptoms [10].
Measures to avoid SLN injury include individually ligating the arterial branches close to the
thyroid gland and identifying the nerve where possible [22].
11.4. Hyperthyroidism / Hypothyroidism
Hypothyroidism occurs with total thyroidecomy. In thyroid lobectomy, the incidence of
hypothyroidism can be as high as 50% although the rate quoted is predominantly less than
this, typically 20% [129]. Port-operative monitoring and follow-up of thyroid function is
therefore needed. Hyperthyroidism, on the other hand, represents failure of the operation or
the presence of thyroid remnants left in situ at the time of the operation. This occurs in around
5% of patients. The three common site of embryological recurrence or persistence of nodular
goitre are within the pyramidal lobe, within thyroid rests in the thyrothymic tract or within
posterior remnants associated with the tubercle of Zuckerkandl (Figure 9).
11.5. Parathyroid insufficiency and hypocalcaemia
Inadvertent damage or removal of a parathyroid gland can result in either temporary or
permanent hypoparathyroidism post operatively. Careful identification of the parathyroid
glands and their preservation are crucial in order to avoid this complication as discussed above.
A study by Thomusch et al demonstrated transient hypoparathyroidism in 7.3% of patients
and permanent parathyroid dysfunction in 1.5% of patients [130]. Ionised calcium and PTH
levels should be measured immediately postoperatively, before discharge and at outpatient
review. Thomusch et al demonstrated a correlation between long term hypoparathyroidism
and the extent of initial surgery [130]. Further work within this group demonstrated other
significant factors for the development of hypoparathyroidism which included patient gender,
hospital operative volume, and Graves' disease [131].
The symptomatic outcome of hypoparathyroidism if either temporary or permanent hypo‐
calcemia [132]. Symptoms of hypocalcemia include paresthesia (especially circumorally and
in digits), cramps, carpopedal spasm, tetany and convulsions. Treatment is with calcium
supplementation orally or intravenously depending on degree of hypocalcemia and the
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presence of symptoms. Oral Vitamin D replacement can also be required. If calcium levels fail
to increase the serum magnesium should be assessed and replaced as required [132].
Surgeons should be aware of the possibility of thyrotoxic patients developing Hungry bone
syndrome post-operatively. As previously mentioned the presence of hyperthyroidism
increases bone turnover [133,134] Therefore similar to its pathogenesis in parathyroid bone
disease, removal of the excess thyroid hormone stimulation post thyroidectomy causes an
imbalance in bone formation-resorption leading to an increase uptake of calcium, phosphate
and magnesium in the osteoporotic bones [135,136] This leads to profound hypocalcemia,
hypophosphatemia and hypomagnesemia. Treatment is with careful monitoring and electro‐
lyte replacement [136].
Figure 9. Embryological development of the thyroid gland [118]
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This life-threatening condition is rarely seen post-operatively and is an acute exacerbation of
thyroitoxicosis with an associated adrenergic response [137]. It accounts for less than 1–2% of
all hospital admissions with hyperthyroidism but the mortality remains high at approximately
20–30% [138,139]. It typically occurs in patients who do not have an underlying diagnosis of
hyperthyroidism. The crisis has an abrupt onset and is almost always evoked by a precipitating
factor, such as infection, trauma, thyroidal surgery or radioactive iodine [3,16]. It is usually
documented in patients undergoing thyroid surgery without adequate pre-operative prepa‐
ration or where the diagnosis of thyrotoxicosis was not established [22]. Hormones released
as a result of thyroid gland manipulation result in acute post-operative thyrotoxicosis[140].
Patients in crisis present with fever, abdominal pain, vomiting, diarrhoea, psychosis, altered
mental state and coma. Signs include tachycardia, hypertension or hypotension, hyperpyrexia,
atrial fibrillation and signs of congestive heart failure [141]. Treatment is aimed at reducing
thyroid hormone secretion, supportive treatment and treatment of any underlying cause. It
includes immediate fluid resuscitation, cooling with ice packs, supplemental oxygen, intra‐
venous dextrose, diuretics and digoxin [22]. Specific treatments include intravenous beta
blockers, propylthiouracil, potassium iodide and high dose steroids. Ensuring adequate and
meticulous pre-operative preparation of patients should prevent this situation.
11.7. Tracheomalacia
Tracheomalacia represents a rare entity that is not completely understood. This condition is
postulated to occur secondary to longstanding extrinsic tracheal compression with subsequent
loss of tracheal cartilage rigidity, culminating in dynamic airway collapse in excess of 50% of
diameter [142]. The typical manifestation of post-operative tracheomalacia is acute respiratory
distress following extubation not explained by any other cause. This necessitates prompt re-
intubation or a tracheostomy and the addition of high doses of glucocorticoids. A number of
series failed to show cases of tracheomalacia [143,144], while a small number has been reported
in others [145]. It has been postulated that this entity has been mistaken for unrecognised
bilateral vocal cord paralysis [146]. Tracheomalacia is treated with intubation, tracheotomy,
mesh repair of the posterior tracheal wall, trachelopexy and grafting.
12. Conclusion
Hyperthyroidism occurs as a result of an increase in thyroid hormone synthesis and secretion
by the thyroid gland. This most commonly manifests as Graves’ disease, multi-nodular goitre
or a solitary toxic nodule. The management of hyperthyroidism is based on three treatment
modalities, namely anti-thyroid medication, radioactive iodine ablation or surgery. Surgery
increasingly plays an important role in the management of benign thyroid disease and has
evolved into a cost-effective treatment with minimal associated morbidity and mortality. Total
thyroidectomy is the surgery of choice in Graves’ disease, while a total thyroidectomy or
thyroid lobectomy are utilised in patients with toxic nodular goitres and this choice is dictated
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by the disease site and extent. Although thyroid surgery can be associated with significant
complications, in high volume operative centres surgery provides effective long-lasting
resolution of hyperthyroidism and therefore should be considered an integral component of
treatment rather than the last resort of clinicians
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1. Introduction
A moderately built 25-year-old female with a 24-week pregnancy and per-vaginal bleeding is brought
to the operation theatre in the wee hours of the morning for suction evacuation. Her medical and surgical
histories are unremarkable. She is highly irritable and moderately pale. She has a pulse rate of 156 beats
per minute, blood pressure of 110/80 mm of Hg, respiratory rate of 32 breaths per minute and mild pedal
oedema. Her haemoglobin level is 8 gm/dl. Her thyroid function tests are markedly deranged showing
severe biochemical hyperthyroidism (SerumT3– 6.46 mmol/L, T4 – 470 nmol/L and TSH – 0.03 μ IU/
ml). The serum β hCG levels are markedly raised. An ultra-sonogram shows signs of a complete molar
pregnancy.
This is a typical presentation of gestational trophoblastic disease with trophoblastic hyper‐
thyroidism.
Gestational trophoblastic disease includes a group of pregnancy-related tumours called
trophoblastic tumours. These include hydatidiform mole and choriocarcinoma. Hyperthyr‐
oidism is a rare complication of gestational trophoblastic disease. It is called trophoblastic
hyperthyroidism.
2. Gestational trophoblastic disease
The abnormal proliferation of trophoblastic tissue in the developing human placenta results
in the condition known as Gestational Trophoblastic Neoplasia [1,2]. Gestational Trophoblastic
Neoplasia lesions are histologically distinct malignant lesions that include hydatidiform mole,
choriocarcinoma, placental site trophoblastic tumour and epithelioid trophoblastic tumour.
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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Gestational Trophoblastic Neoplasia often arises after molar pregnancy. It can also occur after
any gestation including miscarriages and term pregnancies [2].
Gestational trophoblastic disease is a family of diseases that includes complete and partial
molar pregnancy also known as hydatidiform mole, locally invasive or Disseminated chorio‐
carcinoma and placental site trophoblastic tumour [3]. Placental site trophoblastic tumour,
invasive mole and choriocarcinoma are termed Gestational Trophoblastic Tumours. They are
malignant while hydatidiform mole is a benign form of Gestational Trophoblastic Disease [4].
2.1. Classification of gestational trophoblastic disease (FIGO) (International Federation of







• Placental site trophoblastic tumor
• Epithelioid trophoblastic tumor
2.2. Hydatidiform mole
It is an abnormal condition of the ovum where there are partly degenerative and partly
hyperplastic changes in the young chorionic villi. These result in the formation of clusters of
small cysts of varying sizes. Because of its superficial resemblance to hydatid cyst, it is named
as hydatidiform mole and the pregnancy associated with it is known as molar pregnancy. It
is best regarded as a benign neoplasia of the chorion with malignant potential [6].
Molar pregnancy is common in Oriental countries – Philippines, China, Indonesia, Japan and
India as also in Africa and Central and Latin America [6]. The incidence of molar pregnancy
has been reported to range between 0.5 and 2 to 2.5 per one thousand pregnancies [7,8,9]. In
some Asian countries, the incidence is as high as 1 in 82 pregnancies [1]. The highest incidence
is in Philippines being 1 in 80 pregnancies and lowest in European countries, North Ameri‐
ca,Australia and New Zealand [6,10]. In the United States,hydatidiform moles are observed in
approximately 1in 600 therapeutic abortions and 1 in 1000-2000 pregnancies [2,11]. The
incidence in India is about 1 in 400 pregnancies [12]. In Nepal, the incidence of gestational
trophoblastic disease as per records from different hospitals is 5.1,2.9,2.8and 4.1 per 1000 live
births [13].The incidence of hydatidiform mole in the Middle East is 1:60 to 1:500 [14].
Molar pregnancies develop as a result of abnormal fertilisation [6]. Risk factors for developing
a molar pregnancy include advanced maternal age, teen age, inadequate nutrition, disturbed
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maternal immune mechanisms, cytogenetic abnormality, environmental factors and a history
of hydatidiform mole [1]. Although most molar pregnancies are sporadic, a familial syndrome
of recurrent hydatidiform mole has been described and first reported in 1980, suggesting an
autosomal recessive inheritance pattern [15,16].
2.2.1. Pathology of hydatidiform mole [6]
Naked eye appearance. (fig 1)
The mass in the uterus is made of multiple chains and clusters of cysts of varying sizes from
a pin head to that of a large grape. The embryo and amniotic sac may or may not be seen. Red
areas may be seen suggesting haemorrhage in the decidual space [6] (fig 1)
Figure 1. Gross appearance of hydatidiform mole
Microscopic appearance
The villus pattern is distinctly maintained. The vesicles are filled with interstitial fluid that is
almost similar to ascitic or oedema fluid but rich in hCG. There are no blood vessels.
2.2.2. Clinical features of hydatidiform mole
The  traditional  presenting  features  include  vaginal  bleeding,  excessive  uterine  size,
hyperemesis gravidarum, theca lutein cysts and preeclampsia in early pregnancy [17,18].
The clinical presentation has significantly changed in the past years [19].Modern facilities
like ultrasonography and serum alpha hCG help early diagnosis even before any signs and
symptoms appear [20].
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1. Vaginal bleeding – It may be mixed with fluid from the ruptured cysts giving the
appearance of ‘white currant in red currant juice’.This is the most common symptom,
being present in about 70-90% cases. [19]
2. Lower abdominal pain-This is due to infection, uterine perforation or uterine contractions.
3. Constitutional symptoms – Patient appears sick, has excessive vomiting, breathlessness,
thyrotoxic features like tremors, palpitations, anxiety, weight loss and increased appetite.
4. Expulsion of grape-like vesicles per vaginum.
Signs: [6]
1. Signs of early pregnancy.
2. Patient looks very ill.
3. Prominent pallor out of proportion to blood loss.
4. Features of toxaemia (hypertension, oedema and proteinuria) are present in about 50% of
cases. Rarely convulsions may occur.
5. Per abdomen –
a. The size of uterus is more than expected for the period of amenorrhoea.
b. The uterus feels firm and elastic(doughy) because of the absence of amniotic fluid
sac.
c. Foetal parts are not felt; absence of foetal movements.
d. Absent foetal heart sounds.
6. Per vaginum-
a. Internal ballotment cannot be elicited.
b. Unilateral or bilateral enlarged palpable ovaries are seen in 25-50% of cases.
c. Vesicles are seen in vaginal discharge.
2.2.3. Investigations and diagnosis
1. Serial quantitative estimation of hCG-The hallmark of diagnosing hydatidiform mole is
a positive β-hCG urine assay pregnancy test [18]. High hCG titre in urine diluted up to 1
in 200 to 1 in 500 beyond 100 days of gestation is very suggestive [6]. A retrospective
analysis of molar pregnancies reported that 75% of patients present with vaginal bleeding,
while 54% presented with enlarged uterus for gestational dates and 100% had excessively
elevated β-hCG levels [18]. Qualitative β-hCG urine assays may be misleading in molar
pregnancy. There have been reports of false negative both, urine and serum β-hCG
pregnancy tests in hydatidiform mole [18].
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Christopher and Ladde reported a case of a molar pregnancy presenting with abdominal pain and vaginal
spotting with multiple false negative urinary pregnancy tests. The laboratory qualitative urine β-hCG
assays were negative. As she was being prepared for transport to the ultrasound suite, she discharged a
large, fleshy vesicular mass followed by profuse vaginal bleeding. They attributed this to the fact that
qualitative β-hCG assays like sandwich chromatography immunoassays may produce false negative
results in a phenomenon known as the high dose hook effect [18].
2. Ultrasonography-The characteristic ‘snowstorm appearance’ is seen (fig 3).
2.2.4. Types of hydatidiform mole – Molar pregnancies are categorised as complete or partial
Complete moles have diploid karyotype of solely paternal origin [18]. In a complete molar
pregnancy, the placenta becomes oedematous secondary to grossly enlarged hydropic
chorionic villi and in most cases the foetus, cord and amniotic membranes are absent [1]. The
traditional presenting features like vaginal bleeding, excessive uterine size, hyperemesis
gravidarum, hyperthyroidism, theca lutein cysts and preeclampsia in early pregnancy are
present [17,18]. Patients with a complete molar pregnancy have excessively high levels of
serum and urinary hCG resulting from trophoblastic proliferation [1]. hCG serves as a marker
for the tumour.The diagnosis is made by ultrasonogram demonstrating a snowstorm appear‐
ance without a foetus (fig 3) [7].
Partial moles have triploid karyotype of both maternal and paternal origin. Partial molar
pregnancies account for 10% of all hydatidiform moles [1]. In partial mole, there will be some
identifiable foetal tissue(fig 2). Sanchez-Ferrer ML et al have described an extremely rare case
of a partial hydatidiform mole with a normal fetus [21]. The classic clinical presentation
described for complete mole is rare in partial mole and significant hCG level elevation is less
common [15].Ultrasonography will not show the classical snow-storm appearance (fig 3). Most
often the diagnosis is made upon histological review of curettage specimens [15].
Figure 2. Specimen of partial mole.
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Figure 3. Transabdominal ultrasonogram showing‘snowstorm’ appearance of a complete mole in the uterus.
2.3. Complications of molar pregnancy
2.3.1. Immediate
Surgical [6]
1. Haemorrhage and shock – due to separation of vesicles or uterine perforation.
2. Sepsis – due to surgery and presence of degenerated vesicles and blood.
3. Uterine perforation – due to perforation by the mole or during surgery.
Medical
Eighty percent of cases of molar pregnancy are uncomplicated and twenty percent are
associated with an extensive list of medical complications like hyperthyroidism, severe
anaemia, haemorrhage, trophoblastic embolisation and pregnancy induced hypertension,
some of which may be of a critical nature [1,12,22].
2.3.2. Late
18-28% of patients with complete mole and 2-4% of patients with partial mole can develop
persistent neoplasia or post molar gestational trophoblastic neoplasia [15]. The development
of choriocarcinoma following hydatidiform mole ranges from 2-10% [6].
2.4. Management of hydatidiform mole [6]
The principles are:
1. To give adequate supportive therapy to restore blood volume.
2. To evacuate the uterus as soon as diagnosis is made. Complete evacuation of the uterus
is made by suction evacuation [1,12]. Hysterotomy is done in case of very low general
condition of the patient or profuse vaginal bleeding. Hysterectomy is done in patients
having three or more children or if patient’s age is more than 35 years.
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Suction dilatation and evacuation-Suction dilatation and evacuation is a safe, rapid and
effective method for evacuating hydatidiform moles [23,24]. If the patient has already started
to expel the mole, the process is hastened by starting an oxytocin drip of 10-20units. The
products can then be rapidly evacuated either digitally or with the help of suction cannula [25].
If the process of expulsion of mole has not started, then a definitive plan for uterine evacuation
is made. The cervix is dilated gently and slowly [19].If necessary,prostaglandin gels can be
introduced into the cervix to promote cervical softening and dilatation [25].Light and careful
curettage should be performed following the suction procedure to ensure complete evacuation
of the uterine content [19].The use of a bedside ultrasound unit at the time of the procedure
will ensure complete evacuation of uterine contents [23].
3. Prophylactic chemotherapy with oral methotrexate for 3 courses of 5 days each.
2.5. Invasive mole
The villus structure is maintained as in hydatidiform mole but the uterine wall may be
perforated in multiple areas (fig 4). Distant metastasis can occur via blood stream to lungs,
vagina or brain. The treatment is hysterectomy followed by cytotoxic therapy [6].
Figure 4. Specimen of an invasive mole
2.6. Choriocarcinoma
The incidence is 1 in 5000 pregnancies in Oriental countries and 1 in 50,000 in Europe and
North America. 50% of cases occur after molar pregnancies. The villous pattern of hydatidi‐
form mole is lost here and invasion of uterine wall accompanied by necrosis and haemorrhage
is seen.(fig 5) Distant metastases can occur to lungs(70%), anterior vaginal wall(50%),
brain(10%) and others [6]. Treatment is done with– [2,6]
1. Cytotoxic drugs.
2. Hysterectomy and cytotoxic drugs.
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Figure 3. Transabdominal ultrasonogram showing‘snowstorm’ appearance of a complete mole in the uterus.
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3. Adjuvant procedures like brain irradiation for cerebral metastasis, craniotomy in cerebral
metastasis, hepatic resection to control bleeding from hepatic metastasis and vaginal
packing for bleeding from vagina.
Figure 5. Specimen of choriocarcinoma of the uterus
2.7. Cytotoxic drugs in Gestational Trophoblastic Neoplasias [2]
Gestational Trophoblastic Neoplasias are highly responsive to chemotherapy. Early stage
Gestational Trophoblastic Neoplasia is often cured with single agent chemotherapy. Advanced
stage requires multiple agent combination regimens. EMACO (Etoposide, Methotrexate,
Actinomycin-D, Cyclophosphamide and Vincristine) is the most commonly used regimen for
stage IV tumours. MAC regimen with Methotrexate,Actinomycin-D and Cyclophosphamide
is also used.
3. Relationship between hCG and thyroid
hCG is a placental glycoprotein. Its levels are high in the first trimester of pregnancy. It
shares some structural similarity with TSH [26,27] (fig6). It is composed of alpha and beta
subunits,  non covalently linked.  The alpha subunit  is  identical  to  that  found in TSH. It
consists of a 92 aminoacid chain containing two nitrogen linked oligosaccharide side chains
[3].  The beta subunit of hCG consists of 145 aminoacid residues with two N linked and
four O linked oligosaccharides. The beta subunit of TSH is composed of 112 residues and
one N linked oligosaccharide [28]. TSH and hCG thus share a molecular mimicry and have
similar effects on the thyroid [29]. Nonetheless, hCG receptors share 45% homology with
the TSH receptors [3].
Several data indicate that hCG is a weak human thyrotropin [30]. In 1967, Burger reported that
impure, commercial hCG had thyroid stimulating activity in a mouse bioassay [31]. Bioassays
in mice, rats, chicks show that hCG stimulates iodine uptake, activates adenylate cyclase and
increases DNA synthesis in cultured rat thyroid cells [32]. It also activates the TSH receptor.
But the relative potency of hCG for the TSH receptor is 4000 times less than TSH [3]. It has
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been calculated that hCG contains approximately 1/4000th of the thyrotropic activity of human
TSH. In bioassays, hCG is only about 1/10000th as potent as human TSH during normal
pregnancy [33]. High circulating levels of hCG with their TSH like activity in the first trimester
of pregnancy may result in a slightly low TSH and an increase in free T4 concentration. hCG
may stimulate maternal T4 secretion [34]. It is estimated that an increment of hCG of
10,000UL-1 results in an increase of free T4 of 0.6pmolL-1 and a decrease in TSH of 0.1mUL-1
[35].Braunstein and Hershman reported that there was an inverse relationship between TSH
and hCG at about 10-12 weeks of pregnancy, the time of peak hCG levels [36]. Harada showed
an increase of free T4 and free T3 associated with the peak hCG [37,38].Serum TSH levels
particularly between 7 and 12 weeks of gestation fall to a nadir and present a mirror image
with peak hCG values.(fig 7) The lower normal TSH limits in first trimester is approximately
0.03-0.08 mIUL-1 secondary to the thyrotropic activity of hCG [7].
Highly purified standard hCG has only trivial TSH like activity [39,40]. Certain fractions of
hCG have greater TSH like activity than others [35]. The thyrotropic activity of hCG is
influenced by the number and structure of its oligosaccharide side chains. Deglycosylation
and partial desialation (removal of sialic acid) of β subunit of hCG enhances its thyrotropic
potency in rat thyroid cells [41]. Nevertheless, the circulating hCG patterns are different at
various stages of gestation [42]. HCG with reduced sialic acid content is increased in pregnant
patients with hyperthyroidism [40]. Partially desialated hCG has the greatest TSH like activity
and is often increased in molar pregnancy [35].
The development of hyperthyroidism due to hCG is largely influenced by the level of hCG.
Clinically  measurable  changes  in  thyroid  hormone concentration  are  only  likely  if  hCG
levels are around 50,000-70,000 mIUL-1 or more [35]. Extremely high levels are required for
the development of clinical hyperthyroidism. Case studies have indicated that, serum levels
of hCG of >100,000 mIUL-1 are usually needed to produce clinical evidence of thyrotoxico‐
sis [3]. Such high levels are seen in conditions like hyperplacentosis, hyperemesis gravida‐
rum, gestational trophoblastic disease, multiple pregnancy and hyper reaction-luteinalis [7].
These conditions are associated with the clinical  entity known as ‘transient non autoim‐
mune hyperthyroidism in early pregnancy’ wherein hCG is the main mediator of hyperthyr‐
oidism [7].
Figure 6. hCG molecular structure and major pituitary TSH glycoforms
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Figure 7. The pattern of serum TSH and HCG changes are shown as a function of gestation age. Between 8 and 14
weeks gestation, changes in serum hCG and TSH are mirror images of each other, and there is a significant negative
correlation between the individual TSH (nadir) and peak hCG levels.
4. Epidemiology of hyperthyroidism in gestational trophoblastic disease
Concomitant biochemical thyroid disease in patients with gestational trophoblastic disease is
relatively common [3]. Although hyperthyroidism has been reported more frequently in
women with a hydatidiform mole than in those with choriocarcinoma, there have been many
reports of hyperthyroidism in women with choriocarcinoma as well as a few men with
testicular tumours [28].
The prevalence of hyperthyroidism in patients with hydatidiform mole and choriocarcinoma
has been reported to be as high as 25-64% [28]. Hyperthyroidism develops in 5-10% cases of
molar pregnancy and an incidence up to 30% is reported in India [43]. The prevalence of
hyperthyroidism during complete molar pregnancy is as high as 7% [43]. In a study, 30 of 52
patients with gestational trophoblastic neoplasia were found to be thyrotoxic. The New
England Trophoblastic Disease Centre estimated that 20% of women with complete moles have
hyperthyroidism [28]. But in the same centre, between 1988 and 1993, none of 74 patients with
complete mole demonstrated evidence of hyperthyroidism [15].Biochemical hyperthyroidism
has been reported in a patient with a dichorionic pregnancy with one viable foetus and a
hydatidiform mole [44].
Clinical hyperthyroidism is found in approximately 5% of women with a hydatidiform mole
[26]. Clinical thyrotoxicosis is rare in molar pregnancy [45]. Clinical thyrotoxicosis is even more
rare in patients with partial mole. The first such case was reported in 2008 [46].Rarely the
thyroid stimulation can have potentially life threatening consequences [3]. The prevalence of
thyrotoxicosis in patients with trophoblastic tumors was reported to be close to 50% in some
older studies [7,47]. But nowadays with the ability of early detection of the disease, the
incidence is much lower.
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5. Aetiology of hyperthyroidism in molar pregnancy
Historically,  the first  association between hyperthyroidism and a product of  the tropho‐
blast was noted in patients with trophoblastic tumours [28]. In 1971, Hirshman and Higgins
reported  two  case  of  severe  hyperthyroidism  in  patients  with  hydatidiform  mole  and
demonstrated for  the  first  time thyrotropic  activity  in  molar  tissue [48].  This  stimulator
differed  biologically  and  immunologically  from  the  other  three  human  stimulators  i.e.
pituitary thyrotropin, chorionic thyrotropin found in normal pregnancies and the LATS in
Grave’s  disease  [7].  They  speculated  that  an  excessive  amount  of  the  extracted  molar
stimulator was responsible for the hyperthyroidism in both people [7].Hyperthyroidism in
patients with molar pregnancy is thought to occur as a manifestation of excessive levels of
circulating hCG which has a weak intrinsic thyroid stimulating activity, or from a thyrotro‐
pin like substance released from the mole [1,33,43].
Extremely high levels of hCG are typically required for the development of clinical hyper‐
thyroidism as the relative potency of hCG for the TSH receptor is relatively low [3].HCG levels
always exceed 300 IUml-1 in patients with hyperthyroidism caused by trophoblastic disease
[41]. The hCG levels are particularly high at 10-14 weeks of gestation in trophoblastic disease
[44]. In gestational trophoblastic disease, high levels of hCG cause activation of the thyrotropin
receptor and stimulate supraphysiological secretion of thyroid hormone [44]. The level of
thyroid stimulation is directly proportional to the hCG concentration [3]. Lemon et al studying
thyroid function in trophoblastic diseases reported a high correlation between levels of hCG
and TSH measured by radio-immunoassay secondary to cross-sensitivity of TSH and hCG
with the antibody they used [49]. None of their patients were clinically hyperthyroid and there
was poor correlation between hCG and T3 or T4 levels although high levels of thyroid hormone
occurred only at hCG levels greater than 100,000mIU/ml. Basic isoforms of hCG with high
bioactivity-immunoactivity ratio may be responsible for hyperthyroidism in some patients
with trophoblastic disease [28]. Nevertheless, the hCG molecule from women with tropho‐
blastic diseases has been found to display enhanced thyrotropic activity [50].
Some studies have however, revealed no significant relationship between elevation of serum
hCG  and  abnormally  high  values  of  free  thyroxine  index  in  patient  with  trophoblastic
tumors. These studies suggest that a substance distinct from hCG and elaborated by the
gestational trophoblastic tissue is responsible for thyrotoxicosis observed in patients with
trophoblastic  tumours.The  molar  thyrotropin  existing  in  the  serum  of  patients  with  a
hydatidiform mole differs from hCG by its larger molecular size and the duration of action,
which is longer [33,43,51].
6. Spectrum of biochemical abnormalities in trophoblastic
hyperthyroidism
1. The level of thyroid stimulation is directly proportional to hCG concentration and hence
the severity of clinical hyperthyroidism reflects the hCG level in gestational trophoblas‐
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tic disease. In patients with molar hyperthyroidism, serum hCG levels usually exceed
300U/ml and always exceed 100 U/ml. Patients with clinical evidence of thyrotoxico‐
sis may have serum levels of hCG of >100,000 mIU/L. However, some patients with
trophoblastic tumors with very high serum hCG levels do not manifest hyperthyroid‐
ism [3,28].
2. In patients with molar pregnancy, evidence for pronounced hypersecretion of T4 is
present. Hence, elevated serum free T4 & T3 levels are found [47].
3. A pattern of high values of serum protein bound iodine(PBI) and serum tri-iodothyronine
reaction(T3test)and relatively low values of serum cholesterol have been seen in most
patients with hydatidiform mole [52].
4. Pronounced increase in urinary P/C ratio occurs in patients with molar pregnancy
suggesting that they are hypermetabolic [47].
5. Dowling, Ingbar and Freinket were the first to note the occurrence of striking abnormal‐
ities in several aspects of thyroid economy in patients with molar pregnancy. They found
marked increases in serum PBI, PB131I, butanol-extractable 131I, thyroidal 131I uptake and
absolute iodine uptake(AIU) in the patients [53]
6. In some cases, even when serum free T4 and T3 concentrations were only slightly elevated,
serum TSH concentrations were low and serum TSH responses to TRH were low [28].
7. Several patients of trophoblastic tumors demonstrated thyroid hyperfunction or marked
increases in serum PBI but failed to display signs or symptoms of frank thyrotoxicosis [47].
7. Comparison of trophoblastic hyperthyroidism with other types of
hyperthyroidism and with the thyroid economy of normal pregnancy
[28,47]
1. Patients with trophoblastic hyperthyroidism have higher serum T4/T3 ratiosthan patients
with Grave’s hyperthyroidism.
2. Thyroid stimulating immunoglobulin is not detectable in trophoblastic hyperthyroidism
unlike Grave’s Disease.
3. Several of the changes in certain aspects of thyroid economy which occur in molar
pregnancy resemble superficially those seen in normal pregnancy. These include the
increase in thyroidal 131I uptake and serum PB131I; inpatients with molar pregnancy,
however, these indices tend to be more markedly increased.Values for serum PBI and
T4 concentration in molar pregnancy are usually much greater than in normal pregnancy.
4. In patients with the usual varieties of hyperthyroidism, the absolute concentration of free
T4 in serum is usually quite elevated as a result of increase in both: the total concentration
of T4 in serum and the free proportion. In patients with molar pregnancy, a smaller increase
in concentration of free T4 is generally seen since the proportion of free T4 is subnormal.
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5. Trophoblastic tumours secrete less oestrogen than normal placental tissue so that the
increase in serum thyroxine-binding globulin (TBG) concentration is less in molar
pregnancy than in normal pregnancy.
8. Some biochemical case profiles of trophoblastic hyperthyroidism
There is a spectrum of thyroid function abnormalities in gestational trophoblastic neoplasias
and thyroid function in an individual patient is determined by the relative influence of the
thyroid stimulator, nonthyroidal illnesses and the pregnancy [54].
1. In a study of the thyroid status of 27 African patients with gestational trophoblastic
neoplasia, 15 patients were found to be biochemically hyperthyroid. Of the 15 patients, 9
were clinically thyrotoxic. It was found that when serum levels of hCG reached a level of
about 0.1x106IU/L, 13 of 16 patients were biochemically hyperthyroid; at serum levels of
0.3x106IU/L of hCG, most patients were clinically thyrotoxic. T4 was invariably raised in
these patients but the T3:T4 ratios tended to be low(0.015 ± 0.005);rT3:T3 ratios were high
and TSH levels were not raised [55].
2. In 7 patients with metastatic trophoblastic disease, there was laboratory evidence of
increased thyroid function but clinical hyperthyroidism was either not present or minimal
and thyroid gland size was normal. There was uniform elevation of 24 hour radioiodine
uptake, serum PBI, BMR and the serum cholesterol was depressed [56].
3. In a study on 47 patients with hydatidiform mole, only 1 was found to be clinically
hyperthyroid, although 10 had serum total thyroxine values exceeding those found in
normal pregnancy(8 to 17 μ gm/dl). Among 34 patients in whom free thyroxine indices
could be calculated, 18 had elevated values for the free thyroxine index(>10.6), and 9 had
elevated values for total thyroxine and free thyroxineindex [57].
4. An 131I –tracer test performed in a patient with molar pregnancy indicated a very high
thyroidal 131I uptake, conversion ratio and thyroidal 131I secretion rate [58].
5. Studies on 11 patients were done before and after removal of a molar pregnancy. Before
evacuation of the mole, all patients demonstrated moderately to greatly elevated values
for thyroidal 131I uptake, absolute iodine uptake and serum protein bound 131I. Values for
serum PBI and serum thyroxine (T4) concentration were consistently increased averaging
more than twice found in normal pregnancy. The maximum binding capacity of the T4-
binding globulin(TBG) was variably affected and ranged between the values found in
normal controls and those found in the normal pregnancy. Values for the absolute of free
T4 in the serum were only moderately elevated since the proportion of free T4 was
moderately low, although not as low as in normal pregnancy [47].
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T4 in the serum were only moderately elevated since the proportion of free T4 was
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9. Clinical presentation of hyperthyroidism in gestational trophoblastic
disease
Hyperthyroidism has been reported as a complication of complete mole and persistent
trophoblastic disease, both metastatic and non metastatic [41]. Trophoblastic hyperthyroidism
has a widely divergent clinical pattern. Clinical hyperthyroidism is usually seen in patients
with extremely high levels of hCG [30]. The clinical scenario may vary from absence of
symptoms to thyroid storm [41,59]. Hyperthyroidism presents clinically as a physiological
state dominated by an increased metabolic rate.Myocardial contractility, heart rate, stroke
volume and ventricular size increase. Peripheral vascular resistance decreases in skin and
muscle The typical clinical findings include fatigue, weight loss, nervousness, excessive
sweating, heat intolerance, hyperactivity, tremor, weakness, hyperdynamic precordium,
diarrhoea, increased appetite, incapacitation [27], muscle weakness, tachycardia, minimal or
no enlargement of thyroid gland. Ophthalmopathy is not observed in this condition [41].
Cardiomyopathy is seen. Reflexes become hyper-reactive. [27].
Mild to moderate hyperthyroidism may be difficult to diagnose clinically during pregnancy
since normal parturients may experience symptoms such as heat intolerance, tachycardia,
emotional instability and vomiting. A resting tachycardia not slowed by the Valsalva ma‐
noeuvre is a strong indication of hyperthyroidism [60]. Several patients develop supra-
ventricular tachycardia and pulmonary oedema. The nausea, vomiting and toxaemia of
pregnancy that occur commonly in molar gestation may obscure the features of hyperthyr‐
oidism [28].
The development of biochemical and clinical thyrotoxicosis in patients with choriocarcinoma
depends upon the duration of the choriocarcinoma and the level of hCG [61]. In choriocarci‐
noma, the symptoms of metastasis to pelvis, lung, liver and brain may dominate the clinical
picture. There may be laboratory evidence of increased thyroid function without clinically
overt hyperthyroidism just as in hydatidiform mole [28].
During emergency surgery, the cardiovascular clinical manifestations of hyperthyroidism like
tachycardia can often be missed because they may be attributed to hypovolaemia [59].
10. Management of trophoblastic hyperthyroidism
Surgical removal of the hydatidiform mole in a hyperthyroid patient rapidly cures the
hyperthyroidism and should be performed as soon as possible [43,59]. Therapy of hyperthyr‐
oidism is not indicated in the vast majority of cases, since evacuation of the mole or chemo‐
therapy in the management of choriocarcinoma, removing high levels of hCG, cures the
hyperthyroidism. In those cases of severe symptoms, Lugol’s solution, intravenous iodine and
β blocking agents are indicated [7]. Therapy with potassium iodide given orally or sodium
iodide given intravenously(1 gm q8 hourly) will rapidly reduce serum free T4 and T3 levels.
Propranolol and other beta-adrenergic antagonist drugs are helpful to control tachycardia and
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other symptoms of sympathetic activation. Supportive measures such as fluid and electrolyte
replacement should be done as needed [28].
When hyperthyroidism occurs in the context of choriocarcinoma, case reports have demon‐
strated that the biomarkers of choriocarcinoma and thyroid function parallel the regression
and subsequent relapse of the tumor [3]. Several women with metastatic choriocarcinoma and
hyperthyroidism have achieved complete remission with chemotherapy. In the thyrotoxic
patient with choriocarcinoma, the hyperthyroidism should be treated by any of the usual
medical therapies [28]. The hyperthyroidism status secondary to molar disease rapidly
resolves after evacuation while that secondary to choriocarcinoma takes a longer time to
resolve [41].
Moskovitz JB and Bond MC reported the successful management of a case of thyroid storm in a 17year
old patient. She presented to a community hospital’s emergency department with history of palpitations
and tachycardia since one week. Βeta blockers and calcium channel blockers were administered. The
tachycardia partially responded. She was then referred to a tertiary centre for evaluation. There the
diagnosis of molar pregnancy was made using ultrasonogram and thyroid storm was diagnosed. She
was given intensive care support, treated with β-blockers and propylthiouracil. Surgical evacuation of
molar pregnancy was done and her symptoms soon resolved [62].
Walkington et al reported a case of a 21 year old woman who presented 2 months after a right salphin‐
gectomy for a ruptured ectopic pregnancy. She was breathless at rest, agitated and had a resting
tachycardia. Pelvis ultrasound and MRI showed a mass near right ovary. She was diagnosed with
choriocarcinoma with no evidence of metastasis. Serum hCG was 1.176x106IUL-1. Thyroid functions
showed her to be hyperthyroid with TSH <0.03 mIUL-1, free T4=73pmolL-1 and free T3=21.6pmolL-1. She
was commenced on carbimazole and propranolol. Her serum hCG and TFT measurements were as
follows (table 1). Her TFTs normalised in parallel with the fall in serum hCG. She was slowly weaned
off her anti-thyroid treatment and she became biochemically euthyroid at commencement of her third
cycle of chemotherapy [3].
Day HCG (IU l –1) TSH(mIU l– 1) FT4(pmol l –1) Carbimazole
0 791711 <0.03 73 40mgOD
7 156420 <0.03 15.2 40mgOD
21 19986 0.15 16.1 20mgOD
42 333 0.83 12.2 Stop
Abbreviations: FT4=free T4; HCG=human chorionic gonadotrophin; OD=once daily; TFT=thyroid function tests; TSH=thy‐
roid stimulating hormone
Table 1. Summary of serial HCG and TFT measurements
11. Perioperative management of trophoblastic hyperthyroidism
20% of cases of trophoblastic hyperthyroidism can develop severe perioperative complica‐
tions like high output cardiac failure secondary to thyrotoxicosis, thyroid storm, embolisa‐
Trophoblastic Hyperthyroidism and Its Perioperative Concerns
http://dx.doi.org/10.5772/57523
257
9. Clinical presentation of hyperthyroidism in gestational trophoblastic
disease
Hyperthyroidism has been reported as a complication of complete mole and persistent
trophoblastic disease, both metastatic and non metastatic [41]. Trophoblastic hyperthyroidism
has a widely divergent clinical pattern. Clinical hyperthyroidism is usually seen in patients
with extremely high levels of hCG [30]. The clinical scenario may vary from absence of
symptoms to thyroid storm [41,59]. Hyperthyroidism presents clinically as a physiological
state dominated by an increased metabolic rate.Myocardial contractility, heart rate, stroke
volume and ventricular size increase. Peripheral vascular resistance decreases in skin and
muscle The typical clinical findings include fatigue, weight loss, nervousness, excessive
sweating, heat intolerance, hyperactivity, tremor, weakness, hyperdynamic precordium,
diarrhoea, increased appetite, incapacitation [27], muscle weakness, tachycardia, minimal or
no enlargement of thyroid gland. Ophthalmopathy is not observed in this condition [41].
Cardiomyopathy is seen. Reflexes become hyper-reactive. [27].
Mild to moderate hyperthyroidism may be difficult to diagnose clinically during pregnancy
since normal parturients may experience symptoms such as heat intolerance, tachycardia,
emotional instability and vomiting. A resting tachycardia not slowed by the Valsalva ma‐
noeuvre is a strong indication of hyperthyroidism [60]. Several patients develop supra-
ventricular tachycardia and pulmonary oedema. The nausea, vomiting and toxaemia of
pregnancy that occur commonly in molar gestation may obscure the features of hyperthyr‐
oidism [28].
The development of biochemical and clinical thyrotoxicosis in patients with choriocarcinoma
depends upon the duration of the choriocarcinoma and the level of hCG [61]. In choriocarci‐
noma, the symptoms of metastasis to pelvis, lung, liver and brain may dominate the clinical
picture. There may be laboratory evidence of increased thyroid function without clinically
overt hyperthyroidism just as in hydatidiform mole [28].
During emergency surgery, the cardiovascular clinical manifestations of hyperthyroidism like
tachycardia can often be missed because they may be attributed to hypovolaemia [59].
10. Management of trophoblastic hyperthyroidism
Surgical removal of the hydatidiform mole in a hyperthyroid patient rapidly cures the
hyperthyroidism and should be performed as soon as possible [43,59]. Therapy of hyperthyr‐
oidism is not indicated in the vast majority of cases, since evacuation of the mole or chemo‐
therapy in the management of choriocarcinoma, removing high levels of hCG, cures the
hyperthyroidism. In those cases of severe symptoms, Lugol’s solution, intravenous iodine and
β blocking agents are indicated [7]. Therapy with potassium iodide given orally or sodium
iodide given intravenously(1 gm q8 hourly) will rapidly reduce serum free T4 and T3 levels.
Propranolol and other beta-adrenergic antagonist drugs are helpful to control tachycardia and
Thyroid Disorders - Focus on Hyperthyroidism256
other symptoms of sympathetic activation. Supportive measures such as fluid and electrolyte
replacement should be done as needed [28].
When hyperthyroidism occurs in the context of choriocarcinoma, case reports have demon‐
strated that the biomarkers of choriocarcinoma and thyroid function parallel the regression
and subsequent relapse of the tumor [3]. Several women with metastatic choriocarcinoma and
hyperthyroidism have achieved complete remission with chemotherapy. In the thyrotoxic
patient with choriocarcinoma, the hyperthyroidism should be treated by any of the usual
medical therapies [28]. The hyperthyroidism status secondary to molar disease rapidly
resolves after evacuation while that secondary to choriocarcinoma takes a longer time to
resolve [41].
Moskovitz JB and Bond MC reported the successful management of a case of thyroid storm in a 17year
old patient. She presented to a community hospital’s emergency department with history of palpitations
and tachycardia since one week. Βeta blockers and calcium channel blockers were administered. The
tachycardia partially responded. She was then referred to a tertiary centre for evaluation. There the
diagnosis of molar pregnancy was made using ultrasonogram and thyroid storm was diagnosed. She
was given intensive care support, treated with β-blockers and propylthiouracil. Surgical evacuation of
molar pregnancy was done and her symptoms soon resolved [62].
Walkington et al reported a case of a 21 year old woman who presented 2 months after a right salphin‐
gectomy for a ruptured ectopic pregnancy. She was breathless at rest, agitated and had a resting
tachycardia. Pelvis ultrasound and MRI showed a mass near right ovary. She was diagnosed with
choriocarcinoma with no evidence of metastasis. Serum hCG was 1.176x106IUL-1. Thyroid functions
showed her to be hyperthyroid with TSH <0.03 mIUL-1, free T4=73pmolL-1 and free T3=21.6pmolL-1. She
was commenced on carbimazole and propranolol. Her serum hCG and TFT measurements were as
follows (table 1). Her TFTs normalised in parallel with the fall in serum hCG. She was slowly weaned
off her anti-thyroid treatment and she became biochemically euthyroid at commencement of her third
cycle of chemotherapy [3].
Day HCG (IU l –1) TSH(mIU l– 1) FT4(pmol l –1) Carbimazole
0 791711 <0.03 73 40mgOD
7 156420 <0.03 15.2 40mgOD
21 19986 0.15 16.1 20mgOD
42 333 0.83 12.2 Stop
Abbreviations: FT4=free T4; HCG=human chorionic gonadotrophin; OD=once daily; TFT=thyroid function tests; TSH=thy‐
roid stimulating hormone
Table 1. Summary of serial HCG and TFT measurements
11. Perioperative management of trophoblastic hyperthyroidism
20% of cases of trophoblastic hyperthyroidism can develop severe perioperative complica‐
tions like high output cardiac failure secondary to thyrotoxicosis, thyroid storm, embolisa‐
Trophoblastic Hyperthyroidism and Its Perioperative Concerns
http://dx.doi.org/10.5772/57523
257
tion  of  pulmonary  arteries  by  trophoblastic  materials,  hypovolaemia,  disseminated
intravascular  coagulation,  pulmonary  oedema  secondary  to  severe  anaemia  and  acute
pulmonary distress secondary to any of these problems. They may require intensive care
support [1]. Hence the perioperative management and optimisation of hyperthyroid state
prior to surgical evacuation of the mole is very important [59].The perioperative manage‐
ment of hyperthyroidism focuses on the control of sympathetic activity so that cardiovascu‐
lar side-effects are not manifested [51].
11.1. Preoperative preparation
Preoperative optimisation with anti-thyroid and chemotherapeutic drugs is imperative to
reduce perioperative morbidity [59]. Every anaesthesiologist should be well aware of the
critical nature of perioperative complications that can be associated with a molar pregnancy.
A detailed pre-anaesthesia work up, preoperative optimisation of the patients’ thyroid and
volume status, planning and conducting anaesthesia carefully and being prepared for
advanced perioperative management are a must [63].
Preoperative evaluation of these patients should be based on history, physical examination
and laboratory testing [64]. The patient must be admitted to an intensive care unit preopera‐
tively. Blood count, electrolytes, blood gases, thyroid, hepatic, renal functions, β-hCG and
chest radiogram should be carefully evaluated [51]. Treatment has to be individualised. The
patient can be prepared for surgery with oral propylthiouracil (50-100mg qid), propranolol
(20mg tid), intravenous glucocorticoids and sodium iodide [27]. Some cases may require only
beta blockers whereas others may require in addition antithyroid drugs. Some may not require
any treatment if the hyperthyroidism is only biochemical and asymptomatic [41]. Dehydration
and anaemia if present should be corrected [25].
The  diagnosis  of  hyperthyroidism  in  molar  pregnancy  is  often  made  in  semi-urgent
conditions. Hence rapid stabilisation of the disease before surgery becomes important [45].
If there is no time to make the patient pharmacologically euthyroid, intravenous adminis‐
tration of iodine and β-adrenergic receptor blockers for emergency treatment of hyperthyr‐
oidism may be advisable [65]. These drugs, however, may be hazardous in patients who
have heart failure or pulmonary complications [64]. The role of plasmapheresis for the rapid
hormonal control in the preoperative period has been described. The use of plasmaphere‐
sis for the first time in the treatment of hyperthyroidism is reported in the 1970s. Erbil et
al  reported the  use  of  plasmapheresis  in  a  patient  with  severe  hyperthyroidism due  to
hydatidiform mole for the rapid control of hormonal levels [66]. A case of successful rapid
preoperative  preparation  by  3-4  sittings  of  plasmapheresis  of  a  patient  with  secondary
hyperthyroidism due to molar pregnancy has been described [67]. A study conducted by
Ozbey et  al  concluded that  plasmapheresis  is  a  treatment  option to  be  considered only
when anti-thyroid drugs are contraindicated [68].
11.2. Anaesthetic management
Sedation, monitored anaesthesia care, TIVA, general anaesthesia and spinal anaesthesia are
the various anaesthetic techniques that can be adopted for a case of evacuation of molar
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pregnancy [1,22,25,63]. Beta blockers for attenuation of sympathetic activity, emergency drugs
like lidocaine for ventricular arrhythmias, steroids and hypotensive agents like sodium
nitroprusside should be kept ready [69]. For patients with thyrotoxicosis due to molar
pregnancy, it is recommended that placement of invasive monitors like central venous
pressure be considered before induction of anaesthesia [1].
General anaesthesia may be the preferred technique in hypotensive bleeding patients sched‐
uled for emergency evacuation. Uterine relaxation caused by inhaled anaesthetics may
however increase blood loss [69]. Hence inhaled anaesthetics with known tocolytic qualities
such as halothane, enflurane and isoflurane should be used in lower concentrations [64]. A
nitrous oxide, opioid, muscle relaxant technique may also be preferred [51,64]. The safe use of
sevoflurane at 2.5 % concentrations has been reported by some authors without increasing the
chances of bleeding due to uterine relaxation [51].Drugs that minimally affect the cardiovas‐
cular system are the most rational choice in these patients [69]. Adequate premedication is
important to decrease unnecessary catecholamine release [69]. The anaesthesiologist should
avoid the administration of medications that stimulate the sympathetic nervous system and
should achieve an adequate depth of anaesthesia prior to surgical stimulation [69]. Medications
associated with tachycardia should be avoided e.g. atropine, ketamine.
In stable patients, spinal anaesthesia is preferable [69]. It can be used because
a. It is probably safe in patients with thyrotoxicosis.
b. It has favourable nontocolytic pharmacological properties.
c. It has preferable effects on the pulmonary system.
d. The sympathetic blockade associated with a regional technique may be desirable.
e. It is associated with a decrease in heart rate and blood pressure during surgery.
f. One can diagnose complications like thyroid storm at an earlier stage than when the
patient is sedated or under GA by maintaining the patients consciousness [64,69].
Intravenous fluids and blood must be administered judiciously as these patients have a
propensity to develop pulmonary oedema. Blood replacement may be required to treat
bleeding. Diuretics may be given intermittently [51].
Successful use of total intravenous anaesthesia (TIVA) has been reported for evacuation of
molar pregnancy with hyperthyroidism. E. Erturk et al reported the anaesthetic management
of a 25 year old woman having a hydatidiform mole with hyperthyroidism using TIVA
technique with propofol, remifentanil and esmolol infusion for controlling sympathetic
hyperactivity during surgery [26].
11.3. Postoperative care
Postoperatively, intensive care management may be indicated because most of the cardiopul‐
monary complications develop in the postoperative period [64]. Mechanical ventilatory
support must be provided if necessary. Treatment of thyroid storm, if it occurs, includes
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general supportive measures plus the administration of glucocorticoids, propylthiouracil,
sodium iodideand propranolol [27].
Solak M and Akturk G reported the successful perioperative management of a case of trophoblastic
hyperthyroidism. A 22 year old woman, in her third month of pregnancy, presented for emergency
evacuation. She had a history of vaginal bleeding and signs of hyperthyroidism like tremor, palpitation,
sweating and tachycardia for three weeks. Examination revealed an arterial blood pressure of 140/70
mm of Hg, a heart rate ranging from 110 to 130 beats per minute, a small thyroid nodule and signs of
hydatidiform mole in sonography and computerised tomography. Studies of thyroid function were
obtained: free triiodothyronine – 8.50pgml-1 (normal range 3.05-5.35 pgml-1) and free thyroxine –
5.56ngdl-1 (normal range 0.71-1.85 ngdl-1). Serum β-hCG was 961.96 mIUml-1 (normal range 0-5
mIUml-1). Serum thyroid stimulating hormone levels were within normal limits. The patient appeared
apprehensive, pale and shivering. She was administered intramusculardiazepam 5 mg 45 minutes
preoperatively. Arterial blood pressure came down to 110/70 mm of Hg and there was sinus tachycardia
(130 beats per minute). Spinal anaesthesia with 4 ml of 0.5% bupivacaine was administered at L3-4 level.
She lost 1000 – 1500 ml of blood intraoperatively and received approximately 100 ml of whole blood.
She was haemodynamically stable throughout the surgery which lasted for 30 minutes. Serum free T4
values were 4.13 and 1.25 ngml-1 on the 7th and 14th post-operative days respectively. She became
euthyroid few weeks after evacuation of the mole [64].
Puneet Khanna, Anil Kumar and Maya Dehran reported the successful perioperative management of a
44 year old female with hydatidiform mole. She had a history of irregular menstrual cycles since three
months. Preoperatively she appeared anxious, afebrile with a pulse rate of 116 per minute, blood pressure
of 120/80 mm of Hg and a respiratory rate of 20 per minute. The height of uterus was 14 weeks on per
abdominal examination. Haemoglobin was 13.1gms%. Thyroid function tests revealed TSH=0.03IU/
ml(0.03-5-5), T3=221IU/ml(70-200) and T4=14IU/ml(4.5-12.5). Ultra-sonogram of the abdomen
showed signs of an invasive hydatidiform mole. β-hCG levels were raised to 8,35,300mIUL-1. She was
put on tab. neomercazole 15 mgTDS, tab. propranolol 20 mgBD, Lugol’s iodine 4 drops TDS and inj.
dexamethasone 2mg 6th hourly.She was also started on chemotherapy with methotrexate on alternate
days and three cycles were given. Her β-hCG levels and thyroid functions were closely monitored. She
was posted for total abdominal hysterectomy and bilateral salphingo-oophorectomy but was postponed
due to persistent tachycardia reflecting an uncontrolled hyperthyroid state. The dose and frequency of
tab. propranolol was increased to 40mg 6th hourly. After three weeks her hyperthyroid state was partly
optimised(T4-9.94IU/ml and T3-0.014IU/ml) and she was accepted for the planned procedure.
Tab.diazepam 5mg was given on the night before and on the day of surgery. Patient was given combined
spinal epidural block in L3-4 space. Intravenous sedation was given with midazolam and fentanyl.
Intravenous dexamethasone was also given. Tabs.neomercazole, propranolol, amlodipine and dexame‐
thasone were continued post-operatively and Lugol’s iodine was stopped. Epidural analgesia with
morphine was provided postoperatively and on 3rd post-operative day thyroid function test started
showing improvement. On the 10th post-operative day, both β-hCG levels and thyroid function tests
normalised [59].
Laurent V and co-authors reported a case of successful perioperative management of a Senegalese
patient with hydatidiform mole. The patient had serum hCG levels of 900,000 IU. She was clinically
hyperthyroid  with  raised  T4  and  T3  levels  but  a  very  low  TSH  concentration.  She  was  given
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propranolol and carbimazole for 2 days. After that suction curettage was performed under general
anaesthesia.  Propranolol  was  again  administered  6  hours  after  surgery.  Thyroid  function  tests
returned  to  normal  levels  two  weeks  after  mole  removal  and  serum hCG concentrations  closely
paralleled those of free thyroxine [45].
12. Complications of hyperthyroidism in molar pregnancy
The two most serious maternal complications of untreated hyperthyroidism are heart failure,
being more common and thyroid storm [70]
12.1. Heart failure
High output cardiac failure secondary to the thyrotoxicosis can occur in the perioperative
period [43]. High output heart failure is caused by the myocardial effects of thyroxine.
Pulmonary hypertension which is correlated with untreated or inadequately controlled
hyperthyroidism can result in heart failure and pulmonary oedema [70]. Haemodynamic
problems like tachycardia, hypertension,increase in total blood volume,decrease in systemic
vascular resistance and increased cardiac output can result in cardiac decompensation and
arrhythmias [69]. Symptoms of high output cardiac failure include breathlessness at rest or on
exertion, exercise intolerance, fatigue, fluid retention and signs like tachycardia,tachyp‐
nea,raised jugular venous pressure, pulmonary rales,pleural effusion, peripheral oedema and
warm peripheries due to peripheral vasodilatation. Cardiac ultra-sound may show preserved
left ventricular ejection fraction [71].
Management of high output cardiac failure includes [72,73]
• Correction of the underlying hyperthyroidism.
• Carbimazole to alleviate thyrotoxicosis.
• Diuretics like frusemide to reverse the volume overload.
• Beta adrenoceptor blockers like esmolol and propranolol in particular to alleviate the
symptoms of hyperthyroidism and to control the heart rate.A cautious trial of ultrashort
acting beta blockers like esmolol can be done with invasive monitoring to detect the
occurrence of depressed myocardial contractility.
• Amiodarone to treat atrial fibrillation if present.
• Digoxin to slow down ventricular response rate in atrial fibrillation.
12.2. Thyrotoxicosis and thyroid storm
Thyroid storm occurs perioperatively in patients who have received either incomplete or no
treatment for the pre-existing hyperthyroidism [43,74]. Thyroid storm can lead to high output
cardiac failure [12].Cases of thyroid storm occurring in the intraoperative period have been
reported [75]. Severe thyrotoxicosis can occur even after surgical evacuation of the mole
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general supportive measures plus the administration of glucocorticoids, propylthiouracil,
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hyperthyroidism can result in heart failure and pulmonary oedema [70]. Haemodynamic
problems like tachycardia, hypertension,increase in total blood volume,decrease in systemic
vascular resistance and increased cardiac output can result in cardiac decompensation and
arrhythmias [69]. Symptoms of high output cardiac failure include breathlessness at rest or on
exertion, exercise intolerance, fatigue, fluid retention and signs like tachycardia,tachyp‐
nea,raised jugular venous pressure, pulmonary rales,pleural effusion, peripheral oedema and
warm peripheries due to peripheral vasodilatation. Cardiac ultra-sound may show preserved
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• Correction of the underlying hyperthyroidism.
• Carbimazole to alleviate thyrotoxicosis.
• Diuretics like frusemide to reverse the volume overload.
• Beta adrenoceptor blockers like esmolol and propranolol in particular to alleviate the
symptoms of hyperthyroidism and to control the heart rate.A cautious trial of ultrashort
acting beta blockers like esmolol can be done with invasive monitoring to detect the
occurrence of depressed myocardial contractility.
• Amiodarone to treat atrial fibrillation if present.
• Digoxin to slow down ventricular response rate in atrial fibrillation.
12.2. Thyrotoxicosis and thyroid storm
Thyroid storm occurs perioperatively in patients who have received either incomplete or no
treatment for the pre-existing hyperthyroidism [43,74]. Thyroid storm can lead to high output
cardiac failure [12].Cases of thyroid storm occurring in the intraoperative period have been
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[76].Thyroid storm is a clinical diagnosis with manifestions like hyperpyrexia, severe dehy‐
dration, tachycardia,tachypnoea, diaphoresis, diarrhoea, atrial fibrillation, extreme anxiety,
altered consciousness and haemodynamic instability leading to cardiovascular collapse
[27,69]. Treatment of thyroid storm includes cooling blankets, intravenous hydration, glucose
and electrolyte replacement, oxygen, glucocorticoids like dexamethasone or hydrocortisone
intravenously, anti-thyroid drugs like oral/rectal propylthiouracil, methimazole, iodine in the
form of intravenous sodium iodide or oral Lugol’s iodine, β blockers like propranolol or
esmolol, plasma exchange, dantrolene and B-complex multivitamins [27].
12.3. Mortality and pulmonary morbidity
Few cases of mortality after surgical evacuation in patients with molar pregnancy have been
described [63,12] and some of them were hyperthyroid [63,77]. Respiratory complications
including pulmonary oedema and acute respiratory distress syndrome (ARDS) were observed
in these cases [63,77]. Few authors have also reported successful intensive treatment of ARDS
occurring in hyperthyroid patients with molar pregnancy [74].
Severe thyrotoxicosis has been reported after commencing treatment for gestational trophoblastic
disease. A 53-year-old woman developed profound cardiovascular instability one day after surgical
evacuation of a complete hydatidiform mole. She was not known to have pre-existing thyroid disease but
investigations confirmed thyrotoxicosis [76]
Carrasco C and Cotoras J reported an interesting case of molar pregnancy with complications of
hyperthyroidism. An 18 year old woman was admitted with a history of four days of cardiac failure with
acute pulmonary oedema, high blood pressure, left ventricular dilatation and moderate to severe systolic
dysfunction. Twenty four hours after admission she had a miscarriage expelling a mole. The diagnosis
of hyperthyroidism caused by a mole and early preeclampsia was confirmed and the patient was managed
with diuretics and dopamine. Symptoms abated. Thyroid function tests, cardiac function and size
returned to normal values [78].
Hershman JM and Higgins HP reported a case of a 29 year old, 4 months pregnant Italian woman. She
came complaining of shortness of breath, extreme fatigue, nervousness and heat intolerance. Since the
past one week she had severe nausea and vomiting and vaginal spotting. On examination, she appeared
anxious with soft, warm skin, fine hair and sweaty palms. The pulse rate was 110 per minute and regular,
the blood pressure was 150/60 mm of Hg. The thyroid gland was slightly enlarged. Grade 2 ejection
murmur was heard over the pulmonary area and a ventricular gallop was heard over the apex. The
peripheral pulses were bounding. Ultrasonography showed signs of a molar pregnancy. The protein
bound iodine(PBI)level was 22.7 mμg, serum thyroxine-iodine was 18mμg/100ml, 24 hour uptake of
radioactive iodine was 75% and serum free thyroxine was raised: 14.8 mμg/100ml (normal 3-5mμg /
100 ml). Carbimazole 60mg per day was started. On the evening of the 7th day, supraventricular
tachycardia suddenly developed and acute pulmonary oedema ensued shortly. She was treated with nasal
oxygen, digoxin, ouabain and diuretics. A plasmapheresis was performed and packed red cells were
transfused. The next day, there was a rapid tachycardia but no evidence of congestive heart failure. On
the 8th day, a total abdominal hysterectomy was performed. Two further episodes of pulmonary oedema
treated successfully with digoxin, occurred on the first and third post-operative days. She improved
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markedly. Tachycardia came back to normal; radio iodine uptake and PBI came back to normal by 14
days [48].
An unusual case of a 13 year old Caucasian patient with a complete hydatidiform mole was reported
wherein during anaesthesia induction, she presented symptoms compatible with a thyrotoxic crisis. The
patient had complaints of amenorrhoea, abdominal pain and vaginal bleeding. She was tachypnoeic,
tachycardic, hypertensive, pale and dehydrated. Her haemoglobin was 9.9gm/dl, serum TSH was
0.009mIU/ml (normal 0.35 – 5.5). HCG levels were higher than 400,000 IU/L. She underwent chest,
abdominal and pelvic CT scanning with iodinated contrast and was scheduled to undergo a uterine
curettage. General anaesthesia was administered via intravenous induction with fentanyl, propofol,
endotracheal intubation and muscle relaxation with atracurium. After oro-tracheal intubation, she
developed sinus tachycardia (170 beats per minute), hypertension (160/120 mm of Hg), hypercarbia (52
mm of Hg) and acute pulmonary oedema. She was diagnosed to be in a thyrotoxic crisis. She was treated
with intravenous esmolol and sodium nitroprusside 75μg/kg/min respectively with satisfactory response
and transferred to the ICU and managed there till she became haemodynamically stable. The use of
iodinated substances can trigger thyrotoxic crisis (Jod-Basedow phenomenon) and in this case, the
iodinated contrast used to perform scan preoperatively could have contributed to the development of
thyrotoxic crisis [79].
13. Conclusions
Trophoblastic tumors are associated with biochemical and clinical hyperthyroidism. Hence
measurement of thyroid function in patients with gestational trophoblastic disease is impor‐
tant. Thyroid function normalises rapidly with treatment of the underlying gestational
trophoblastic disease and consequent fall in hCG levels. Treatment of gestational trophoblastic
disease includes surgical evacuation or chemotherapy. Hydatidiform mole with hyperthyr‐
oidism is a perioperative challenge. All patients should be stabilised with β-blockers and anti-
thyroid medications prior to induction of anaesthesia for surgical evacuation. Vigilant
monitoring and intensive care should be done perioperatively to watch for the occurrence of
cardiopulmonary complications or thyroid storm.
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The thyroid disorders are one of the most common and exciting areas of endocrinology. 
Hypothyroidism, multinodular goiter, hyperthyroidism and thyroid cancer are 
only few of the several implications that the thyroid disorders have in health. In 
fact, thyroid hormones regulate not only metabolism process, but also many other 
molecular and physiological systems. From this point of view, hyperthyroidism 
complications are a good example of the significance of thyroid hormone actions. This 
book aims to provide a general view of thyroid disorders, and a deeper explanation of 
hyperthyroidism and its complications and impact in health.
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